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 i 
Abstract 
 
UV radiation from the sun to which the skin is exposed is largely UVA. UVA is oxidative in 
nature and may generate redox-active labile iron within skin cells, inducing severe damage 
through the production of reactive oxygen species (ROS), and leading to skin photoaging and 
cancer. Light-activated caged iron chelators (CICs) are compounds that become active when 
exposed to environmentally relevant doses of UVA, releasing a potent iron-trapping agent or 
chelator, and providing UVA dose-dependent protection from harmful labile iron.  
 
This work describes first the optimisation of the synthesis of CICs where the iron-binding 
capability of the well-known iron chelators SIH, PIH and deferasirox (EXJADE®) was masked 
with a cinnamic acid photo-cleavable caging group. UVA irradiation uncaged the CICs to give 
the free iron chelator and a photoproduct, generated from cyclization of the caging group. 
The CICs were assessed for photoprotective ability in human skin fibroblasts (FEK4) by use of 
the MTT assay after a dose of 500 kJ/m2 UVA irradiation. One such CIC 51 (20 µM) provided 
significant photoprotection upon UVA irradiation, increasing the number of viable cells 
compared to cells irradiated without addition of the CIC. A second series of CICs was then 
synthesised by rational design; caging groups were selected based on the antioxidant 
potential of their carbostyril photoproducts. Two lead carbostyrils were identified which 
could significantly quench UVA-induced ROS especially in combination with an iron chelator, 
as determined by flow cytometry using the oxidative stress indicator, CM-H2DCFDA. This 
analysis led to the synthesis of the corresponding multi-functional CIC 115, which also showed 
significant photoprotection in the MTT assay. The capacity of sub-optimal thicknesses of 
commercially available sunscreen formulations to provide photoprotection against UVA-
induced cell death and labile iron release was also investigated using the calcein assay. At a 
thickness of 0.5 mg/cm2, UVA-induced labile iron was generated in all cases at fold-increases 
of 1.63-2.08 compared to the unirradiated control. The cell death consequences of this effect 
were confirmed by flow cytometry with annexin V/PI staining. The addition of CICs 
significantly reversed UVA-induced cell death and generation of labile iron, showing the 
potential real-world impact of combining a CIC with UVA/B filters in a sunscreen formulation. 
Finally a synthetic pathway to the natural iron chelator pulcherrimic acid was developed, 
followed by an investigation into its photoprotective potential. 
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CHAPTER 1: INTRODUCTION 
 
1. Sunlight and skin cancer 
 
1.1 The spectrum of sunlight and penetration through skin 
 
The sun provides us with a vital source of energy for human life in the form of light. Sunlight 
is crucial to photosynthesis, the process performed by plants to convert light energy into 
chemical energy that fuels cellular activity. Sunlight is composed of infrared, visible and 
ultraviolet (UV) electromagnetic radiation in the range of 100 nm - 1 mm. UV radiation (UVR) 
from the sun compromises the 100-400 nm portion, which is further divided into UVC (100-
280 nm), UVB (280-320 nm), UVA2 (320-340 nm) and UVA1 (340-400 nm).1 UVC is absorbed 
by the ozone layer and therefore human exposure is unlikely, whereas UVB is also 
substantially absorbed, though not completely, by the ozone layer. However, ozone is 
transparent to UVA and therefore the UVR that reaches the Earth’s surface is up to 95% 
UVA.2,3 A wide range of applications of UVR in healthcare and medicine have been identified 
since the discovery of UVR by Johann Wilhelm Ritter in 1801. In the late 18th century, the 
cytotoxic effect of UVC irradiation on bacteria was discovered, and hence the possibility of 
using short wavelength UVR in the sterilization of food was realised.1 In 1903, UVR was used 
along with X-ray radiation to treat the facial swellings of patients with Lupus (a chronic 
inflammatory disease),4 and following this in 1927 the First International Conference on Light 
and Heat in London included abstracts on the application of UVR for curing a range of ‘human 
ills’ with the suggestion being made  that ‘man was on the threshold of something that would 
be of great advantage’.5 
 
Human skin is the interface between a person and their environment, and as such it is exposed 
to UVR very regularly. Factors that increase the amount of UVR an individual’s uncovered skin 
is exposed to include: spending time outdoors during the summer months, being at a high 
altitude, living close to the equator and the amount of ozone in the atmosphere.6 Human skin 
is separated into two main sections: the epidermis and the dermis. The epidermis is the outer 
cellular layer and has an depth of 50-150 µm. 95% of the cells in the epidermis are 
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keratinocytes, with the remainder being melanocytes and Langerhans cells.7 Keratinocytes 
are derived from the basal layer (stratum basale) of the epidermis which sits on the basement 
membrane, next to the dermis (shown in Figure 1). Keratinocytes from the stratum basale 
will differentiate and then migrate, whilst maturing, to the surface of the skin (stratum 
corneum) through a series of defined layers (described in Figure 1), this process takes 
approximately one month in humans. The stratum corneum has between 10-20 layers of dead 
keratinocytes (corneocytes) with a thickness of approximately 10 µm. Over the course of their 
differentiation from the stratum basale to the stratum corneum, keratinocytes build up 
proteins such that they become surrounded by a cornified envelope. At this stage the 
keratinocytes are termed corneocytes, and their cornified envelope consists of involucrin 
cross-linked with insoluble keratin which acts as a very important physical barrier for the body 
against pathogenic invasion, heat and water loss and to defend against UVR.8 Turnover of the 
epidermis is tightly controlled so that corneocyte loss (desquamation) and keratinocyte 
division are at equilibrium.9 
 
Underneath the epidermis sits the mainly non-cellular dermis, which is 3-5 mm thick and 
contains fibroblasts and mast cells surrounded by an extracellular matrix of collagen and 
elastin fibres. In the uppermost layer of the dermis (the papillary layer), capillary loops are 
connected to small veins which then travel down through the lower dermis (reticular layer) 
to connect with cutaneous veins.7 
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Figure 1. Structure of the human skin (adapted from  www.eucerin.co.uk/about-skin/basic-skin-knowledge/skin-
structure-and-function).10 The epidermal layer consists of keratinocytes differentiating and maturing upwards 
from the lowest level the stratum basale, through the stratum spinosum and the stratum granulosum before 
reaching the outermost skin surface, the stratum corneum.3 The dermal layer sits underneath the epidermis and 
consists mainly of fibrous materials (collagen and elastin) and vasculature along with fibroblast cells.9 
 
The constituent molecules in the skin contain a range of chromophores, which are the parts 
of a molecule responsible for its colour via the absorption of radiation, often through a 
conjugated system. Each chromophore has a characteristic absorption spectrum and as such 
the extent of absorption of a specific wavelength of radiation by the skin is dependent on the 
endogenous chromophores present, for example urocanic acid, DNA and proteins containing 
tyrosine or tryptophan.9 These chromophores all have maximal absorbance primarily in the 
UVC-UVB range (260-320 nm) with minimal UVA absorbance, see Table 1. 
 
 
 
 
 
 
 
Cutaneous vein 
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Table 1. Examples of endogenous epidermal chromophores and their maximal absorbance wavelengths.9 
 
 
As long wavelength UVA is not absorbed by the majority of epidermal chromophores, it is 
able to penetrate further into the skin and reach the dermal layer.3 It is estimated that up to 
50% of UVA can reach melanocytes on the basal membrane compared to only around 14% of 
UVB.11 Longer wavelength UVA can also penetrate through unprotected car and office 
windows.11 A computational study was carried out by Ash et al. to analyse the tissue 
penetration of different wavelengths of light, confirming that UVA penetrates further into the 
skin than UVB (approximately 500 µm to 1000 µm for UVB and UVA respectively, Figure 2).12      
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Figure 2. Depth penetration of 300-500 nm wavelengths of light into computational tissue matrix from Ash et 
al.12 The tissue matrix was modelled as an 80 µm thick epidermis with a 5% melanin concentration and a 
melanin-free dermis. The model was calibrated against thermography measurements of Caucasian, Indian and 
Afro Caribbean skin tones exposed to a range (2-20 J/cm2) of intense pulsed light (IPL). The simulated photon 
distribution was subsequently calculated using the Monte Carlo process.12 
 
1.2 Types of skin cancer 
 
Overexposure to UVR is known as the major risk factor associated with skin cancer13 as well 
as  promoting skin ageing, wrinkling and pigmentation and immune system suppression. Skin 
cancers can be classified into two groups known as non-melanoma skin cancer (NMSC) and 
malignant melanoma, with the classification being based on the cell type where the tumour 
originates. NMSCs are derived from keratinocytes and as such may also be termed 
keratinocyte cancers (KCs). NMSCs are sub-divided into basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC). NMSC is the most common skin cancer, with the worldwide 
incidence being 18-20 times higher than for malignant melanoma.14 A systematic review by 
Lomas et al. in 2012 revealed that the incidence of NMSC has been increasing worldwide over 
the past 50 years.15 Of the NMSC category of skin cancers approximately 20-30% are SCC and 
70-80% are BCC.14 More than 80% of NMSC are found on areas of the body susceptible to life-
long cumulative sun-exposure such as ears, nose, cheeks and the top of hands.14 Typically 
NMSC has a good prognosis as the metastatic capacity of these cancers is low compared to 
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melanoma skin cancer. Thus although the incidence of NMSC is far higher, the mortality rate 
is lower.16 
 
Malignant melanoma are tumours that originate from the melanocytes, which are found at 
the basement membrane of the epidermis and produce the skin pigment melanin. Although 
this form of cancer is the least common, it is responsible for approximately 80% of skin cancer-
related deaths due to its high propensity to metastasise.16 The prognosis for metastatic 
melanoma is between 12-28% survival after 5 years.17  
 
Figure 3 shows the number of deaths from malignant melanoma in England over a 25 year 
period from 1985 to 2010, divided into age groups. It indicates that the number of deaths for 
under 44-year-olds is reasonably stable, while deaths in the 45-64 year old group increased 
until the year 2000 but have since stabilised. However, the number of deaths in people above 
the age of 65 has increased rapidly since 1985 and shows no sign of diminishing. This may 
simply be due to increased life expectancy 18 and therefore the accumulation of many more 
years of sun exposure. Travel abroad to hot countries has also become increasingly easy and 
cheap, and sun-filled holidays are now much more common, exposing unconditioned skin to 
high UVR intensities.19 The introduction of UVR tanning beds and the desire to have a tanned 
skin complexion may  be another factor that could contribute to the increasing number of 
deaths.3 
 
 
 
 
 
 
 
Figure 3. Graph showing the number of deaths from malignant melanoma in England over a 25 year period, 
divided into four age groups. Data from the Office for National Statistics, UK.20 
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The role of the melanocyte pigment melanin with respect to UVR-protection is currently not 
very well understood,21 and more knowledge is required to help interpret this interaction in 
terms of the transformation to malignant cells. Melanin exists in two different forms, 
pheomelanin and eumelanin. The relative proportions of these melanins, along with the way 
that they are packaged and distributed in melanosomes determines the colour of the skin.21 
Melanosomes are organelles specific to melanocytes where melanin is biosynthesized 
(melanogenesis). Melanin is then distributed to adjacent keratinocytes through dendritic 
projections, where it subsequently accumulates.21 Melanin is thought to shield DNA from UVR 
by scattering it, however the specific chromophore and thus absorption spectrum of natural 
melanin has not been identified due to its insolubility.9 Tyrosine is the fundamental structural 
unit of melanins, and the first step of melanogenesis is the conversion of tyrosine to 
dopaquinone via oxidation by the enzyme tyrosinase.22 In the absence of cysteine, 
dopaquinone forms 5,6-dihydroxyindole (DHI), 5,6-dihydroxyindole-2-carboxylic acid (DHICA) 
and their oxidised forms which are polymerized to give eumelanin. In the presence of 
cysteine, dopaquinone is oxidised to benzothiazine intermediates which are polymerized to 
pheomelanin.22 The macromolecules are highly conjugated and cross linked through 
heteroaromatic units via C-C bonds, making them non-hydrolysable.22,23 The type and amount 
of melanin produced by melanocytes is mainly influenced by the individual’s genetics as well 
as a range of factors such as hormonal changes, inflammation, age and exposure to UVR.24 It 
has been suggested that UVR-induced photodamage and the subsequent repair process 
induces melanogenesis and therefore increases tanning.24 Due to this, melanin has been 
termed  an endogenous ‘sunscreen’ with a sun protection factor (SPF, see Section 2.1) of 
approximately 3-5.25 There is an inverse relationship between the amount of skin 
pigmentation and the incidence of melanoma cancer.25 
 
1.3 Mechanisms of UVB damage 
 
The damaging effects of UVB radiation are initiated through the direct absorption of UVB by 
consituents of the skin.26 UVB radiation is associated with the painful experience of sunburn 
through an inflammatory response induced by over-exposure to the sun. Inflammatory 
mediators such as interleukin-1, IL-6, IL-8 and IL-10, as well as tumour necrosis factor-a, are 
produced in keratinocytes upon UVB radiation.27 The absorption spectrum of DNA overlaps 
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mainly with the UVC radiation wavelength range, however a significant portion lies in the UVB 
range.9 Therefore in the context of sunlight reaching the human skin, most UVB radiation will 
be absorbed by epidermal DNA. The predominant feature of UVB-induced skin damage is the 
formation of two types of DNA-damage photoproducts between adjacent pyrimidine bases: 
cyclobutane pyrimidine dimer (CPD) and pyrimidine 6-4 pyrimidone (6-4PP), shown in Scheme 
1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. The formation of the two DNA photoproducts; cyclobutane pyrimidine dimer (CPD) and pyrimidine 
6-4 pyrimidone (6-4PP) upon UVB absorption by two adjacent thymine bases. 
 
CPDs are observed at a 5-10-fold higher frequency than 6-4PP.28 These lesions in DNA can 
lead to the transition of C to T and CC to TT. Such mutations have been found to be the most 
frequent (50-90%) in p53 (tumour suppressor gene).28 Post-UVR exposure, there is normally 
a transcriptional activation of p53 leading to the induction of high levels of the p53 protein in 
cells.29 The p53 protein triggers cell cycle arrest (G1 and G2) which allows the repair of DNA 
lesions prior to DNA synthesis and mitosis. It also initiates apoptosis, therefore DNA-damaged 
cells are either usually repaired or eliminated by the increased expression of this protein.29 
Ananthaswamy et al. demonstrated that mutations in p53 were first detectable 6 weeks after 
cumulative irradiation of mouse skin with UVB.30 In their in vivo progression model for UVB-
induced skin carcinogenesis, Tyagi et al. demonstrated that after repetitive exposure of HaCaT 
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(immortalized human epidermal keratinocytes) cells to UVB radiation, they exhibited an 
enhanced proliferation rate, apoptotic resistance and colony and sphere-forming abilities. 
Furthermore, inoculation of these cells into mice led to the formation of aggressive SCC.31 
Thus UVB induced formation of CPD and 6-4PP photolesions leads to mutations in the p53 
gene and a reduction in the expression of the p53 protein which subsequently initiates skin 
carcinogenesis. 
 
Lesions cause torsional strain of the DNA double helix and under normal circumstances 
mutagenic photodimers such as CDPs and 6-4PPs are often removed by nucleotide excision 
repair (NER), a repair pathway for regions of DNA damage up to 30 bases in length.32 However 
when exposed to high-dose UVB, the NER process can become saturated and lead to an 
accumulation of mutations.32 Differences in the expression of repair genes may also account 
for varying levels of unrepaired damage between individuals.32 Inherited genetic diseases 
such as xeroderma pigmentosum (XP), Cockayne syndrome (CS) and trichothiodystrophy 
(TTD) are all caused by mutations to genes which encode for critical NER proteins. XP patients 
have a >10,000-fold increased risk of skin cancer in exposed parts of the body in comparison 
to a healthy individual.33 
 
UVR from the sun is only 5-10% UVB with the remaining 90-95% being UVA.3 With this in 
mind, the ability of UVB radiation to behave as a strong carcinogen is quite surprising, one 
would expect UVA radiation to be approximately 9 times more dangerous. However the 
action spectrum (a plot of wavelength against the dose required for a given biological 
outcome) of UVB shows that it is approximately 1000 times more effective at developing 
erythema than UVA per unit dose (kJ/cm2).34 The relative erythemogenic weighting of UVB 
radiation is due to its action as a ‘direct’ carcinogen. Skin constituents directly absorb the 
lower wavelength but higher frequency energy, as described above, which makes UVB 
radiation a significant carcinogen. This is worsened in areas with low ozone as a higher 
percentage of UVB radiation will reach the surface of the Earth.35 Conversely UVA radiation is 
termed an ‘indirect’ carcinogen despite being responsible for a larger portion of the total UVR 
from the sun. The mechanisms of action of UVA radiation damage are described in the 
following section. 
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1.4 Mechanisms of UVA damage  
 
Whereas the mechanisms of UVB-induced skin damage have been long studied, UVA-induced 
damage has received less attention as it was not considered a direct DNA damaging agent.11,36 
There is now substantial evidence to support the claim that UVA plays a significant role in the 
pathogenesis of skin cancers. UVA-damage results from the reactivity of endogenous 
(porphyrins, riboflavin, melanin) and exogenous (thiopurine drugs, fluoroquinolone 
antibiotics) photosensitizers which generate ROS, for example singlet oxygen, hydrogen 
peroxide, superoxide anion. These ROS lead to serious oxidative stress causing DNA single 
strand breakage, nuclear base damage, protein, membrane and organelle damage.11 Peak et 
al. showed that there was a >20-fold higher number of DNA single strand breaks in human 
teratocarcinoma cells that were irradiated with monochromatic UVA at 365 nm in comparison 
to UVB at 313 nm, with 9000 lesions/cell and 430 lesions/cell respectively.37 Following this, it 
was found that DNA single-stranded breaks found in melanocytes after UVA exposure were 
most likely initiated by a photosensitizing reaction with pheomelanin.38 40 times more DNA 
single-stranded breaks were observed in melanocytes in dark skin compared to melanocytes 
in light skin.39 This evidence suggests that the oxidative nature of UVA may play a crucial role 
in the positive progression of melanoma skin cancer.   
 
The monomeric lesion 7,8-dihydro-8-oxoguanine (8-oxoG) is a frequently observed 
oxidatively damaged DNA guanine base and is classed as a pre-mutagenic photoproduct40 (see 
Scheme 2). Analysis of the effect of monochromatic radiation ranging from UVB (312 nm) to 
visible light (434 nm) on human skin fibroblasts demonstrated that UVA radiation above 334 
nm was responsible for almost all of the yield of 8-oxoG.40 It was estimated that the total 
amount of 8-oxoG formed by sunlight exposure would be equal to or exceed the amount of 
direct DNA damage and CPD formation.40 In relation to this it has also been determined that 
the level of 8-oxoG formation induced by UVA irradiation in melanocytes is 2-fold higher than 
in keratinocytes.41  
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Scheme 2. The monomeric photolesion 7,8-dihydro-8-oxoguanine (8-oxoG) formed through UVA-induced 
oxidation of a guanine DNA base. 
 
Mouret et al. demonstrated in 2006 that CPDs, typically a hallmark of UVB-induced damage, 
were significantly produced in whole human skin exposed to UVA. Furthermore, a recent in 
vivo study by Tewari et al. showed a significant increase in CPD with increasing skin depth 
after irradiation with UVA.42 The mechanism for this occurrence is unknown, and it was also 
shown by Mouret et al. that the rate of removal of UVA-induced CPDs was slower than that 
of UVB-induced CPDs.43 This suggests that the repair of CPDs is compromised by the longer 
wavelength UVA. Consistent with this is the knowledge that UVA radiation can cause 
extensive protein unfolding and aggregation, leading to changes in cellular signalling and 
homeostasis.44 Tryptophan, tyrosine, phenylalanine, methionine and histidine side chains 
have all been shown to be susceptible to photo-oxidation.44 There is also evidence that direct 
absorption of UVR by disulphide bonds between two cysteine residues causes homolytic 
cleavage of the bond to form two thiyl radicals (RS.).44 The CPD repair NER proteins are a 
possible oxidation target and therefore UVA radiation could compromise the DNA repair in 
cells via inhibition of the activity of NERs, subsequently prolonging the repair process. Other 
DNA repair proteins known to be targets for UVA-induced oxidation include PARP-1, APE-1 
and XPE.45 
 
Oxidative stress of cells is usually managed by endogenous antioxidant defences working in 
unison, for example the enzymes superoxide dismutase (SOD), catalase and glutathione 
peroxidases (GPx).46 SOD catalyses the conversion of the superoxide anion (O2-) into oxygen 
and hydrogen peroxide (H2O2). H2O2 can then be converted to water and oxygen by catalase46: 
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2HO2 ® O2 + H2O2 
2H2O2 ® O2 + 2H2O 
 
GPx catalyses the conversion of H2O2 to water through the transformation of glutathione 
(GSH) to glutathione disulphide (GS-SG)47: 
 
2GSH + H2O2 ® GS-SG + 2H2O 
 
GSH can also neutralise lipid peroxides, and the GS-SG formed can be reduced back to GSH 
through the action of glutathione reductase.47 The excessive ROS that are generated 
intracellularly through UVA-radiation affect the oxidative homeostasis of cells, overcoming 
the neutralising of ROS by enzymes.48 The negative balance of ROS is also aided by UVA 
irradiation significantly decreasing the activity of catalase and SOD in human keratinocytes.49 
This was demonstrated by Hoerter et al., who assessed the impact of UVA radiation in the 
presence of an incompletely functioning antioxidant enzyme system using a mutant strain of 
E.coli lacking SOD. A 9-fold increase in mutagenesis occurred when the mutant bacterial strain 
was UVA-irradiated in comparison to the wild-type.50  
 
Iron is a redox-active transition metal and therefore can cycle between its two principal 
oxidation states, Fe3+ and Fe2+. Ferrous iron (Fe2+) is well known as being capable of catalysing 
redox reactions in vitro,51 and in the presence of hydrogen peroxide, ferrous iron can catalyse 
the formation of the hydroxyl radical through Fenton chemistry:  
 
Fe2+ + H2O2 ® OH. + OH- + Fe3+ 
 
Excessive intracellular ROS generated by UVA-irradiation via this pathway can be exacerbated 
through iron-catalysed lipid peroxidation of membranes in human primary fibroblasts and 
keratinocytes, with the formation of harmful alkoxyl and peroxyl radicals.52 There is an 
accessible intracellular pool of metabolically and catalytically active ‘free’ iron, termed the 
labile iron pool (LIP) which is thought to be bound to low molecular weight ligands 
(glutathione, citrate53, phosphate).54 Iron that is not metabolically required is stored in the 
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iron storage protein ferritin (Ft) with up to 4,500 atoms of ferric (Fe3+) iron being stored and 
protected from reduction in a single protein molecule.55 The LIP is monitored by the cytosolic 
iron regulatory proteins 1 and 2 (IRPs) which regulate the uptake and distribution of iron 
throughout cells. Increased iron supply will inactivate IRP-1 and degrade IRP-2 leading to 
synthesis of Ft. Pourzand et al. showed that upon UVA irradiation of human skin fibroblasts 
(FEK4 cells) there was an immediate loss of activity in IRP-1 binding which returned after 6 
h.56 At higher doses of UVA radiation the reduction was present 24 h post irradiation. This 
result correlated with a dose-dependent decrease in Ft levels, which suggests that there is a 
release of free iron due to degradation of Ft upon UVA radiation.56 This phenomenon was 
reversed by the addition of the protease inhibitor chymostatin, which is known to specifically 
block the activity of lysosomal chymotrypsin. This indicated that the release of free iron from 
Ft was via proteolysis by lysosomal proteases.56 The stability of lysosomal membranes after 
UVA-irradiation was assessed using a fluorescent probe. The result demonstrated the loss of 
integrity of the lysosomal membrane and subsequently the leakage of lysosomal contents 
into the cytosol.56 Figure 4 outlines the molecular mechanisms described above. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Representation of UVA-induced oxidative stress and labile iron release in a human skin FEK4 cell. UVA 
irradiation destabilises the membrane integrity of lysosomes, releasing lysosomal proteases such as 
chymotrypsin. These proteases degrade ferritin which releases labile iron into the cytosol. Redox active iron can 
contribute to the generation of ROS, damaging membranes, mitochondria and DNA.57   
 
2. Photoprotection 
 
2.1 The use of sunscreens 
 
The detrimental effects of over-exposure to UVA and UVB have been already been described 
in Section 1.3 and 1.4. Protection from these damaging wavelengths is crucial in order to 
prevent skin cancer and photoaging. Protection methods such as wearing long-sleeved 
clothing and hats and staying in the shade between the hours of 12-3pm, when the intensity 
of UVB is highest, are the best ways to stay safe in the sun.36 The major breakthrough of 
sunscreen technology has enabled people to feel protected whilst spending time outdoors, 
ferritin 
lysosome 
labile iron 
release 
ROS 
FEK4 cell 
lipid peroxides 
lysosomal proteases 
UVA irradiation 
Fe 
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however there are gaps in consumer understanding about the proper use of sunscreens which 
may result in incomplete sun protection for the user.36 
 
Up until the 1930s a pale complexion was fashionable in America and Europe as it was 
considered to indicate wealth and status, and as a result there were many cases of lead 
poisoning through the white lead used to whiten faces and necks.58 The fashion for a tanned, 
‘healthy’ complexion has risen through the 19th century, opening up the sun care market for 
cosmetic companies. Through the lack of research into the harmful effects of UVR during 
these times, people were subject to high levels of exposure. Certain products on the market 
provided a damage-inducing effect rather than being protective, such as the photosensitizing 
product Sun-bi-Sun.59 One of the most common reasons for using sunscreens is to prevent 
the painful sunburn experience, and for this reason the first sunscreens invented were biased 
towards UVB protection and did not contain any UVA protection, therefore the user was lulled 
into a false sense of security in terms of skin cancer prevention. This may have increased the 
incidence of skin cancers including melanoma as people felt they could spend more time 
outdoors and not be sunburned, but were subject to high doses of UVA radiation.11,36  
 
As early as 1985, Diffey et al. highlighted the need to include protection against UVA when 
this was still not a general consideration.60 Once the role of UVA in photocarcinogenesis and 
ageing was better understood, a change to sunscreen formulation was brought about which 
introduced ‘broad spectrum’ UVA/UVB protection.36 In a study by Young et al the use of a 
daily-care broad spectrum sunscreen was shown to inhibit most of the damage caused by 
daily sub-erythemal (sunburn) exposure.61 The SPF of a sunscreen relates to the relative 
protection that a product provides against UVB radiation. It is calculated using the ratio of 
UVR doses required to trigger erythema on human skin with and without the sunscreen 
formulation, the dose required is termed the minimal erythema dose (MED). The testing is 
performed using solar-simulated radiation (SSR); a lamp which emits the specified 
percentages of UVA and UVB radiation to act as a ‘solar mimic’.34 There is a true relationship 
between the factorial difference in SPF values and the protection afforded by the sunscreens. 
For example, an SPF 15 sunscreen applied correctly absorbs 93.3% of erythemogenic UVB 
rays, whereas an SPF 30 sunscreen absorbs 96.7%. Therefore the amount of UVB rays 
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transmitted through the skin using an SPF 15 sunscreen (6.7%) is double that of the SPF 30 
sunscreen (3.3%), relating to half the protection (shown in Figure 5).62 
 
 
 
 
 
 
 
 
 
 
Figure 5. Graph from Osterwalder et al. showing the absorbance and transmittance of UVB irradiation through 
sunscreens of varying SPF.62 
 
The UVA protection (PF-UVA) is analysed by either an in vivo method based on UVA-induced 
persistent pigment darkening (PPD) or an in vitro method based on UVA transmittance 
through a film of the formulation. Sunscreens are now tightly regulated in the EU and the UK 
so that the SPF/PF-UVA ratio must be less than or equal to 3, i.e a SPF 30 sunscreen must have 
a PF-UVA of at least 10 to pass, and the sunscreen must be clearly labelled with the outcome.36 
However as the biological outcomes of UVA and UVB damage are very different, the question 
should be asked as to whether there is a better way of testing UVA protection that involves 
the direct biological endpoint of UVA, namely ROS. One such test is the radical sun protection 
factor (RSF) which is a ratio of the detected amount of radicals generated in unprotected skin 
compared to protected skin using electron spin resonance (ESR). A significant correlation has 
been found between PF-UVA and RSF values for a range of sunscreen formulations, therefore 
this may be a more appropriate test for the UVA protection afforded by sunscreens.63,64 
 
Consumer compliance is a huge factor in the misuse of sunscreens, along with a lack of 
understanding of proper use of sunscreens. There are many reasons why people use 
sunscreens sparingly or not at all, such as: it takes too much time to apply, it is greasy, it is 
expensive, it prevents a tan, they have skin that ‘does not burn easily,’ or they have a 
UV dose (%) that is filtered 
out by the sunscreen 
UV dose (%) that reaches the 
skin to give the sunburn dose 
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‘protective tan’.65 These reasons include many that are relevant to the formulation of the 
sunscreen and therefore it is in the hands of cosmetic companies to make more user- friendly 
sunscreens. Public health education is also paramount to increasing compliance in sunscreen 
use to prevent skin cancers,66,67 indeed in a study by Ghiasvand et al. the general use of a SPF 
>15 sunscreen was estimated to reduce the incidence of melanoma by 18%.68 Poor 
compliance leads to the incorrect use of sunscreens, for example applying the formulation 
unevenly or not rubbing it in, not reapplying after water immersion or towelling, and not 
applying the recommended amount of sunscreen (2 mg/cm2).65  When the SPF of a product 
is determined, 2 mg/cm2 of formulation is used in the testing procedure, therefore using less 
than 2 mg/cm2 will significantly lower the SPF (and subsequently PF-UVA) protection provided 
by the sunscreen. There are many human sunscreen studies which indicate that typically 
people apply much less than the recommended amount of sunscreen, with amounts varying 
between 0.5 and 1.5 mg/cm2.69-71 This is worsened especially when using ‘physical’ 
sunscreens containing TiO2 or ZnO, as these tend to leave a white film on the skin. It is 
postulated that most sunscreen users achieve a protection between 20-50% of the labelled 
SPF value, as there is a logarithmic relationship between application thickness and SPF 
value.71 This again raises the question of a need to change the SPF testing method. 
 
Solar UVB radiation is a critical environmental trigger for the biosynthesis of vitamin D, with 
all other vitamin D sources being through the diet. Along with calcium, vitamin D is essential 
for healthy bones especially in growing children. There are concerns over the inhibition of 
vitamin D biosynthesis whilst using sunscreen formulations.62 A human study using 32 healthy 
children indicated that a low daily dose of UVR gave a modest but significant improvement in 
25-hydroxyvitamin D3 (a widely used serum marker for vitamin D status) of 24%, however 
there was a 1162% increase in the level of skin CPDs generated.72 If there are changes made 
to the SPF testing method along with increased public health campaigns to apply more 
sunscreen, it is feasible that vitamin D biosynthesis from UVB could be compromised.73 
However a recent study by Young et al. into the impact of sunscreen on vitamin D status 
showed that the application of two sunscreens during a week long holiday in Tenerife 
prevented sunburn whilst there was also a significant increase in the level of 25-
hydroxyvitamin D3 across the cohort, thus providing evidence that sunscreen application does 
not prevent vitamin D biosynthesis.74 A daily 15 min exposure to sunlight is adequate to 
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provide an individual’s vitamin D requirements from spring until autumn, however in winter 
there is insufficient UVB to synthesise vitamin D.2 For these reasons it is essential that the 
vitamin D requirements of the human body are sufficiently supplemented through the diet, 
as would be the case throughout the winter months. 
 
2.2 Types of UVR filters, their efficiency and new developments 
 
The UVR filters used in sunscreen can be categorized as either organic or inorganic. The two 
approved inorganic UVR filters are titanium dioxide (TiO2) and zinc oxide (ZnO) which are 
classed as broad spectrum filters that form a physical barrier to scatter, absorb and reflect 
UVR.75 The main drawback of these filters is the white film that the particulates leave behind 
on the skin65, and because of this the use of ZnO and TiO2 in sunscreens is mostly in the 
nanoparticle form. The ZnO and TiO2 nanoparticles are typically spheroidal and have average 
diameters of 18.2 nm and 21.5 nm respectively.76 There is some concern over the safety of 
the long term use of nanoparticles due to the possibility of penetration through the skin and 
systemic absorption.77 In a study by Osmond-McLeod et al. sunscreen formulations containing 
ZnO or TiO2 nanoparticles were applied topically once a week to hairless mice.76 The ZnO 
formulation did not cause any significant increase in the level of Zn in serum and internal 
organ tissue, however the TiO2 formulation caused a very small increase in liver Ti although 
this was not deemed an adverse biological outcome.76 
 
There are approximately 55 organic filters that are approved in different countries worldwide 
and of that number only 9 are approved for use by regulatory bodies globally due to clinical 
efficacy and side effect concerns. The properties of these approved filters are outlined in 
Table 2.34,36,75 
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Table 2. Comparison of UVR filters globally approved for use in sunscreen formulations. 
 
 
 
 
Name 
(common 
name) 
Structure Class UVR absorbing 
region, 
absorbance 
maximum (nm) 
Benzophenone-3 
(oxybenzone) 
 
 
Benzophenones UVB/UVA2,  
286 and 324 
Butyl 
methoxydibenzoyl
methane 
(avobenzone) 
 
 
Dibenzoyl 
methanes 
UVA1/2, 357 
Ethylhexyl dimethyl 
PABA (padimate O) 
 para-amino 
benzoates 
UVB, 311 
Ethylhexylmethoxy
cinnamate 
(octinoxate) 
 
 
Cinnamates UVB, 311 
2-Ethylhexyl 
salicylate 
(octisalate) 
 Salicylates UVB, 305 
Homomenthyl 
salicylate 
(homosalate) 
 
 
 
 
 
Salicylates UVB, 306 
Octocrylene  - UVB, 303 
4-aminobenzoic 
acid (PABA) 
 
 
para-Amino 
benzoates 
UVB, 283 
Phenyl 
benzimidazole 
sulfonic acid 
(ensulizole)  
- UVB, 302 
 20 
The ability of UVR filter structures to delocalise electrons determines their maximum 
wavelength of absorption, and therefore the UVR region in which they absorb.75 The PABA 
moiety was one of the first UVR filters to be developed. It contains an electron-donating group 
(NR2) para to an electron-withdrawing group (CO2R) which provides an efficient route for 
electron delocalization, (see Table 2).75 However, PABA filters in sunscreens are a common 
cause of allergy and have also been shown to have relatively high percutaneous absorption 
(1.6-9.6% recovered in the urine 48 h after topical application), therefore they are rarely used 
in modern sunscreen formulations.77 The structure of the salicylate group of UVR filters (seen 
in octisalate and homosalate, Table 2) allows electron delocalization as well as the possibility 
of internal hydrogen bonding through the ortho hydroxyl substituent.75 This additional 
internal interaction lowers the HOMO-LUMO energy gap of the salicylates in comparison to 
PABA, and therefore increases the absorption maximum of the molecules (there is an inverse 
relationship between the energy of an electronic transition of a compound and the 
wavelength of UVR absorbance it exhibits).75 Cinnamates (see octinoxate, Table 2) have a 
similar basic structure to PABA, in which the aromatic ring is 1,4-disubstituted with an 
electron-donating and electron-withdrawing group, however there is an extra double bond 
leading to additional conjugation and electron delocalization in the molecule, further 
increasing the UVR wavelength of absorption.75 These filters are subject to E/Z photo-
isomerisation (shown in Scheme 3) which reduces the efficiency of their UVR absorption due 
to the Z isomer being poorer at absorbing UVR. For example the molar absorption coefficients 
of the E and Z isomers of octinoxate are 19,500 dm3 mol-1 cm-1 and 10,000 dm3 mol-1 cm-1 
respectively.75  
 
 
 
 
 
 
 
Scheme 3. Photo-isomerisation of a cinnamate UVR filter from the E to the Z isomer, which is a poorer UVR 
absorber. 
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Benzophenone derivatives have an electron-donating group in either or both of the ortho and 
para positions (see oxybenzone, Table 2) to increase electron delocalization, along with the 
possibility of an intramolecular hydrogen bond.75 This results in the filters exhibiting two 
absorption maxima: 286 nm (UVB) and 324 nm (UVA2). Oxybenzone is one of the most 
bioavailable photoactive compounds after cutaneous application and as such its use has 
declined.77 Dibenzoyl methane filters, for example avobenzone, have the lowest energy 
requirements of the original classes of UVR filters and therefore mainly absorb in the UVA 
region. This is due to their ability to undergo keto-enol tautomerism, which provides a 
conjugated structure that is stabilised by intramolecular hydrogen bonding, shown in Scheme 
4.75  
 
 
 
 
 
 
Scheme 4. The keto-enol tautomerism of avobenzone gives the UVR filter a wavelength of absorption in the 
UVA1/2 region. 
 
Avobenzone is the most widely used UVA filter in sunscreens and as shown in Table 2, it is 
the only UVA1/2 filter to be approved for use by regulatory bodies worldwide. It has been 
suggested that avobenzone has poor photostability. The keto and enol forms of avobenzone 
are in equilibrium in solution and the equilibrium always lies in the direction of the enol 
tautomer, however upon UVA irradiation at 357 nm the enol form is converted to the keto 
form78 (see Scheme 4). The keto form absorbs in the UVC range from 260-280 nm which 
therefore renders the photoprotective properties of the sunscreen inadequate.78 
Photodegradation of avobenzone also occurs through α-cleavage of the keto form to give 
benzoyl or phenacyl radicals.78 Avobenzone can be stabilized by octocrylene and therefore 
they are often formulated together in sunscreens.79,80 The requirement for more stable and 
non-toxic UVA filters is high, and one possible option is a camphor derivative, 
terephthalylidene dicamphor sulfonic acid (shown in Figure 6). This filter is patented by 
L’Oréal under the name Mexoryl SX (ecamsule)81 and it has been approved for use globally 
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as a UVA filter, except in the USA. The camphor family of filters generally have high molar 
absorption coefficients in the UVA range and are photostable.75 It is claimed that Mexoryl SX 
formulations gave higher protection than equivalent sunscreen formulations, reducing the 
formation of CPDs and significantly decreasing ferritin and lysosome expression induced by 
repeated UVA exposure.81 In one human study it was found that a 5% formulation of 
Mexoryl SX gave an equal protection against photolesions and sunburn compared to a 5% 
formulation of a commonly used UVB filter, even though the former absorbs in the UVA 
region.82 
 
 
 
 
 
 
 
 
 
Figure 6. The structure of the UVA filter terephthalylidene dicamphor sulfonic acid, patented by L’Oréal as 
Mexoryl SX. 
 
The use of sunscreens does not come without concerns about the effect on the environment. 
Sunscreen components can enter the environment as a result of recreational water activities, 
showering, rubbing off and excretion. Approximately 25% of sunscreen ingredients applied to 
the skin is thought to leach into the sea following a 20 minute submersion.83 782 ng/g of 
octocrylene has been found in the livers of Franciscana dolphins due to the ability of 
octocrylene to bioaccumulate.84 In the same study it was reported that octinoxate caused a 
mortality of 33.3% and a bleaching of 83.3% in the coral species S.caliendrum at a dose of 
1000 µg/L.84 A recent study also showed that the UVR filters octocrylene, avobenzone, 
octisalate and homosalate amongst others can mimic the effect of progesterone on Ca2+ 
signalling in human sperm cells, and therefore have the potential to impair male fertility.85 
Due to the deleterious effects of synthetic sunscreen ingredients, significant research has 
been carried out into the potential use of natural products as photoprotectants. One example 
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is the protection of human HaCaT keratinocytes by palaythine (shown in Figure 7), a 
mycosporine-like amino acid (MAA) extracted from the red algae Chrondus yendoi.86 MAAs 
are secondary metabolites produced by organisms that live in high sunlight environments 
such as shallow waters. They are natural UVR absorbers, often called ‘microbial sunscreens’.87 
Palythine absorbs in the UVB and UVA2 regions with a maximum absorbance at 320 nm. In 
the study by Lawrence et al. HaCaT cells were significantly protected from solar-simulated 
radiation (SSR) at a 0.3% w/v palythine concentration.86 The addition of palythine inhibited 
cell death, the formation of photolesions and upregulation of inflammatory cytokine genes 
(IL-8, 6 and 20) in irradiated cells. Palythine also exhibited antioxidant activity in irradiated 
HaCaT cells using the DCFDA assay.86 
 
 
 
 
 
 
 
 
 
Figure 7. Structure of the natural UVB/UVA2 filter palythine, a mycosporine-like amino acid extracted from the 
red algae Chrondus yendoi.86 
 
Recently Ellison et al. demonstrated as proof of concept that natural collagen loops or other 
helix interruptions in the skin could be bound by collagen mimetic peptides (CMPs) tethered 
to salicylic acid. Derivatives of salicylic acid form a popular class of UVB filters, including the 
widely used octisalate and homosalate. In this study it was shown that attachment of salicylic 
acid to a CMP invoked no change in the wavelength of absorption in comparison to free 
salicylic acid.88 The pendant UVB filter also remained attached to the collagen surface through 
multiple washes.88 This research may be useful in improving the water resistant properties of 
sunscreens which could lead to better photoprotection as well as a reduction in the level of 
UVR filters affecting aquatic life. This concept could also decrease any systemic cytotoxicity 
through percutaneous absorption of the filter.88 
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The inclusion of antioxidants in sunscreens and daily moisturisers is becoming ever more 
popular, with many sunscreens on the market containing antioxidants such as vitamin E and 
C, or botanical extracts that suggest an antioxidant action.89-91 This development is rational 
based on the increasing body of knowledge concerning UVA-induced generation of ROS in 
skin.57 In a study by Wu et al. HaCaT cells were incubated with a range of concentrations of 
a-tocopherol prior to UVA irradiation. The results demonstrated that the lowest 
concentration, 2.9 IU/ml, gave a significant increase in cell viability while the highest 
concentration, 14.7 IU/ml, returned cell viability to that of the unirradiated control, 
significantly reducing lipid peroxidation and preventing UVA-induced GSH depletion.92 
 
3. The role of iron 
 
3.1 Systemic iron homeostasis and dysregulation 
 
Iron is an essential bioelement, required for human growth and development. The transition 
metal plays a vital role as a co-factor in many proteins and enzymes involved in oxygen 
transport (haemoglobin and myoglobin), energy metabolism, DNA synthesis and electron 
transport, for example cytochromes and ribonucleotide reductase.93,94 In healthy adults, free 
iron in the body is sequestered in haemoglobin (60-70%), muscle myoglobin (10%) or in iron-
sulphur clusters of proteins or heme enzymes (1%), the remainder is stored in ferritin where 
it is ready for use when required by the body.93,94  The capacity of iron to lose and gain 
electrons is pivotal to its role in cellular function, however this property also makes it 
dangerous for ROS generation, and thus the presence of iron is a double-edged sword in 
biology.93 This makes iron homeostasis in the body a crucial part of life.  Bioavailable iron is 
transported in the blood by transferrin (Tf), a glycoprotein capable of binding two units of 
ferric iron (Fe3+).95 Two molecules of diferric-Tf can form a complex at the cell surface with 
the transferrin receptor (TfR), and this complex is then internalized within an endosome. A 
decrease in pH inside the endosome via a proton pump releases Fe3+ from Tf and reduces it 
to Fe2+. This mediates the release of iron through the endosomal membrane and into the cell 
by the divalent metal transporter 1 (DMT-1).96 Once in the cytosol, free ferrous iron (the labile 
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iron pool, LIP) is available for use or for uptake into the iron storage protein, ferritin. The 
intracellular regulation of labile iron is controlled by the iron regulatory proteins (IRPs).97 
Ferritin has the capacity to oxidise Fe2+ to Fe3+ and incorporate it anaerobically at neutral pH 
without natural iron-binding molecules.53 The principal pool of ferritin and therefore iron is 
in the liver, which holds approximately 25% of body iron.93 Iron can only be excreted from the 
body through the desquamation of the stratum corneum, sweat, urine, gastrointestinal 
secretions and menstruation in women.93 Figure 8 outlines the processes relating to the 
transport and homeostasis of intracellular iron. 
 
Over the last two decades, several genes that control iron homeostasis have been discovered. 
For example, in the hereditary iron overload disorder hemochromatosis, the HFE gene which 
regulates the interaction of the TfR with Tf is commonly mutated, thus increasing uptake of 
dietary iron into cells.95 Regular blood transfusions are required for the treatment of β- 
thalassaemia, an inherited blood disorder which is characterized by abnormal haemoglobin 
production resulting in anaemia. These blood transfusions often lead to the excessive loading 
of iron into a patient, which cannot be excreted.98 In cases of iron overload, Tf becomes 
saturated with iron and the excess iron is unable to bind; this is called non-transferrin bound 
iron (NTBI). This iron is loosely bound by citrate and albumin and can be taken up into cells 
independently of the TfR, and thus highly vascular organs such as the heart become iron-
overloaded.99  
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Figure 8. Diagram illustrating the uptake and cellular homeostasis of iron. Transferrin (Tf) can bind two ferric 
iron molecules (Fe3+) in the bloodstream, and two molecules of diferric-Tf form a complex with the transferrin 
receptor (TfR) which is internalized in an endosome. A proton pump lowers the pH of the endosome which 
releases Fe3+ from Tf and reduces it to ferrous (Fe2+) iron. Fe2+ is pumped out of the endosome by the divalent 
metal transporter (DMT-1), whereupon iron regulatory proteins (IRPs) control its destination. 
 
For over 40 years, patients with an iron overload disorder have been treated clinically with 
iron chelation therapy to reduce the tissue damage caused by excess iron stored in the heart, 
liver and endocrine organs.100 Systemic iron-overload has similarities with the challenge 
posed by UVA-induced release of labile iron and the subsequent oxidative damage that may 
result. There are no clinical iron chelators included in over-the-counter sunscreen 
formulations and with the building awareness of the UVA-induced release of labile iron in 
human skin cells, this is an interesting research area. Improving the photoprotective 
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capabilities of current sunscreen formulations with iron chelators could truly provide ‘broad-
spectrum’ protection and could be very advantageous. 
 
3.2 Design and critical features of iron chelators for clinical application  
 
When designing an iron chelator for therapeutic use there are a number of features to 
consider. The coordination of Fe3+ is best fulfilled in an octahedral geometry with six donor 
atoms, and  ligand affinity is in the general order: hexadentate>tridentate>bidentate.99 Under 
biological conditions the most commonly used comparison standard for the affinity of a ligand 
for ferric iron is pFe3+, defined as the negative logarithm of the concentration of free Fe3+ in 
solution at pH 7.4.99 Most hexadentate ligands have high pFe3+ values and can scavenge Fe3+ 
efficiently at concentrations as low as 30 mg/kg/day.101 A pFe3+ value of ³ 20 seems to be 
sufficiently high to prevent the distribution of iron in the body.99 
Fe3+ is a hard Lewis acid due to its high charge density and ability to readily accept 6 lone pairs 
into empty 4s, p and d orbitals. Therefore Fe3+ makes the most stable coordination complexes 
with hard Lewis bases, ligands which have small electronegative donor atoms (O and F). N-
containing ligands are often borderline between hard and soft Lewis bases and therefore have 
the potential to coordinate softer Lewis acids. The most probable off-target metals that could 
be ligated by therapeutic N-containing iron chelators and cause toxicity are Cu2+ and Zn2+, as 
these metals are borderline soft Lewis acids.99 Zn2+ is required for the catalytic activity of more 
than 200 enzymes in the human body which have roles in the immune system, wound healing, 
protein synthesis and cell division.102 Zn2+ also plays a key role in synaptic plasticity and thus 
learning. Cu2+ is essential for maintaining the strength of the skin, blood vessels and 
connective tissue.102 Cu2+ is very tightly bound to proteins (such as ceruplasmin)102 in most 
biological systems and is chaperoned between proteins by specialised molecules, making 
coordination by iron chelators improbable.103 This knowledge helps the design of high affinity 
iron chelators (high pFe3+) which have minimal toxicity due to off-target metal chelation. 
Under aerobic conditions, high affinity Fe3+ iron chelators have been shown to chelate Fe2+ 
and autooxidise it to Fe3+ to form a stable complex, therefore under most physiological 
conditions chelators with a high pFe3+ will also chelate Fe2+.104 
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The key property for an orally active iron chelator is the ability to be absorbed through the 
gastrointestinal tract and reach the desired target areas in the body. Thus oral iron chelators 
need to be sufficiently lipophilic to pass across biological membranes, but not be too lipophilic 
to remain within the phospholipid bilayer of the plasma membrane.99 A chelator with a logP 
value (water-octanol partition coefficient) above 0.2 should fulfil this requirement.99 A 
molecular weight of less than 500 Da is also a crucial feature that a chelator should possess 
in order to ensure an efficient rate of drug absorption through non-facilitated diffusion.99   
3.3 Types of iron chelators and their limitations 
There are three clinical iron chelators used worldwide for iron overload disorders, and a 
comparison of their properties is presented in Table 3.  
 
Table 3. A comparison of the properties of the three clinically used iron chelators99,101,105 
 
Desferrioxamine (DFO, 1) is a hexadentate iron chelator that forms a 1:1 complex with iron, 
shown in Figure 9. It is a naturally occurring Streptomyces pilosus siderophore which has been 
used since the 1970s and is classed as the ‘gold standard’ of iron chelators for its high affinity 
for Fe3+.99 DFO is a relatively large (MW= 560 Da) hydrophilic molecule and as such it is not 
orally bioavailable and has quite a short plasma half-life. Clinically, it is typically administered 
iv via a diffusion pump, which is painful and cumbersome and therefore patient compliance 
 Desferrioxamine 
(DFO, desferal) 
Deferasirox 
(Exjade©) 
Deferiprone 
(Ferriprox©) 
Molecular weight (Da) 560 373 139 
Chelating property Hexadentate Tridentate Bidentate 
Iron binding affinity 
(pFe3+) 
26.6 22.5 20.4 
Delivery Diffusion pump Oral Oral 
Half life 20-30 min 12-16 h 3-4 h 
LogP (lipid solubility) -0.61 (low) 3.8 (high) 0.61 (medium) 
Adverse effects Ocular, auditory growth 
inhibition, allergy 
Gastrointestinal, 
hepatitis 
Gastrointestinal, 
arthralgia 
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is poor.96 Hence the development of orally active iron chelators that are comparable to DFO 
in their affinity for iron was necessary.  
 
 
Figure 9. Structure of the hexadentate siderophore iron chelator DFO and its 1:1 complex with ferric iron. 
 
Deferiprone 2 (Figure 10) was licensed for use in Europe in 1999 as an orally active bidentate 
iron chelator and has comparable effectiveness to DFO.99 Deferiprone is a chelator of the 
hydroxypyridone class which coordinates iron through its two adjacent oxygen atoms to form 
a neutral 3:1 complex (FeL3). This complex can also permeate biological membranes and thus 
is readily removed,99 including from cardiac tissue where it has been demonstrated to reduce 
the myocardial iron burden in thalassemia major patients more effectively than either DFO or 
deferasirox 6.106 Despite these positive features, the results of a variety of clinical trials have 
led to concerns over the therapeutic value of deferiprone.107 These concerns led to the 
discovery that the incompletely coordinated biscomplex [FeL2]+ (present due to the 
concentration of deferiprone not being high enough to fully chelate iron) can potentiate H2O2- 
mediated oxidative DNA damage in iron-loaded liver cells.108 The incomplete coordination of 
deferiprone could enable reductants or oxidants to reach the metal centre, and thus in a 
clinical setting low Fe:L ratios may lead to long-term toxicities.96 The deferiprone dosage 
required to keep an iron-overloaded patient balanced is very high (75-100 mg/kg/day) due to 
extensive metabolism (glucuronidation) of the 3-hydroxyl function of the chelator. As this 
functional group is essential for iron coordination, the efficacy of deferiprone is greatly 
reduced by metabolism in this way: urinary studies have shown that >85% of the administered 
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dose is recovered as the 3-O-glucuronide conjugate.109 The 1,2-diethyl analogue of 
deferiprone (CP94, 3), shown in Figure 10, appeared to be a more efficient derivative at 
mobilizing liver iron in a study using iron-overloaded rats, however the increased efficiency 
was not thought to translate into humans due to differences in metabolism.110 Further 
analogues of deferiprone with higher iron affinities have been devised to counteract the high 
dosages needed to compensate for metabolism. The Novartis lead compound 4 with an 
aromatic substituent in the 2-position was found to be orally active in the iron- loaded rat and 
marmoset (Figure 10).111 Hider and co-workers demonstrated that introducing an electron- 
withdrawing substituent in the 2-position of the ring (i.e 1-hydroxyalkyl or amido group) 
increased the iron affinity due to stabilisation of the negatively charged hydroxyl oxygen at 
physiological pH.99 As a result of these studies,  a further analogue (CP502, 5) was identified 
with a pFe3+ of 21.7, which thus binds iron ten times more strongly than deferiprone at pH 
7.4.99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. The structure of deferiprone 2 and subsequent analogues 3-5 with higher pFe3+ values, along with the 
structure of the 3:1 complex that deferiprone forms with ferric iron. 
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Deferasirox 6 is a triazole-based tridentate chelator which binds Fe3+ as a FeL2 complex 
through its two phenolic oxygens and one triazolyl nitrogen, as shown in Figure 11.98 It is 
relatively hydrophobic compared to the other two clinically used iron chelators with a logP 
value of 3.8 and can therefore easily penetrate membranes, but has good oral 
bioavailability.99 The pFe3+ of deferasirox is 22.5,99 indicating that it binds iron 100 times more 
effectively than the bidentate chelator, deferiprone (pFe3+= 20.4, see Table 2). Upon chelation 
the deferasirox-iron complex formed has a net charge of -3 and a combined molecular weight 
of more than 800 Da, and for these reasons it is likely that iron complexes formed 
intracellularly become trapped within the cell.99 Significantly, it has been shown that the 
[ML2]3- deferasirox complex is redox-inactive under biological conditions.98  
 
 
 
Figure 11. The structure of the tridentate iron chelator deferasirox and its 2:1 complex with ferric iron. 
 
In a study using hypertransfused rats, deferasirox promoted the hepatocellular chelation and 
excretion of iron 4-5 times more effectively than DFO,112 and has been proven to be efficient 
at removing liver iron from patients receiving regular transfusions.113 There have been some 
concerns over the potential of the triazolyl nitrogen in deferasirox to coordinate to the 
divalent metal cations Zn2+ and Cu2+ since this sp2-hybridised nitrogen atom is a somewhat 
softer donor (Lewis base).98 However, steric factors are also important to consider in complex 
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formation, and it has been shown by Hancock that ligands forming six-membered chelate 
rings prefer small metal centres compared to 5-membered chelate rings which are suited to 
larger metals.114 It has been shown that the bond lengths of Fe-O and Fe-N in deferasirox 
complexes are very short (1.60 Å and 1.90 Å respectively)98 compared to a [Fe(H2O)6]3+ 
complex which has an average Fe-O bond length of 2.01 Å.115 The deferasirox:iron complex is 
therefore somewhat strained. The degree of strain for similar complexes will increase with 
increasing ionic radius of the central metal, thus binding of the larger Zn2+ by deferasirox is 
disfavoured sterically in comparison to the smaller Fe3+.98 
 
The aroylhydrazone family of tridentate chelators contains two analogues which have 
received much attention due to their noteworthy iron binding ability, namely pyridoxal 
isonicotinoyl hydrazone (PIH, 7) and salicylaldehyde isonicotinoyl hydrazone (SIH, 8),116,117 
which are shown in Figure 12. Both of these ligands bind Fe3+ through phenolic and carbonyl 
oxygens and an imine nitrogen to form [ML2]- complexes. PIH, SIH and other analogues can 
easily be synthesized through Schiff base condensation of the relevant aldehyde with 
isonicotinylhydrazide.116 These iron chelators are lipophilic in nature and are uncharged at 
physiological pH, which along with their relatively low molecular weights should in principle 
make them favourable for clinical use as orally active iron chelators. PIH is a member of the 
original ‘100 series’ of aroylhydrazone chelators, and recently the pFe3+ value of PIH has been 
revised and is now considered to be 26.2, which is comparable to the iron-binding ability of 
DFO.105 An initial study of PIH demonstrated its efficacy at removing Fe3+ from the 
mitochondria of reticulocytes, showing its ability to pass the plasma and mitochondrial 
membranes.116  In a study by Baker et al., PIH was found to be as efficient as DFO in preventing 
the uptake of 59Fe by Tf in hepatocyte cells, reducing the uptake to approximately half the 
control value.118 The ‘200 series’ of aroylhydrazones was created by replacing the pyridoxal 
moiety with the more lipophilic salicylaldehyde group, and SIH is a member of this series. The 
200 series of analogues display decreased intracellular iron mobilization capability in 
comparison to the 100 series,119 for example SIH has a pFe3+ value of 24.6.105 However, SIH 
has been used extensively by cell biologists researching the cytosolic labile iron pool, in 
particular in the development of fluorescent calcein-based assays.120,121 
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Figure 12. The structures of two tridentate aroylhydrazone iron chelators, SIH 7 and PIH 8, along with the 
complex formed through ferric iron coordination by SIH. 
 
The use of natural products in drug discovery and in cosmetics is rising due to consumer 
concerns about safety, toxicology and sustainability of synthetic compounds.122,123 Indeed, a 
recent review by Newman et al. highlighted that drug discovery seemed to be moving away 
from large compound libraries for drug discovery and moving towards smaller, more 
focused libraries based around many structural aspects of natural products.124 Siderophores 
excreted by bacteria and fungi, such as DFO, are naturally occurring high affinity Fe3+ chelators 
that pathogens use when in low iron environments or during host invasion.125 
Siderophore:iron complexes are internalized into the cells of pathogenic organisms and then 
iron is released from the complex for use.126 The most common groups of siderophores are 
hydroxamates and catecholates.125 DFO is an example of a hydroxamate chelator, with 
coordination of Fe3+ being through the hydroxyl functions on the nitrogen along with the 
carbonyl oxygen. Catecholates are phenolic compounds in which the 1,2-dihydroxy structural 
moiety coordinates Fe3+ in a bidentate manner, for example as in enterobactin 9 which is 
found in Gram-negative bacteria such as E.coli,127 shown in Figure 13.  
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Figure 13. The structure of the natural hexadentate iron chelator enterobactin 9 found in E.coli which 
coordinates iron through its three catecholate moieties. 
 
Catecholate iron chelators are of interest due to the number of plant-derived flavanols such 
as catechin 10 which contain the catechol moiety.128 Many such natural products have been 
researched in terms of their antioxidant effects, and these studies have now progressed into 
investigations of their iron-binding ability.128 For example, baicalein 11 found in the Chinese 
herb Scutellaria baicalensis, has been found to inhibit iron-induced Fenton chemistry through 
both its radical scavenging properties and its ability to chelate iron.129 In one study by Zhang 
et al. both 11 and quercetin 12, which is found in cranberries, were shown to significantly 
inhibit iron-induced lipid and protein peroxidation of the liver and decrease hepatic iron 
content in iron-overloaded mice.130 Another naturally occurring catechin derivative which is 
abundant in green tea is epigallocatechin gallate (EGCG, 13). In a study by Reznichenko et al., 
13 was found to have an iron-binding activity comparable to DFO.131 Figure 14 shows the 
structures of the natural iron chelators described above. 
 
Other natural products have been identified with various novel iron-binding motifs, for 
example the cyclodipeptide N-oxide derivative pulcherriminic acid (PA, 14), produced by the 
yeasts C. pulcherrima and M. pulcherrima (found on grapes132) as well as the Bacillus family 
of aerobic sporeforming bacteria.126 Cook and Slater showed that 14 depletes iron by forming 
9 
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an insoluble Fe3+ complex called pulcherrimin.133 Molecules such as 14 may thus provide 
interesting new leads for the development of therapeutic natural iron chelators.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. The structures of plant flavanol derived natural iron chelators 10-13 along with PA 14, a natural N-
oxide iron chelator. 
 
3.4 Alternative uses for iron chelators 
 
The successful clinical development of iron chelators to reduce tissue damage associated with 
iron overload diseases has generated interest into expanding the use of chelators for treating 
other iron-dependent diseases. For example, iron-promoted oxidative damage is a major 
contributor to neurodegenerative disorders and cardiovascular disease.100 It could be fruitful 
to repurpose already clinically approved chelators for new uses, specifically for localized iron 
accumulation in comparison to systemic imbalance.123 One of the many biological roles of 
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iron is in the enzyme ribonucleotide reductase which catalyses the rate- limiting step in the 
formation of deoxyribonucleotides from ribonucleotide precursors.96 The rate of DNA 
synthesis and proliferation in tumour cells is higher than in normal cells, and therefore the 
demand for iron as a cofactor of ribonucleotide reductase is also higher. In order to meet the 
higher demand for iron in cancerous cells, TfR expression is upregulated  and subsequently 
iron uptake is increased.96 This highlights the possibility to use iron chelators as potent anti-
tumour agents, for example in a study by Richardson et al. a series of PIH analogues were all 
found to inhibit tumour cell growth in culture more effectively than DFO.134 Similarly, iron 
chelation may also be a suitable strategy for the development of anti-microbial agents to 
prevent biofilm formation (where microorganisms adhere to each other and also to a surface 
within an extracellular matrix of polymeric substances), especially as the resistance to current 
antibiotics is growing rapidly.135 
 
The transition metals iron, copper and zinc have all been implicated in the neurodegenerative 
disorders Alzheimer’s disease (AD), Parkinson’s disease (PD) and Friedreich’s ataxia.131,136 
Analysis of animal and human brains has shown that iron distribution in the brain is not 
uniform compared to other metals. The substantia nigra, globus pallidus and dentate gyrus 
are all associated with iron accumulation and also with these neurodegenerative disorders.131 
Additionally, mutations in genes that regulate iron homeostasis have also been implicated in 
a number of neurodegenerative diseases. Most key iron homeostasis proteins (such as Ft and 
TfR) contain iron-responsive elements (IREs) in the 5’-untranslated region (UTR) of their 
mRNA, therefore either their synthesis or degradation is promoted by the presence or 
absence of iron.137 Amyloid precursor protein (APP) and a-synuclein are the major proteins 
implicated in accelerating the disease progression of AD and PD respectively; they also 
contain 5’ UTR IREs.131,137 In the case of AD, iron can promote the deposition of monomeric 
amyloid b (Ab) peptides which can aggregate and form oligomers; oligomers that are 
misfolded then form Ab plaques, a hallmark of AD.138 As iron is a potent redox catalyst, its 
promotion of oxidative stress may also lead to neurodegeneration in parts of the brain 
associated with iron accumulation.131,136 This indicates that iron chelation therapy could be at 
the heart of strategies of neuroprotection by preventing oxidative stress and so aggregation 
of Ab and a-synuclein. In one clinical trial, DFO was found to significantly slow the progression 
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of AD137 and in a study by Reznichenko et al. the natural iron chelator 13 (see Figure 11) 
reduced Ab generation in Chinese hamster ovary cells overexpressing the APP mutation.131 
Other studies have shown the efficacy of PIH for removing iron from mitochondria and its 
potential usefulness for the treatment of Friedrich’s ataxia, a neurodegenerative disease 
where mitochondria are iron-overloaded.96 
 
4. Iron chelation for skin photoprotection 
 
4.1 Phototherapy 
 
At a basic level, light from the sun has been attributed to positive therapeutic outcomes in 
terms of improving mood, especially seasonal affective disorder, through the increased 
biosynthesis of vitamin D via the absorption of UVB radiation.14 Light has also been proven to 
be beneficial as a targeted therapy for certain pathologies. One of the most recognised light 
therapies is photodynamic therapy (PDT), where a photosensitizing drug is administered to 
the patient prior to targeted   exposure with light of the required wavelength to activate the 
drug.139,140 This offers the potential of destroying the targeted tissue without damaging the 
surrounding tissue. The therapeutic effect depends principally on the generation of ROS at 
the site of action, which promote oxidative stress-induced damage to proteins, nucleic acids 
and lipids and subsequently cellular necrosis. The use of PDT has gained clinical recognition 
for the treatment of actinic keratosis (AK), BCC and SCC in many European countries including 
Germany, Sweden, Austria, Italy and Switzerland, as well as in the USA and Canada.139,141,142 
Very recently, a clinical trial on the use of PDT for prostate cancer treatment in 30 men has 
provided promising results that may lead to the widespread acceptance of this technique for 
the treatment of solid tumours.143 A further development of PDT is the use of antibodies to 
target photosensitizers to tumour-associated antigens. Coupling photosensitizers with 
monoclonal antibodies can improve the specificity and efficacy of the therapy.144 Due to the 
worldwide increase in antibiotic resistance, the use of PDT for the treatment of microbial 
infections has also been studied extensively;145 this method could be very beneficial as it is 
unlikely that bacteria would develop resistance to ROS.  
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Atopic dermatitis and psoriasis are common chronic inflammatory skin diseases characterized 
by abnormally dry red skin lesions which are worsened by itching.146 There are three main 
types of phototherapy that are currently used to treat inflammatory skin conditions: 
broadband UVB, narrowband UVB and PUVA. The type of phototherapy used depends on the 
specific skin condition and clinical factors such as previous patient responses to treatment.147 
In narrowband UVB a small range of UVB wavelengths is used to treat skin conditions. It is 
very effective for severe psoriasis and atopic dermatitis.147 However for chronic plaque 
psoriasis where narrowband UVB treatment has not been effective, phototherapy via PUVA 
is recommended as well as for other skin dermatoses such as vitilago.147,148 PUVA is the 
combination of UVA irradiation with the potent photosensitizing agent, 8-methoxypsoralen, 
which  can be administered orally or topically in a bath or cream.148 This is an example of a 
drug that can provide a topical or systemic therapeutic effect upon stimulation by UVA 
irradiation, illustrating again that the use of light to activate a pre-administered drug is an 
efficient and useful mechanism with proven clinical efficiency.148,149 
 
4.2 Iron chelators and the UVA-induced labile iron pool 
 
As previously described in Section 1.4, one of the hallmarks of UVA-induced damage is the 
release of redox-active intracellular labile iron into the LIP.48,57 With the substantial 
knowledge surrounding iron chelators and their therapeutic use not solely for systemic iron 
overload disorders, it would appear reasonable to target UVA-induced LIP with an iron 
chelator in order to provide a potential photoprotective effect. In this context, Glickstein et 
al. assessed the effect of the three clinically approved iron chelators deferiprone, DFO and 
deferasirox along with SIH on cytosolic LIP. It was revealed that in three cultured cell lines, 
the lipophilic iron chelators (deferiprone, deferasirox and SIH) readily chelated labile iron in 1 
h as they were able to quickly permeate the plasma membrane.150 In contrast, prolonged 
treatment (12-18 h) with the hydrophilic chelator DFO was required for the chelator to enter 
cells by endocytosis and subsequently reduce cytosolic LIP.150  
 
Zhong et al. sought to ascertain the importance of the level of labile iron in determining the 
susceptibility of both human skin keratinocytes and fibroblasts towards UVA-induced necrotic 
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cell death.151 In this study, skin cells were treated with or without the iron chelator DFO 18 h 
prior to UVA-irradiation. Using the calcein assay, DFO treatment was shown to abolish the 
UVA-induced labile iron release in both keratinocytes and fibroblasts.151 The immediate 
depletion of intracellular adenosine triphosphate (ATP) has been identified as a hallmark of 
pre-necrotic cells,152 and pre-treatment of fibroblasts with DFO in this study was also found 
to significantly decrease UVA-induced ATP depletion.151  Furthermore, it was confirmed using 
flow cytometry that pre-treatment with DFO did indeed significantly protect fibroblasts 
against UVA-induced necrotic cell death, although an important observation was the ability 
of DFO to completely abolish the basal level of iron without UVA-irradiation.151 In a parallel 
investigation, Seité et al. used a reconstructed organotypic culture to analyse UVA-induced 
lipid peroxidation and iron chelation.153 The organotypic culture consisted of human 
keratinocytes which formed a stratified epidermis, seeded on a dermal substitute containing 
a collagen matrix. The study pre-treated the epidermis model with the iron chelator N,N'-bis-
(3,4,5-trimethoxybenzyl) ethylenediamine N,N,-diacetic acid (OR10141, 15), shown in Figure 
15, for 1 h prior to UVA exposure. The percentage of UVA-induced lipid peroxidases (LPO) was 
greatly reduced by use of 15, as was the induction of ferritin synthesis.153  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. The structure of OR10141, 15, which has been shown to greatly reduce lipid peroxidation and ferritin 
synthesis in an organotypic skin model.153  
 
15 
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In a study by Bendova et al. the cytoprotective effects of the iron chelators DFO, deferiprone, 
deferasirox, SIH and PIH in H9c2 cells were assessed using the oxidative stress inducer tert-
butyl hydroperoxide (t-BHP).154 All chelators afforded cellular protection when co-treated for 
24 h with t-BHP, with the relative protection from highest to lowest with respect to 
concentration used being in the order deferasirox > SIH > PIH >deferiprone >DFO.154 The study 
also examined the cytotoxicity of the iron chelators after 72 h of treatment, and while DFO 
and deferiprone did not cause any significant loss of cell viability up to concentrations of 100 
µM,  deferasirox, SIH and PIH caused a 50% reduction in cell viability at concentrations of 3, 
30 and 44 µM respectively.154 In another study by Hasinoff et al., the ability of deferasirox to 
protect cardiac myocytes from doxorubicin-induced oxidative damage was analysed. The 
results showed that exposure of myocytes to deferasirox for longer than 24 h induced 
cytotoxicity 155 These studies thus show that over-exposure to iron chelators, in particular 
high affinity lipophilic chelators can lead to detrimental effects due to the removal of essential 
iron from critical metalloproteins.100,154-156 
 
4.3 Prochelators and their applications 
 
Due to the potential cytotoxicity that may result from over-exposure to iron chelators, the 
positive therapeutic use of chelators for specific iron-related disorders also involves safety 
concerns. In an attempt to combat the side effects of long-term use of iron chelators but still 
harness their protective qualities, several studies have investigated the administration of 
prochelators, which are molecules that are unable to bind iron until they are activated in an 
oxidative atmosphere. These ‘oxidative stress-activatable iron chelators’ provide a means of 
targeting tissues that are at risk of excessive iron-induced oxidative damage.153,157,158  
 
For example Kielar et al. masked the iron-binding ability of deferasirox through a group 
containing a boronic ester that is cleaved upon exposure to H2O2.100 One of the phenolic 
oxygens required for the tridentate coordination of Fe3+ by deferasirox was esterified with 4-
bromomethylphenylboronic acid pinacol ester before basic hydrolysis of the boronate ester 
to give the prochelator TIP 16, (Scheme 5).100 UV/Vis analysis of deferasirox and 16 ± Fe3+ 
showed no spectral change when Fe3+ was added to 16 compared  to an observed spectral 
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change when Fe3+ was added to deferasirox, indicating that the prochelator does not bind 
iron.100 Unmasking of 16 occurs via oxidation of the boronic acid with H2O2 to give a phenol 
intermediate which undergoes spontaneous elimination to release deferasirox and p-quinone 
methide; this by-product is converted to 4-hydroxybenzyl alcohol in water (see Scheme 5). 
Clean conversion of the 16 to deferasirox and 4-hydroxybenzyl alcohol upon addition of 
excess H2O2 was shown using LC/MS.100 16 showed a similar protective ability to deferasirox 
when pre-treated cells were exposed to H2O2, however upon exposure for 24 h, 16 exhibited 
greater cellular cytotoxicity compared to the parent chelator at concentrations above 25 
µM.100 The apparent cytotoxicity could be due to the ability of boronic acids to inhibit certain 
proteases such as subtilisin and chymotrypsin.159  
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Scheme 5. The masking of deferasirox 6 to form the prochelator 16, which is activated upon reaction with H2O2 
to give the free iron chelator and 4-hydroxybenzyl alcohol as a by-product. Synthesis reagents and conditions: a. 
4-bromomethylphenylboronic acid pinacol ester, K2CO3, acetonitrile; b. KOH, H2O, MeOH. 
 
In a similar study looking at protective agents for cardiomyocyte oxidative injury, the iron- 
coordinating phenolic oxygen of SIH was masked with a boronic ester to give the prochelator 
BSIH 17,160 shown in Figure 16. When H9c2 cardiomyoblast cells were pre-treated with 17 and 
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the parent chelator prior to 24 h treatment of 200 µM H2O2, the EC50 (concentration required 
to reduce H2O2 induced toxicity to 50% of the viability of the untreated control) values for SIH 
and 17 were 8 and 84 µM respectively, indicating that a higher concentration of 17 was 
required before protection was afforded.160 However, it was discovered that 17 was less 
cytotoxic than SIH at the time points of 24 and 72 h exposure, and furthermore when cells 
were incubated with 17 for seven days no cytotoxicity was observed.160 
 
 
 
 
 
 
 
 
 
 
Figure 16. The structure of the boronate prochelator BSIH 17 which is activated upon reaction with H2O2 to give 
the free iron chelator SIH 8. 
 
In the context of photoprotection, a study by Pygmalion et al. investigated UVA-induced labile 
iron release and oxidative stress reduction using a diisopropyl ester prochelator (Sideroxyl, 
18) of a low affinity iron chelator (DBED, 19).161 The aminocarboxylate 19 was hypothesised 
to undergo intramolecular hydroxylation in the presence of H2O2 to form a high affinity iron 
chelator (HBBED, 20) due to the additional phenolic Fe3+ coordination site, shown in Scheme 
6. Prior to activation, 19 would be unlikely to compete with iron contained in Tf and would 
only bind free Fe3+.161 18 was found to decrease intracellular UVA-induced ROS in human 
fibroblasts and keratinocytes in a dose-dependent manner, however it was not shown 
whether the presence of 18 modulated the UVA-induced LIP level. The conversion of 18 to 19 
in cell culture was also not proven, but was hypothesised to occur via non-specific esterase 
hydrolysis as such enzymes are abundant in human skin.161 19 is ionised at physiological pH 
and so cannot easily be administered in cell culture due to its poor bioavailability.161 This novel 
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idea of UVA photoprotection against labile iron release is promising, however it is limited by 
the two-step intracellular reaction required for generation of an active chelator. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 6. Sideroxyl 18, a diisopropyl ester, is converted to the low affinity iron chelator DBED 19 by cellular 
esterases. 19 is subsequently activated by H2O2 to give the high affinity iron chelator HBBED 20. 
 
4.4 Photocleavable protecting groups in caged iron chelators 
 
Photocleavable or photolabile protecting groups (PPGs) provide an opportunity to reversibly 
deactivate a target biological entity, which can be released upon irradiation with a specific 
wavelength of light.162 The use of PPGs to ‘cage’ active compounds has been valuable in 
chemical synthesis, biochemistry and fluorescence-based studies in vivo and in vitro.162-166 An 
ideal PPG should: render the caged group inactive, have a strong absorption at the relevant 
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wavelength for their release, be released through a clean photoreaction with  a high quantum 
yield (efficiency of photorelease), and be stable in the absence of light.162 2-Nitrobenzyl and 
2-nitrophenethyl moieties, for example 1-(2-nitrophenyl) ethyl (NPE, 21), and their alkoxy 
derivatives, have been some of the most commonly used PPGs (see Figure 17). The caging of 
ATP with 21 (giving 22) was reported in 1988 by Walker et al., with the release of free ATP 
from the caged product being achieved upon irradiation at 342 nm.167 Nucleobases caged 
with NPE-type PGGs have also been incorporated into DNA rendering them inactive, but they 
could be reactivated upon irradiation at 365 nm.168,169 However, photolysis of this class of 
caging group generates potentially toxic by-products, for example o- nitrosobenzaldehyde 
which has also been shown to convert to azobenzene-2,2’-dicarboxylic acid and thus compete 
for the incident light, reducing the efficiency of cleavage of the PPG.162,169 Therefore the use 
of alternative photolabile groups that do not possess these drawbacks would be desirable.  
 
 
 
 
Figure 17. NPE photolabile group (21) along with some photocleavable analogues and the first caged group, NPE-
ATP (22). 
 
In 1988, Turner et al. were the first to demonstrate the use of 2-hydroxycinnamoyl as a PPG 
for amines.170 In this study, thrombin, a serine blood coagulation protease, was caged with 2-
hydroxycinnamic acid to give the caged protease 23. Photolysis of the inactivated enzyme 
resulted in the release of active thrombin along with a coumarin photoproduct 24 within 15 
min (Scheme 7).170 Subsequently, a series of photolabile compounds based on the 2-
hydroxycinnamoyl scaffold were synthesised and tested for their ability to selectively inhibit 
proteases, enabling isolation and purification of these enzymes.165 
 
The 2-hydroxycinnamoyl scaffold has also found use as a fluorescent reporter, termed the 
‘optical microsyringe’.166,171 A simple alcohol, e.g ethanol, can be caged with this photolabile 
group, which can then be administered to probe a biological site of interest with unknown 
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characteristics, for example the volume of an organelle. Quantification of the fluorescent 
coumarin-type photoproduct released upon irradiation can then provide detailed biological 
insights.166  In this context, 3,5-dibromo-2,4-dihydroxycinnamic acid has been described as a 
proof of concept photolabile group for the purpose of fluorescence reporting in vivo. The 3,5-
dibromo-2,4-dihydroxycinnamoyl caged ethanol 25 is non-fluorescent, but upon irradiation 
at wavelengths >350 nm the fluorescent coumarin 26 is released, acting as a biomarker 
(Scheme 7).171 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7. Examples of 2-hydroxycinnamoyl photolabile caging groups and their coumarin photoproducts. 
 
A development of this useful type of caging group is the 2-aminocinnamoyl caging group, 
which undergoes photolysis and subsequent expulsion of an alcohol or amine via the same 
mechanism as a 2-hydroxycinnamoyl derivative.172 Aminocinnamoyl compounds may indeed 
provide more versatile functionality than the corresponding hydroxycinnamoyl groups. This 
is because the amino group provides a further site for substitution, unlike the hydroxyl group, 
while photocleavage results in the release of a carbostyril photoproduct as opposed to a 
coumarin.172 A patent in 2000 described the use of the 2-aminocinnamic acid-derived PGGs 
to cage a range of amino acids in order to quantitatively measure the rise and fall of levels of 
certain amino acids in a biological system, for example glutamic acid173 (Scheme 8). 
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Scheme 8. An example of a 2-aminocinnamoyl-caged amino acid, glutamic acid. Upon irradiation the free amino 
acid and a carbostyril photoproduct are released. 
 
The substantial information available around the use of photolabile groups and their 
applications in chemistry and biology led to the concept of forming a light-activated caged 
iron chelator (CIC) as a prodrug. Most iron chelators contain an iron-coordinating phenolic 
group which is a suitable moiety for caging with a PPG in order to render the iron chelator 
inactive. As UVA irradiation has been shown to give a substantial increase in labile iron,57,151 
the concept of a caged chelator that is activated upon UVA irradiation in order to chelate the 
excess iron produced is highly attractive. Yiakouvaki et al. investigated a proof of concept 
study into CICs where the phenolic groups of both SIH and PIH were masked with the 
photocleavable group 21 to give 27 and 28 (Scheme 9).156 Upon UVA irradiation the free iron 
chelator was released along with the nitroso photoproduct. High performance liquid 
chromatography (HPLC) confirmed the conversion of the caged compound to the desired iron 
chelator upon exposure to UVA.156 The calcein assay was used to investigate the level of UVA-
induced labile iron in cells pre-treated with the caged compounds. Human fibroblasts pre-
treated with CICs significantly reduced the UVA-induced labile iron in comparison to 
untreated UVA-irradiated cells.156 Furthermore, the CICs did not deplete the basal levels of 
labile iron without UVA irradiation. However, high concentrations (100 µM) of the CICs were 
required to prevent UVA-induced necrotic cell death, and in particular 28 performed worse 
than the parent SIH for cell photoprotection.156 It was suggested that the expected toxic 
properties of the nitroso photoproducts may be the cause of decreased efficiency of the 
CICs.156 
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Scheme 9. Examples of CICs: NPE caged PIH 27 or SIH 28. Upon UVA irradiation the free iron chelator PIH 7 or 
SIH 8 and a nitroso photoproduct are released. 
 
In post-menopausal women, the major pathway of iron excretion is skin desquamation, and 
increased levels of iron in the skin have been implicated with an increase in oxidative damage 
here.174 When combined with UVA exposure, this poses a serious health risk to this group of 
women. In a pilot study by Pelle et al., the photoprotective ability of CIC 27 was also analysed 
in a post-menopausal cellular model.174 At a concentration of 100 µM, 27 was able to 
significantly protect cells against lipid peroxidation in comparison to the untreated and 
irradiated control.174 
 
Recently, Franks et al. described the caging of an aroylhydrazone chelator analogue, HAPI 29, 
with an o-hydroxycinnamic acid PPG to give CIC 30.175 Upon UVA irradiation, 30 gives the free 
iron chelator along with a coumarin photoproduct, umbelliferone 31 (Scheme 10). 30 was 
analysed in terms of its ability to reduce UVA-induced ROS, and was shown to decrease ROS 
production in a concentration-dependant manner upon UVA irradiation.175 30 also showed 
efficient UVA photoprotection of ARPE-15 cells against necrotic cell death at concentrations 
up to 25 µM, which was comparable to the parent iron chelator on its own.175 However, 30 
showed a decrease in photoprotective ability at high concentrations of 50- 100 µM, which 
may indicate cytotoxicity.  
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Scheme 10. The CIC 30 is cleaved upon UVA irradiation to give the free iron chelator HAPI 29 along with 
umbelliferone 31. 
 
These studies highlight the promise of light-activated CICs for combatting UVA-induced iron 
release, which leads to oxidative stress and subsequently photoaging and skin cancer. Further 
investigation into potent light-activated CICs should enable their full potential to be 
harnessed as prospective additions into current sunscreen formulations, to provide truly 
broad spectrum photoprotection and help reduce the current worldwide incidence of skin 
cancer. 
 
5. Project aims 
 
The incidence of skin cancer in the UK is increasing, and there is a direct link to over-exposure 
of the skin to harmful UVA and UVB radiation from the sun. The increasing incidence of skin 
cancer may be due to an increase in outdoor pursuits without correct photoprotection, the 
improper use of current sunscreen formulations, and also a lack of sunscreen ingredients that 
meet the necessary requirements for broad spectrum photoprotection. The mechanism of 
initiation of UVA-induced skin cancer is due to the oxidative nature of UVA and its ability to 
release intracellular labile iron (Section 1.4). Thus far there have been some attempts to 
develop ‘activatable’ iron chelators or ‘prochelators’ which are triggered by exogenous stimuli 
to release a high affinity iron chelator that can trap harmful iron. The activation of these 
prochelators proceeds either via oxidation or UVA irradiation, and these promising studies 
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have opened an interesting area of research into novel prochelating compounds that may add 
a new approach to photoprotection.  
 
The overall aim of this project was to build upon the current strategies of activatable 
prochelators, and develop novel ‘light-activated caged iron chelators’ (CICs), capable of 
exhibiting a photoprotective effect in human fibroblasts when exposed to a physiological 
relevant dose of UVA. A key element of this work was to demonstrate the extent to which 
such optimised CICs may be able to complement the protection that is currently afforded by 
existing sunscreen products against iron-related UVA damage. 
 
Within the overall project aim, the following detailed objectives were identified: 
 
 
1. To develop an efficient synthetic pathway to a series of CICs, where well-studied iron 
chelators (including the clinically used deferasirox) were masked with 
hydroxycinnamic acid and aminocinnamic acid-derived photo-cleavable groups, and 
to assess the photoprotective capacity of these CICs. 
2. To rationally design a novel series of CICs where the caging group is converted to an 
antioxidant moiety upon activation, based upon analysis of the capacity of the isolated 
antioxidants to scavenge UVA-induced ROS. 
3. To investigate the capacity of improperly applied sunscreen formulations to prevent 
UVA-induced cell death and labile iron release, and the potential of CICs to augment 
the photoprotection afforded by sunscreen formulations. 
4. To explore the synthetic pathway to a natural iron chelator, pulcherriminic acid, and 
assess its potential as a photoprotectant. 
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CHAPTER 2: RESULTS AND DISCUSSION 
 
1. Introduction 
 
The concept of light-activated caged iron chelators (CICs) as a tool to protect against UVA-
induced labile iron release and subsequently skin cancer has been described in Section 1.4.4. 
In order to incorporate CICs into a suitable broad spectrum sunscreen formulation they need 
to have the following features: be activated readily under environmentally relevant doses of 
UVA irradiation e.g practical dose levels of solar UVA which would be commonly achieved 
whilst outdoors in the summer or on holiday; be lipophilic enough to enter skin cells easily; 
be non-toxic both with and without activation. Regarding toxicity,  CICs should not bind iron 
and should not release cytotoxic photoproducts, but should provide a photoprotective effect 
against UVA-induced skin damage.156 One of the most important design features of CICs is to 
render the parent iron chelator inactive when not exposed to UVA irradiation, as prolonged 
exposure to iron chelators has been shown to be harmful in a variety of cell lines.100,154-156 For 
this reason, as well as the synthesis of iron chelators relevant to this work, an assessment of 
their cytotoxicity profiles under normal cellular conditions was initially required. 
 
The structures and features of the three clinically used iron chelators, DFO 1, deferiprone 2 
and deferasirox 6 have been discussed in Section 1.3.3. The advantage of working with these 
iron chelators is that their clinical profiles have been elucidated, i.e. their metabolic stability, 
lipophilicity and dosage. DFO 1 has been long considered the ‘gold standard’ of iron chelators 
due to its high affinity for iron (pFe3+ = 26.6)96 but its relatively high molecular weight and 
hydrophilicity, already make it unsuitable for topical application, and severely limit the scope 
for development of CICs  . Deferiprone 2 has proven its worth as a bioavailable bidentate iron 
chelator, but its metabolic profile and the high dosage required to reach clinical efficiency is 
of concern. The tridentate iron chelator deferasirox 3 has a higher pFe3+ than 2 (22.5 and 20.4 
respectively)99,105 and is also more lipophilic, and these features make it the most desirable 
clinical iron chelator to use in a light-activated CIC.  Although not used clinically, the 
aroylhydrazone family of iron chelators has been widely studied for therapeutic use, in 
particular PIH 7 and SIH 8, as they both possess high pFe3+ values (26.2 and 24.6 
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respectively).105 These iron chelators are lipophilic and uncharged at physiological pH, which 
along with their relatively low molecular weights makes them ideal for developing CICs.96 
Importantly, all of the suitable iron chelators mentioned above have structures in which one 
of their iron-binding functions can be readily masked or deactivated.  
 
2. Synthesis of iron chelators and their cellular activity 
 
The synthesis of the two aroylhydrazone iron chelators 7 and 8 via a simple condensation 
reaction is shown in Scheme 11. The required aldehyde was treated with 
isonicotinylhydrazide (INH) in EtOH at reflux176 giving the desired iron chelators 7 and 8 in 
85% and 95% yields respectively. 
 
 
 
 
 
 
 
 
 
 
Scheme 11. Synthetic route to aroylhydrazone iron chelators PIH 7 and SIH 8. Reagents and conditions: 7. EtOH, 
aq. NaOAc, reflux, 1.5 h, 85%; 8. EtOH, reflux, 3 h. 95%. 
 
 
The synthesis of the clinical iron chelator 6 was achieved by a straightforward two-step 
procedure starting from salicylic acid and salicylamide, as shown in Scheme 12.8 In the first 
step, reaction of salicylic acid with thionyl chloride generates an acid chloride in situ, which 
then combines with salicylamide under reflux in xylene. This gave the water-sensitive 
benzoxazinone intermediate 32 in a 65% yield.98 Condensation of 32 with 4-hydrazinobenzoic 
acid was then achieved by refluxing in EtOH in the presence of NEt3 to give deferasirox 6 in 
85% yield.98 In order to simplify the subsequent preparation of CIC derivatives, the carboxylic 
acid function of 6 was converted to the methyl ester, which would also have the added benefit 
of producing CICs that would be uncharged at physiological pH and therefore would pass into 
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cells more easily. Esterification of 6 was simply achieved by refluxing overnight in anhydrous 
MeOH with a catalytic amount of H2SO4 to give 33 in high yield.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 12. Synthetic route to clinical iron chelator deferasirox 6 and deferasirox ester 33. Reagents and 
conditions: a. pyridine, thionyl chloride, xylene, reflux, 3.5 h, 65%; b. 4-hydrazinobenzoic acid, NEt3, EtOH, reflux, 
2.5 h, 85%; c. MeOH, H2SO4, reflux, O/N, 95%.  
 
The synthesised iron chelators 7, 8 and 33 were analysed for their cytotoxicity under 
conditions of prolonged exposure in a human skin cell line. FEK4 cells, primary human dermal 
fibroblasts, were chosen for this work as they have been previously shown to be a good cell 
model in which to study the exposure of human skin to solar UVA irradiation, which 
penetrates as far as the dermal layer of skin.56,156,177 Cell viability upon exposure to iron 
chelators was assessed using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide) assay. In this simple quantitative colorimetric assay, MTT, which is colourless in 
solution, is converted by cellular and mitochondrial dehydrogenase enzymes into formazan, 
 54 
a dark-blue material that is water-insoluble. The amount of formazan produced is directly 
proportional to the number of viable cells.178 Concentrations of 10, 20 and 50 µM of iron 
chelators were chosen; this range was based on concentrations previously reported in studies 
of skin cell photoprotection with iron chelators.48,156,174 Incubation periods of 24 and 48 h 
were used, as shown in Figures 18 and 19. 
 
Figure 18. MTT assay evaluation of the effect of prolonged exposure of FEK4 fibroblasts to iron chelators PIH 7, 
SIH 8 and deferasirox ester 33. Cells were treated with 10, 20 and 50 µM iron chelator for 24 h followed by MTT 
analysis 24 h later. Data is expressed as mean ± SD compared to the untreated control, which was fixed at 100% 
enzymatic activity (n=3).  
*= p< 0.05, significantly different from the untreated control.   
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Figure 19. MTT assay evaluation of the effect of prolonged exposure of FEK4 fibroblasts to iron chelators PIH 7, 
SIH 8 and deferasirox ester 33. Cells were treated with 10, 20 and 50 µM iron chelator for 48 h followed by MTT 
analysis 24 h later. Data is expressed as mean ± SD compared to the untreated control, which was fixed at 100% 
enzymatic activity (n=3).  
*= p< 0.05, significantly different from the untreated control.   
 
The results of the MTT cytotoxicity assays indicated that after 24 h of exposure 8 and 33 
decreased cell viability to 85-90% of the untreated control at all concentrations, however not 
all results were statistically significant. On the other hand, cells exposed to 7 for 24 h remained 
above 90% cell viability in comparison to the control. Upon exposure of FEK4 cells to 8 and 33 
for 48 h, there was a marked reduction in cell viability at concentrations of 20 and 50 µM. 7 
also exhibited a reduction in cell viability to 82% of the untreated control at a concentration 
of 50 µM. These results indicate that there is some evidence of both dose level and exposure 
time affecting cell viability as the iron chelators remove iron from essential enzymes. For the 
purpose of skin photoprotection, these findings exemplify the need to deactivate these iron 
chelators with a group that can be removed upon exposure to an environmentally relevant 
dose of UVA irradiation to release an active iron chelator. 
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3. Hydroxycinnamoyl-caged iron chelators 
 
The group of Porter first introduced the hydroxycinnamoyl group as a useful PPG in work 
involving caged serine proteinases165,170 as described in Section 1.4.4. The mechanism of 
photo-cleavage of the hydroxycinnamoyl protecting group proceeds via the alkene bond 
absorbing a photon and subsequently undergoing E/Z photoisomerization. This conversion of 
stereochemistry brings the ester carbonyl group into closer proximity with the o-phenolic 
hydroxyl group, which enables nucleophilic attack on the carbonyl and subsequent cyclization 
with release of an alcohol or phenol,170 as shown in Scheme 13.  
 
The photoproduct formed from a hydroxycinnamoyl PPG is a coumarin, which is of particular 
interest because of the reported antioxidant activity of coumarin-type molecules found in 
plants.179,180 Various plant-derived coumarins have been investigated for their potential as 
therapeutic agents, for example against intestinal inflammatory disease, due to their 
antioxidant properties and ability to inhibit lipid peroxidation.180 Different substituents on the 
benzopyrone scaffold of coumarins have been shown to alter the antioxidant potential of 
natural coumarins, for example umbelliferone, esculetin and scopoletin 34b-d shown in 
Scheme 13. In particular, the presence of electron-donating groups such as hydroxy and 
methoxy groups seems to enhance the radical scavenging properties of these 
compounds.179,180 In two recent studies on the antioxidant activity of plant-derived 
coumarins, it was found that 34c (with the 6,7-dihydroxy motif) was one of the strongest ROS 
quenchers amongst a range of coumarin derivatives.179,180 
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Scheme 13. Mechanism of photo-release of a hydroxycinnamoyl-caged alcohol upon UVA irradiation to give a 
coumarin photoproduct. 
 
The hydroxycinnamoyl group is therefore an attractive PPG for an iron chelator. The phenolic 
group of iron chelators 7, 8 and 33 would normally be involved in coordinating iron, 
consequently this phenolic group provides the perfect opportunity to mask the iron-binding 
capability of an iron chelator through protection as an ester. Upon cleavage of the photolabile 
group by UVA irradiation, an active iron chelator would be released to quench the generation 
of intracellular labile iron along with a coumarin fragment which could provide a 
complementary antioxidant effect.  
 
To begin the synthesis of cinnamoyl-based CICs, trans-2-hydroxycinnamic acid 35 was chosen 
as the starting material as it was commercially available and upon photo-cleavage of the CIC, 
the simplest photoproduct 34a would be released. The use of carbodiimide reagents is one 
of the most common approaches for carboxylic acid activation in order to form an ester or 
amide bond,181 with the most well-known carbodiimide being N, N’- dicyclohexylcarbodiimide 
(DCC). During a coupling reaction using DCC, the by-product dicyclohexylurea (DCU) is formed, 
which can often be simply filtered off due to its insolubility in non-polar solvents. In many 
cases, N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide (EDC) can be a more advantageous 
carbodiimide as its urea by-product is water-soluble and can therefore be removed easily in 
 
34 Name R1 R2 
a Coumarin H H 
b Umbelliferone H OH 
c Esculetin OH OH 
d Scopoletin OMe OH 
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an aqueous work-up.181 As shown in Scheme 14, the initial reaction between a carboxylic acid 
and a carbodiimide activating reagent forms an O-acylisourea. This intermediate can either 
react with another carboxylate species to form a symmetric anhydride, or it may react directly 
with an alcohol (or amine) nucleophile to form the desired coupled product.181 Intramolecular 
rearrangement of the O-acylisourea intermediate to an unreactive N-acylurea occurs readily 
between pH 3-6 and slowly at pH values above 7, which prevents formation of the coupled 
product whilst consuming the carboxylate. In the synthesis of esters this may be overcome by 
addition of N,N’-dimethylaminopyridine (DMAP) which rapidly converts the O-acylisourea 
intermediate to an acyl pyridinium species which can then react with an alcohol to give the 
desired ester.181,182  
 
 
Scheme 14. Carbodiimide-mediated ester or amide formation starting from a carboxylic acid. The mechanism 
for rearrangement of the initial O-acylisourea formed to an unreactive N-acylurea is shown. 
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The acid 35 was activated with one equivalent of both EDC.HCl and DMAP at 0oC for 10 min 
in anhydrous DMF, before addition of the iron chelator 8 in the presence of one equivalent of 
diisopropylethylamine (DIPEA) in anhydrous DMF (Scheme 15). Mass spectrometry and NMR 
analysis of the crude reaction material indicated the presence of the desired CIC 36 along with 
coumarin 34a, presumably formed by cyclisation of the activated acid 35.  The two products 
were impossible to separate via column chromatography. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 15. Attempted synthetic route to 2-hydroxycinnamoyl SIH CIC 36 along with 34a by-product. Reagents 
and conditions: DMAP, EDC.HCl, 8, DIPEA, dry DMF, 0 oC → RT, O/N. 
 
Although these results showed that the desired CIC 36 could be synthesised via this coupling 
method, the difficult purification and formation of a significant amount of 34a was 
unsatisfactory. In order to prevent the formation of 34a during the reaction, protection of the 
2-hydroxyl group in 35 was required. Masking of a phenolic hydroxyl can be typically 
accomplished through conversion to a benzyl ether. However for our purposes protection via 
a benzyl ether was unsuitable due to the deprotection methods required. Cleavage of benzyl 
ethers is usually achieved by using hydrogenation or strong acid,183 which are both 
incompatible with the structures of 35 or the desired CIC.  For this reason, a silyl ether was a 
very attractive form of protection as they are easy to form and inert under a range of acidic 
and basic conditions,184 but can be effectively removed in the presence of fluoride ions, for 
example with tetra-N-butylammonum fluoride (TBAF), due to the strength of the Si-F bond.184-
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186 There is a variety of silyl ether protecting groups available with various substituents, the 
most commonly used being trimethylsilyl (TMS), triethylsilyl (TES), t-butyldimethylsilyl (TBS), 
triisopropylsilyl (TIPS) and t-butyldiphenylsilyl (TBDPS).183 Generally the bulkier silyl groups 
decrease the rate of ether cleavage under acidic or basic conditions.184 TBS was chosen as the 
most suitable protecting group for this work as it is reasonably stable under both acidic and 
basic conditions, but the alkyl substituents are not too large, and so limited interference with 
the acylation reaction should be expected.186  
 
Silyl ether protection of the hydroxyl function of 35 was achieved by first globally protecting 
both the acid and hydroxyl function with TBS in the presence of imidazole as base and 
catalyst185 to give 37 (Scheme 16). Selective deprotection to give the acid 38a was first 
attempted under basic conditions using a method by Okamoto et al. which described selective 
cleavage of the more labile TBS ester protecting group using the mild base, K2CO3.187 This 
method was however only partially successful as the phenolic TBS ether of 37 was also found 
to be cleaved under Okamoto’s conditions. Switching to acidic conditions, it was found that 
stirring 37 in 0.3% TFA in MeCN at room temperature was an effective alternative method for 
selective cleavage of the TBS ester, giving excellent yields of the protected cinnamic acid 38a. 
Coupling of 38a to the iron chelator 8 was attempted using the same conditions as previously 
described in Scheme 15. However, no reaction was observed, possibly due in fact to the 
additional steric bulk of the TBS protecting group. It was therefore decided to convert 38a 
into a more powerful acylating agent, an acyl halide. Acyl halides are strongly electrophilic 
and therefore useful for forming hindered esters.181 Conversion of 38a to the acid chloride 
38b using thionyl chloride proceeded well, with the TBS protecting group stable enough to 
withstand the HCl generated,187 (Scheme 16). Due to the expected moisture sensitivity of 38b, 
it was reacted immediately with 8 in the presence of one equivalent of pyridine and a catalytic 
quantity of DMAP (0.1 equivalent) in anhydrous DMF to give the desired protected CIC 39 in 
27% yield. 24% of the starting acid 38a was recovered giving an overall conversion of 36%. 
 
 61 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 16. Synthetic route to 2-hydroxycinnamoyl SIH CIC, 36. Reagents and conditions: a. TBS-Cl, imidazole, 
anhydrous DMF, RT → 60 oC, O/N, 83%; b. (i) 0.3% TFA, MeCN, RT, O/N, 98%; (ii) SOCl2, anhydrous DCM, reflux 
4 h; c. 8, pyridine, DMAP, anhydrous DMF/dry DCM, 30 oC, 2 days, 27%; d. (i) (COCl)2 in DCM, DMF, 0 oC, 3 h (ii) 
8, pyridine, DMAP, anhydrous DMF/anhydrous DCM, 30 oC, 2 days, 22-25%; e. TBAF, AcOH, anhydrous DMF, 0 
oC, 30 min, 86%. 
 
In order to improve the efficiency of the preparation of 39, some variations of the acid 
chloride coupling were also explored. Using the same conditions but with anhydrous DCM as 
an alternative coupling solvent gave no increase in yield. Wissner et al. reported the 
conversion of TBS-protected carboxylic acids directly to the acid chloride using oxalyl chloride 
and catalytic DMF to form a Vilsmeier reagent.188 This method was employed and 37 was 
directly converted to the acid chloride and coupled with SIH as previously to give 39 in a 22-
25% yield depending on the chosen solvent (route d, Scheme 16). The overall conversion 
taking into account the recovery of 38a was 31-35%. Cleavage of the protecting group was 
achieved using TBAF186 in the presence of acetic acid, which provided a neutral reaction pH 
to prevent basic hydrolysis of the ester bond. This gave the final 2-hydroxycinnamoyl caged-
SIH CIC 36.  
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An analogous approach was taken to synthesise the 2,4-hydroxycinnamoyl-SIH CIC 44 shown 
in Scheme 17. Upon UVA irradiation this PPG would give the photoproduct umbelliferone 34b. 
The synthesis was carried out via the same methodology as with the 2-hydroxy derivative and 
the globally silyated ester 41 was obtained in good yield (73%) and converted to the silyated 
cinnamic acid 42a with 0.3% TFA in excellent yield (95%). The thionyl chloride method to 
convert 42a to 42b and subsequent esterification with SIH gave an overall conversion to the 
coupled product of 10-18% (4-10% yield) depending on the solvent used. Complete 
conversion of acid 42a to the acid chloride 42b was observed and no generation of 
umbelliferone 34b was seen during the esterification step. HPLC analysis of the crude reaction 
material after two days of reaction indicated the presence of both the acid 42a and SIH 8.  
 
The coupling reaction using oxalyl chloride was also attempted (route d, Scheme 17), and it 
was found necessary to increase the equivalents of pyridine to equal the equivalents of oxalyl 
chloride (3 equivalents). With fewer equivalents of pyridine, complex mixtures were observed 
presumably due to cleavage of the TBS groups by the HCl generated. The overall conversion 
to 43 using this method was 31% from a yield of 9%, as 71% of the starting acid 42a was 
recovered. Similarly to the thionyl chloride method, HPLC analysis of the crude material 
showed that other than the coupled product 43, only 42a and 8 were present. Presumably 
the steric bulk of both the 2 and 4-TBS protecting groups again limited the reaction of the acid 
chloride 42b with 8, such that the reaction was proceeding so slowly that the acid chloride 
42b was competitively hydrolysed back to the unreactive acid 42a. Cleavage of the protecting 
group was again accomplished using TBAF186 in the presence of acetic acid to give full 
conversion to the final 2,4-dihydroxycinnamoyl CIC 44, however it was very water soluble and 
remained in the aqueous phase upon extraction leading to only a 15% recovery.  
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Scheme 17. Synthetic route to 2,4-hydroxycinnamoyl SIH CIC, 44. Reagents and conditions: a. TBS-Cl, imidazole, 
anhydrous DMF, 60 oC, O/N, 73%; b. (i) 0.3% TFA, MeCN, RT, O/N, 95%; (ii) SOCl2, anhydrous DCM, reflux 4 h; c. 
8, pyridine, DMAP, anhydrous DMF/dry DCM, 30 oC, 2 days, 4-10%; d. (i) (COCl)2 in DCM, DMF, 0 oC, 3 h (ii) 8, 
pyridine, DMAP, anhydrous DMF, 30 oC, 2 days, 9%; e. TBAF, AcOH, anhydrous DMF, 0 oC, 1.5 h, 15%. 
 
 
As it was envisaged that the steric bulk of both the 2 and 4-TBS protecting groups was limiting 
the coupling of the acid chloride 42b with 8, an alternative approach was explored. In order 
to overcome the difficulty of coupling the sterically hindered 42b to the ortho-substituted 
phenolic component 8, coupling of 42b to the scaffold aldehyde of 8, salicylaldehyde, was 
performed. Salicylaldehyde is a phenol with a much smaller ortho substituent than 8 
therefore it was expected that the steric impact on the coupling reaction would be reduced. 
Scheme 18 shows the coupling of salicylaldehyde and 42b which proceeded in a 33% yield to 
give the intermediate 45, although full conversion of salicylaldehyde was not observed. 45 
was used in the next step without purification. After refluxing 45 with INH in EtOH for 24 h, 
TLC analysis showed that 45 was still present in the reaction mixture, but conversion to 43 
was observed. The reaction gave a 21% yield of 43, corresponding to a 7% yield over the two 
steps from salicylaldehyde.  
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Scheme 18. Alternative synthetic route to 2,4-TBS cinnamoyl-SIH, 43.  Reagents and conditions: a. 
salicylaldehyde, pyridine, DMAP, anhydrous DCM, 30 oC, 2 days, 33%; b. INH, EtOH, 40 oC → reflux, 24 h, 21%. 
 
The coupling reactions to form hydroxycinnamoyl-SIH CICs 36 and 44 were successful, 
although the yields were very modest, and so the synthesis of a hydroxycinnamoyl-caged 
deferasirox derivative was also attempted. Deferasirox 6 has two phenolic hydroxyl groups 
involved in iron coordination, which could both be masked with a photo-cleavable 
hydroxycinnamoyl protecting group. Both phenolic groups are chemically very similar, 
therefore little selectivity for the esterification of either phenolic function was anticipated, 
implying a mixture of products would be formed. For this reason coupling of the 2-TBS 
cinnamic acid chloride 38b to the deferasirox intermediate 32 was first attempted as it only 
presented one phenolic hydroxyl (Scheme 19). This intermediate 32 was anticipated to be less 
sterically hindered than deferasirox methyl ester 33. Unfortunately the attempted coupling 
with 32 to give the proposed CIC intermediate 46 failed, with neither starting material being 
consumed after two days of reaction, consequently this synthetic route was not pursued any 
further. 
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Scheme 19. Attempted coupling of 2-TBS cinnamic acid chloride 38b with benzoxazinone 32. Reagents and 
conditions: 32, pyridine, DMAP, anhydrous DMF/anhydrous DCM, 30 oC → 100 oC, 2 days. 
 
The UV/Vis absorbance spectra of both synthesised CICs 36 and 44 were recorded to confirm 
that the CICs absorbed in the relevant UVA wavelength range (320- 400 nm). Figure 20 shows 
that 36 absorbs maximally at 290 nm (in the UVB wavelength range) with a molar absorptivity 
of Ɛ290= 15,200 L mol-1 cm-1, and continues to absorb significantly up to 380 nm, which covers 
a considerable portion of the UVA range.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. UV/Vis absorbance spectrum of CIC 36 in DMSO (50 µM). 
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The additional 4-hydroxy group in CIC 44 gives a red shift in absorbance, as shown in Figure 
21. The maximal absorbance is 304 nm with a lower molar absorptivity of Ɛ304= 7,500 L mol-1 
cm-1, while 44 also continues to absorb through the UVA region to 395 nm. This corresponds 
to the observation of Gagey et al. that in a series of hydroxycinnamoyl-caged ethanol 
compounds, increasing the electron-donating power of substituents on the aromatic ring red-
shifts the wavelength of maximum absorption. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. UV/Vis absorbance spectrum of CIC 44 in DMSO (100 µM). 
 
 
As the CICs 36 and 44 were shown to absorb within the relevant UVA window, it was next 
important to ensure that they would be ‘uncaged’ by environmentally relevant doses of UVA 
irradiation to which a person’s skin may be exposed to on a summer’s day. It has previously 
been reported that a few hours of sun exposure at noon in Southern Europe would provide a 
dose of 500 kJ/m2 of UVA radiation.189 To confirm this, an IL1700 radiometer was used 
outdoors at the University of Bath on the 26th June 2017 to obtain readings for solar UVA on 
a British summer day. Readings were taken between 12.00 and 15.00 BST and the 
temperature in direct sunlight during this time was 35oC. The readings indicated that a 500 
kJ/m2 UVA dose was equivalent to only 80 min in the sun on this day, which highlights the 
importance of adequate sunscreen protection.  
 
The erythema response to UVR exposure is significant in SPF testing and is also a useful 
biological endpoint for the comparison of UVA radiation doses. Conversly to UVB-induced 
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erythema where damage is caused by direct absorption, UVA-induced erythema is mediated 
via ROS generation.190 An erythemal response to UVR exposure can either be expressed as a 
physical dose (kJ/m2) or as a biological dose (MED), the MED differs between individuals as 
skin type controls sensitivity to UVR. Therefore it is important to make reference to MED along 
with dose of UVA radiation used throughout this discussion. In a study by Harrison et al. an 
MED response was visualised in volunteers with skin types I and II after UVA doses ranging 
between 300-700 kJ/m2, thus on average a 500 kJ/m2 UVA dose is approximately equivalent 
to one MED.190 When SSR is used rather than solely UVA radiation, one MED in skin types I 
and II is equivalent to a dose of approximately 40 kJ/m2 due to the impact of the additional 
damaging UVB radiation.  
 
The  percentage of the incident dose of UVA radiation that would reach the accumulation of 
CIC in the cytosol depends largely on the individual’s skin type (pigmentation), but it is 
estimated to be on average 10-20% of the incident dose due to absorption by 
chromophores.191 For example, performing chemical (extracellular) irradiation of a CIC using 
a dose of 50 kJ/m2 would be equivalent to a dose of 250-500 kJ/m2  (0.5- 1 MED) if the CIC was 
in the skin. Therefore the uncaging of CICs by a dose of 50 kJ/m2 to give a free iron chelator is 
critical. The intact CIC 36 was irradiated at increasing doses of UVA and the extent of uncaging 
was followed on analytical HPLC (the detailed method is outlined in the Experimental 7.2.4.2. 
The HPLC chromatograms are shown in Figure 22.  
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Figure 22. HPLC uncaging chromatograms of CIC 36: A. Non-irradiated control of ‘intact’ 36; B. 10 kJ/m2 
irradiation; C. 25 kJ/m2 irradiation; D. 50 kJ/m2 irradiation showing complete uncaging; E. Reference SIH 8 
injection; F. Reference coumarin 34a injection. Samples in DMSO solution (1 mg/mL) were irradiated with a 4 
kW broad spectrum UVA lamp (Sellas, Germany). 
 
Chromatogram A in Figure 22 shows that the peak at 10.25 min for pure 36 disappears to 
form two new peaks at 7.38 min and 9.44 min which correspond to SIH 8 and coumarin 34a. 
These were both injected separately on the same gradient system of the analytical HPLC as 
references (chromatograms E and F respectively). 36 was completely uncaged upon 50 kJ/m2 
UVA irradiation (chromatogram D), equivalent to 250-500 kJ/m2 solar UVA irradiation or 0.5- 
1 MED. This indicates that the CIC would be fully uncaged near to the dose required for the 
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appearance of minimal erythema, therefore it would exert powerful iron chelating activity at 
exactly the right time.    
 
In the same manner the intact CIC 44 was also irradiated at increasing doses of UVA and the 
extent of uncaging was followed on analytical HPLC, with the chromatograms shown in Figure 
23. The peak at 6.56 min for pure 44 (chromatogram A) disappears completely after 10 kJ/m2 
irradiation to form two new peaks at 5.71 min and 6.18 min, which correspond to SIH 8 and 
umbelliferone 34b respectively (reference chromatograms C and D). The complete uncaging 
of 44 with a dose of 10 kJ/m2  is equivalent to 100 kJ/m2 of human skin sun exposure (1/5th 
MED). This efficient uncaging may limit the utility of 44 as a practical photoprotectant because 
the iron chelating activity would be expended after a significantly sub-erythemal dose rather 
than providing prolonged activity during UVA exposure. A representative comparison of the 
dose-dependent UVA uncaging of CICs 36 and 44 is shown in Figure 24, highlighting that the 
addition of the 4-hydroxyl group has a significant effect on the photostability of 44, increasing 
the absorption in the UVA window. 
 
 Figure 23. HPLC uncaging chromatograms of CIC 44: A. Non-irradiated control of ‘intact’ 44; B. 10 kJ/m2 
irradiation showing complete uncaging; C. Reference umbelliferone 34b injection; D. Reference SIH 8 injection. 
Samples in DMSO solution (1 mg/mL) were irradiated with a 4 kW broad spectrum UVA lamp (Sellas, Germany). 
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Figure 24. Representative comparison of the dose-dependent UVA uncaging of hydroxycinnamoyl-SIH CICs 36 
and 44. Percentage uncaging calculated using the peak area of the remaining CIC compared to the peak area of 
the unirradiated sample.  Samples in DMSO solution (1 mg/mL) were irradiated with a 4 kW broad spectrum 
UVA lamp (Sellas, Germany). 
 
The MTT assay was used to assess the photoprotective ability of CICs 36 and 44. A 
concentration of 20 µM of CICs was used, which was incubated with the cells for 18 h before 
irradiation of the monolayers of cells at 500 kJ/m2. The assay was carried out 24 h after 
irradiation as after this time cellular iron homeostasis would have returned to normal and 
therefore any reduced cell viability would reflect severe oxidative damage.56 The results are 
shown in Figure 25, which show that the photoprotective effect of both 36 and 44 is less than 
that of the parent iron chelator 8 alone. This result is similar to the outcome seen by Franks 
et al. for their compound 30 (Scheme 10, Introduction 1.4.4), an aroylhydrazone iron chelator 
HAPI 29 caged with 2,4-dihydroxycinnamic acid (as seen in our CIC 44). In concentrations 
above 25 µM they report that 30 is cytotoxic, which may suggest that coumarin-type 
photoproducts actually exhibit a pro-oxidant effect. Both CICs significantly improve the cell 
viability in comparison to the untreated irradiated control but are cytotoxic in unirradiated 
cells, similar to the cytotoxicity of 8 alone.  
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Figure 25. MTT assay evaluation of the photoprotection afforded by the hydroxycinnamoyl CICs 36 and 44 along 
with their parent iron chelator SIH 8 in FEK4 fibroblasts. Cells were treated with the compounds (20 µM) 
overnight before ± 500 kJ/m2 UVA irradiation followed by MTT analysis 24 h later. Data is expressed as the mean 
± SD compared to the untreated unirradiated control, which was fixed at 100% enzymatic activity (n=3).  
*= p< 0.05, significantly different from the untreated irradiated control.   
Φ= p <0.05, significantly different from the untreated unirradiated control. 
 
4. Aminocinnamoyl-caged iron chelators 
 
The aminocinnamoyl group was also introduced by Porter’s laboratory as a useful photo-labile 
moiety and has certain advantages over the hydroxycinnamoyl group.172 The photo-cleavage 
reaction follows the same mechanism as shown in Scheme 13 and the aminocinnamoyl 
compounds tend to absorb at slightly longer wavelengths than the corresponding 
hydroxycinnamoyl compounds. There is also the possibility to substitute the amino function 
with one or two alkyl groups which also shifts the absorption to longer wavelengths.172 The 
initial work carried out in the Porter laboratory on a series of aminocinnamoyl derivatives 
included the 4,5-dimethoxy aminocinnamic acid 50, which contained a methyl substituent on 
the double bond. This photo-cleavable group was chosen to begin studies into 
aminocinnamoyl CICs due to its established photo-cleavage within the UVA window and its 
ease of synthesis in a good yield. 
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4,5-Dimethoxy aminocinnamic acid 50 is not commercially available so a synthetic procedure 
reported by Li et al. was adapted.172 Beginning with 6-nitroveratraldehyde 47, the olefinic 
ethyl ester 48 was obtained via a Wittig reaction using 
(carbethoxyethylidene)triphenylphosphorane (ECETP) which proceeded in a good yield (88%), 
as shown in Scheme 18. The stabilised ylid should give only the E alkene isomer, and the 
stereochemistry of 48 has been previously confirmed in this laboratory by X-ray 
crystallography.192 Hydrolysis of the ester with aqueous 1M NaOH in a mixture of EtOH and 
THF followed by an acidic work-up gave complete conversion to the carboxylic acid 49. 
Reduction of the nitro group to the amine was first attempted by refluxing with iron powder 
and acetic acid in EtOH,193 which gave a good conversion to the desired intermediate 50, 
however it was difficult to remove impurities even after column chromatography. Applying 
an alternative reduction method using ferrous sulphate solution and concentrated aqueous 
ammonia194 gave an excellent yield and a much purer product, which did not require column 
chromatography.  
 
The coupling of 50 with both aroylhydrazone iron chelators 7 and 8 was attempted using 
EDC.HCl and DMAP as previously described. PIH 7 contains a phenolic hydroxyl along with a 
primary alcohol, but the nucleophilicity of the phenol is greater than the primary alcohol and 
therefore using one equivalent of the aminocinnamic acid 50 during the coupling reaction 
was expected to only give a single acylated esterification product. The reactions proceeded 
as anticipated giving a 79% yield of the aminocinnamoyl-SIH CIC 51 and a 54% yield of the 
aminocinnamoyl-PIH CIC 52 (Scheme 18). 
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Scheme 18. Synthesis of 3,4-dimethoxy aminocinnamoyl CICs 51 and 52. Reagents and conditions: a. ECETP, dry 
toluene, 85 oC, 36 h, 88%; b. 1M NaOH, 4:1 THF:EtOH, RT, 42 h, 99%; c. FeSO4.7H2O, water, aq. 35% NH3, RT, 2 
h, 91%; d. EDC.HCl, DMAP, 7 or 8, dry DMF, 30 oC, O/N, 79% (51) and 54% (52). 
 
As these coupling reactions proceeded well in good yields to give the desired CICs, the 
coupling of aminocinnamic acid 50 was tried with the deferasirox intermediate 32 as 
previously attempted with the hydroxycinnamoyl derivatives. Coupling of 50 to 32 proceeded 
in a 38% yield shown in Scheme 19. This intermediate was moisture-sensitive and quickly 
degraded, therefore it was transformed directly into the desired CIC 54 by treating with 4-
hydrazinobenzoic acid and Et3N in EtOH as per the synthesis of deferasirox 6. The reaction 
proceeded well, however 54 also degraded during column chromatography and could only be 
characterised by mass spectrometry.  
 
Kieler et al. reported the alkylation of deferasirox methyl ester 33 with complete 
regioselectivity for the phenol moiety attached to position 5 of the triazole ring, which was 
confirmed by X-ray crystallography of the alkylated structure.100 Steinhauser et al. reported 
the crystal structure of deferasirox 6, which indicated that the phenolic hydroxyl in position 3 
of the triazole ring was rotated in order to form a stable intramolecular hydrogen bond with 
the triazole nitrogen in the 2-position.98 This may be the explanation for the totally 
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regioselective alkylation of the other phenol group which is therefore more readily available 
for reaction with electrophilic reagents. Based on this premise, the esterification of 
deferasirox ester 33 with 50 was attempted (route c, Scheme 19). The reaction proceeded in 
a purified 28% yield with the formation of a single acylated CIC 55. TLC and HPLC analysis also 
showed some unconverted acid 50 and deferasirox ester 33.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 19. Synthetic routes to 3,4-dimethoxy aminocinnamoyl-caged deferasirox derivatives 54 and 55. 
Reagents and conditions: a. EDC.HCl, DMAP, 32, DIPEA, dry DMF, RT, 40 h, 38%; b. 4-hydrazinobenzoic acid, NEt3, 
EtOH, 60 oC, 48 h; c. EDC.HCl, DMAP, 33, DIPEA, dry DMF, RT, 24 h, 28%.     
 
As with the hydroxycinnamoyl CICs, the UV/Vis absorbance spectra of synthesised CICs 51, 52 
and 55 were recorded to ensure that the CICs absorbed in the relevant UVA wavelength range 
(320- 400 nm). Figure 26 shows that 51 absorbs maximally at 302 nm (in the UVB wavelength 
range) with a molar absorptivity of Ɛ302= 2,870 L mol-1 cm-1, and continues to absorb over the 
whole UVA range and into visible light up to 426 nm. The PIH-based CIC 52 has a maximal 
absorbance of 298 nm with a higher molar absorptivity of Ɛ298= 9,250 L mol-1 cm-1, and 52 
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continues to absorb to over 450 nm, significantly into visible light, as shown in Figure 27. 55 
absorbs maximally at 302 nm (molar absorptivity of Ɛ302= 7,640 L mol-1 cm-1), but also has a 
significant absorbance peak at 380 nm in the UVA region (molar absorptivity of Ɛ380= 3,370 L 
mol-1 cm-1) and also absorbs up to 450 nm, as shown in Figure 28. 
 
 
 
Figure 26. UV/Vis absorbance spectrum of CIC 51 in DMSO (100 µM). 
 
 
 
 
Figure 27. UV/Vis absorbance spectrum of CIC 52 in DMSO (100 µM). 
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Figure 28. UV/Vis absorbance spectrum of CIC 55 in DMSO (100 µM). 
 
 
Upon UVA irradiation of aminocinnamoyl photo-cleavable groups, a carbostyril photoproduct 
is released as opposed to the coumarin photoproducts seen with the hydroxycinnamoyl 
groups. Carbostyril structures have not been studied extensively and the photoproduct 
released from the 3,4-dimethoxy aminocinnamoyl CICs 51, 52 and 55 is not commercially 
available. Therefore the synthesis of this photoproduct was important to act as a reference 
for HPLC analysis of the uncaging profiles. In 1981 Meth-Cohn et al. reported the use of 
Vilsmeier-Haack formylation with DMF and phosphoryl chloride to synthesise quinolones 
from acetanilides.195 Following this synthetic approach, 3,4-dimethoxy aniline 56 was 
acetylated using acetyl chloride to give 57, before performing a Vilsmeier-Haack reaction to 
give 2-chloro-6,7-dimethoxyquinoline-3-carbaldehyde 58 in a yield of 51% (Scheme 20). 58 
was then treated with 70% aq. AcOH at reflux to give the quinolone aldehyde 59 in 50% yield. 
Reduction of the aldehyde of 59 with triethylsilane in the presence of TFA196 gave the desired 
carbostyril product 60, which would be released upon photo-cleavage of the corresponding 
CIC via the mechanism seen in Scheme 13.       
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Scheme 20. Synthesis of 6,7-dimethoxy carbostyril 60. Reagents and conditions: a. Et3N, acetyl chloride, dry 
DCM, RT, 20 min, 75%; b. POCl3, dry DMF, 85 oC, 3 h, 51%; c. 70% aq. AcOH, reflux, 16 h, 50%; d. TFA, Et3SiH, RT, 
2 h, 41%. 
 
In the same manner as for the hydroxycinnamoyl CICs, the intact CICs 51, 52 and 55 were 
irradiated at increasing doses of UVA and the extent of uncaging was followed on analytical 
HPLC. The HPLC chromatograms in Figure 29 correspond to the uncaging of SIH-based CIC 51. 
Chromatogram A is a single peak at 6.10 min for pure 51 which disappears to form two new 
peaks at 5.72 min and 6.37 min respectively which correspond to SIH 8 and carbostyril 60. 
These were both injected separately on the same gradient system of the analytical HPLC as 
references (chromatograms E and F respectively). 51 was completely uncaged upon 100 kJ/m2 
UVA irradiation (chromatogram D), equivalent to 500-1000 kJ/m2 solar UVA irradiation or 1-
2 MED. 
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Figure 29. HPLC chromatograms of aminocinnamoyl-SIH CIC 51: A. Non-irradiated control of ‘intact’ 51; B. 25 
kJ/m2 irradiation; C. 50 kJ/m2 irradiation; D. 100 kJ/m2 irradiation showing complete uncaging; E. Reference SIH 
8 injection; F. Reference carbostyril 60 injection. Samples in DMSO solution (1 mg/mL) were irradiated with a 4 
kW broad spectrum UVA lamp (Sellas, Germany). 
 
 
The chromatograms in Figure 30 show that the peak at 8.78 min for pure 52 (chromatogram 
A) disappears completely after 250 kJ/m2 irradiation to form two new peaks at 4.28 min and 
8.50 min, which correspond to PIH 7 and carbostyril 60 (reference chromatograms E and F 
respectively). The uncaging of 52 after 250 kJ/m2 is equivalent to approximately 400 min of 
human skin sun exposure (~2500 kJ/m2 physical dose) which is 5 MED. Therefore a severe 
amount of erythema would be reached before 52 exerted its full iron chelating activity. The 
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dose required for full uncaging of 52 is significantly higher than that required for 51, despite 
CIC 52 absorbing more strongly at the principal wavelength of the UVA lamp output (360 nm). 
This indicates that PIH-based CICs have a slower mechanism of photo-release than SIH-based 
CICs. Considering the mechanism of photo-cleavage of cinnamic acids (shown in Scheme 13), 
the second step involving nucleophilic attack of the carbonyl is the more likely step to be 
affected by the ester group (i.e SIH or PIH) rather than the photoisomerization step. Therefore 
the extra ortho methyl group present in PIH may sterically hinder the nucleophilic attack and 
thus slow down the uncaging mechanism. Further investigations into the kinetics of the 
uncaging mechanism would be required to confirm this proposition. 
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Figure 30. HPLC chromatograms of aminocinnamoyl-PIH CIC 52: A. Non-irradiated control of ‘intact’ 52; B. 50 
kJ/m2 irradiation; C. 100 kJ/m2 irradiation; D. 250 kJ/m2 irradiation showing complete uncaging; E. Reference 
PIH 7 injection; F. Reference carbostyril 60 injection. Samples in DMSO solution (1 mg/mL) were irradiated with 
a 4 kW broad spectrum UVA lamp (Sellas, Germany). 
 
The HPLC chromatograms in Figure 31 correspond to the uncaging of deferasirox ester-based 
CIC 55. Chromatogram A is a single peak at 9.51 min for pure 55 which disappears to form 
two new peaks at 6.37 min and 10.42 min which correspond to deferasirox ester 33 and 
carbostyril 60. These were both injected separately on the same gradient system of the 
analytical HPLC as references (chromatograms E and F respectively). 55 was completely 
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uncaged upon 50 kJ/m2 UVA irradiation (chromatogram D). This uncaging process proceeded 
faster than that of the SIH-based CIC 51 which may be due to 55 absorbing more strongly at 
360 nm, the principal output of the UVA lamp, as well as over the entire UVA wavelength 
range. 
 
 
Figure 31. HPLC chromatograms of aminocinnamoyl-deferasirox ester CIC 55: A. Non-irradiated control of 
‘intact’ 55; B. 10 kJ/m2 irradiation; C. 25 kJ/m2 irradiation; D. 50 kJ/m2 irradiation showing complete uncaging; 
E. Reference deferasirox ester 33 injection; F. Reference carbostyril 60 injection. Samples in DMSO solution (1 
mg/mL) were irradiated with a 4 kW broad spectrum UVA lamp (Sellas, Germany). 
 
A respresentative comparison of the dose-dependent UVA uncaging of CICs 51, 52 and 55 is 
seen in Figure 32. The PIH-based CIC 52 required a considerably higher dose of UVA (250 
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kJ/m2) to uncage in comparison to the SIH and deferasirox ester-based CICs 51 and 55, which 
both uncaged between 50-100 kJ/m2 UVA. Full uncaging of 52 (and thus photoprotection) 
would not be observed until several hours of human skin sun exposure and severe erythema, 
which may be not suitable for a photoprotective CIC which should uncage at relevant 
environmental levels of human sun exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. A representative comparison of the dose-dependent uncaging of the 3,4-dimethoxy aminocinnamoyl 
CICs 51, 52 and 55. Percentage uncaging calculated using the peak area of the remaining CIC compared to the 
peak area of the unirradiated sample. Samples in DMSO solution (1 mg/mL) were irradiated with a 4 kW broad 
spectrum UVA lamp (Sellas, Germany). 
 
The MTT assay was used to assess the photoprotective properties of aminocinnamoyl CICs 
51, 52 and 55. In the same manner as for the hydroxycinnamoyl CICs, a final concentration of 
20 µM of CICs was used, which was incubated with the cells for 18 h before irradiation of the 
monolayers of cells at 500 kJ/m2 (Figure 33). Among the iron chelators, SIH 8 is a very good 
photoprotectant in its own right, significantly improving cell viability to 58% in comparison to 
the untreated control (36% enzymatic activity). Deferasirox ester 33 and PIH 7 increased cell 
viability to 46% and 43% respectively. The only aminocinnamoyl CIC to significantly improve 
the cell viability in comparison to the untreated irradiated control was the SIH-based CIC 51 
(58%), which gave the same level of photoprotection as the parent iron chelator 8, but was 
much less cytotoxic to unirradiated cells. Both 52 and 55 were less photoprotective than their 
parent iron chelators 7 and 33 and gave very little photoprotection in comparison to the 
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irradiated control (40% and 38% respectively). In the case of 52 this may be due to the afore-
mentioned slow uncaging and therefore at a dose of 500 kJ/m2 (equivalent to a dose of 50 
kJ/m2 in chemical irradiation) only approximately 25% of the active iron chelator would be 
released. CIC 55 has a relatively high molecular weight (MW=606.635) and therefore may also 
have a reduced ability to permeate the cell membrane and thus chelate labile iron in the 
cytosol upon UVA irradiation. This is consistent with the explanation provided by Glickstein 
et al. for the relative cell permeating efficiency of deferiprone 2 and deferasirox 6 compared 
to the larger DFO 1.150 
 
Figure 33. MTT assay evaluation of the photoprotection afforded by the aminocinnamoyl CICs 51, 52 and 55 
along with their parent iron chelators SIH 8, PIH 7 and deferasirox ester 33 in FEK4 fibroblasts. Cells were treated 
with the compounds (20 µM) overnight before ± 500 kJ/m2 UVA irradiation followed by MTT analysis 24 h later. 
Data is expressed as the mean ± SD compared to the untreated unirradiated control, which was fixed at 100% 
enzymatic activity (n=3).  
*= p< 0.05, significantly different from the untreated irradiated control.   
Φ= p <0.05, significantly different from the untreated unirradiated control. 
 
As already highlighted, the choice of using the 3,4-dimethoxy aminocinnamoyl caging group 
derived from 50 as a starting point was due to its previously reported use as a photo-cleavable 
group.172 In comparison to the 2-hydroxy and 2,4-dihydroxy cinnamoyl PPGs studied above, 
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the 3,4-dimethoxy aminocinnamoyl group selected differs not only in its 2-amino group rather 
than 2-hydroxyl group, and different aromatic substituents, but it also has a methyl 
substituent on the olefinic bond. Coumarins are fluorescent molecules and Gagey et al. used 
this property to quantify the amount of coumarin produced upon two-photon uncaging of 
hydroxycinnamoyl-caged derivatives of ethanol. One series of compounds had methyl 
substitution on the olefinic bond whilst the other series did not, and Gagey et al reported that 
this substitution increased the quantum yield of coumarin.166 The explanation for this 
outcome is that the presence of the methyl group increases the steric hindrance around the 
double bond which is thought to destabilize the E stereoisomer more than the Z isomer, thus 
giving rise to a larger proportion of the desired Z stereoisomer after one photocycle.  
 
In order to investigate how the effect of methyl substitution affects the photostability of 
aminocinnamoyl CICs, the analogous 3,4-dimethoxy aminocinnamic acid without methyl 
substitution was synthesised. The synthesis began with 1-bromo-4,5-dimethoxy-2-
nitrobenzene 61 which was converted into the ester 62 via a Heck reaction using the catalyst 
palladium(II) acetate with triphenylphosphine as the ligand to form the required reduced 
bis(triphenylphosphine)palladium(0) complex.197 This palladium complex inserts into the aryl-
Br bond via an oxidative addition step and then reacts with the activated alkene, ethyl 
acrylate, to give the desired ester 62 with E stereoselectivity.197 The presence of the base Et3N 
regenerates the catalyst. Saponification of the ester gave the carboxylic acid 63 which was 
then reduced with aqueous ferrous sulphate solution and concentrated aqueous ammonia194 
to give the desired 3,4-dimethoxy aminocinnamic acid 64, as shown in Scheme 21. Coupling 
of 64 with SIH 8 and deferasirox ester 33 was attempted using the previously described 
coupling method. This gave CICs 65 and 66 in yields of 47% and 17% respectively (route d in 
Scheme 21). The relatively low yield obtained for 66 is similar to that obtained for the 
methylated 3,4-dimethoxy aminocinnamoyl CIC 55, and once again unchanged iron chelator 
and aminocinnamic acid were observed upon TLC and HPLC analysis of the crude reaction 
mixture. This is consistent with the relatively hindered environment of the more reactive 
phenolic function of deferasirox, with the bulky ortho substituent apparently having a 
significant effect on the efficiency of esterification with different activated acids. 
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Scheme 21. Synthesis of 3,4-dimethoxy aminocinnamoyl CICs 65 and 66. Reagents and conditions: a. Pd(OAc)2, 
PPh3, ethyl acrylate, Et3N, dry DMF, 90 oC, O/N, 80%; b. 1M NaOH, 4:1 THF:EtOH, 40 oC, O/N, 88%; c. FeSO4.7H2O, 
water, aq. 35% NH3, RT, 2 h, 81%; d. EDC.HCl, DMAP, 8 or 33, dry DMF, 30 oC, 24 h, 47% (65) and 17% (66). 
 
Synthesis of the carbostyril photoproduct released from irradiation of CICs 65 and 66 was 
required and the synthetic pathway by Park et al. was adopted.198 6-Nitroveratraldehyde 47 
was reduced to the amine 67, followed by acetylation with acetyl chloride to give 68 in good 
yield (Scheme 22). Base-catalysed intramolecular aldol-type condensation198 was reported to 
give the final carbostyril 69, however in our hands only a 10% yield of the desired product 69 
was recovered. The main product instead appeared from 1H NMR analysis to be the result of 
an intermolecular aldol condensation, as shown in Figure 34. Making the solution more dilute, 
adding the substrate more slowly and using a different base (NaH rather than Cs2CO3) were 
all alternative methods employed, however no improvement in yield was obtained. Finally, a 
much simpler route to 69 was discovered via a one-step acid-catalysed cyclization from the 
aminocinnamic acid 64.194 This reaction proceeded very well giving a 78% yield of the desired 
carbostyril 69 (route d, Scheme 22). Due to the ease and effectiveness of this method it was 
also used with the methyl-substituted aminocinnamic acid derivative 50, which also 
proceeded very well giving an 83% yield of carbostyril 60. 
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Scheme 22. Synthesis of carbostyril 69 along with alternative carbostyril synthesis. Reagents and conditions: a. 
FeSO4.7H2O, water, aq. 35% NH3, RT, 2 h, 76%; b. Et3N, acetyl chloride, dry DCM, RT, 30 min, 81%; c. Cs2CO3, dry 
DMF, 60 oC, 22 h, 10%; d. 1.4 M HCl, reflux, 2-4 h, 78%. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Predicted structure of the product of intermolecular aldol condensation of 68. 
 
The intact CICs 65 and 66 were irradiated at increasing doses of UVA (10-250 kJ/m2) to 
monitor the extent of uncaging, which was followed on analytical HPLC. Upon irradiation a 
clean conversion to a single carbostyril photoproduct 69 was not observed. Instead three new 
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peaks appeared on each chromatogram, one of which corresponded to the parent iron 
chelator 8 or 33, and one of which corresponded to the carbostyril 69. A sample 
chromatogram of complete uncaging of CIC 66 at a dose of 100 kJ/m2 is shown in Figure 35. 
The peak for the iron chelator 33 is seen at 10.5 min, carbostyril 69 is seen at 5.7 min and an 
unknown compound is at 6.8 min.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. HPLC analysis of CIC 66 irradiated at a dose of 100 kJ/m2 UVA. Sample in DMSO solution (1 mg/mL) 
were irradiated with a 4 kW broad spectrum UVA lamp (Sellas, Germany). 
 
A representative comparison of the dose-dependent UVA uncaging of CICs 66 with the 
analogous CIC 55, where deferasirox ester 33 is also masked is shown in Figure 36. The 
amount of cleavage of 66 at the lower doses of 10 and 25 kJ/m2 is less than that of 55 which 
contains olefinic methyl substitution. However, once the dose of UVA increases to 50 kJ/m2 
the levels of cleavage are equal. This outcome is consistent with the work of Gagey et al.,171 
indicating that the presence of the olefinic methyl substituent increases the quantum yield of 
the reaction at lower UVA doses. 
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Figure 36. A representative comparison of the dose-dependent uncaging of the 3,4-dimethoxy aminocinnamoyl 
CICs 55 and 66, with and without olefinic methyl substitution respectively. Percentage uncaging calculated using 
the peak area of the remaining CIC compared to the peak area of the unirradiated sample. Samples in DMSO 
solution (1 mg/mL) were irradiated with a 4 kW broad spectrum UVA lamp (Sellas, Germany). 
 
It was postulated that the additional peak (6.8 min) was the product of a photoreaction of the 
carbostyril 69. Therefore a solution of 69 in DMSO (1 mg/mL) was irradiated at a dose of 100 
kJ/m2 UVA and a sample in MeOH was injected on the analytical HPLC, and as hypothesised 
an additional peak at 6.8 min appeared, with a 45% relative peak area. This additional peak 
at 6.8 min was separated by HPLC and analysed using 1H NMR which indicated the presence 
of a single compound, 69. Tashima et al. have suggested that a carbostyril 2-quinolinone can 
undergo amide tautomerism to the 2-quinolinol derivative, as shown in Scheme 23.199 To test 
whether the unknown compound observed could be a tautomer of 69, a comparable solution 
of 69 in DMSO (1 mg/mL) was also left in the dark at room temperature for 3 days before 
analysis on HPLC. The appearance of the additional peak at 6.8 min was seen, however only 
in a 5% relative peak area. It therefore appears that in DMSO there is a low level of 
tautomerisation of 69, which is intensified by UVA irradiation, however this does not occur 
with the methyl substituted carbostyril 60. The biological activity of CICs 65 and 66 was not 
examined due to the apparently more complex uncaging of these CICs under UVA irradiation. 
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Scheme 23. Amide tautomerism of carbostyril 69 to 2-quinolinol.  
 
 
5. Summary 
 
In summary, the iron chelators PIH 7, SIH 8, and the methyl ester derivative of deferasirox 33 
were all synthesised efficiently and their cytotoxicity in the human skin fibroblast model, FEK4 
cells, was assessed. After 48 h of exposure, 7, 8 and 33 were all significantly cytotoxic at 
concentrations of 10-50 µM. This analysis confirmed the requirement for deactivated, or 
caged, iron chelators which can be dose-dependently activated upon UVA exposure to 
provide a photoprotective effect via chelation of intracellular labile iron.  The well-
documented 2-hydroxycinnamoyl PPG was chosen as the starting group to mask an iron 
chelator. Two hydroxycinnamoyl CICs 36 and 44 were synthesised and their chemical and 
photochemical properties were fully characterized and showed that both CICs absorb in the 
UVB and UVA wavelength range (280-400 nm). Although synthesis and purification of the CICs 
was achieved, the yields were rather low. The photoprotective capacity of both CICs was 
assessed in FEK4 cells exposed to an environmentally relevant dose of UVA radiation. 36 and 
44 were analysed using the MTT assay and were shown to significantly increase the cell 
viability in comparison to the untreated irradiated control. However, neither CIC was more 
photoprotective than their parent iron chelator, SIH 8. There are some concerns over the 
photosensitizing activity of coumarins which questions their utility in this project,200 indeed 
the furanocoumarin psoralen is used as the photosensitizing drug in PUVA as described in the 
Introduction 1.4.1. 
 
Subsequently the 2-aminocinnamoyl PPG was investigated as an appropriate alternative 
caging group for an iron chelator. A series of 3,4-dimethoxy aminocinnamoyl-caged iron 
chelators was efficiently synthesised (CICs 51, 52 and 55) and their chemical and 
photochemical properties were also fully characterized, revealing that CICs containing the 
N
H
O N OH
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same caging group attached to a different iron chelator may uncage at significantly different 
rates. The UV/Vis absorbance spectra of CICs 51, 52 and 55 showed that as well as covering 
the UVB-UVA wavelength range, the CICs also absorbed marginally into visible light. This may 
prove detrimental to the stability of the CICs in ambient lighting however it could also be a 
very interesting property due to the recent work by Lawrence et al. demonstrating that 
shortwave visible wavelengths (400-420 nm) induce photodamage including loss of cell 
viability and DNA damage.201 In this 2-aminocinnamoyl CIC series the only CIC to significantly 
increase cell viability upon UVA irradiation when assessed in the MTT assay was the SIH-based 
CIC 51. 51 was equally as photoprotective as the parent iron chelator 8 and importantly was 
less cytotoxic than 8 after overnight incubation. Deferasirox ester 33 on its own also 
significantly increased cell viability.  
 
These results show that CICs with the appropriate structure may be promising 
photoprotectants which can deliver a highly efficient iron chelator when activated. In order 
to exploit CICs to their full potential, the correct choice of iron chelator and caging group is 
needed. In particular, it would be interesting to incorporate additional protective properties 
into the photoproduct released upon uncaging, to provide a multi-functional CIC. To this end, 
as UVA irradiation delivers a highly oxidative environment it would be interesting to attempt 
to choose the caging group so as to co-deliver a novel antioxidant alongside the active iron 
chelator. The diversity and ease of synthesis of aminocinnamoyl-based CICs makes them more 
attractive as CICs, and thus the functionalisation of the carbostyril photoproduct could be 
advantageous. Carbostyrils are structurally similar to coumarins, some of which are known 
antioxidants. Therefore researching the properties of carbostyrils may provide a way to 
incorporate a pro-antioxidant function into CICs. 
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CHAPTER 3: RESULTS AND DISCUSSION 
 
1. Introduction 
 
The structure of carbostyrils (2-quinolones) mimics that of coumarins, whereby the ester is 
replaced with an amide. Therefore it would be reasonable to hypothesise that carbostyrils 
could also have an inherent antioxidant activity. Thuong et al. isolated 21 coumarins from 
medicinal plants and of these eight inhibited lipid peroxidation in rat liver mitochondria.179 In 
all of the natural coumarins that had a positive effect, they contained one or more electron-
donating hydroxyl or methoxy substituents. In particular, the compound that possessed 
considerable antioxidant activity contained a catechol group as seen in 34c.179 Sankaran et al. 
has highlighted the importance of nitrogen-containing heterocycles such as quinolones 
(carbostyrils) in medicinal chemistry research into compounds with antioxidant, 
antiproliferative, anti-inflammatory and anticancer biological activity.202 For example, in a 
study by Chung et al. 4-carbomethoxy-6-hydroxy-2-quinolone 70 (Figure 37) was extracted 
from the purple-pigmented rice Oryza sativa cv. Heugjinmi and was shown to possess 
moderate antioxidant activity.203  Similarly, a fused quinolone derivative 71 was found to be 
highly effective at free radical scavenging.202 The free radical scavenging activity of the series 
of synthesised quinolone derivatives was thought to arise from either a phenolic hydroxyl 
group or from the imino function of the quinolone, which are both available sites for a free 
radical to undergo electron transfer or abstract a hydrogen atom.202  
 
 
 
 
 
 
 
 
 
 
 
Figure 37. The structures of two quinolone derivatives 70 and 71 which have been investigated for their 
antioxidant activity.202,203 
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Upon UVA-induced photo-cleavage of an aminocinnamoyl caging group, a carbostyril 
photoproduct is released. This provides an opportunity to include a novel potentially 
antioxidant by-product as part of the release of an active iron chelator from a CIC. In order to 
investigate the antioxidant potential of carbostyril photoproducts, a ‘retrosynthetic’ 
approach was used, represented in Scheme 24. This process required the synthesis of a series 
of potential carbostyrils to find the photoproduct with the most biological potential. The 
corresponding caging group could then be synthesised and subsequently coupled to an iron 
chelator to provide a CIC with a multi-functional action. 
 
 
 
 
 
 
 
Scheme 24. ‘Retrosynthetic’ approach to synthesising a multi-functional CIC, beginning with the photoproduct 
that would be released upon UVA-cleavage. 
 
 
2. Carbostyril photoproduct series: synthesis and antioxidant properties 
 
To synthesise a series of carbostyrils, the route already developed in Chapter 2.4 for the 
synthesis of an aminocinnamic acid was used, followed by acid-catalysed cyclization to form 
the carbostyril (Scheme 22). Varying the electron-donating substituents on the aromatic ring 
of the starting materials would be expected to positively affect the ROS scavenging activity of 
the final carbostyril.202,204 Synthesis of the series relied partially on the availability of starting 
materials containing suitable electron-donating groups such as methoxy and hydroxyl groups. 
 
Table 4. The starting materials for the synthesis of a range of carbostyrils with varying aromatic substituents. 
 
 
Starting 
material 
    
Compound 
number 
72 73 74 75 
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All of the required nitrobenzaldehyde starting materials 72-74 were commercially available 
except for the 4-hydroxy-3-methoxybenzaldehyde derivative, 6-nitrovanillin, which was 
instead available as the aldehyde vanillin 75, as shown in Table 4. Regiospecific nitration of 
vanillin via an electrophilic aromatic substitution reaction was required, however due to the 
deactivating meta-directing aldehyde, the product of direct nitration of 75 would be 5-
nitrovanillin rather than the desired 6-nitrovanillin, as shown in Scheme 25.205  
 
 
 
 
 
Scheme 25. The product of direct nitration of vanillin 75: 5-nitrovanillin. 
 
In order to change the regioselectivity of the nitration to give only 6-nitrovanillin, it was 
necessary to first protect the free 4-hydroxyl group of 75 as a benzyl ether. The steric 
hindrance from the benzyl group along with the para- directing potential of the electron-
donating methoxy group has been used previously as a successful means to achieve selective 
nitration in the 6-position.206-209 Benzyl protection of 75 using benzyl bromide and K2CO3 
proceeded efficiently, and recrystallization from EtOH gave the protected vanillin derivative 
76 in a 93% yield (Scheme 26). Regiospecific nitration was then carried out using 65% nitric 
acid at 0oC to give 77 in a 60% yield after recrystallisation. 
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Scheme 26. Benzyl protection of vanillin 75 followed by regiospecific nitration to give the desired 6-
nitrovanillin derivative 77. Reagents and conditions: a. BnBr, K2CO3, MeOH, reflux, 4 h, 93%; b. aq. 65% nitric 
acid, 0oC, 1 h, 60%. 
 
Due to possible side reactions associated with the free nucleophilic hydroxyl group of 5-
hydroxy-2-nitrobenzaldehyde 72 (Table 4) during the subsequent synthetic pathway, the 
hydroxyl group of this starting material was also protected with a benzyl ether. The reaction 
was carried out in the same manner as for vanillin 75 to give the protected derivative 78 in 
an 80% yield, as shown in Scheme 27. The addition of the benzyl group also was expected to 
improve the solubility of 78 in organic solvents and thus the ease of synthesis of subsequent 
intermediates. 
 
 
 
 
 
 
 
 
 
Scheme 27. Benzyl protection of 5-hydroxy-2-nitrobenzaldehyde 72 to give the desired protected derivative 
78. Reagents and conditions: BnBr, K2CO3, MeOH, reflux, 4 h, 80%. 
 
All of the nitrobenzaldehydes 73, 74, 77 and 78 were then subjected to the same synthetic 
pathway as described in Chapter 2.4 to synthesise the aminocinnamic acids, as shown in 
Scheme 28. The Wittig reaction was carried out with ECETP in anhydrous toluene to give 
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esters 79-82 in excellent yields. Subsequent saponification of the esters to the carboxylic acids 
83-86 also proceeded in high yields. Chemoselective reduction of the nitro group to an amino 
group using FeSO4 and aqueous NH3 to give aminocinnamic acids 87-90 then proceeded in 
good yields ranging from 59-80%. All of the aminocinnamic acids except for 88 were 
successfully cyclized to the respective carbostyril by refluxing in 4% HCl.194 The acidic 
conditions also removed the benzyl protecting group of 89 and 90 to give the free hydroxyl 
group, and thus the desired carbostyrils 91, 93 and 94 were synthesised. In the case of 88, 
there was no conversion of the starting material to the desired carbostyril 92 after refluxing 
in 4% HCl, as judged by TLC and HPLC. A different acid-catalyzed cyclization was therefore 
attempted using the alternative mineral acid, 70% H2SO4 instead. Under these conditions 
conversion of the starting material proceeded slowly, giving carbostyril 92 in a 25% yield after 
refluxing for 12 h.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 28. The synthetic route to a series of carbostyril photoproducts 91-94. Reagents and conditions: a. b. 
ECETP, dry toluene, 65oC, 98-99%; c. 1M NaOH, 4:1 THF:EtOH, RT- 40 oC, 90-99%; d. FeSO4.7H2O, water, aq. 35% 
NH3, 80oC→ RT, 59-80%; e. 4% aq. HCl, reflux, 2-4 h, 57-95% or 70% aq. H2SO4, reflux, 12 h, 25%. 
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To complete the series of carbostyrils, the 6,7-dihydroxy derivative 95 was synthesised to 
compare its antioxidant activity to the strong free radical scavenging capabilities of the 6,7-
dihydroxy coumarin, esculetin 34c.179,180 The easiest route of synthesis to the 6,7-dihydroxy 
carbostyril 95 was via cleavage of the 6,7-dimethoxy groups in the previously synthesised 
carbostyril 60 (Chapter 2.4). Methyl ether cleavage of coumarin derivatives using the strong 
Lewis acid boron tribromide has been described in the literature,210,211 therefore this method 
was employed. A solution of 60 in anhydrous DCM was treated with a solution of 1M BBr3 in 
DCM at 0oC under an argon atmosphere, giving the desired carbostyril 95 in an 82% yield, as 
shown in Scheme 29. 
 
 
 
 
 
 
 
 
 
Scheme 29. Synthesis of a 6,7-dihydroxy carbostyril 95. Reagents and conditions: 1M BBr3, anhydrous DCM, 
0oC→ RT, 18 h, 82%. 
 
Seven synthesised carbostyrils (60, 69 and 91-95) were now available for analysis of their free 
radical scavenging capacity and potential photoprotective effects. All carbostyrils were fully 
characterised and their absorbance over the UVA/B range was recorded, as shown in Figure 
38, with the absorption profiles compared in Table 5. The majority of carbostyrils exhibit a 
maximum absorption at 340-345 nm, except for 92 which is blue-shifted by approximately 20 
nm. Li et al. reported a series of purified carbostyrils formed by UVA irradiation of the 
respective aminocinnamic acid.172 This series had varying substituents on the aromatic ring as 
well as N-alkyl substitutions. The maximum absorption values reported in Li’s study for 
carbostyrils which are comparable with those in our series ranged from 342-364 nm, in line 
with the maximum absorption values reported here. Likewise Li et al. also reported a blue-
shift to 324 nm for carbostyril 92. These results suggest that groups with a +M (mesomeric) 
effect may cause a red-shift in the maximum absorption of such compounds. However 
carbostyril 94 has a very different absorbance profile to the other carbostyrils, with a 
maximum absorbance at 203 nm. Carbostyril 95 absorbs quite significantly between 320-370 
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nm in the UVA wavelength range with a molar extinction coefficient, Ɛ345, of 10,130 L mol-1 
cm-1 and has the highest maximum absorption which is explained by the presence of the two 
strongly electron-donating methoxy groups on the aromatic ring. This is also consistent with 
work by Fabian et al. who reported that donor substituents in the 6-position of carbostyrils 
produced substantial red-shifts in both absorption and fluorescence spectra.212 
 
 
Figure 38. The UV/Vis absorbance spectra of all the synthesised carbostyrils 60, 69 and 91-95 in EtOH (100 µM). 
 
Table 5. A comparison of the absorption profiles of carbostyrils 60, 69 and 91-95. 
 
 
 
Carbostyril Spectrum 
colour 
Absorption Maximum 
(nm) 
Molar extinction coefficient, 
Ɛmax (L mol-1 cm-1) 
60  341 4,500 
69  344 1,890 
91  343 930 
92  323 566 
93  341 4,710 
94  203 (not  shown) 9,070 
95  345 10,130 
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A literature review was carried out to find the most suitable chemical assay to perform an 
initial screen of the antioxidant potential of the synthesised carbostyrils. The 2,2-diphenyl-1-
picryl-hydrazyl-hydrate (DPPH) assay is widely used,179,180,202,211,213-215 , and is a simple assay 
which can be carried out with minimal reagents and resources. The only drawback of this 
assay is that experimental procedures are not standardised and therefore results from 
different research groups cannot easily be compared. However, due to its simplicity, it was 
considered to be the most appropriate assay to screen the carbostyrils, alongside a positive 
antioxidant standard such as α-tocopherol or its water soluble derivative, trolox. DPPH itself 
is a stable free radical that can be reduced by an antioxidant molecule (A) via electron 
transfer. DPPH absorbs visible light at 520 nm giving a violet colour, and is converted to a 
colourless compound upon quenching, therefore disappearance of the violet colour reflects 
the presence of an active free radical-neutralising compound213,215: 
 
DPPH. + A-H → DPPH-H + A.  
 
The DPPH assay was carried out on carbostyrils 60, 69 and 91-95, coumarin 34a and 
umbelliferone 34b along with positive controls trolox and ascorbic acid as described in the 
Experimental Section 7.2.6. Three of the compounds tested (93, 94 and 95) showed 
antioxidant properties, the results of the DPPH assays for these compounds are summarised 
in Table 6. Figure 39 represents the percentage radical scavenging activity against 
concentration for the three active carbostyrils.  
 
Table 6. The free radical scavenging activity of compounds 93, 94 and 95, along with the positive controls trolox 
and ascorbic acid. The straight line equation over the linear concentration range of activity is shown, and the 
calculated IC50 value is presented which represents the concentration at which 50% of the radicals are 
scavenged. 
 
 
Compound Linear range of activity (µM) Line equation IC50 (µM) 
trolox 10-100 y = 0.9508x 52.3 
ascorbic acid 10-100 y = 0.8682x 57.6 
93 10-200 y = 0.4386x 114.0 
94 10-100 y = 0.9151x 54.6 
95 10-50 y = 1.979x 25.3 
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Figure 39. Plot of the percentage free radical scavenging activity against concentration of compounds 93-95 that 
were found to have a positive antioxidant effect, along with the positive controls trolox and ascorbic acid. 
 
The DPPH assay confirmed the hypothesis that carbostyril 95 containing the catechol 6,7-
dihydroxy motif should possess considerable antioxidant activity. In this assay 95 had an IC50 
value (the concentration at which 50% of the radical was scavenged) of 25.3 µM, 
approximately twice as effective as the positive control, trolox (IC50 = 52.3 µM). The 6-hydroxy 
derivative 94 also performed well with an IC50 value of 54.6 µM, comparable to trolox and 
ascorbic acid (57.6 µM). Carbostyril 93 was a moderately good free radical scavenger with an 
IC50 value of 114.0 µM. All other carbostyrils and coumarins were inactive in this assay. The 
antioxidant power of 95 was proposed to be via the ability of the catechol group to neutralise 
two free radicals, such as the hydroxyl radical .OH generated upon UVA irradiation, as 
represented in Scheme 30.216 
 
0 20 40 60 80 100 120 140 160 180 200
0
20
40
60
80
100
Concentration (µM)
%
 ra
di
ca
l s
ca
ve
ng
in
g 
ab
ilit
y trolox
ascorbic acid
93
94
95
 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 30. Proposed free radical scavenging mechanism for carbostyril 95.216 
 
 
After determining the antioxidant potential of the series of carbostyrils in a chemical assay, 
the performance of the carbostyrils against UVA-generated ROS in a cellular assay was 
assessed. The two carbostyrils that displayed the most positive free radical scavenging activity 
(94 and 95) were taken forward to the DCFDA assay. CM-H2DCFDA is the chloromethyl 
derivative of 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) which is a ROS indicator 
used in live cells. The chloromethyl derivative displays much better retention in live cells than 
H2DCFDA. CM-H2DCFDA passively diffuses into cells where the acetate groups are cleaved by 
intracellular esterases and the chloromethyl group reacts with intracellular glutathione and 
other thiols to trap the indicator inside the cell217 (Scheme 31). Subsequent oxidation via an 
intracellular source of ROS yields the fluorescent adduct 2',7'-dichlorodihydrofluorescein, 
which absorbs at 492–495 nm and emits at 517–527 nm.  
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Scheme 31. Mechanisms of intracellular trapping and subsequent oxidation of the ROS probe CM-H2DCFDA. 
 
The level of fluorescence of 2',7'-dichlorodihydrofluorescein correlates directly to the level of 
intracellular ROS. In order to assess the photoprotective effects of the carbostyrils, FEK4 cells 
were treated with ± 20 µM of 94 and 95 for 18 h before exposure to ± 250 kJ/m2 dose of UVA 
radiation. Cells were incubated with CM-H2DCFDA after irradiation and the fluorescence was 
monitored by flow cytometry, with the results shown in Figure 40. 
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Figure 40. Evaluation of the free radical scavenging capacity of carbostyrils 94 and 95 against UVA-induced ROS 
in FEK4 fibroblasts. Cells were treated with ± compounds (20 µM) for 18 h before exposure to ± 250 kJ/m2 dose 
of UVA radiation. The level of ROS was monitored by flow cytometry using the fluorescent CM-DCFDA dye.      
Data is expressed as the mean fluorescence ± SD (n=3–13).  
*= p <0.05, significantly different from untreated irradiated cells. 
 
The addition of 20 µM 94 and 95 to FEK4 cells prior to UVA irradiation significantly reduced 
the level of fluorescence (therefore the amount of ROS present intracellularly) in comparison 
to the 250 kJ/m2 UVA positive control. The positive control had a fluorescence of 6323 RFU 
which decreased to 5708 and 5787 RFU in the presence of carbostyrils 94 and 95 respectively.  
 
To mimic the photoproducts released from UVA uncaging of a potential CIC, the combined 
free radical scavenging capacity of 94 and 95 was examined in the presence of an iron chelator 
at equivalent concentration (20 µM). Using this approach, the best combination of an iron 
chelator and carbostyril could potentially be found, and the CIC that corresponded to the 
identified photoproducts could then be synthesised. In Chapter 2.4 the photoprotective 
capacity of the iron chelators PIH 7, SIH 8 and deferasirox ester 33 were compared using the 
MTT assay after 500 kJ/m2 UVA irradiation. The results showed that whilst 8 and 33 were 
significantly photoprotective at a concentration of 20 µM, 7 was not. For this reason only iron 
chelators 8 and 33 were used in the following DCFDA assay. FEK4 cells were treated with ± 20 
µM of either the iron chelator alone or the iron chelator plus 94 or 95. After exposure to ± 
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250 kJ/m2 UVA radiation, cells were incubated with CM-H2DCFDA and the cell fluorescence 
was monitored by flow cytometry. The results of the assay using 33 combined with or without 
94 or 95 are shown in Figure 41. 
 
 
Figure 41. Evaluation of the combined free radical scavenging capacity of the iron chelator 33 and carbostyrils 
94 and 95 against UVA-induced ROS in FEK4 fibroblasts. Cells were treated with  ± compounds (20 µM) for 18 h 
before exposure to ± 250 kJ/m2 dose of UVA radiation. The level of ROS was monitored by flow cytometry using 
the fluorescent CM-DCFDA dye. Data is expressed as the mean fluorescence ± SD (n=3–13).  
*= p <0.05, significantly different from irradiated untreated cells. 
 
These results indicated that both deferasirox ester 33 alone and the combination of 33 and 
94 or 95 all significantly reduced the level of intracellular ROS in comparison to the positive 
control. The combinations of iron chelator and carbostyrils reduced the free radicals slightly 
more than the iron chelator alone, with the fluorescence lower than that of the negative 
control without UVA irradiation. The same assay was repeated for SIH 8 along with 
carbostyrils 94 and 95, and the results are shown in Figure 42.  
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Figure 42. Evaluation of the combined free radical scavenging capacity of the iron chelator 8 and carbostyrils 94 
and 95 against UVA-induced ROS in FEK4 fibroblasts. Cells were treated with ± compounds (20 µM) for 18 h 
before exposure to ± 250 kJ/m2 dose of UVA radiation. The level of ROS was monitored by flow cytometry using 
the fluorescent CM-DCFDA dye. Data is expressed as the mean fluorescence ± SD (n=3–13).  
*= p <0.05, significantly different from irradiated untreated cells. 
Φ= p <0.05, significantly different from both irradiated untreated cells and  irradiated cells treated with 8 only. 
 
Both SIH 8 alone and the combination of 8 and 94 or 95 all significantly reduced the level of 
intracellular ROS in comparison to the positive control. The combinations of 8 + 94 and 8 + 95 
significantly reduced the UVA-induced ROS more than 8 alone (2202, 2157 and 2714 RFU 
respectively). The combined action of 8 + 94 and 8 + 95 also markedly lowered the 
fluorescence in comparison to the negative control without UVA irradiation. These results 
indicate that a multi-functional CIC combining the iron chelator SIH 8 and either carbostyril 
94 or 95 should have the most favourable photoprotective and antioxidant potential. The 
combinations of deferasirox ester 33 and either carbostyril are also very promising. 
 
3. Synthesis of multi-functional CICs 
 
Carbostyrils 93, 94 and 95 showed the best antioxidant activity in the synthesised carbostyril 
series. Therefore the synthesis of the caging groups relating to carbostyrils 93, 94 and 95 was 
carried out in order to synthesise multi-functional CICs containing these photo-cleavable 
groups. The benzyl-protected aminocinnamic acids 89 and 90 were synthesised as part of the 
Co
ntr
ol 8
8 +
 94
8 +
 95
0
1000
2000
3000
4000
5000
6000
7000
Fl
uo
re
sc
en
ce
 (R
FU
)
No UVA
+ 250 kJ/m2
  * 
   F  F 
 105 
synthetic route to carbostyrils 93 and 94 (Scheme 28). Removal of the benzyl protection 
would therefore give the required caging derivative for subsequent coupling to an iron 
chelator. Lai et al. reported the use of TFA to remove the benzyl group from protected 6-
nitrovanillin,218 therefore this method was attempted with aminocinnamic acid 89 at room 
temperature to give the desired product 96 (Scheme 32). The reaction effectively removed 
the benzyl group, but also catalysed the cyclization of 89 to give the carbostyril 93.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 32. Attempted removal of benzyl protecting group of 89 to give acid 96 generating carbostyril 93 
instead. Reagents and conditions: TFA, RT, O/N, 74%. 
 
Removal of benzyl ethers via palladium-catalyzed hydrogenolysis is another commonly used 
synthetic method.183 Due to the presence of the reducible alkene unit in 89, benzyl ether 
hydrogenation was first attempted with 10% Pd/C and H2 in the moderately polar aprotic 
solvent EtOAc to slow the undesired reduction process.219 However after 12h, there was no 
conversion of the starting material observable on TLC. The reaction was then repeated with 
the polar protic solvent AcOH. After 3 h the starting material was consumed, however the 
product was both debenzylated and the alkene function was saturated, as confirmed by 1H 
NMR and mass spectrometry. Jung et al. have described the dealkylation of a large range of 
alkyl and aryl ethers using 1.3 equivalents of the Lewis acid, trimethylsilyl iodide (TMS-I).220 
This method was adopted and 89 was treated with TMS-I in anhydrous DCM under argon, but 
there was no consumption of starting material after 2 h at room temperature, so the reaction 
was heated to reflux. This also did not convert 89 to the desired product 96. 89 was poorly 
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soluble in anhydrous DCM, which may have prevented the reaction from occurring, so the 
reaction was repeated in anhydrous MeCN at reflux as 89 was most soluble in this solvent. 
However 89 still did not convert to 96 in anhydrous MeCN. 
 
As removal of benzyl protection in the aminocinnamic acid 89 to give 96 was difficult to 
achieve, debenzylation of the 6-nitro ester derivative 81 was attempted instead. Benzyl 
cleavage was carried out in TFA at 30oC and proceeded cleanly in a 93% yield after column 
chromatography to give the debenzylated product 97 (route a in Scheme 33). Hydrolysis of 
the ester using the previously described method worked well to give 98 in an excellent yield. 
Reduction of 98 failed under the standard FeSO4 conditions (previously used for a range of 
nitrocinnamic acids) giving a complex mixture of products on TLC. The reduction was also 
unsuccessful under conditions described for reduction of 6-nitrovanillin,193 which has a free 
phenolic hydroxyl like 98 (step d in Scheme 33). This reaction also gave a complex mixture of 
products on TLC and a major product could not be identified by 1H NMR analysis. Gowda et 
al. described the use of hydrazinium monoformate with zinc dust to selectively reduce nitro 
compounds in 2- 5 min in the presence of a range of reducible groups (e.g alkene, acid and 
ester groups).221 This method was attempted, with hydrazinium monoformate being 
generated in situ by first neutralizing hydrazinium hydrate with equimolar formic acid, which 
was then added to 98 and zinc dust in MeOH. Under these conditions, there was no 
conversion of 98 to the desired reduced product after 2 h as judged by TLC. 
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Scheme 33. Alternative attempted synthetic route to cinnamic acid 96. Reagents and conditions: a. TFA, 30oC, 
O/N, 93%; b. 1M NaOH, 4:1 THF:EtOH, RT- 40 oC, 98%; c. FeSO4.7H2O, water, aq. 35% NH3, 80oC→ RT; d. iron 
powder, NH4Cl, 80% (aq.) EtOH, 80oC; e. hydrazinium monoformate, Zn dust, MeOH, 30oC. 
 
In parallel, a similar synthetic pathway was attempted towards the synthesis of 
aminocinnamic acid 99 (Scheme 34). Benzyl ether cleavage of 82 with TFA at 30oC proceeded 
well to give a good yield of 100. The ethyl ester was then hydrolysed to give 101 which was 
taken forward for reduction of the nitro group to give the desired aminocinnamic acid 99 
using iron powder and NH4Cl.193 This reaction also gave a complex mixture of products on TLC. 
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Scheme 34. Attempted synthetic route to cinnamic acid 99. Reagents and conditions: a. TFA, 30oC, O/N, 93%; b. 
1M NaOH, 4:1 THF:EtOH, 30 oC, 98%; c. iron powder, NH4Cl, 80% (aq.) EtOH, 80oC. 
 
These results indicated that either the presence of a phenolic hydroxyl in the 4-position (98) 
or the 3-position (101), or the carboxylic acid functional group in both 98 and 101 were 
affecting the reduction of the nitro group to the amine. Therefore to decipher which 
functional group was affecting the reaction, the deprotected nitro ester 97 was submitted to 
reduction using iron powder and NH4Cl (Scheme 35). This reaction proceeded well to give 
pure 102 in a 92% yield, indicating that the presence of the phenolic hydroxyl did not affect 
the nitro group reduction under these conditions. Ethyl ester hydrolysis of 102 however gave 
a mixture of products, one of which was the carbostyril 93 which may have formed upon 
acidic work-up of the reaction.  
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Scheme 35. Alternative synthetic route to aminocinnamic acid 96. Reagents and conditions: a. iron powder, 
NH4Cl, 80% (aq.) EtOH, 80oC, 2 h, 92%; b. 1M NaOH, 4:1 THF:EtOH, 30 oC. 
 
So far all of the alternative routes to synthesise one of the desired aminocinnamic acids with 
a free hydroxyl function had proved unsuccessful. Cleavage of the benzyl protecting group 
with TFA proceeded well if the possibility of intramolecular cyclization to the carbostyril was 
not present (e.g route a in Scheme 33 and route a in Scheme 34). It was therefore proposed 
that the benzyl groups of the aminocinnamoyl unit could instead be cleaved after coupling 
with an iron chelator. The ester unit of a CIC is relatively sterically hindered and therefore 
acid-catalysed cyclization of the aminocinnamate group should be slower than for a simple 
ethyl ester. To test this hypothesis, a sample of one of the previously synthesised 
aminocinnamic acid CICs 51 was stirred in TFA at room temperature, and after 12 h the sample 
was analysed by HPLC which indicated that the CIC had not cleaved to the parent iron chelator 
and the carbostyril, but still remained as a single pure compound. Therefore the protected 
aminocinnamic acids could potentially be coupled with an iron chelator before cleavage of 
the benzyl groups with TFA.  
 
The protected aminocinnamic acids that corresponded to the attractive carbostyrils 93 and 
94 had already been synthesised (89 and 90). However the protected aminocinnamic acid that 
would release the most promising catechol-type carbostyril 95 was not yet available. The 
synthesis of this protected aminocinnamic acid began with 3,4-dihydroxybenzaldehyde and 
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proceeded via the previously used routes (Scheme 36). Protection of the catechol motif to 
give 103 was achieved using slightly more than two equivalents of benzyl chloride and K2CO3 
in anhydrous DMF. Nitration of 103 was directed to the 6-position and proceeded in a 92% 
yield. The nitro ester 105 was generated using the Wittig reagent ECETP and was then 
hydrolysed to 106 in 1M NaOH and EtOH. Finally, reduction of the nitro group appeared to 
proceed efficiently by TLC and the desired protected aminocinnamic acid 107 was successfully 
isolated, although in a relatively low yield (16%). Aqueous filtration of the reaction mixture 
through Celite may have been responsible for the loss of product due to the water insolubility 
of 107.   
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 36. Synthetic route to protected aminocinnamic acid 107. Reagents and conditions: a. BnCl, K2CO3, 
anhydrous DMF, 80oC, 3 h, 96%; b. aq. 65% nitric acid, 0oC, 4 h, 92%; c. ECETP, dry toluene, 65oC, 24 h, 76%; d. 
1M NaOH, 4:1 THF:EtOH, 40 oC, 92%; e. FeSO4.7H2O, water, aq. 35% NH3, RT, 16%. 
 
With the three protected aminocinnamic acids in hand (89, 90 and 107), coupling to the iron 
chelators SIH 8 and deferasirox ester 33 was attempted using the coupling reagents EDC.HCl 
and DMAP (route a in Scheme 37). This gave three SIH-based protected CICs 108-110 in yields 
of 60-87% and deferasirox ester-based protected CICs 111-113 in yields of 19-39%. All of the 
coupling reactions with SIH 8 proceeded to completion with complete consumption of the 
phenolic component. In comparison, all of the deferasirox ester 33 coupling reactions failed 
to proceed to completion after 24 h with the presence of both the starting acid and phenol 
being detectable on TLC and HPLC analysis. The acid starting materials (89, 90 and 107) have 
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increased steric bulk due to the benzyl protecting groups in comparison to the 3,4-dimethoxy 
aminocinnamic acid 50 which could hinder the coupling reactions. The pKa of the phenol in 
33 was predicted to be approximately 12.2 in comparison to the pKa of the phenol of 8 which 
was predicted to be 8.4, therefore the non-nucleophilic base diisopropylethylamine (DIPEA) 
was added to 33 before coupling to try and improve the effectiveness of the reaction, 
however no significant increase in yield was observed.  
 
TFA cleavage of the benzyl protecting groups gave the final SIH-based CICs 114-116 and 
deferasirox ester-based final CICs 117-119 in yields ranging from 16% to 92%. The SIH-based 
CIC 116 and the deferasirox ester-based CIC 119 gave the lowest yields. These CICs both 
required cleavage of two benzyl groups, and TLC and HPLC analysis indicated the presence of 
the starting material after 24 h. The UV/Vis absorbance spectra of CICs 114-119 were 
recorded and are compared in terms of their caging groups in Figures 43-45. 
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Scheme 37. Synthetic route to CICs 114-119. Reagents and conditions: a. 108-110: EDC.HCl, DMAP, anhydrous 
DMF, RT, O/N, 87% (108), 84% (109), 60% (110), 111-113: EDC.HCl, DMAP, DIPEA, anhydrous DMF, 30oC, 24 h, 
39% (111), 32% (112), 19% (113); b. TFA, 30oC, O/N, 78% (114), 77% (115), 37% (116), 92% (117), 57% (118), 
16% (119). 
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Figure 43. UV/Vis absorbance spectra of CICs 114 (A) and 117 (B) in EtOH (100 µM). 
 
 
 
Figure 44. UV/Vis absorbance spectra of CICs 115 (A) and 118 (B) in EtOH (100 µM). 
 
 
Figure 45. UV/Vis absorbance spectra of CICs 116 (A) and 119 (B) in EtOH (100 µM). 
 
The two CICs containing the aminocinnamoyl group with the 4-hydroxy-3-methoxy 
substituents (114 and 117) have a strong maximum absorbance between 295-305 nm and 
absorb considerably up to 440 nm in visible light. 115 and 118 have a 3-hydroxy substituent 
on their caging group and have a maximum absorbance between 290-295 nm and absorb 
weakly to 440 nm. The presence of the 3,4-dihydroxy substituents in 116 and 119 reduces the 
absorptivity at the maximum absorbance (295- 305 nm). CIC 116 absorbs weakly to 440 nm, 
whereas 119 does not absorb higher than 380 nm. 
 
A B 
A B 
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The intact CICs 114-119 were irradiated at increasing doses of UVA (10-250 kJ/m2) and the 
extent of uncaging was followed on analytical HPLC. The corresponding carbostyrils and iron 
chelators were injected on the HPLC as references for the uncaging process. The 
chromatograms for the uncaging of CICs 114-119 are shown in Appendix 1.  Figures 46 and 47 
compare the dose-dependent uncaging of CICs 114-119. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. A representative comparison of the dose-dependent uncaging of the SIH-based CICs 114- 116. 
Percentage uncaging calculated using the peak area of the remaining CIC compared to the peak area of the 
unirradiated sample.   Samples in DMSO solution (1 mg/mL) were irradiated with a 4 kW broad spectrum UVA 
lamp (Sellas, Germany). 
 
 
 
0 50 100 150 200 250
0
20
40
60
80
100
Dose (kJ/m2)
%
 u
nc
ag
in
g 
of
 C
IC
s
114
115
116
 115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47. A representative comparison of the dose-dependent uncaging of the deferasirox ester-based CICs 
117- 119. Percentage uncaging calculated using the peak area of the remaining CIC compared to the peak area 
of the unirradiated sample.  Samples in DMSO solution (1 mg/mL) were irradiated with a 4 kW broad spectrum 
UVA lamp (Sellas, Germany). 
 
CICs 114 and 117 which contain the 4-hydroxy-3-methoxy caging group (red lines on Figures 
46 and 47) both uncage the most efficiently. This is consistent with the absorbance profiles 
of 114 and 117, as they displayed significant absorption over the UVA range (320- 400 nm). 
In general the SIH-based CICs 114-116 uncaged less effectively than the equivalent 
deferasirox ester- based CICs 117-119. Both 115 and 116 did not fully uncage until a dose of 
250 kJ/m2 was delivered, thus photoprotection from these CICs would not be observed before 
several hours of human skin sun exposure and approximately 5 MED. This trend is consistent 
with the uncaging profiles observed in the first series of synthesised CICs. There are no striking 
differences between the absorption spectra of the equivalent SIH- and deferasirox ester-
based compounds which suggests that intramolecular nucleophilic attack upon the ester 
carbonyl is the rate determining step here in the aminocinnamate photo-cleavage 
mechanism. 
 
The MTT assay was used to assess the photoprotective capacity of CICs 114- 119. A final 
concentration of 20 µM of CICs was used, which was incubated with FEK4 cells for 18 h before 
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irradiation of the monolayers of cells at 500 kJ/m2. The results for the photoprotective ability 
of the SIH-based CICs 114-116 are displayed in Figure 48.  
 
 
 
 
 
 
 
 
 
 
 
Figure 48. MTT assay evaluation of the photoprotection afforded by the SIH-based CICs 114-116 along with their 
parent iron chelator SIH 8 in FEK4 fibroblasts. Cells were treated with the compounds (20 µM) overnight before 
± 500 kJ/m2 UVA irradiation, followed by MTT analysis 24 h later. Data is expressed as the mean ± SD compared 
to the untreated unirradiated control, which was fixed at 100% enzymatic activity (n=3-7).  
*= p< 0.05, significantly different from the untreated irradiated control. 
Φ= p <0.05, significantly different from the untreated unirradiated control. 
 
CICs 114 and 115 both improved the cell viability in comparison to the untreated irradiated 
control and CIC 115 significantly protected fibroblasts from UVA-induced loss of cell viability. 
Although none of the CICs improved cell viability more than the parent iron chelator 8 under 
UVA irradiation, CIC 115 was not cytotoxic without UVA irradiation in comparison to the 
significant cytotoxicity seen by 8, 114 and 116 without UVA. CIC 116 did not display an 
increased photoprotective effect due to the antioxidant potential of the carbostyril 95 
released, and this may be due to the aforementioned UVA absorbance profile of 116 and only 
partial uncaging at the applied dose of 500 kJ/m2 (only 40% chemical uncaging was observed 
at a dose of 50 kJ/m2 during chemical irradiation– see Figure 46). Figure 49 shows the 
photoprotective ability of the deferasirox ester-based CICs 117-119. Unfortunately the 
presence of CICs 117 and 118 during UVA irradiation caused a higher loss of cell viability in 
comparison to the untreated irradiated control; they also induced a significant loss of cell 
viability without UVA irradiation, similar to the parent iron chelator 33. CIC 119 with the 3,4-
Co
ntr
ol 8
11
4
11
5
11
6
0
20
40
60
80
100
%
 E
nz
ym
at
ic
 a
ct
iv
ity
No UVA
+ 500 kJ/m2 UVA
* 
* 
Φ 
 
Φ 
 Φ 
 
 117 
dihydroxy motif improved cell viability in comparison to the untreated irradiated control but 
not significantly, however it was not cytotoxic without UVA irradiation. 
 
 
 
 
 
 
 
 
 
 
. 
Figure 49. MTT assay evaluation of the photoprotection afforded by the deferasirox ester-based CICs 117-119 
along with their parent iron chelator deferasirox ester 33 in FEK4 fibroblasts. Cells were treated with the 
compounds (20 µM) overnight before ± 500 kJ/m2 UVA irradiation, followed by MTT analysis 24 h later. Data is 
expressed as the mean ± SD compared to the untreated unirradiated control, which was fixed at 100% enzymatic 
activity (n=3-7).  
*= p< 0.05, significantly different from the untreated irradiated control. 
Φ= p <0.05, significantly different from the untreated unirradiated control. 
 
4. Summary 
 
The synthetic route to a series of interesting carbostyrils with different substituents was 
developed to give carbostyrils 91-95. This synthetic route has the potential to be used with a 
diverse range of starting benzaldehydes. Analysis of the antioxidant potential of the series 
of synthesised carbostyrils using the chemical DPPH assay showed that three of the 
carbostyrils 93, 94 and 95 possessed a positive radical scavenging effect. Of these 
carbostyrils, 94 and 95 were analysed further in the cellular DCFDA assay and showed a 
significant antioxidant potential, especially combined with the iron chelator SIH 8.  
 
Synthesis of SIH and deferasirox ester-based CICs which would release the carbostyrils 93, 94 
and 95 upon UVA-irradiation was achieved via coupling the iron chelators with benzyl- 
protected precursors of the caging groups. The benzyl protecting groups could then be easily 
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removed by stirring the protected CICs in TFA without compromising the stability of the CIC. 
This method afforded a series of six novel multi-functional CICs 114-119 which were fully 
characterised and their UV/Vis absorbance recorded. Out of these synthesised CICs, the 3-
hydroxy aminocinnamic acid-caged SIH CIC 115 performed the best, significantly improving 
the cell viability of UVA- irradiated human fibroblasts. This result correlates with the 
significant antioxidant activity of the combination of SIH 8 and carbostyril 94 in the DCFDA 
assay. 115 delivers a significant photoprotective effect even though it is likely to be only 
partially uncaged under the experimental irradiation dose (500 kJ/m2), thus 115 might provide 
more photoprotection upon longer environmental UVA exposure than 51. 
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CHAPTER 4: RESULTS AND DISCUSSION 
 
1. Abstract 
 
The aim of this chapter was to assess the capacity of improperly applied UVR filters and 
sunscreen formulations to prevent UVA-induced cell death and labile iron release. Sunscreen 
application by consumers is usually far below the recommended application thickness of 2 
mg/cm2, and current formulations do not contain compounds that are designed specifically 
to trap harmful labile iron. As such the potential of CICs to augment the photoprotection 
afforded by sunscreen formulations was also investigated. The studies carried out and the 
underlying aim described above are represented graphically in Scheme 38. 
 
 
 
 
 
 
 
 
Scheme 38. Representation of the investigation into the protection afforded by UVR filters and sunscreen 
formulations against UVA exposure using an in vitro equivalent of real life sunscreen application. 
 
2. Introduction 
 
The SPF of a sunscreen formulation is determined using an application thickness of 2 mg/cm2. 
It has been well documented that sunscreen application by consumers is usually far below 2 
mg/cm2 and is thought to range on average from 0.5- 1.3 mg/cm2.36,65,222-225 For example, in 
a study by Bech-Thomsen et al. in 1993, the average sunscreen application thickness used by 
42 volunteers on a beach holiday was 0.5 mg/cm2.69 In another study by Autier et al., the 
median application thickness applied by 124 European students was 0.39 mg/cm2,226 while 
Cell	viability:	MTT	assay
Labile	iron	release:	calcein assay
Cell	death:
annexin V/PI	 flow	cytometryReal	life	sunscreen	 application In	vitro	equivalent
UVA
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the median quantity of sunscreen applied in a trial by Neale et al. on randomly selected 
Australian residents was 0.79 mg/cm2.227 Sunscreen formulations are also applied rather 
haphazardly, leading to a non-uniform layer of protection. Rhodes et al. demonstrated the 
diversity of sunscreen application by the public by asking 5 patients to apply a quantity of 
sunscreen on their forearm ‘as if they were on the beach’.225 The sunscreen formulation 
applied was excited at 340 nm and gave a strong fluorescence emission at 400 nm, so that 
the sunscreen fluorescence could be quantified using a spectrometer. The results showed a 
significant variability in surface densities and most patients had some sites where no 
sunscreen had been applied.225 
 
These factors greatly affect the actual SPF the consumer receives from a sunscreen 
formulation in comparison to their perceived photoprotection. Liu et al. compared the 
difference in actual SPF at different application thicknesses of low and high SPF 
formulations.222 It was found that sunscreens with SPFs ranging from 4 to 15 showed a linear 
dose-response relationship with application thickness, for example an SPF 10 sunscreen 
applied at a thickness of 0.5 mg/cm2 would give an actual SPF of 2.5. On the other hand, the 
relationship was exponential in high SPF (30+) sunscreens, therefore consumers may be 
receiving an even lower actual SPF when using high SPF products at sub-optimal application 
thicknesses.222  
 
The fact that the general public is actually receiving a much lower level of sun protection than 
they believe is not only relevant to UVB mechanisms of photo-damage and skin cancer 
initiation (described in the Introduction 1.1.3), but also the level of UVA radiation experienced 
and thus oxidative stress and labile iron release in skin cells. 
  
3. Analysis of common sunscreen filters 
 
A range of filters was chosen for analysis of their UVA-photoprotection, based on their Food 
and Drug Administration (FDA) approval status along with market research of the most 
commonly found filters in popular sunscreen brands such as Neutrogena, Nivea, L’Oréal, La 
Roche-Posay, Banana Boat and Piz Buin. The organic filter avobenzone absorbs in the UVA 
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region (320-400 nm) and is the only chemical UVA absorber that has worldwide approval for 
use in sunscreen formulations, therefore it is the most popular UVA filter currently on the 
market despite its photo-instability.75,78 For this reason, including avobenzone in this work 
was very important.  
 
The other available UVR filters that have worldwide approval for use (including the sought 
after FDA approval) are all UVB filters.75 Of these UVB filters, oxybenzone from the 
benzophenone class has the interesting property of also absorbing at 324 nm which is just 
inside the UVA2 range (320-340 nm). Oxybenzone is included in many sunscreen formulations 
as one of the UVB filters with an added UVA advantage, therefore it was also chosen for 
analysis. Octocrylene is a very popular UVB filter and has the added benefit of stabilising 
avobenzone against photodegradation, therefore it is usually included alongside avobenzone 
in a sunscreen formulation to provide a dual function.79,80 The presence of 3.6% (w/v) 
octocrylene has been shown to increase the stability of avobenzone after a quantity of sun 
exposure from 23% avobenzone remaining to 90%, and likewise 5% (w/v) oxybenzone 
increased the amount of avobenzone remaining to 80%.36 The UVA filter Meroxyl SX® 
(ecamsule) is patented by L’Oréal and has a very promising UVA photoprotection profile,81,82 
along with being photo-stable.228 However, it has not been approved for use in the USA, 
except via a new drug application by L’Oréal in 2006 which allowed it to be used in 
concentrations up to 3% (w/v), solely in their products.36 Meroxyl is approved for use in 
Europe and Australia, and as the newest organic UVA filter on the market it was included in 
this selection of organic filters.  
 
The inorganic class of UVR-blocking sunscreen products contain either ZnO or TiO2. These 
products have lower consumer compliance due the likelihood of leaving a white opaque film 
on the skin.65 On the other hand, these inorganic materials are popular UVR filters as they 
provide broad spectrum photoprotection and they are marketed as ‘natural’ and 
‘hypoallergenic’,228 although they are often chemically treated in order to formulate them 
into a sunscreen product.75 In order to combat the unappealing application of ZnO or TiO2-
based formulations, the use of nanoparticle forms of the oxides has become widespread since 
the 1990s, leading to creams that are lighter textured on the skin.76 Nanoparticle formulations 
of TiO2 are approved worldwide, however ZnO is not approved for nano grade in Europe.36 
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Due to the broad spectrum protection that these inorganic blockers provide, these were also 
included in the selection for this work. Nanoparticle sizes of 21 nm and 18 nm for TiO2 and 
ZnO respectively were chosen. This was based on a study by Osmond-McLeod et al. into the 
biological impact of commercially available sunscreen formulations containing TiO2 and ZnO 
nanoparticles. The ZnO and TiO2 nanoparticles in the chosen formulations were characterised 
by transmission electron microscopy (TEM) and found to have average diameters of 18.2 ± 
0.4 nm and 21.5 ± 0.6 nm respectively.76 
 
To have a clear picture of the UVR photoprotection profile of all of the selected sunscreen 
filters, the UVR absorbance spectra of each was recorded in EtOH (10 µg/mL). The spectra are 
shown in Table 7 along with the experimentally determined maximum absorbance (nm). All 
experimentally determined absorption profiles compared well with the reported values for 
each filter,36,229 except for ZnO which did not absorb well above 340 nm (UVA1 region). This 
may have been due to the nanoparticle size, as decreasing the size of the particle leads to 
protection at shorter wavelengths, or the formation of UVR-inactive agglomerates despite 
attempts to make a uniform suspension in EtOH.230  
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Table 7. The sunscreen filters chosen for analysis of their photoprotective effect along with their experimentally 
determined UVR absorbance spectra and their maximum absorbance wavelength in EtOH (10 µg/mL). 
 
Name Absorbance Spectrum Determined 
Maximum 
Absorbance 
(nm) 
Avobenzone 
 
358 
Mexoryl SX 
 
337 
Octocrylene 
 
304 
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Oxybenzone 
 
287, 324 
TiO2 
 
300 
ZnO 
 
300 
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The reported photo-instability of avobenzone occurs due to conversion of the UVA-absorbing 
enol form to the UVC-absorbing keto form upon irradiation at 357 nm75 (Scheme 4, 
Introduction 1.2.2). This significantly decreases the ability of the filter to absorb damaging 
solar radiation. Cantrell et al. examined the kinetic decay of the enol form of avobenzone in 
different solvents using the change in UVR absorbance. The results showed that protic 
solvents such as butanol and ethanol accelerated the transition to the keto form of 
avobenzone, as did the presence of water.79 In a study by Mturi et al., the photostability of 
avobenzone was examined using HPLC. A method was found whereby the enol form of 
avobenzone eluted as a distinct peak at a longer retention time than the keto form, thus 
allowing the relative concentrations of each form (relative peak areas) to be examined after 
irradiation. The HPLC analysis (monitored at a wavelength of 272 nm) confirmed that before 
irradiation avobenzone exists predominantly in the enol form in a variety of solvents, 
indicating that the keto-enol equilibrium of avobenzone lies towards the enol form.78  
 
As the irradiation of avobenzone was central to our work, these findings were checked using 
our broad spectrum UVA lamp and HPLC analysis at a detection wavelength of 280 nm, which 
is very similar to the detection wavelength used by Mturi et al. Figure 50 shows the HPLC 
chromatogram of avobenzone in DMSO before irradiation, along with the retention time of 
the two peaks and their relative areas. Based on the study by Mturi et al. it was assumed that 
the peak with the longer retention time of 12.13 min was the enol form, and the peak at 10.58 
min corresponded to the keto form. The chromatogram obtained before irradiation would 
then be consistent with the tendency of avobenzone to exist in the enol form in unirradiated 
solution, as the relative area of the peak at 12.13 min (75%) was significantly greater in 
comparison to the peak at 10.58 min. 
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Figure 50. HPLC chromatogram at a detection wavelength of 280 nm of unirradiated avobenzone in DMSO (1 
mg/mL) diluted 1 in 10 with MeOH before injection onto the HPLC. The keto form is assumed to be at 10.58 min 
and the enol form is at 12.13 min.78  
 
Mturi et al. reported that the irradiation of avobenzone in DMSO for 15 h (a dose was not 
given but a significant amount of time), decreased the proportion of the enol form of 
avobenzone by 75% according to HPLC analysis. The spectral output of the irradiation source 
used by Mturi et al. was at wavelengths higher than 300 nm, with a maximum output in the 
UVA range of 360 nm. In order to verify the observation in this work, a solution of avobenzone 
in DMSO was irradiated with increasing doses of UVA from 100- 1000 kJ/m2, as this range of 
radiation was relevant to the typical doses used in our cellular experiments. In our hands, 
HPLC analysis at 280 nm showed that even the dose of 1000 kJ/m2 UVA did not decrease the 
percentage relative peak area of the enol form below that of the unirradiated control (shown 
in Table 8). This was consistent across the other 3 detection wavelengths of the HPLC (214, 
220 and 254 nm). This finding indicated that a 1 mg/mL solution of avobenzone in DMSO 
would be photostable at all doses required for our cellular experiments without the addition 
of a photostabilizer. However, in order to closely represent a typical sunscreen filter 
combination, avobenzone was used in conjunction with octocrylene during the latter cellular 
experiments subsequently described here.   
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Table 8. The relative peak areas (percentage) of the keto and enol forms of avobenzone after UVA irradiation at 
doses 100-1000 kJ/m2, established by HPLC analysis at a detection wavelength of 280 nm to analyse the 
photostability of avobenzone in DMSO. 
 
 
4. UVA photoprotection of FEK4 cells by sunscreen filters 
 
In order to test the UVA photoprotection afforded by the chosen sunscreen filters, a suitable 
assay method was required. Previous studies analysing the photoprotection afforded by 
various sunscreens have mostly been carried out by applying a layer of sunscreen or an 
individual filter to a patient or to porcine epidermis,71,231-234 with the amount of sunscreen or 
filter applied being typically calculated from the difference in sunscreen weight before and 
after application. This method was a good starting point for assay development in this study, 
however a more accurate way of applying the filters at exact thicknesses (e.g 0.5 mg/cm2) 
was required. The procedure that was established (described in the Experimental section 
7.2.5) involved using a ‘reservoir’ of filter in DMSO at the correct concentration corresponding 
to the required thickness for the experiment. The reservoir was placed over the top of the 
Petri dish containing a monolayer of FEK4 cells during UVA irradiation. Controls cells were 
covered with a Petri dish containing only DMSO so that transmission of light through the dish 
and the carrier were accounted for. 
 
The FDA stipulates a maximum concentration of filter which can be formulated into a 
sunscreen product (shown in Table 9). Using these concentrations as a starting point, a 
UVA dose (kJ/m2) Relative peak area (%) % of control 
Keto Enol 
0 25 75 - 
100 25 75 100 
250 25 75 100 
500 26 74 99 
750 27 73 97 
1000 26 74 99 
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comparison of publicly available common sunscreen products was carried out and the 
experimental concentrations shown in Table 9 were chosen.  
 
Table 9. The FDA-approved sunscreen filters chosen for this work along with their approved maximum 
concentrations in a sunscreen formulation.  
* This concentration is approved by the FDA solely for L’Oréal products.235  
 
Filter name FDA approved maximum 
concentration in a sunscreen 
formulation (% w/v) 
Concentration used in 
these experiments (% w/v) 
Avobenzone 3 3 
Mexoryl SX 3* 3 
Octocrylene 10 5 
Oxybenzone 6 6 
TiO2 25 20 
ZnO 25 20 
 
 
The amount of filter required to correspond to the chosen concentration of filter at different 
sunscreen thicknesses was calculated as shown in the following worked example for 
avobenzone: 
 
Area of the reservoir used in the experiment= 9.6 cm2 
Amount of sunscreen for a thickness of 2 mg/cm2= 19.2 mg/reservoir 
Concentration of filter in sunscreen formulation= 3% w/v 
Amount of filter required for reservoir= 0.03*19.2= 0.576 mg 
Amount of filter required for reservoir for a thickness of 0.5 mg/cm2= 0.576/4= 0.144 mg 
 
The correct amount of filter required per reservoir was made up into 500 µL DMSO in every 
experiment. Using this method, FEK4 cells were irradiated at 500 kJ/m2 UVA covered by a 
reservoir of sunscreen filter at thicknesses of 2 mg/cm2 and 0.5 mg/cm2. The thickness of 2 
mg/cm2 is the amount used for the SPF calculation of a sunscreen,100 therefore this thickness 
was chosen as a control along with the thickness of 0.5 mg/cm2, which is closer to the 
thickness of sunscreen that a consumer commonly applies. MTT assay analysis was carried 
out 24 h after UVA exposure, and the results of the assays for the four chosen organic filters 
avobenzone, Mexoryl SX®, oxybenzone and octocrylene are shown in Figure 51. 
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Figure 51. MTT assay evaluation of the UVA photoprotection afforded by four popular organic sunscreen filters 
in FEK4 fibroblasts. Cells were ± covered with a reservoir of the sunscreen filter at thicknesses of 0.5 mg/cm2 or 
2 mg/cm2 and then exposed to a 500 kJ/m2 dose of UVA radiation followed by MTT analysis 24 h later. Data is 
expressed as the mean ± SD compared to the unirradiated control, which was fixed at 100% enzymatic activity 
(n=3-5).  
* = p <0.05, significantly different from cells covered by 2 mg/cm2 of the same filter. 
Φ = p <0.05, significantly different from the unprotected cells. 
 
The results of this assay show that at the recommended sunscreen thickness of 2 mg/cm2 
there is no significant loss of enzymatic activity for the three organic filters that absorb in the 
UVA region (avobenzone, Mexoryl SX and oxybenzone), as expected. The enzymatic activity 
for 5% (w/v) octocrylene decreased to 72% at 2 mg/cm2 which is consistent with octocrylene 
being primarily a UVB filter, but which has some absorption between 320-360 nm in the UVA 
region (absorbance spectrum shown in Table 7). At a sunscreen thickness of 0.5 mg/cm2, the 
two predominantly UVA filters, avobenzone and Mexoryl SX®, both afforded significantly less 
photoprotection (74% and 75% enzymatic activity respectively) compared to the 2 mg/cm2 
control. The photoprotective capacity of oxybenzone was also significantly reduced to a 
similar level to that of the unprotected control, indicating that at the reduced concentration 
(thickness) the UVA-absorbing capacity of the filter was exceeded. These results suggest that 
at the thickness of sunscreen that a consumer usually applies, the level of UVA 
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photoprotection afforded by the specific filters investigated is markedly reduced. The same 
assay was carried out with the two inorganic filters TiO2 and ZnO in suspensions in DMSO to 
the required concentrations for 2 mg/cm2 and 0.5 mg/cm2 sunscreen thicknesses, and the 
results are shown in Figure 52. 
 
Figure 52. MTT assay evaluation of the UVA photoprotection afforded by the two inorganic sunscreen filters in 
FEK4 fibroblasts. Cells were ± covered with a reservoir of the sunscreen filter at thicknesses of 0.5 mg/cm2 or 2 
mg/cm2 and then exposed to a 500 kJ/m2 dose of UVA radiation followed by MTT analysis 24 h later. Data is 
expressed as the mean ± SD compared to the unirradiated control, which was fixed at 100% enzymatic activity 
(n=3-5).  
* = p <0.05, significantly different from cells covered by 2 mg/cm2 of the same filter. 
Φ = p <0.05, significantly different from the unprotected cells. 
 
These results indicate that at 0.5 mg/cm2 the broad spectrum UVB/UVA filter TiO2 (20% w/v) 
provided the best photoprotection (82% enzymatic activity) out of all the individual filters 
tested. At a sunscreen thickness of 0.5 mg/cm2 the photoprotective capacity of ZnO (20% w/v) 
was markedly less, with a reduction to 60% enzymatic activity, consistent with the lack of 
absorption above 340 nm that was observed previously (spectrum shown in Table 7) and 
hence inadequate UVA photoprotection. 
 
Figure 53 presents photographic evidence to support the loss of enzymatic activity upon 
photoprotection by 3% (w/v) avobenzone in a sunscreen thickness of 0.5 mg/cm2. The images 
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were taken 24 h post-UVA irradiation before the MTT assay was carried out. Panel A shows 
the characteristic morphology of healthy FEK4 fibroblasts, with elongated flattened cells 
growing in an irregular manner. Panel B is after a dose of 500 kJ/m2 UVA irradiation (1 MED), 
where many of the cells have become rounded and raised as they detach from the surface of 
the dish. Blebbing of the plasma membrane occurs, characterized by the spherical bulky 
morphology of the cells. The photoprotection afforded by 3% (w/v) avobenzone at a 
sunscreen thickness of 0.5 mg/cm2 is seen in panel C. Here, there is smaller percentage of 
blebbing cells relative to the number of healthy fibroblasts which have remained elongated 
and attached to the dish surface. 
 
 
Figure 53. Images of FEK4 fibroblasts taken 24 h post UVA irradiation. A. Negative control, cells were not 
irradiated; B. Positive control, cells irradiated with 500 kJ/m2 UVA; C. Cells protected with 3% (w/v) avobenzone 
at a sunscreen thickness of 0.5 mg/cm2 and irradiated with 500 kJ/m2 UVA. Images captured on a Motic AE2000 
inverted microscope (Motic Deutschland GmbH, Wetzlar, Germany) via a Moticam 580 digital camera. 
 
5. Intracellular labile iron release in UVA irradiated cells 
 
As described in the Introduction 1.1.4, the release of labile iron in the cell cytosol through 
UVA-induced oxidative damage is a significant mechanism of cell death. To determine the 
extent of UVA-induced labile iron release in FEK4 fibroblasts, the fluorescent divalent metal 
probe calcein (CA) was employed. Calcein acetoxymethyl (CA-AM) is a non-fluorescent 
compound which is readily loaded into live cells. Intracellular esterases then convert CA-AM 
into the green-fluorescent CA via cleavage of the acetoxymethyl groups, as shown in Scheme 
39. Fluorescent CA is excited at 490 nm and emits at 517 nm. 
 
 
A B C 
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Scheme 39. Conversion of CA-AM to the fluorescent CA in the cytosol of cells by intracellular esterases. 
 
CA can act as a metal-sensitive probe in solution and has been shown to bind iron with a 1:1 
stoichiometry.236,237 When CA is bound to iron [CA-Fe], the fluorescence of CA is quenched. It 
is considered that not all CA will be bound to iron in the cytosol, but instead is in equilibrium 
with free iron that is loosely bound to endogenous ligands (e.g ATP, glutathione)238 as follows:  
 
[CA]* + [Fe] ⇌ [CA-Fe]    
                                                                                                  
The quenching of CA by iron can be reversed by the addition of an excess of the lipophilic cell 
membrane-permeant iron chelator SIH 8, which has a very high affinity for ferric iron (pFe3+ = 
24.6)105. The unquenched CA gives rise to an increase in fluorescence (ΔF) which is equivalent 
to the available chelatable labile iron (Fe2+) in the cytosol, [CA-Fe]. UVA-induced labile iron 
release is overlooked in conventional commercially available sunscreen products, therefore 
when a consumer applies a typical amount of sunscreen formulation (0.5 mg/cm2) there is a 
possibility that they are compromised in terms of the detrimental effects of labile iron 
generated within skin cells. In order to analyse the hypothesis that the application of a sub-
optimal thickness of sunscreen before UVA exposure could lead to intracellular labile iron 
release, FEK4 cells were ± protected by 3% (w/v) avobenzone + 5% (w/v) octocrylene at 0.5 
mg/cm2 prior to irradiation at a dose of 250 kJ/m2 and analysed using the calcein assay via the 
spectrofluorimeter method as described in the Experimental Section 7.2.10.1.  
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Following UVA-irradiation, FEK4 cells were incubated with CA-AM (0.05 µM) and the cell 
suspension was transferred to a cuvette. The fluorescence of the cell suspension was 
recorded on the F-4500 (Hitachi High-Technologies), and then SIH 8 (40 µM) was used to elicit 
a change in fluorescence due to displacement of CA by the iron chelator, giving the free [CA]* 
as a function of the original [CA-Fe]= 
 
[CA-Fe] ® [SIH-Fe] + [CA]* 
  
A schematic to explain this change in fluorescence as described above is represented in Figure 
54. Table 10 presents the results from a typical assay showing the calculation of the change 
in fluorescence per 106 cells and the fold- increase in intracellular chelatable labile iron upon 
250 kJ/m2 UVA irradiation ± 3% (w/v) avobenzone + 5% (w/v) octocrylene at 0.5 mg/cm2 in 
comparison to the level of intracellular chelatable labile iron in the control. 
 
 
 
 
Figure 54. Diagram representing the fluorescence signal of a cell suspension before and after addition of SIH 8 
(40 µM). The average fluorescence is indicated by F1 and F2, which were used to calculate the change in 
fluorescence (ΔF). 
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Table 10. Example assay results and the respective calculations to find the fold-increase in chelatable labile iron 
per 106 FEK4 cells. 
 
  
Control 250 kJ/m2 UVA 0.5 mg/cm
2 filters + 
250 kJ/m2 UVA 
no SIH 
(F1) SIH (F2) 
no SIH 
(F1) SIH (F2) 
no SIH 
(F1) SIH (F2) 
Average 
fluorescence (AU) 8640 9142 8348 9042 7074 7638 
Cell count (x106) 0.413 0.378 0.401 
 ΔF 0.055 0.077 0.074 
 ΔF/ 106 0.133 0.203 0.185 
Fold increase 1 1.53 1.39 
 
 
This experiment was repeated to n=8 to give the average fold-increase in chelatable labile 
iron in comparison to the unirradiated control, and the results are displayed in Figure 55. The 
average fold-change in fluorescence for the cells irradiated with 250 kJ/m2 UVA was 1.92 ± 
0.42, whereas the corresponding increase for irradiated cells protected with 0.5 mg/cm2 3% 
(w/v) avobenzone + 5% (w/v) octocrylene was 1.31 ± 0.18. The fold-change in intracellular 
labile iron with 0.5 mg/cm2 3% (w/v) avobenzone + 5% (w/v) octocrylene was significant 
compared to the control unirradiated cells, indicating that using a sub-optimal sunscreen 
thickness of the filter avobenzone stabilized with octocrylene does indeed lead to release of 
detrimental intracellular labile iron which can cause severe oxidative damage within the cell. 
This is consistent with the loss of enzymatic activity seen in the MTT assays. These results 
confirmed that this version of the calcein assay could be used to reproducibly monitor 
changes in the level of intracellular labile iron upon UVA irradiation. Although a highly 
valuable assay, the single cuvette format does not allow sufficiently high throughput. This is 
due to the timescale of the experiment: stabilisation of the base-line fluorescence plus 
stabilisation of the fluorescence after addition of SIH takes approximately 15 min per cuvette 
sample. Zhong et al. demonstrated that FEK4 cells irradiated at 250 kJ/m2 UVA returned to 
the basal level of intracellular labile iron 6 h post UVA irradiation.151 Consequently, this is the 
amount of time required for the intracellular homeostasis of iron to return to normal. In order 
to minimise the time-sensitive loss of labile iron, it was therefore practical to translate the 
assay to a microplate format to achieve greater throughput in the subsequent studies. 
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Figure 55. Calcein assay for FEK4 cells protected by ± 3% avobenzone + 5% (w/v) octocrylene at 0.5 mg/cm2, 
showing the fold-changes in intracellular labile iron upon irradiation with a dose of 250 kJ/m2 UVA. (n= 8) 
* = p <0.05, significantly different from unirradiated control cells. 
 
 
6. Combination of sunscreen filters and CICs 
 
The results of the MTT assays revealed that in all cases the photoprotection provided by a 0.5 
mg/cm2 sunscreen thickness of individual common UVR filters was significantly lower than 
the photoprotection afforded by the recommended 2 mg/cm2 of the same filter. Alongside 
these results was the observation that a 0.5 mg/cm2 sunscreen thickness of 3% (w/v) 
avobenzone + 5% (w/v) octocrylene (the FDA maximum concentration) results in a 1.31 fold 
increase in intracellular labile iron upon UVA irradiation. Together these data build the 
argument that implementing a CIC into a sunscreen formulation could lead to improved 
protection against UVA-induced oxidative damage and enhanced cell survival when 
sunscreens are applied at sub-optimal thicknesses. In order to investigate this hypothesis, two 
commercially available sunscreen formulations from well-known brands were chosen. The 
sunscreen formulations were selected because they contained either avobenzone or Mexoryl 
SX® or both as their primary UVA filter, however the concentrations are unknown as 
formulation information is not disclosed in the UK: 
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Formulation 1 
Name: Nivea Sun Protect & Moisture Lotion SPF30  
Active UVR filters: avobenzone (UVA), homosalate (UVB), octocrylene (UVB), octisalate 
(UVB), nanoparticle TiO2 (UVA/B).  
Contains vitamin E as an antioxidant. 
 
Formulation 2 
Name: La Roche-Posay Anthelios XL Ultra Light Fluid SPF50+ 
Active UVR filters: avobenzone (UVA), Mexoryl SX (UVA), octocrylene (UVB), ethylhexyl 
triazone (UVB-not FDA approved), Mexoryl XL (UVA/B-not FDA approved), bis-
ethylhexyloxyphenol methoxyphenyl triazine (UVA/B- not FDA approved). 
 
In order to assess whether CICs had a positive photoprotective effect when used in 
conjunction with a sunscreen formulation applied at a thickness of 0.5 mg/cm2, the dual 
staining  annexin V and propidium iodide (PI) assay was employed to assess necrotic cell death 
rather than enzymatic activity as per the MTT assay. The translocation of phosphatidylserine 
(PS) from the cytoplasmic surface of the plasma cell membrane (as per normal viable cells) to 
the outer cell membrane, is a well-known hallmark of cell apoptosis.239 The Ca2+-dependent 
phospholipid-binding protein, annexin V, has a high affinity for PS, therefore exposure of PS 
to the external cellular environment allows it to be detected by annexin V. Conjugation of 
annexin V with the dye, Alexa Fluor 488, provides a highly fluorescent probe that can reliably 
detect cell apoptosis in a cell suspension, with excitation at 495 nm and emission at 519 nm. 
Apoptosis is a normal process of programmed cell death which is required for the 
maintenance of tissue under pathological conditions. In apoptosis, the cell actively 
participates in its own destruction, and annexin V-positive staining can therefore provide an 
indication of early apoptosis of cells as they perform their natural function.  
 
PI is a DNA base intercalator with limited sequence preference, and as it does not permeate 
live cells, it is a popular fluorescent stain for the detection of dead or damaged cells (necrotic 
cells). PI is excited at 535 nm and emits at 617 nm.239 Dual positive staining of cells with both 
annexin V and PI indicates a loss of membrane integrity which accompanies late apoptotic or 
necrotic ‘unprogrammed’ cell death due to external factors. This assay therefore allows one 
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to distinguish between the two forms of cell death.239 It has previously been reported that 
necrosis is the primary mode of fibroblast cell death induced by UVA irradiation, and 
therefore this end point is commonly used to analyse the impact of UVA radiation.151 However 
due to the highly oxidative environment induced by UVA radiation and the potentital of the 
ROS generated to damage DNA, repair processes such as the tumour suppressor protein p53 
may be activated. Apoptosis is regulated by p53 and therefore may be induced if repair 
processes fail, as such it is possible for some UVA-induced apoptosis to occur as well as 
necrosis under UVA irradiation.240 The ability to stain for both of these cell death procedures 
in the annexin V/PI assay enables analysis of the amount of live cells remaining after UVA 
irradiation which is more reliable than analysing the presence of necrotic cells.  
 
The assay was carried out as described in the Experimental 7.2.9, and the photoprotective 
capacity of 0.5 mg/cm2 of the sunscreen formulations along with 3% (w/v) avobenzone + 5% 
(w/v) octocrylene were first tested independently. The outdoor radiometer readings that 
were reported in Chapter 2.3 indicated that on a British summer’s day, a dose of 500 kJ/m2 
UVA would equate to 80 min of sun exposure. The mean daily sun exposure ranges from 2.6-
3.1 h depending on the SPF of the sunscreen applied,241 therefore UVA doses of 500 kJ/m2 
and 750 kJ/m2 ( 2 h of sun exposure or 1-1.5 MED) were used in the initial experiments. FEK4 
cells were covered with ± 0.5 mg/cm2 of an appropriate sunscreen/filter before irradiation, 
and then 24 h post-irradiation, the assay was carried out and analysis was performed on the 
flow cytometer. 10,000 events were recorded which were gated to separate intact cells from 
cell debris. This population was split into quadrants Q1-4, where Q1= PI-positive cells only; 
Q2= dual stained annexin V/PI-positive cells; Q3= cells negative for both stains; Q4= annexin 
V-positive cells only. A representative example of the gating for the negative control, 750 
kJ/m2 UVA and 0.5 mg/cm2 formulation 1 + 750 kJ/m2 UVA conditions is shown in Figure 56. 
The average percentage live cells (percentage of Q3) for each condition were used to create 
Figure 57. 
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Figure 56. Representative example of the gating in an annexin V/PI assay. Panel 1. Control unirradiated cells; 
Panel 2. Cells irradiated with 750 kJ/m2 dose of UVA; Panel 3. Cells covered with 0.5 mg/cm2 of formulation 1 
and irradiated with 750 kJ/m2 dose of UVA. a. Initial gating of cells to exclude cell debris to give P1; b. Splitting 
of P1 into quadrants Q1-4 with the annexin V stain on the x axis and PI stain on the y axis; c. Table showing the 
percentage of events in each quadrant of P1.  
 
 
 
 
1a 1b 
1c 
2a 2b 
2c 
3c 3b 3a 
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Figure 57. Flow cytometry analysis of UVA photoprotection of FEK4 cells, showing the average percentage of 
live cells. Cells were irradiated with a UVA dose of either 500 kJ/m2 or 750 kJ/m2 and covered with 0.5 mg/cm2 
of either formulation 1, formulation 2, or filters (3% (w/v) avobenzone + 5% (w/v) octocrylene). The assay was 
carried out 24 h post irradiation (n= 4). 
* = p <0.05, significantly different from unirradiated control cells. 
Φ = p <0.05, significantly different from cells protected with the same formulation irradiated at 500 kJ/m2. 
 
The results of the assays reveal that both of the commercial sunscreen formulations protect 
human skin fibroblasts against UVA-induced cell death at an application thickness of 0.5 
mg/cm2 for 80 min on a British summer day (500 kJ/m2 UVA or 1 MED). Without any 
photoprotection, the 500 kJ/m2 irradiated control has an average of 52.2 % live cells. 
Protection with 3% (w/v)  avobenzone + 5% (w/v) octocrylene is significantly different from 
the unirradiated control at a dose of 500 kJ/m2 which indicates the increased UVA protection 
afforded by the additional active UVA filters in the sunscreen formulations. When the dose 
was increased to 2 h (750 kJ/m2), all three conditions were significantly different to the 
unirradiated control which indicates that the UVA radiation protection afforded by an 
application thickness of 0.5 mg/cm2 sunscreen only lasts between 80-120 min.   
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The photoprotection afforded by CICs is expected to be through their quenching of labile iron 
generated by UVA rather than by acting as UVA filters. CICs 51 and 115 were evaluated 
independently in the annexin V/PI assay for their photoprotective capacity as they had been 
observed to be the best-performing compounds in the MTT assays (Chapter 2.4 and Chapter 
3.3). This assay also allowed the lack of cytotoxicity of 51 and 115 without irradiation to be 
confirmed. FEK4 cells were treated with ± CICs 51 and 115 (20 µM) before irradiation with 
500 kJ/m2 or 750 kJ/m2 UVA, and the results are shown in Figure 58. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58. Flow cytometry analysis of UVA photoprotection of FEK4 cells, showing the average percentage of 
live cells. Cell were incubated overnight with CICs 51 and 115 (20 µM) before irradiation with a UVA dose of 
either 500 kJ/m2 or 750 kJ/m2 UVA. The assay was carried out 24 h post irradiation (n= 4). 
* = p <0.05, significantly different from untreated control cells irradiated with a dose of 750 kJ/m2. 
 
Both CICs 51 and 115 were found to be effective in protecting human skin cells against UVA-
induced cell death. At a dose of 500 kJ/m2, the control irradiated cells have an average of 
52.2% live cells, which is markedly increased by CICs 51 and 115 to 76.4% and 73.6% live cells 
respectively. At a dose of 750 kJ/m2, the presence of CICs 51 and 97 significantly increases the 
percentage of live cells compared to the irradiated control from 17.5% to 32.5% and 43.6% 
live cells respectively. 
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Finally, we tested whether CICs such as 51 and 115 are able to act as a secondary line of 
defence once the full photoprotective capacity of a sunscreen applied at sub-optimal 
thickness is exceeded. A dose of 750 kJ/m2 was chosen for these assays since at this dose it 
had been observed that the photoprotection afforded by the sunscreen formulations had 
diminished and the CICs also provided the most significant increases in protection. FEK4 cells 
were incubated overnight with CICs 51 and 115 (20 µM) and then covered with 0.5 mg/cm2 
sunscreen formulation or filter combination before irradiation. The assay was carried out 24 
h later and the results are displayed in Figure 59. 
 
Figure 59. Flow cytometry analysis of UVA photoprotection of FEK4 cells, showing the average percentage of 
live cells. Cell were incubated overnight with CICs 51 and 115 (20 µM) before irradiation with a UVA dose of 750 
kJ/m2 UVA whilst covered with 0.5 mg/cm2 of sunscreen formulation or filters (3% (w/v) avobenzone + 5% (w/v) 
octocrylene). The assay was carried out 24 h post irradiation (n= 3).  
* = p <0.05, significantly different from cells only protected by the respective sunscreen/filter. 
 
The combined photoprotective effect of CICs with 0.5 mg/cm2 sunscreen formulation or filters 
when irradiated at 750 kJ/m2 was found to be significant in comparison to the sunscreen 
formulation/filter alone in all cases except for CIC 51 with formulation 2. CIC 115 performed 
very well, restoring the percentage of live cells of formulation 1, formulation 2 and 3% (w/v) 
avobenzone + 5% (w/v) octocrylene to 91.0%, 91.4% and 88.0% respectively. Conducting a 
comparison of the levels of uncaging of CICs 51 and 115 with increasing doses of UVA (shown 
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in Figures 32 and 46 respectively) suggests that the superior photoprotection observed for 
CIC 115 at the higher dose of 750 kJ/m2 UVA may be due to its slower uncaging profile, with 
respect to CIC 51. Thus 115 exerts more powerful photoprotection at higher UVA doses where 
uncaging of the CIC also delivers an antioxidant moiety.  
 
These data are important as they suggest that the presence of an iron chelator that is 
activated upon UVA irradiation provides increased photoprotection compared to a sunscreen 
alone. As seen in Chapter 3.2, the presence of an iron chelator alone has a more substantial 
effect on reducing intracellular ROS than the presence of a carbostyril alone. This indicates 
that the increase in photoprotection seen here is primarily through the mechanism of labile 
iron chelation, with the release of a secondary antioxidant molecule playing a more minor 
role. The real impact of these results however, is that CICs do provide extra photoprotection 
that is relevant to a real-world setting and thus may help prevent skin cancer in consumers 
who apply sunscreen formulations too thinly, unevenly or infrequently.  
 
To confirm that the increased photoprotection observed with these CICs was by chelation of 
UVA-induced labile iron, the calcein assay was performed on FEK4 cells ± incubated with CIC 
51 (20 µM) before irradiation with 500 kJ/m2 UVA. The following calcein assays were 
performed in microplate format on the CLARIOstar microplate reader rather than in the 
cuvette format, due to the greater throughput that could be achieved with this equipment  
for these time-sensitive experiments. The results are shown in Figure 60 as a fold-change in 
fluorescence per 106 cells in comparison to the unirradiated, untreated control cells. 
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Figure 60. Calcein assay analysis of the change in intracellular labile iron upon irradiation with 500 kJ/m2 UVA ± 
CIC 51 (20 µM). Data is represented as a fold- change in fluorescence (ΔF) per 106 cells of FEK4 cells, compared 
to the untreated unirradiated control which was set to 1. (n= 3)  
* = p <0.05, significantly different from the respective control cells. 
 
Irradiation at 500 kJ/m2 UVA increased the fluorescence per 106 cells by an average fold-
change of 4.59 compared to the unirradiated control cells. Cells that were incubated with CIC 
51 (20 µM) prior to UVA irradiation reduced the fold-increase in fluorescence to an average 
of 1.10, indicating a positive uncaging of the iron chelator SIH 8 to yield a UVA-induced labile 
iron quenching effect. The assay was then repeated by incubating cells with ± CIC 51 overnight 
and then covering cells with 0.5 mg/cm2 sunscreen formulation 1, 2 or filter combination (3% 
(w/v) avobenzone + 5% (w/v) octocrylene) during irradiation at 500 kJ/m2 UVA. These results 
are represented in Figure 61. 
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Figure 61. Calcein assay analysis of the change in intracellular labile iron upon irradiation of FEK4 cells protected 
by 0.5 mg/cm2 of formulation 1, formulation 2 or combined filters (3% (w/v) avobenzone + 5% (w/v) octocrylene) 
with 500 kJ/m2 UVA ± CIC 51 (20 µM). Data is represented as a fold- change in fluorescence (ΔF) per 106 cells of 
FEK4 cells, compared to the untreated unirradiated control which was set to 1. (n= 3)  
* = p <0.05, significantly different from the respective cells protected solely by the sunscreen formulation or 
filter. 
 
The results of this assay show average fold-changes in fluorescence in comparison to the 
untreated unirradiated control of 2.68, 2.40 and 3.08 for 0.5 mg/cm2 of formulation 1, 
formulation 2 and the filter combination respectively, after a dose of 500 kJ/m2 UVA 
irradiation. This data is consistent with the significant cell death observed under the same 
conditions in the flow cytometry assays, using a dose of 750 kJ/m2. However, after overnight 
incubation of the cells with CIC 51 (20 µM) the fold-change in fluorescence is significantly 
decreased to a similar level as the untreated, unirradiated control in all three conditions. This 
result is also consistent with the observed recovery of live cells seen in the flow cytometry 
analysis upon addition of a CIC to cells covered by 0.5 mg/cm2 of a sunscreen formulation or 
filter. This indicates that a sub-optimal thickness of a commercial sunscreen formulation does 
not prevent UVA-induced labile iron release and that the presence of an activatable strong 
iron chelator, such as SIH 8, can be very beneficial in quenching the immediate onset of free 
intracellular iron. The annexin V/PI assays were carried out 24 h post-irradiation, hence the 
presence of apoptotic and necrotic cells were due to immediate cell death initiated by acute 
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UVA irradiation, however this does not account for the accumulation of damage caused by 
severe labile iron-induced oxidative stress which is demonstrated by these calcein assays. 
 
The fluorescence of the supernatant from the final centrifugation step of the 500 kJ/m2 UVA 
condition was also recorded during the calcein assays. This allowed the calculation of the 
fluorescence leakage of CA out of the cells due to loss of membrane integrity during 
irradiation. The average fluorescence leakage calculated as a percentage of the total 
fluorescence from the 500 kJ/m2 sample was 11.6%, therefore all fluorescence data for these 
calcein assays has an error of ± 11.6%.  
 
Understanding the significance of a change in fluorescence of CA (ΔF) within the FEK4 
fibroblast cell system in terms of the concentration of chelatable labile iron rather than just 
the fold-change in fluorescence compared to the unirradiated control would enable the 
qualitative data displayed in Figures 60 and 61 to be converted into quantitative data. To 
achieve this, a titration was carried out whereby the ΔF of CA was monitored by quenching 
with Fe2+ in the form of ferrous ammonium sulphate (FAS). The titration was performed in 
microplate format on the CLARIOstar microplate reader to be consistent with the calcein 
assays performed for Figures 60 and 61. FEK4 cells were cultured and prepared for the 
titration as explained in the Experimental Section 7.2.10.3, and the ionophore A23187 (5 µM) 
was first added to the cells in suspension as described by Breuer et al. to permeabilise the cell 
membranes towards divalent metal ions.236 The first fluorescence reading was recorded and 
then deoxygenated FAS was added in 0.5 µM increments as a source of Fe2+ ions to elicit step 
decreases in fluorescence.238 The results of the average of three repeats of the titration are 
shown in Figure 62, with the fluorescence being normalised against the initial fluorescence 
reading before addition of FAS. The results indicate that CA forms a non-fluorescent [CA-Fe] 
adduct with Fe2+ permeabilised to the cytosol, assuming that the concentrations of Fe2+ in the 
buffer and the cytosol are equivalent. In the presence of physiological levels of glutathione, 
Fe2+ is scavenged by SIH as Fe3+, therefore the Fe2+ delivered by FAS corresponds to the labile 
iron that would be released upon UVA exposure and is suitable for quantification of cytosolic 
labile iron in the calcein assay.105 
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Figure 63 was generated by converting the normalised fluorescence into the change in 
fluorescence (ΔF) upon addition of increasing concentrations of FAS, and a cell count was 
performed after the assay and the change in fluorescence was adjusted per 106 cells. The line 
of best fit was obtained using linear least-squares regression, with an R2 value of 0.9753 
indicating a good fit of the data. The line equation (y = 0.8057x – 0.05286) could then be used 
to calculate the concentration of chelatable labile iron in the cytosol, [Ca-Fe], that was 
associated with an experimentally determined change in fluorescence.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 62. Titration of CA-AM (0.05 µM) with 0.5 µM increments of ferrous ammonium sulphate (FAS) in FEK4 
fibroblasts, represented as the change in fluorescence normalised to the control (0 µM FAS) against FAS 
concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 63. Change in fluorescence (ΔF) per 106 cells upon addition of increasing concentrations of FAS. The line 
of best fit was obtained using linear least-squares regression.  
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An estimate of the concentration of chelatable intracellular labile iron was made using the 
FAS titration and the equation of the line from Figure 63, and the data is shown in Table 11. 
This transformed data gives a more comprehensive representation of the calcein assay data 
than Figures 60 and 61.  
 
Table 11. Estimation of the concentration of intracellular chelatable labile iron (µM) in FEK4 cells under different 
conditions, calculated using FAS titration of CA giving the line equation y=0.8057x – 0.05286, represented as the 
mean ±SD. The fold-change in average concentration compared to the untreated unirradiated control is also 
shown. (n=3) 
* = p <0.05, significantly different from the respective cells protected solely by the sunscreen formulation or 
filter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The fold-changes (in comparison to the untreated unirradiated control) were calculated using 
the average estimated concentrations of intracellular chelatable labile iron rather than the 
differences in fluorescence. Calibrating the change in fluorescence using the FAS 
concentration titration curve gives more accurate data which follows the same trend as 
Figures 60 and 61. Table 11 indicates that the fold-change in chelatable labile iron 
concentration is 3.56 for the condition irradiated with 500 kJ/m2 UVA, while overnight 
incubation with CIC 51 (20 µM) reduces the chelatable labile iron to 1.64-fold. The presence 
 
Condition 
Concentration 
intracellular labile 
iron (µM) 
Fold change in 
concentration 
No UVA 0.39 ±0.32  1.00 
500 kJ/m2 UVA 1.39 ±0.53 3.56 
CIC 51 - UVA 0.42 ±0.23 1.08 
CIC 51 + UVA 0.64 ±0.33 1.64 
formulation 1 + UVA 0.81 ±0.45 2.08 
formulation 1/CIC 51 + UVA 0.42 ±0.06 1.08 
formulation 2 + UVA 0.69 ±0.17 1.77 
formulation 2/CIC 51 + UVA 0.41 ±0.10 * 1.05 
3% (w/v) avobenzone + 5% (w/v) 
octocrylene + UVA 
0.64 ±0.11 1.63 
3% (w/v) avobenzone + 5% (w/v) 
octocrylene /CIC 51 + UVA 
0.43 ±0.10 * 1.10 
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of the CIC after overnight incubation in unirradiated cells does not seem to cause a reduction 
in the chelatable labile iron in comparison to the control (1.08), indicating that the CIC is stable 
and does not chelate iron using the two available coordination sites. When sunscreen 
formulation 2 or the filter combination was irradiated with 500 kJ/m2 UVA in the presence of 
CIC 51, there was a significant reduction in the chelatable labile iron compared to the 
sunscreen alone, for example formulation 2 under irradiation gives a fold-increase in 
chelatable iron concentration of 1.77 which is decreased to 1.05 with overnight incubation of 
CIC 51. 
 
7. Summary 
 
The results of both the annexin V/PI flow cytometry and the calcein assays suggest that the 
use of a CIC in conjunction with a sunscreen formulation can be beneficial in increasing the 
cell survival of human skin cells through quenching of UVA-generated labile iron, which may 
have noteworthy impact in preventing skin photoaging or cancer. A CIC as an additive in a 
sunscreen formulation could act as a second line of defence when a sub-optimal thickness of 
sunscreen is applied to the skin (0.5 mg/cm2). The annexin V/PI assays were carried out using 
a dose of 750 kJ/m2 which elicited a reduction in percentage live cells in cells protected by 0.5 
mg/cm2 sunscreen, however this dose (2 h sun exposure or 1.5 MED) is still lower than the 
suggested average time of sun exposure (2.6- 3.1 h). With this in mind if the trend in reduction 
of percentage live cells continued in the same manner as it did between the doses of 500-750 
kJ/m2, it could be hypothesised that at the higher doses there would be considerably fewer 
live cells and therefore the presence of a CIC would be more important and would have the 
potential to significantly bridge the gap in sun photoprotection. This has the impact of a 
sunscreen formulation potentially being awarded a higher UVA-PF rating thus improving the 
level of photoprotection consumers would receive.  The calcein assays were carried out 
immediately post-500 kJ/m2 UVA irradiation and as such demonstrate the presence of 
intracellular chelatable iron immediately after 80 min of sun exposure. At this time the 
endogenous antioxidant defences of the cell (described in the Introduction 1.1.4) are 
overcome with the highly oxidative environment induced by UVA, and intracellular iron 
homeostasis is disturbed.  
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CHAPTER 5: RESULTS AND DISCUSSION 
 
1. Introduction 
 
In 1908 Beijerinck made the observation that the yeast Candida pulcherrima formed a red 
pigment when grown in media containing iron salts, conversely if the yeast was grown on 
iron- deficient media the pigment was not produced. The addition of a ferric salt solution to 
yeast growing on iron-deficient media caused the colonies and the surrounding media to turn 
red.242 It was postulated in this study that C. pulcherrima produces a colourless precursor that 
reacts in the presence of iron and oxygen to form the pigment. In 1946, Roberts further 
investigated the factors affecting the production of this pigment and found that strongly 
pigmented cells were non-viable. This finding indicated that pigment production by the yeast 
was a pathological defence reaction against a toxic concentration of iron in the media.243  
The pigment was named pulcherrimin by Van Der Walt and the chemical structure was 
subsequently investigated.244 Kluyver et al. isolated pulcherrimin from C. pulcherrima in 1953 
and reported some of its chemical properties. It was shown that the iron content of the 
pigment was 12.4% or higher, and that it was very resistant to hydrolysis by relatively strong 
acid. Even after boiling in 50% concentrated HCl in EtOH for 6-10 h, some of the pigment 
remained undissolved.245 Notwithstanding its high acid resistance, the resulting liquid 
produced from hydrolysis was tested for the presence of amino acids and the only amino acid 
found in a significant amount was leucine. Pyrolysis of the pulcherrimin pigment was carried 
out using zinc dust under vacuum at 220oC, which allowed elemental analysis of the white 
needles which formed. The molecular formula from pyrolysis in this way was reported as 
C12H18N2O2. At a similar time, parallel work was being undertaken by Dutcher into the 
structure of aspergillic acid (shown in Figure 64), an antibiotic compound excreted by the 
fungus Aspergillus flavus.246 Research into aspergillic acid gave the same basic molecular 
formula C12H18N2O2 as that obtained for the product of pyrolysis of pulcherriminic acid. The 
elucidation of the structure of aspergillic acid along with further similarities in the UV spectra 
of both products led to the proposal of a diketo-pyrazine nucleus (Figure 65), with the 
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remaining C8H18 attributed to aliphatic side chains.245 Hydrogenation of pulcherrimin gave a 
diketopiperazine product, also shown in Figure 65.  
 
 
 
Figure 64. The structure of aspergillic acid, an antibiotic excreted by Aspergillus flavus, elucidated by Dutcher.246 
Based on this evidence, a symmetrical structure for the pulcherrimin nucleus was suggested 
(i.e related to a 2,5-diketopiperazine) and the final structure for the precursor pulcherriminic 
acid 14 was presented as shown in the Introduction Section 1.3.3, Figure 14. Dutcher 
proposed that the formation of a red iron complex in the presence of aspergillic acid was via 
the hydroxamic acid moiety of the molecule.246 Due to the similarities in structure and the 
formation of a red pigment, it was strongly suggested that the binding of ferric iron in 
pulcherrimin is also via a hydroxamate-like moiety in a 3:1 complex,245 shown in Figure 66. 
However, the exact chemical structure of this complex has yet to be elucidated by X-ray 
crystallography.  
 
 
 
 
Figure 65. The structures proposed by Kluyver et al. of the product of pyrolysis of pulcherrimin (diketopyrazine) 
and the product of hydrogenation of pulcherrimin (diketopiperazine).245 
Pulcherrimin production has also been found to occur in the yeast Metschnikowia 
pulcherrima (found on wine grapes)132 and is not limited to yeasts; it is also excreted by 
Bacillus subtilis and  Bacillus cereus244 along with Bacillus licheniformis.126 As described in the 
Introduction Section 1.3.3, siderophores such as DFO 1 (produced by Streptomyces pilosus) 
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are naturally occurring iron chelators which are part of a pathogen’s mechanism for 
scavenging iron from the environment or during host invasion. The scavenged 
iron:siderophore complex is internalized by the pathogen and the ferric iron is reduced to 
ferrous iron which triggers release from the complex in order for the Fe2+ to be used 
intracellularly.126 Pulcherriminic acid has similarities to siderophores through its tautomeric 
N-oxide iron chelating group which is similar to the DFO hydroxamic acid iron-binding motif.  
However, the insoluble pulcherrimin complex cannot act as an iron carrier as siderophores 
do.126,132 The excretion of pulcherriminic acid only performs a ‘biocontrol’ mechanism, for 
example in the case of pulcherriminic acid production by M. pulcherrima, the iron chelator 
protects grapes, apples and peaches from rot caused by post-harvest pathogens, which is 
particularly important in the wine-making industry.132  
 
 
 
 
 
 
 
 
Figure 66. Pulcherrimin, the red pigment produced on binding of pulcherriminic acid with ferric iron in a 3:1 
complex through the hydroxamate-like moiety of pulcherriminic acid, as proposed by Kluyver et al.245 
Pulcherriminic acid 14 is of great interest as a naturally occurring high affinity iron chelator as 
consumers move towards more ‘natural’ and ‘eco-friendly’ ingredients in cosmetics (including 
sunscreen formulations). A considerable amount of 14 is generated as a by-product in 
bioreactor processes producing high value materials such as lipids, monosaccharides, and 2-
phenylethanol, which shows its potential as a sustainable natural reagent.247 For these 
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reasons, the chemical synthesis of 14 was attempted to allow its chemical and biological 
analysis as a potent natural iron chelator. 
2. Synthesis of pulcherriminic acid 
The structure of pulcherriminic acid 14 was determined by Kluyver and later further 
investigated by Cook et al.133 and Macdonald.248 Combining all of the evidence including 
functional group analysis by 1H NMR of purified 14 from C. pulcherrima gave 14 the empirical 
formula C12H20N2O4, which as noted above may be related to an oxidised 2,5-
diketopiperazines (2,5-DKP). 2,5-DKPs are attractive chemical scaffolds as they are small and 
conformationally constrained heterocycles. Structural diversity can be introduced in six 
positions and stereochemical control is available at four positions. 2,5-DKPs are abundant in 
nature  and as such are interesting candidates for drug discovery and for medicinal 
chemistry.249 For example tryprostatin B, shown in Figure 67, is isolated from A. fumigatus 
and has gained interest for development as an anti-cancer drug due to its ability to inhibit 
growth of human breast, prostate and lung cancer cell lines in the G2/M phase of the cell 
cycle.250 Many drugs have been synthesised by chemists through structure-activity 
relationship (SAR) analysis of a 2,5-diketopiperazine core. For example, a 
spirodiketopiperazine derivative (shown in Figure 67) was found to be a potent cytotoxic 
compound in kidney, melanoma and cervical adenocarcinoma cancer cell lines that were 
resistant to the anti-cancer drug doxorubicin.251  
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Figure 67. The structures of two drug candidates containing a 2,5-diketopiperazine core which have shown 
potential in cellular studies. 
The 2,5-DKP core is a cyclic dipeptide (CDP). CDPs are generated by the coupling and end-to-
end cyclization of two amino acids, and thus are the simplest of cyclic peptides. In natural 
organisms (ranging from bacteria to humans), CDPs are biosynthesised through the action of 
cyclodipeptide synthases and non-ribosomal peptide synthetases.252 Kluyver et al. confirmed 
that the only amino acid present in pulcherriminic acid is L-leucine. The molecular formula 
from pyrolysis of pulcherriminic acid was reported as C12H18N2O2 which indicates that the two 
identical R groups attached to the DKP structure (Figure 65) would consist of a C4H9 unit, 
consistent with the side chain of L-leucine. In order to chemically synthesise the starting CDP 
core of pulcherriminic acid, two units of L-leucine would need to be cyclized via formation of 
two amide bonds. A preparation of pulcherriminic acid via pulcherrimin was reported by 
Ohta253 in 1964, starting from racemic cyclo(leucyl-leucine), however very limited 
experimental detail was reported and no spectroscopic characterisation was presented.253,254 
In 1992 Cook et al. reported the synthesis of the CDP cyclo(L-isoleucyl-L-isoleucine) through 
a self-condensation reaction of two units of L-isoleucine by refluxing in ethane-1,2-diol.255 
Although efficient, the drawback of this method is that the stereochemistry of the chiral 
centres is compromised, which in Cook’s report led to a mixture of cis-(3S, 6S), trans- and cis-
(3R, 6R) products. In view of this, a more controlled, classical peptide synthesis approach was 
employed in this work to stereoselectively synthesise a leucine-derived CDP intermediate. 
This approach had the advantage of more simple NMR analysis due to the generation of a 
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single stereoisomer, and the progress of subsequent reaction steps might also be different 
using a single CDP stereoisomer compared to a mixture of 3 stereoisomers. 
Cyclic dipeptide synthesis is typically achieved by first forming a protected linear precursor 
via an amide bond between an N-protected amino acid (carboxy component) and an amino 
acid alkyl ester (amino component).249 The synthesis is then completed by removal of the N-
terminal protecting group and cyclisation via direct intramolecular nucleophilic attack upon 
the C-terminal ester carbonyl.  
In order to couple the two amino acid starting materials together, the carboxylic acid function 
of the carboxy component requires activation. As described in Chapter 2.3, carbodiimides are 
extensively used coupling reagents for ester and amide bond formation and therefore 
EDC.HCl was once again employed as a coupling reagent (see Scheme 39), together with 1-
hydroxy-1H-benzotriazole (HOBt), which is an additive that is commonly used in amide bond 
formation to prevent formation of an unreactive dialkylurea by-product.256 HOBt reacts with 
the O-acylurea (shown in Chapter 2.3, Scheme 14) to give an activated ester in a similar 
manner to DMAP. Using HOBt as a reaction catalyst has also been shown to reduce 
epimerisation during coupling, which is a potential problem for the activation of certain amino 
acids during amide bond formation.256  
Furukawa et al. synthesised 20 CDPs containing L-leucine in high yields using the general 
synthetic route: dipeptide formation with an N-protected amino acid and an amino acid 
methyl ester, cleavage of the N-protecting group and cyclization. This general route was 
therefore employed here to synthesise cyclo(L-leucyl-L-leucine) 124 starting with the 
commercially available t-butyl carbamate (Boc)-protected L-leucine 120 and L-leucine methyl 
ester hydrochloride 121, as shown in Scheme 40. The Boc protecting group in 120 is stable 
towards nucleophilic attack and therefore effectively prevents polypeptide formation, 
whereas it can also be easily removed using a strong acid such as TFA, generating isobutylene 
and CO2 as by-products.183 A solution of 120 in anhydrous DMF was cooled to 0oC and treated 
with 1.5 equivalents of HOBt followed by 1.5 equivalents of EDC.HCl. After stirring for 30 min, 
a solution of 121 in anhydrous DMF with 3 equivalents of DIPEA was added. A single 
stereoisomer (cis-3S, 6S) of the desired dipeptide 122 was obtained as a white powder in a 
74% yield. Treatment of 122 with TFA at RT for 1.5 h then gave the N-deprotected dipeptide 
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123 as the trifluoroacetic salt in 99% yield. Cyclization by forming a second amide bond to 
give the CDP 124 was then achieved by a modification of the method of Suzuki et al.257 This 
method involved acetic acid-catalyzed cyclization of the dipeptide under reflux in the 
presence of one equivalent of the tertiary amine base N-methylmorpholine (NMM).257 The 
yield of CDP achieved using this method was reported to surpass that of base-catalyzed or 
autoaminolysis reactions.257-259 Therefore 123 was refluxed in 0.1 M acetic acid in butanol 
with one equivalent of DIPEA as an alternate tertiary amine to NMM, in order to neutralize 
the TFA released in solution. This gave the desired cis-3S, 6S CDP 124 in a 93% yield.  
 
Scheme 40.  Synthetic route to cyclo(L-leucyl-L-leucine) 124. Reagents and conditions: a. HOBt, EDC.HCl, DIPEA, 
anhydrous DMF, RT, 24 h, 74%; b. TFA, DCM, RT, 1.5 h, 99%; c. 0.1 M acetic acid in butanol, DIPEA, reflux, O/N, 
93%. 
 
The next steps in the synthesis of 14 required the conversion of the DKP nucleus to a pyrazine 
system and the oxidation of both nitrogen atoms. In 1982 Göktürk et al. investigated pyrazine 
N-oxides related to the synthesis of mycelianamide, wherein one of the synthesised 
intermediates 125 (shown in Figure 68) has a very similar structure to pulcherriminic acid 
14.260 More recently Usui et al. reported the total synthesis of phellodonin, a complex alkaloid 
isolated from the fungus Phellodon niger, whose structure contains an embedded DKP-like 
component.261 This synthetic pathway involved the preparation of an L-isoleucine CDP which 
was manipulated to give the intermediate 126 shown in Figure 68, which also has an 
analogous structure to a 2-trimethylsilyl ether derivative of pulcherriminic acid. Both of the 
described papers carried out chlorination of the respective CDP to give a 2,5-dichloropyrazine 
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derivative which was then subjected to N-oxidation to give a pyrazine-bis-N-oxide, followed 
by displacement of the chloro groups with an oxygen nucleophile.  
 
 
 
 
 
 
 
 
 
 
 
Figure 68. Intermediates 125 and 126 in the synthesis of mycelianamide and phellodonin respectively, which 
have structural similarities to pulcherriminic acid 14. 
 
The first steps of Ohta’s original synthesis are shown in Scheme 41. Cyclo(leucinyl-leucine) 
was reacted with a mixture of chlorinating reagents, phosphorous oxychloride (POCl3) and 
phosphorous pentachloride (PCl5), which gave a mixture of products that were then subjected 
to further oxidation and chlorination via a series of steps253 to give the 2,5-dichloropyrazine 
derivative 127. 
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Scheme 41. Synthetic pathway reported by Ohta for the synthesis of the 2,5-dichloropyrazine intermediate 127 
from a racemic mixture of cyclo(leucinyl-leucine).253 
 
For this work, the well-described synthetic pathways elucidated by Göktürk et al. and Usui et 
al. were instead applied, and with 124 (the required core structure of pulcherriminic acid) in 
hand, the synthesis of the 2,5-dichloropyrazine intermediate 127 was attempted. Usui et al. 
reported the attempted generation of a dichloropyrazine derivative via Vilsmeier-Haack-type 
chemistry using an excess of the chlorinating reagent POCl3 at 100oC. However, rather than 
producing the desired dichloropyrazine, it was reported that the principal product was 
instead the monochloropyrazine (shown in Scheme 42).  
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Scheme 42. The two products generated from chlorination of cyclo(L-isoleucyl-L-isoleucine) reported by Usui et 
al. The major product (70%) was the monochloropyrazine derivative.261 
 
These conditions were nonetheless applied using the CDP 124 in an excess of POCl3, which 
was heated to 100oC in a sealed pressure tube overnight (route a in Scheme 43). As 
anticipated, both mono and dichlorinated products were obtained which were easily 
separated by column chromatography. Unlike Usui’s synthesis from an isoleucine CDP starting 
material, the reaction here gave a higher proportion of dichlorination, however the desired 
dichloropyrazine 127 was still the minor product (17%) in comparison to the 
monochloropyrazine 128 (39%).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 43. Attempted synthesis of 2,5-dichloro-3,6-diisobutyl pyrazine 127 along with the major 
monochlorinated side product 128. Reagents and conditions: a. excess POCl3, 100OC , O/N; b. excess POCl3, RT, 
O/N; c. 2 eq. POCl3, 1 eq. pyridine, 160oC, 2 h.  
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Göktürk et al. reported that reacting a CDP containing one benzyl and one methyl side chain 
with an excess of POCl3 at RT for 20 h formed the dichloropyrazine as the principal product 
with a trace of monochloropyrazine.260 The chlorination reaction of 124 was therefore 
repeated with an excess of POCl3 at RT, however this was found to give the opposite result, 
and only the monochloropyrazine 128 was generated in a 30% yield (route b in Scheme 43). 
It would appear that the disparity in yields of products compared to the reports of Usui et al. 
and Göktürk et al. may be due to the difference in steric bulk of the amino acid side chains in 
the DKP starting materials. A suggested mechanism for the generation of the mono and 
dichloropyrazines is presented in Scheme 44. With increased steric bulk of the substituents, 
R, the intermediate formed upon activation with a second equivalent of POCl3 may undergo 
rearrangement and elimination of OPOCl2 rather than addition of the chloride nucleophile, 
thus leading to a monochloropyrazine rather than the desired dichloropyrazine. It is 
noteworthy that Ohta et al. reported that chlorination of a racemic mixture of cyclo(alanyl-
alanine), R= CH3, with excess POCl3 at reflux led to a similar ratio of mono and dichlorinated 
products to that observed for 124 in this work (R= CH2CH(CH3)2).262 
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Scheme 44. Proposed reaction mechanism of the chlorination reaction with POCl3 generating either the 
monochloropyrazine or the dichloropyrazine derivative. 
 
Wang et al. have reported the chlorination of a wide range of compounds including hydroxy 
pyrimidines, pyrazines and amides using one equivalent of POCl3 per reactive OH or amide 
group, and one equivalent of pyridine at 160oC for 2 h.263 With this reaction method 72% and 
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76% yields respectively were obtained of the dichloropyrazines derived from cyclo(alanyl-
alanine) and cyclo(phenylalanyl-phenylalanine), as shown in Figure 69.  
 
 
 
 
 
 
 
 
Figure 69. The structures of two dichloropyrazines synthesised in good yields via an alternative POCl3 method 
proposed by Wang et al.263 
 
As the 3,6-dimethyl and 3,6-dibenzyl substituents of these CDP starting materials have quite 
different steric demands, it was considered that it might be suitable for the preparation of 
127. Wang’s method was therefore employed and 124 was treated with two equivalents of 
POCl3 and one equivalent of pyridine and heated to 160oC for 2 h (route c in Scheme 43). 
Under these conditions, the main product was still the monochloro derivative 128 in a 56% 
yield with 127 being obtained in a 4% yield, however this reaction had a slightly higher overall 
conversion to either 127 or 128 than the previous two methods, with the starting material 
being fully consumed in all cases. The results of the various chlorination reactions attempted 
are collated in Table 12. 
 
Table 12. Comparison of reaction conditions and yields of di and mono chlorination products 127 and 128 from 
reaction of CDP 124 with POCl3. 
 
Method Yield of 127 (%) Yield of 128 (%) Total conversion (%) 
a261 17 39 56 
b260 0 30 30 
c263 4 56 60 
 
 
All three chlorination methods were unsuccessful in generating a good yield of the desired 
dichloropyrazine 127, therefore an extra synthetic step was employed to make use of the 
monochloropyrazine side-product 128. Usui et al. demonstrated that it was possible to drive 
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the formation of the dichloropyrazine derivative through N-oxidation of the 
monochloropyrazine.261 The nucleophilicity of the N-oxide promotes the reaction with POCl3 
to encourage a second chlorination. As per the methodology of Usui et al., the 
monochloropyrazine 128 was treated with three equivalents of m-CPBA (meta- 
chloroperoxybenzoic acid) in DCM and stirred at 40 oC overnight. This reaction gave a yellow 
oil which was a 4:1 mixture of mono 129 and di-N-oxides 130 respectively (route a in Scheme 
45). The structure of 129 was verified using 1H- 15N HMBC and 13C NMR. The mixture of 129 
and 130 was then treated with excess POCl3 and stirred at 100oC overnight261 to give the 
desired dichloropyrazine 127 in a 59% yield. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 45. Synthesis of N-oxide derivatives 129 and 130 of the monochloropyrazine 128. Reagents and 
conditions: a. 3 eq. m-CPBA, DCM, 40OC, O/N; b. 3 eq. m-CPBA, DCM, 40OC , 3 h, 98% of 129 only.   
  
The presence of the di-N-oxide derivative 130 in the mixture taken forward for the next 
chlorination step lowers the yield of the desired dichloropyrazine 127 by generating a dichloro 
mono-N-oxide derivative. With this in mind, the oxidation of 128 was repeated using Usui’s 
conditions (route b, Scheme 45), however the reaction was stopped as soon as complete 
consumption of the starting material was observed on TLC (3 h). This gave pure mono-N-oxide 
129 in a 98% yield, which was reacted with excess POCl3 at 100oC261 (shown in Scheme 46) to 
give an 84% yield of the desired dichloropyrazine 127, thus providing a practical synthetic 
route to 127 from 124 in a good overall yield with minimal side-product formation. 
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Scheme 46. Synthesis of dichloropyrazine 127 from pure mono-N-oxide derivative 129. Reagents and conditions: 
excess POCl3, 100oC, O/N, 84%. 
 
In order to transform the dichloropyrazine 127 into the di-N-oxide derivative 131 (shown in 
Scheme 48), the synthetic route used by Usui et al. was applied once again. Usui reported 
that it was necessary to use vigorous oxidation to convert the pyrazine to the di-N-oxide and 
two rounds of the oxidation reaction were necessary to achieve a 52% overall yield with 
respect to recovered starting material (Scheme 47).261  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 47. The synthetic method reported by Usui et al. to generate a di-N-oxide derivative over two steps, 
resulting in a 52% overall yield with respect to recovered starting material. Reagents and conditions: a. TFA, 50% 
H2O2, 50OC, 3 h. 
 164 
 
The conditions of Usui et al. were nonetheless applied and as such 127 was dissolved in TFA 
and treated dropwise with 50% H2O2 (see Scheme 48). The reaction was stirred at 50oC for 3 
h before the peroxides were neutralised with ice-cold sat. Na2S2O5. In our hands this reaction 
gave a 67% isolated yield of the desired di-N-oxide product 131 along with a 20% yield of the 
mono-N-oxide 132, which is vastly different to the outcome seen by Usui et al.  It was 
therefore unnecessary to carry out a further oxidation to recycle the mono-N-oxide 132, in 
an analogous fashion to the approach of Usui et al. Once again, the significant difference in 
behaviour compared to the corresponding isoleucine derivative probably reflects a change in 
steric bulk of the side chain; the α-methyl group of the Ile-derived side chain may hinder the 
approach of the electrophilic oxidant leading to a much less effective di-oxidation. Previous 
reports by Ohta also support this proposal; oxidation of 127 with other less practical reagents, 
i.e permaleic acid (generated in situ using 90% H2O2)253 or potassium persulphate (K2S2O8) in 
concentrated sulphuric acid,254 gave similar proportions of 131 and 132. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 48. Synthesis of di-N-oxide 131 from dichloropyrazine 127. Reagents and conditions: TFA, 50% H2O2, 
50OC, 3 h, 67% (131), 20% (132). 
 
Intermediate 131 could now be converted to pulcherriminic acid 14 through displacement of 
the chloro groups with an alkoxy nucleophile via nucleophilic aromatic substitution,253 
followed by cleavage of the alkyl fragment in the resulting product to yield the final 2,5-
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dihydroxy structure of 14. Usui et al. carried out nucleophilic displacement of the dichloro 
groups of the di-N-oxide derivative (shown in Scheme 47) using TMS-ethanol with NaOtBu as 
the base to form the oxyanion,261 while Göktürk et al. used sodium benzyloxide, generated in 
situ from benzyl alcohol and sodium hydride. 260 Both methods were attempted on the di-N-
oxide 131, and it was anticipated that the presence of the positive N atom adjacent to the 
chloro carbon would facilitate nucleophilic attack and substitution. However, the reaction of 
131 with TMS-ethanol in the presence of the base KOtBu did not proceed as expected giving 
a mixture of products. 1H NMR and mass spectrometry analysis were not consistent with the 
formation of a TMS-ethyl-protected structure, although all of the starting material had been 
consumed (assessed by TLC). On the other hand, the reaction with benzyl alcohol in the 
presence of KOtBu proceeded well on TLC giving conversion to a single new spot. The crude 
product was purified by column chromatography to give compound 133 in a 46% yield (route 
a in Scheme 49).  
 
 
 
 
 
 
 
 
 
Scheme 49. Synthesis of a benzyl-protected compound 133 via nucleophilic displacement of the chloro groups 
in 131. Reagents and conditions: a. benzyl alcohol, KOtBu, anhydrous THF, RT, O/N, 46%; b. benzyl alcohol, 
NaOtBu, anhydrous THF, RT, O/N, 44%. 
 
HPLC analysis of 133 showed a single peak, however upon 1H NMR analysis it was evident that 
another product was present. Göktürk et al. described the formation of a new product upon 
attempts to recrystallise their benzyl-protected compound, or when it was left standing at 
room temperature for several days. The new compound was identified as an N-
benzyloxypyrazinone, where the benzyl group had migrated onto the N-oxide group.260 
Applying this knowledge allowed the 1H NMR spectrum obtained to be rationalised; the 
desired symmetrical product 133 gave one set of signals for the CH3, CH2, CH and OCH2 groups, 
while for the unsymmetrical rearranged product 134 all of the 1H signals are duplicated. The 
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1H NMR spectrum obtained is shown in Figure 70 and the structure of 134 is shown in Scheme 
49.  
 
 
Figure 70. 1H NMR spectrum of isolated symmetrical benzyl-protected pulcherriminic acid 133 showing the 
presence of unsymmetrical rearranged product 134 in a 6:1 ratio. Key signals are labelled in black for 133 and 
red for 134. The signal at 4.65 ppm corresponds to the CH2 signal for trace benzyl alcohol. 
 
In our hands, the rearrangement of 133 appeared to occur very quickly rather than after a 
few days of standing. 1H NMR analysis was carried out on the crude reaction mixture 
immediately after work-up and the presence of more than one compound was already visible, 
in a 6:1 ratio of 133 to 134 respectively (Figure 70). The mechanism of rearrangement of 133 
to the new unsymmetrical compound 134 is presented in Scheme 50. The reaction was 
repeated using NaOtBu as the base, in line with the method of Göktürk et al., but under these 
conditions only the rearrangement product 134 was seen in the crude 1H NMR. Infrared 
analysis of the isolated product was also carried out and a strong absorption at 1644 cm-1 was 
observed, corresponding to an amide C=O stretch, again consistent with the structure of 134. 
The chemical shifts for the pure rearrangement product 134 obtained in the reaction using 
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NaOtBu were slightly different to those seen in the 1H NMR for the KOtBu reaction. This is 
presumably due to intermolecular interactions between the two distinct components in the 
mixture of 133 and 134 which results in a displacement of chemical shifts compared to 134 
alone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 50. Mechanism for the migration rearrangement of the O-benzyl group in 133 to a N-benzyloxy isomer 
134. 
 
Cleavage of the benzyl groups was required in order to generate the desired pulcherriminic 
acid 14. Göktürk et al. demonstrated that treatment of either the O-benzyl compound or the 
N-benzyloxy rearrangement compound with TFA and anisole yielded the desired product. The 
mixture of 133 and 134 was therefore treated with 1:1 anisole:TFA (1:1) and stirred at RT 
under an inert atmosphere for 2.5 h (Scheme 51). This gave pure pulcherriminic acid 14 as a 
pale yellow solid, which corresponded with the description of 14 isolated by Macdonald and 
Kupfer et al.244,248 Chemical analysis by mass spectrometry, 1H and 13C NMR, and melting point 
confirmed the structure of 14. 
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Scheme 51. Conversion of a mixture of N-oxides 133 and 134 to pulcherriminic acid 14. Reagents and conditions: 
TFA, anisole, RT, 2.5 h, 75%.   
 
3. Activity of pulcherriminic acid 
 
With the sought after pulcherriminic acid 14 in hand, its solubility and stability were tested. 
14 was found to be insoluble in a range of organic solvents (MeOH, chloroform, DCM, MeCN, 
and THF) and was sparingly soluble in DMSO (soluble to a concentration of 2 mM). This lack 
of solubility is consistent with the report by Kluyver et al. where 30 different solvents were 
tested to dissolve the pulcherrimin pigment. However, 14 was completely soluble and stable 
in pure TFA and formic acid. A solution of 14 in TFA (1 mg/mL) was left in the dark for 24 h, 
after which time HPLC analysis showed that there was no apparent change or degradation. 
Conversely, when 14 was added to 1M NaOH, the compound converted immediately to a new 
peak on HPLC. 14 was also found to be sensitive to visible light. When a solution of 14 in TFA 
(1 mg/mL) was left under ambient laboratory lighting, HPLC analysis showed that complete 
degradation had occurred after 5 h. 
 
In order to compare the photoprotective capacity of 14 to the other iron chelators used in 
this project, a solution of 14 in DMSO (20 µM) was incubated in FEK4 cells overnight prior to 
UVA irradiation at doses of 250 kJ/m2 and 500 kJ/m2. MTT assay analysis was carried out 24 h 
post-UVA irradiation, and the results from these assays are presented in Figure 71. 
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Figure 71. MTT assay analysis of the photoprotective capacity of 14 (20 µM) in FEK4 cells after 250 or 500 kJ/m2 
UVA irradiation. Data is represented as percentage enzymatic activity of the untreated unirradiated control, 
which was set to 100% enzymatic activity. (n=4) 
* p <0.05, significant decrease compared to the respective 250 kJ/m2 UVA irradiated cells. 
 
MTT analysis showed that pulcherriminic acid 14 was not cytotoxic to cells at a concentration 
of 20 µM, however it did not provide any photoprotection in comparison to the untreated 
irradiated cells at a dose of 250 kJ/m2 UVA. Moreover 14 seemed to be cytotoxic to cells in 
comparison to the untreated cells irradiated at a dose of 500 kJ/m2 UVA. This outcome may 
have been due to the observed instability of 14 under visible light. 
 
Furukawa et al. examined the hydroxyl radical scavenging activity of 20 L-leucine based CDPs 
by using electron spin resonance (ESR). Although they reported that cyclo(L-leucyl-L-leucine) 
had a lower scavenging effect than the control vitamin E, it was decided to investigate 
whether pulcherriminic acid 14 derived from this CDP nucleus possessed any antioxidant 
activity. Manchineella et al. reported the synthesis of 5 CDPs from alternative L-amino acids 
that were tested for their radical scavenging activity in the DPPH assay. Therefore 14 was 
analysed in the DPPH assay method developed in Chapter 3.2, alongside the positive control, 
trolox. Figure 72 shows the percentage radical scavenging activity of 14 and trolox over the 
range of concentrations required to give a linear relationship. 
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Figure 72. DPPH assay analysis of 14 along with the positive antioxidant control, trolox, showing the percentage 
free radical scavenging activity against concentration. Each concentration point represents an average of n=3. 
 
The DPPH assay demonstrates for the first time a free radical scavenging activity for 
pulcherriminic acid 14. The percentage radical scavenging profiles of 14 and trolox are very 
similar, and the line equation of 14 is y=0.8571*x + 7.429 which gives an IC50 value of 49.7 
µM. This IC50 value is comparable to the IC50 value of 94 (54.6 µM), a lead carbostyril which 
performed well in the DCFDA assay in reducing the level of UVA-induced intracellular free 
radicals and was incorporated into CIC 115, the best photoprotectant in annexinV/PI flow 
cytometry assays. 
 
4. Attempted caging of pulcherriminic acid 
 
The instability of 14 to ambient light undoubtedly affects its ability to act as an iron-chelating 
photoprotective agent. We hypothesised that a photo-cleavable group would protect 14 
against ambient light for long enough for it to be localised within the cytosol and therefore 
be in a suitable location to exert its iron-chelating effect upon UVA irradiation. Therefore as 
a proof of concept for future investigations, caging of the phenolic groups of 14 was 
attempted with the simple and well-known photo-labile group 2-NPE (discussed in the 
Introduction 1.4.4) This was attempted by nucleophilic displacement of the chloro groups of 
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the di-N-oxide intermediate 131 using the alkoxide generated from 1-(2-nitrophenyl)ethan-
1-ol. The reaction was carried out using NaOtBu as the base and using the same reaction 
conditions as the previous nucleophilic aromatic substitution reactions, as shown in Scheme 
52. After overnight reaction, the starting material had been converted to two new products 
on TLC. Mass spectrometry analysis of the crude reaction mixture after aqueous work-up 
indicated the presence of both the mono- and di-NPE caged pulcherriminic acid derivatives 
135 and 136 which could not however be separated by column chromatography. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 52. Synthesis of mono- and di-NPE protected compounds 135 and 136 via nucleophilic displacement of 
the chloro groups in 131. Reagents and conditions: 2-NPE, NaOtBu, anhydrous THF, RT, O/N. 
 
5. Summary 
 
A 9-step synthesis of pulcherriminic acid 14 has been developed and all intermediates 
investigated have been fully characterised. The synthetic route was optimised to give the 
highest yields and to limit the by-products generated at each step. The examination of this 
pathway enables the scale-up of the synthesis of 14, a natural product iron chelator that 
may have potential as a protective agent against UVA-induced iron release and ROS. 14 was 
found to be quite insoluble in a range of organic solvents and unstable under ambient light 
and in basic solutions in agreement with previous reports. Further investigation into 
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derivatives of this natural product may provide an opportunity to create related iron 
chelators with better bioavailability and physicochemical properties. DPPH assay analysis 
demonstrated that 14 has a promising free radical scavenging activity which could provide 
an extra benefit alongside its inherent iron-chelating activity. 
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CHAPTER 6: FINAL CONCLUSIONS AND FUTURE WORK 
 
This project was directed towards the synthesis and biological evaluation of novel caged iron 
chelators (CICs) as potential agents for use in skin photoprotection. 
 
Chapter 2 focussed on the development of synthetic routes to hydroxycinnamoyl and 
aminocinnamoyl derivatives of iron chelators with known clinical potential which have a 
phenolic iron-binding motif that can be caged. For this purpose, two aroylhydrazone iron 
chelators PIH 7 and SIH 8 were synthesised as well as the methyl ester derivative of the 
clinically used iron chelator deferasirox 33. Hydroxycinnamoyl caging groups were 
investigated as photo-cleavable groups and two TBS-protected SIH derivatives 38a and 42a 
were synthesised, exploiting a novel approach for the generation of selectively protected 
hydroxycinnamic acids via selective cleavage of a silyl ester group over a silyl ether (using 
0.3% TFA in MeCN).  Hydroxycinnamoyl caged CIC derivatives of SIH could be successfully 
prepared using acid chloride coupling chemistry, however the yields were modest due to the 
steric hindrance introduced by the silyl protecting groups. Neither of the SIH-derived CICs 36 
and 44 were more UVA photoprotective than the parent iron chelator SIH 8 towards FEK4 
human skin fibroblasts as assessed by the MTT assay. Aminocinnamoyl caging groups were 
also investigated for the development of CICs. A three-step optimised synthetic route to the 
known 3,4-dimethoxyaminocinnamic acid 50 was achieved and the three iron chelators 7, 8 
and 33 were esterified with this derivative to produce prototype aminocinnamoyl CICs. The 
photoprotective ability of the respective CICs 51, 52 and 55 under UVA irradiation was 
analysed using the MTT assay, and the SIH-based CIC 51 was significantly photoprotective 
compared to the untreated irradiated control. A simple synthetic route was also elaborated 
for the carbostyril photo-products that are generated upon UVA uncaging of aminocinnamoyl 
CICs, by stirring the respective carboxylic acid in 4% HCl at reflux. This allowed detailed 
analysis of the photoproducts of CIC cleavage upon UVA irradiation. 
 
In Chapter 3 the route discovered for the generation of the carbostyril photoproducts was 
exploited. A retrosynthetic approach was taken to identify and synthesise a series of CICs with 
the potential to release an antioxidant photoproduct by first synthesising a series of 
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carbostyrils with varying substituents in the aromatic ring. Three novel carbostyrils 93, 94 and 
95 tested positive for free radical scavenging activity in the chemical colorimetric DPPH assay, 
with IC50 values of 114.0, 54.6 and 25.3 µM respectively compared to the IC50 value of the 
positive control trolox (52.3 µM). The antioxidant effects of the two carbostyrils with the best 
potential, 94 and 95, were also tested in the cellular DCFDA assay with FEK4 fibroblasts post-
UVA irradiation. Carbostyril 94 on its own and in combination with equimolar SIH 8 was the 
most exciting prospect, markedly reducing the intracellular UVA-induced ROS present. The 
use of electron spin resonance spectroscopy (ESR) in future investigations of antioxidant 
compounds such as 94 would give more insight into the type of free radical scavenged, 
potentially allowing for further structural fine-tuning. This technique is also particularly 
relevant as it is used to measure the radical skin protection factor (RSF) of sunscreen 
formulations.63,64 
 
The aminocinnamic acids corresponding to carbostyrils 93, 94 and 95 were integrated into a 
series of SIH- and deferasirox ester-based CICs, 114-119. MTT assay analysis of these CICs 
indicated that CIC 115 which releases carbostyril 94 and SIH 8 upon UVA irradiation was the 
best photoprotectant, significantly improving the cell viability of UVA-irradiated human skin 
fibroblasts. These results suggest that the design of a novel multi-functional CIC with the best 
photoprotective properties is a balance between incorporating motifs which provide an 
antioxidant effect (through alteration of substituents on the photo-cleavable group), whilst 
sustaining high maximum absorption over the target UVA wavelength window (320-400 nm). 
These properties alongside clean and efficient photo-cleavage at environmentally relevant 
doses of UVA are very desirable for a multi-functional CIC. Therefore to develop a more 
effective aminocinnamoyl CIC, a two-pronged exploration as follows would be valuable. 
Firstly, an investigation into the kinetics of the photo-release mechanism would clarify the 
role of steric hindrance in the nucleophilic attack of the ester carbonyl and subsequent 
cyclization. Synthesising derivatives of iron chelators 7, 8 and 33 containing additional groups 
ortho to the ester bond present upon caging would be beneficial in this respect. Secondly, it 
would be useful to expand the series of aminocinnamic acids to include derivatives containing 
electron-donating groups in alternative positions around the aromatic ring, not only to fine-
tune the antioxidant potential of the corresponding carbostyrils, but also the UVR absorption 
maxima of resulting CICs. Consistent with the results discussed in Chapter 3.2, the presence 
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of electron-donating or +M groups should cause a red-shift in the absorption maximum. 
Similarly Li et al. reported that N-alkylation of aminocinnamates causes a red-shift in the 
spectrum, and this would be an interesting principle to investigate.172 Deferasirox ester also 
has the potential to be masked by two photo-cleavable groups through its two phenolic 
hydroxyls, providing a synthetic opportunity to create a multi-functional CIC which could 
release two molecules of antioxidant per iron chelator. 
 
Following on from the work of the previous chapter, Chapter 4 investigated the detrimental 
effects of applying a sub-optimal thickness of sunscreen formulation (0.5 mg/cm2), and how 
this might be compensated using CICs. An assay was developed which involved the addition 
of a reservoir of filter, at the desired concentration to equate to specified thicknesses of 
sunscreen formulation, sitting above the dish containing a monolayer of cells. Using this 
format during UVA irradiation followed by the MTT assay, the photoprotective capacity of a 
range of sunscreen filters could be analysed. Both of the two chosen UVA filters, avobenzone 
and Mexoryl SX®, provided full protection at the recommended thickness of 2 mg/cm2, but 
the protection provided by them significantly reduced at a thickness of 0.5 mg/cm2. Similarly, 
the UVA protection afforded by two broad spectrum inorganic blockers, ZnO and TiO2, was 
significantly reduced at 0.5 mg/cm2 formulation thickness. The capacity of a sub-optimal 
thickness of an individual filter or commercial sunscreen formulation to prevent against UVA-
induced intracellular labile iron release was analysed using the calcein assay. The key outcome 
of this chapter was the finding that two commercial sunscreen formulations as well as 3% 
(w/v) avobenzone + 5% (w/v) octocrylene at a concentration equating to a sunscreen 
thickness of 0.5 mg/cm2 did not prevent the release of intracellular labile iron upon UVA 
irradiation. Building on this, the addition of CIC 51 (20 µM) prior to UVA irradiation 
significantly reduced the concentration of chelatable labile iron produced with protection by 
3% (w/v) avobenzone + 5% (w/v) octocrylene or a typical commercial formulation. Flow 
cytometry analysis using annexin V/PI staining was carried out on cells protected with 0.5 
mg/cm2 sunscreen ± CIC 51 or 115. The results of these assays confirmed the conclusions of 
the calcein assays showing that the presence of a CIC leads to a decrease in UVA-induced cell 
death, in comparison to the cells where the protection is not supplemented with a CIC. 
Analysis of the percentages of apoptotic and necrotic cell death under different conditions, 
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rather than live cells, in the future could give more insight into the mode of cell death induced 
by UVA radiation and the release of labile iron. 
 
To build on the work carried out in Chapter 4, it would be useful to modify the experimental 
design to use poly (methyl methacrylate) (PMMA) plates rather than Petri dishes as the 
sunscreen ‘reservoir’. Although a simple and easily reproducible method, the limitation of 
using Petri dishes for the experiments in Chapter 4 is that their smooth and even surface is 
not typical of the peak and troughs found naturally on the surface of the human stratum 
corneum. PMMA plates are sand-blasted to give a rough texture which mimics the stratum 
corneum and have been indicated in the European Cosmetic and Perfumery Association 
(COLIPA) guidelines as the substrate of choice for the UVA-PF sunscreen testing method.264 
However work by Ferrero et al. and Sohn et al. has demonstrated the difficulties associated 
with experiments using PMMA plates in terms of reproducibility of results due to variation in 
plate roughness.265,266  
 
It would also be very interesting to repeat the photoprotection experiments using SSR rather 
than UVA radiation, this would give an idea how the CICs would perform in a ‘real world’ 
format and would be essential before CICs could be implemented into a sunscreen 
formulation. Using SSR as a solar mimic of exposing the CICs to direct sunlight would enable 
the full benefits of CICs to be quantified. For example the absorption spectra for all CICs 
synthesised in Chapters 2 and 3 show that the CICs absorb in the UVB wavelength region as 
well as the UVA region. Therefore, although not their primary purpose, CICs may also exhibit 
a UVR filtering effect which would provide protection against the effects of UVB radiation as 
well. In order to asess the UVR filtering potential of CICs, the same experimental procedure 
used for testing the sunscreen formulations could be used. A reservoir of a CIC in solution 
could be placed over untreated cells before irradiation, this method would separate the iron-
chelating mechanism from the UVR absorption mechanism. It is also important to point out 
that the uncaging profiles of all synthesised CICs may be different under SSR or real sunlight 
conditions. From analysing the absorption spectra of the CICs one could hypothesise that they 
would uncage faster when a broader spectrum of radiation is used (SSR) as they also absorb 
UVB radiation, this would be a key experiment to advance the CICs into potential sunscreen 
ingredients. Work by Lawrence et al. demonstrated the photodamaging effects of short 
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wavelength visible radiation (400 -420 nm) on keratinocytes,201 a selection of synthesised CICs 
also absorbed over these visible wavelengths (CICs 51, 51, 55, 114 and 117). So in a similar 
sense to CICs exhibiting a beneficial UVB radiation absorbing profile, these CICs may also 
provide ‘real world’ protection against the potentially damaging visible radiation that is part 
of solar radiation. 
 
The ability of a multi-functional CIC to provide skin photoprotection through chelation of UVA-
induced labile iron and quenching of harmful free radical species is the primary purpose of 
CICs, and as such should only be required as a second line of defence behind the UVR 
absorbing/blocking profile of sunscreen filters and not as a sole photoprotectant. The 
potential real-life impact of this research is that the presence of a CIC in a sunscreen 
formulation may help to bridge the gap in sun protection that frequently exists due to 
ineffective application of current sunscreens, and ultimately help prevent skin cancer and 
other consequences of exposure to harmful levels of UVA. In order to investigate the full 
potential of CICs, it would be necessary to conduct research into their penetration through 
the stratum corneum to reach the epidermis and the dermis. Current methodologies for 
assessing the transdermal delivery of drugs include stratum corneum tape-stripping where a 
topical formulation is applied to the skin and after an established amount of time the stratum 
corneum is collected using adhesive tapes. The amount of drug in each tape is then quantified 
to give the clearance of the drug.267 This method is often used alongside in vitro skin 
permeation tests using porcine skin where the topical drug formulation is applied to the 
stratum corneum and the dermal side is in contact with a physiological buffer. Time-course 
HPLC analysis of the buffer can then be used to quantify the transdermal clearance of the 
drug.267 Certain coumarin photoproducts have the additional benefit of being fluorescent, 
indeed the fluorescence of 3,5-dibromo-4-hydroxy coumarin has been exploited as an ‘optical 
syringe’ by Gagey et al.171 This property of coumarins and carbostyrils has the potential to be 
used to identify the transdermal location of a CIC upon UVA irradiation.   
 
Chapter 5 examined the synthetic pathway towards the natural iron chelator pulcherriminic 
acid 14, which has been previously studied for its ability to form an iron-containing pigment, 
pulcherrimin.133,244,245 A 9-step synthesis of pulcherriminic acid 14 was developed, with all 
intermediates fully characterised. A study of the desired reaction at each stage led to 
 178 
optimised conditions to give the highest yields and to limit the by-products generated. The 
developed synthetic pathway allows the opportunity to scale-up the synthesis starting with 
easily accessible amino acid derivatives. The final step of the synthesis gave 14 in 75% yield 
from a benzyl ether-protected derivative. In order to further probe the disparity in yields seen 
in the key dichlorination step between this work and other studies with related CDPs260,261,263 
(Schemes 41 and 42, and Figure 69) a systematic approach would need to be taken. 
Synthesising a series of CDPs with varying side chains (either symmetrical or using two 
different amino acids) should be straightforward using the synthetic pathway developed here. 
This series could then be subjected to the POCl3 chlorination reaction to investigate how the 
nature and size of the R-groups may affect the relative yields of the mono- and 
dichloropyrazine products. A further advantage of generating a series of CDPs with varying 
side chains is exemplified in two studies by Manchineella et al. and Furukawa et al.252,268 . In 
these studies amino acids whose side chains have potential ROS scavenging activity, for 
example L-serine, L-lysine, L-tyrosine and L-DOPA, were incorporated into CDPs. The free 
radical scavenging capacity of these CDPs was assessed in the DPPH assay, with some 
derivatives giving very promising results. As pulcherriminic acid 14 was shown for the first 
time in this project to have some inherent antioxidant activity (DPPH IC50 = 49.7 µM), it would 
be interesting to generate derivatives of pulcherriminic acid using different amino acids which 
would allow it to act not only as a potent iron chelator but also as a highly effective 
antioxidant. Variation of the amino acid side chains may also improve the problematic 
bioavailability and physicochemical properties observed for 14 itself. The preliminary 
investigation into the conversion of the dichloro di-N-oxide intermediate 131 to a derivative 
of 14 that is caged with the photo-cleavable group 2-NPE was promising, and continuation of 
this research to drive the reaction to completion would provide a basis for subsequent UVA-
activated uncaging experiments and further investigation into applying a range of suitable 
photo-cleavable groups.162 This could then lead to the synthesis of a new generation of 
natural product-inspired light-activated CICs as potential UVA photoprotectants. 
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CHAPTER 7: EXPERIMENTAL 
 
1.Chemistry 
 
1.1 General 
 
Solvents, chemical reagents and starting materials were purchased from Sigma Aldrich, Alfa 
Aesar, VWR and Fisher Scientific. Analytical thin layer chromatography was performed on 
Merck silica gel 60 aluminium plates F254. Column chromatography was carried out using 
Sigma Aldrich Silica gel 60Å (particle size 40-63 μm).  
 
1H, 13C and 15N NMR were obtained using Bruker Avance III 400 MHz and 500 MHz 
instruments, 13C NMR data was either at 100 MHz or 125 MHz, and 15N NMR data was at 50 
MHz. Chemical shift values stated are in parts per million (ppm) and coupling constant values 
(J) are given in Hertz (Hz). Routine mass spectrometry was carried out using a Bruker Daltonics 
micrOTOF instrument with electrospray ionisation (ESI). Atmospheric pressure chemical 
ionisation (APCI) quadrupole time-of-flight (QTOF) analysis was conducted using a Bruker 
Daltonics MaXis HD mass spectrometer operated in ESI mode. The QTOF was equipped with 
an APCI source and direct analysis probe. Melting points were determined using an 
Electrothermal IA9000 series digital melting point apparatus. Infrared spectra were recorded 
on a Perkin-Elmer 782 infrared spectrometer using a KBr disk, and values are given in cm-1 as 
either strong (s), medium (m) or weak (w) intensity. UV absorbance spectra were obtained on 
either a Perkin-Elmer Lambda 35 UV/Vis spectrometer or a BMG LABTECH CLARIOstar 
microplate reader; ʎmax values are reported in nm, extinction coefficients are in L mol-1 cm-1. 
    
Analytical HPLC was performed on a Dionex Ultimate 3000 system using a Phenomenex 
Gemini 5μm C-18 110A column with a flow rate of 1 mL/min at 35oC, and UV detection of 214, 
220, 254 and 280 nm. For solvent system A; the mobile phase A was 0.1% CF3CO2H in water 
and mobile phase B was 0.1% CF3CO2H in acetonitrile. For solvent system B; the mobile phase 
A was 0.1% HCO2H in water, mobile phase B was 0.1% HCO2H in acetonitrile. Gradient: t = 0, 
%B = 5; t = 10, %B = 95; t = 15, %B = 95; t = 15.1, %B = 5. 
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1.2 Compound synthesis 
 
 
 
 
 
 
 
 
 
(E)-N'-((3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-
yl)methylene)isonicotinohydrazide (PIH, 7)176 
 
A solution of INH (1.37 g, 9.99 mmol) in EtOH (100 mL) was treated with pyridoxal. HCl (2.03 
g, 9.99 mmol) followed by a solution of NaOAc (820 mg, 9.99 mmol) in H2O (100 mL). The 
reaction was stirred at reflux for 1.5 h, concentrated by 50% and then cooled overnight. The 
resulting orange precipitate was collected under suction filtration. Drying under vacuum at 
40°C gave 7 as a bright orange powder (2.43 g, 85%). Rf = 0.62 (30% acetone: DCM); Rt= 5.7 
min (solvent system A); mp = 263-265°C (lit.269  261-262°C); 1H NMR (DMSO-d6, 400 MHz) δ 
2.43 (3H, s, CH3), 4.28 (1H, s, OH), 4.74 (2H, d, J = 6.4, CH2OH), 6.91 – 6.95 (2H, m, Ar), 7.32 
(1H, td, J = 7.7, 1.8, Ar), 7.61 (1H, dd, J = 7.6, 1.6, Ar), 7.85 (2H, dd, J = 4.4, 1.6, Pyr), 8.68 (1H, 
s, HC=N), 8.80 (2H, dd, J = 4.6, 1.8, Pyr), 11.08 (1H, s, OH), 12.29 (1H, s, NH); 13C NMR 
(DMSO-d6, 100 MHz) δ 18.53 (CH3), 58.86 (CH2), 120.60 (Pyr), 121.52 (Pyr), 132.82 (Pyr), 
137.97 (Pyr), 139.13 (Pyr), 147.33 (Pyr),  147.51 (C=N), 150.47 (Pyr), 150.90 (Pyr), 161.59 
(C=O). 
 
 
 
 
 
 
 
(E)-N-(2-Hydroxybenzylidene)isonicotinohydrazide (SIH, 8) 176 
 
A solution of salicylaldehyde (1.00 g, 8.19 mmol) and INH (1.12 g, 8.19 mmol) in EtOH (25 mL) 
was heated at reflux for 3 h, when a solid white precipitate had formed. The reaction mixture 
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was cooled and the precipitate was collected under suction filtration. Drying under vacuum 
at 40°C gave 8 as a white powder (1.88 g, 95%). Rf = 0.48 (10% MeOH in DCM); Rt= 5.7 min 
(solvent system A); mp = 249- 252°C (lit.269  253-255°C); 1H NMR (DMSO-d6, 400 MHz) δ 2.50 
(3H, s, CH3), 4.69 (2H, s, CH2), 5.50 (1H, br s, OH), 7.95 (2H, d, J = 6.4, Pyr), 8.05 (1H, s, Pyr), 
8.89 (2H, d, J = 5.2, Pyr), 9.06 (1H, s, HC=N), 12.24 (1H, s, OH), 12.92 (1H, s, NH); 13C NMR 
(DMSO-d6, 100 MHz) δ 116.41 (Ar), 118.69 (Ar), 119.42 (Ar), 121.49 (Pyr), 129.12 (Ar), 131.73 
(Ar), 139.96 (Ar), 148.83 (C=N), 150.38 (Pyr), 157.43 (Ar), 161.30 (C=O). 
 
 
 
 
 
 
 
 
 
2-(2-Hydroxyphenyl)-4H-benzo[e][1,3]oxazin-4-one (32)98 
 
A mixture of salicylic acid (2.10 g, 15.2 mmol), salicylamide (1.90 g, 13.9 mmol) and pyridine 
(150 µL) was heated to reflux in p-xylene (6 mL). The solution was then treated with thionyl 
chloride (2.1 mL, 29 mmol), added dropwise over 1 h. The evolution of HCl and SO2 gas was 
absorbed using a H2O scrubber. The reaction was allowed to reflux for a further 2.5 h and 
then the heat was removed. The solvent was evaporated to give a yellow solid. This was 
resuspended in EtOH (20 mL) and acetic acid (200 µL) and heated gently, then allowed to cool 
to RT and placed at -20 oC overnight. The precipitate which formed was filtered off under 
suction then dried under vacuum at 50 oC to give 32 as a pale yellow solid (2.16 g, 65%). Rf = 
0.45 (20% EtOAc: petroleum ether); Rt = 9.1 min (solvent system A); mp = 204-206 oC (lit.270 
200- 201 oC); 1H NMR (DMSO-d6, 400 MHz) δ 7.12-7.17 (2H, m, Ar), 7.64-7.71 (2H, m, Ar), 7.84 
(1H, dd, J = 8.4, 0.4, Ar), 8.00 (1H, td, J = 8.0, 1.6, Ar), 8.12 (1H,dd, J = 7.6, 1.6, Ar), 8.26 (1H, 
dd, J = 7.6, 1.6 Ar), 12.97 (1H, s, OH);  13C NMR (DMSO-d6, 100 MHz) δ 111.51 (Ar), 117.49 (Ar), 
117.80 (Ar), 117.99 (Ar), 119.59 (Ar), 126.78 (Ar), 127.21 (Ar), 129.01 (Ar), 136.02 (Ar), 136.72 
(Ar), 153.91 (Ar), 161.85 (C=N), 163.44 (Ar), 164.83 (C=O); [Found (ESI+) 240.0657 [M+H]+, 
C14H9NO3 requires 240.0661].  
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4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid (deferasirox, 6)98 
 
4-Hydrazinobenzoic acid (100 mg, 0.657 mmol) and NEt3 (92 µL, 0.66 mmol) were dissolved 
in boiling EtOH (10 mL) under stirring. This solution was treated with 32 (142 mg, 0.594 mmol) 
and the reaction was stirred at reflux for 2.5 h then allowed to cool to RT. H2O (75 mL) was 
added until the first sign of precipitation then the mixture was concentrated by 50% and 6M 
HCl was added (10 mL). The resulting precipitate was collected by suction filtration and dried 
under high vacuum to give 6 as a beige solid (186 mg, 85%). Rf = 0.4 (5% MeOH: DCM); Rt = 
9.4 min (solvent system A); mp = 260-263 oC (lit270 261-163 oC); 1H NMR (DMSO-d6, 400 MHz) 
δ 6.93 (1H, d, J = 8.4, Ar), 7.05 (3H, m, Ar), 7.44 (2H, m, Ar), 7.61 (3H, m, Ar), 8.05 (2H, m, Ar), 
8.11 (1H, dd, J = 8.0, 1.6, Ar), 10.08 (1H, s, OH), 10.84 (1H, s, OH), 13.20 (1H, s, CO2H); 13C NMR 
(DMSO-d6, 100 MHz) δ 113.65 (Ar, Cq), 114.41 (Ar, Cq), 116.14 (Ar), 117.05 (Ar), 119.44 (Ar), 
119.67 (Ar), 123.33 (Ar), 126.77 (Ar), 130.27 (Ar), 130.55 (Ar, Cq), 131.04 (Ar), 131.44 (Ar), 
132.53 (Ar, Cq), 141.17 (Ar), 152.04 (Ar, Cq), 155.18 (Ar, Cq), 156.33 (Tri), 159.88 (Tri), 166.39 
(C=O). 
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Methyl 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoate (deferasirox ester, 33) 
 
A solution of 6 (190 mg, 0.51 mmol) in MeOH (10 mL) was treated slowly with H2SO4 (50 µL) 
then heated to reflux overnight with stirring. The solvent was evaporated and the residue was 
dried to give a pale brown solid (170 mg, 86%). Rf = 0.9 (4% acetone:DCM); Rt = 10.4 min 
(solvent system A); mp = 170-173 oC (lit271 172-175 oC); 1H NMR (DMSO-d6, 400 MHz) δ 3.92 
(3H, s, CH3), 6.92 (1H, dd, J = 8.0, 0.8, Ar), 7.02- 7.10 (3H, m, Ar), 7.41-7.48 (2H, m, Ar), 7.61 
(1H, dd, J = 7.6, 1.6, Ar), 7.64 (2H, d, J = 8.8, Ar), 8.07 (2H, d, J = 8.8, Ar), 8.10 (1H, dd, J = 8.0, 
1.6, Ar); 13C NMR (DMSO-d6, 100 MHz) d 48.57 (CH3), 113.45 (Ar), 114.02 (Ar), 116.11 (Ar), 
117.03 (Ar), 119.45 (Ar), 119.69 (Ar), 123.45 (Ar), 126.88 (Ar), 129.31 (Ar), 130.19 (Ar), 131.06 
(Ar), 131.57 (Ar), 132.67 (Ar), 141.38 (Ar), 151.96 (Ar), 155.11 (Ar), 156.27 (Tri), 159.58 (Tri), 
165.33 (C=O). 
 
 
 
 
 
 
tert-Butyldimethylsilyl (E)-3-(2-((tert-butyldimethylsilyl)oxy)phenyl)acrylate (37)272 
 
trans-2-Hydroxycinnamic acid (1.5 g, 9.1 mmol), imidazole (1.25 g, 18.4 mmol) and TBDMS-Cl 
(2.82 g, 18.7 mmol) were added to a N2 purged flask. Anhydrous DMF (20 mL) was added and 
the solution was stirred at RT under N2 overnight, then for 2 h at 60 oC. The solvent was 
evaporated to give a beige oil which was dissolved in DCM (60 mL) and extracted with brine 
N
NN
O
O
OH HO
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(3 x 50mL). The organic phase was dried over MgSO4, filtered, and the solvent was 
evaporated. Purification by column chromatography eluting with 0-2% MeOH in DCM + 0.1% 
pyridine gave 37 as a colourless oil (2.95 g, 83%). Rf = 0.75 (5% EtOAc: petroleum ether); Rt = 
14.3 min (solvent system A); 1H NMR (CDCl3, 400 MHz) δ 0.25 (6H, s, Si(CH3)2), 0.33 (6H, s, 
Si(CH3)2), 0.99 (9H, s, SitBu), 1.02 (9H, s, SitBu), 6.38 (1H, d, J = 16.0, HC=C), 6. 83 (1H, dd, J = 
8.2, 1.0, Ar), 6.95 (1H, t, J = 7.4, Ar), 7.24 (1H, t, J = 7.4, Ar), 7.53 (1H, dd, J = 8.0, 1.6, Ar), 7.97 
(1H, d, J = 16.0, HC=C); ); 13C NMR (CDCl3, 100 MHz) δ -9.43 (Si(CH3)2), -8.95 (Si(CH3)2), 12. 69 
(C(CH3)3), 13.05 (C(CH3)3), 20.34 ((CH3)3), 20.59 ((CH3)3), 114.54 (Ar), 114.88 (Ar), 116.32 (Ar), 
120.80 (C=C), 122.54 (Ar), 125.90 (Ar), 135.02 (Ar), 149.48 (C=C), 161.91 (C=O).   
 
 
 
 
 
 
(E)-3-(2-((tert-Butyldimethylsilyl)oxy)phenyl)acrylic acid (38a)  
 
Method A187:  
 
A solution of 37 (1.0 g, 2.6 mmol) in 2:1 THF and MeOH (6 mL) was treated with K2CO3 (0.90 
g, 6.5 mmol) in H2O (2 mL). The reaction was stirred for 1 h then diluted with Et2O (15 mL) 
and extracted with 10% HCl (3 x 30 mL) and water (3 x 30 mL). The organic phase was dried 
over MgSO4, filtered, and the solvent was evaporated. The crude product was purified by 
column chromatography eluting with 10% acetone in DCM to give a colourless oil (256 mg, 
35%) which was found to be a mixture of desilylated products by 1H NMR. 
 
Method B: 
 
A solution of 37 (400 mg, 1.78 mmol) in 0.3% TFA in MeCN (10 mL) was stirred at RT overnight, 
after which the solvent was evaporated and the residue was co-evaporated with MeCN to 
remove traces of TFA. The crude material was purified by column chromatography eluting 
with 2-10% acetone in DCM +0.1% pyridine and dried under high vacuum to give 38a as a 
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white solid (280 mg, 98%). Rf = 0.5 (10% acetone: DCM); Rt = 10.6 min (solvent system A); mp 
= 80-84 oC (lit.187 127- 129 oC); IR (KBr) 3441s (O-H), 1681s (C=O); 1H NMR (CDCl3, 400 MHz) δ 
0.24 (6H, s, Si(CH3)2), 1.04 (9H, s, SitBu), 6.41 (1H, d, J = 16, HC=C), 6. 85 (1H, dd, J = 8.2, 1.0, 
Ar), 6.97 (1H, t, J = 7.4, Ar), 7.28 (1H, t, J = 7.4, Ar), 7.55 (1H, J = 8, 1.6, Ar), 8.17 (1H, d, J = 16, 
HC=C); 13C NMR (CDCl3, 100 MHz) δ -4.30 (Si(CH3)2), 18.27 (C(CH3)3), 25.70 ((CH3)3), 116.98 
(Ar), 120.03 (Ar), 121.55 (Ar), 122.81 (C=C), 127.79 (Ar), 131.69 (Ar), 142.44 (Ar), 154.88 (C=C), 
172.79 (C=O). 
 
 
 
 
 
 
 
 
 
 
 
2-((E)-(2-Isonicotinoylhydrazono)methyl)phenyl (E)-3-(2-((tert-
butyldimethylsilyl)oxy)phenyl)acrylate (39) 
 
Method A: 
 
Acid chloride formation via the cinnamic acid187: 
 
A solution of 38a (0.20 g, 0.72 mmol) in anhydrous DCM (2 mL) was treated with SOCl2 (500 
µL, 6.89 mmol) and stirred under N2 at reflux for 4 h. The volatiles were evaporated and the 
yellow residue was co-evaporated with DCM to remove traces of SOCl2.  
 
Coupling: 
 
The crude acid chloride 38b was treated with a solution of 8 (157 mg, 0.651 mmol), DMAP (9 
mg, 0.1 mmol) and anhydrous pyridine (53 µL, 0.72 mmol) in anhydrous DMF (3 mL). The 
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solution was stirred at 30 oC under N2 for 24 h. The solvent was evaporated to give an orange 
oil which was dissolved in DCM (20 mL) and extracted with H2O (3 x 20 mL) and brine (3 x 20 
mL). The organic phase was dried over MgSO4, filtered and the solvent was evaporated to give 
a residue which was purified by column chromatography, eluting with 10- 20% acetone in 
DCM + 0.1% pyridine. This gave unchanged 38a (60 mg, 24%) and 39 as a colourless oil (108 
mg, 27%; 36% based on recovered 38a).  Rf = 0.30 (10% acetone: DCM); Rt = 9.7 min (solvent 
system A); 1H NMR (CD3OD, 400 MHz) δ 0.33 (6H, s, Si(CH3)2), 1.09 (9H, s, SitBu), 6.84 (1H, d, 
J = 16.4, HC=C), 7.02 (1H, dd, J = 8.4, 0.8, Ar), 7.13 (1H, t, J = 7.8, Ar), 7.29 (1H, dd, J = 8.0, 0.8, 
Ar), 7.45 (2H, m, Ar), 7.60 (1H, td, J = 7.8, 1.6, Ar), 7.84 (1H, dd, J = 7.8, 1.4, Ar), 7.92 (2H, d, J 
= 6, Pyr), 8.33 (1H, dd, J = 8.0, 1.6, Ar), 8.44 (1H, d, J = 16.4, HC=C), 8.63 (1H, s, HC=N), 8.78 
(2H, d, J = 5.6, Pyr); 13C NMR (CD3OD, 100 MHz) δ -4.08 (Si(CH3)2), 19.26 (C(CH3)3), 26.30 
((CH3)3), 116.78 (Ar), 121.33 (Ar), 123.12 (Pyr), 124.14 (Ar), 126.60 (Ar), 127.51 (Ar), 127.80 
(Ar), 128.13 (Ar), 128.79 (Ar), 129.26 (Ar), 132.92 (Ar), 133.57 (Ar), 142.26 (Pyr), 143.96 (C=C), 
146.23 (C=N), 151.11 (Pyr), 151.65 (Ar), 156.37 (Ar), 164.53 (C=O), 166.97 (C=O); [Found (ESI+) 
502.2131 [M+H]+, C28H31N3O4Si requires 502.2162]. 
 
Repeating the preparation on a similar scale but with anhydrous DCM as the coupling solvent 
gave unchanged 38a (45 mg, 20%) and 39 (88 mg, 20%; 34% based on recovered 38a). 
 
Method B:  
 
Acid chloride formation via the TBS-ester188: 
 
A solution of 37 (153 mg, 0.390 mmol) and catalytic DMF (2 drops) was treated with 2M oxalyl 
chloride in DCM (0.25 mL, 0.98 mmol) at 0oC and the mixture was stirred under N2 for 4 h. 
The volatiles were evaporated and the residue was co-evaporated with DCM.  
 
Coupling: 
 
This crude acid chloride 38b was treated with a solution of SIH (75 mg, 0.31 mmol), DMAP (5 
mg, 0.04 mmol) and anhydrous pyridine (29 µL, 0.39 mmol) in anhydrous DMF (1 mL). The 
solution was stirred at 30 oC under N2 for 24 h. The solvent was evaporated to give an orange 
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oil which was dissolved in DCM (20 mL) and extracted with H2O (3 x 20 mL) and brine (3 x 20 
mL). The organic phase was dried over MgSO4, filtered and the solvent was evaporated to give 
a residue which was purified by column chromatography, eluting with 10- 20% acetone in 
DCM + 0.1% pyridine. This gave unchanged 38a (40 mg, 37%) and 39 as a colourless oil (34 
mg, 27%; 35% yield based on recovered 38a). 
Repeating the preparation on a similar scale but with anhydrous DCM as the coupling solvent 
gave unchanged 38a (30 mg, 20%) and 39 (55 mg, 25%; 31% based on recovered 38a). 
 
 
 
 
 
 
 
 
 
2-((E)-(2-Isonicotinoylhydrazono)methyl)phenyl (E)-3-(2-hydroxyphenyl)acrylate (36) 
 
Method A: 
 
A stirred solution of trans-2-hydroxy cinnamic acid (121 mg, 0.74 mmol) in anhydrous DMF 
(20 mL) under N2 was cooled to 0 oC and DMAP (90 mg, 0.74 mmol) was added, followed by 
EDC.HCl (142 mg, 0.74 mmol). The solution was allowed to stir for 15 min, then a solution of 
8 (99 mg, 0.41 mmol) and DIPEA (71 µL, 0.41 mmol) in anhydrous DMF (5 mL) was added and 
the temperature was increased to 30 oC. The reaction was stirred under N2 overnight, after 
which time the solvent was evaporated to give an orange oil. This oil was dissolved in DCM 
(20 mL) and extracted with sat. NH4Cl (3 x 20 mL) and brine (1 x 20 mL). The organic phase 
was dried over MgSO4, filtered and the solvent evaporated. Mass spectrometry indicated the 
presence of 36, however all attempts to separate it from coumarin 34a by column 
chromatography failed. 
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Method B: 
 
A stirred solution of 38a (150 mg, 0.54 mmol) in anhydrous DMF (20 mL) under N2 was cooled 
to 0 oC and DMAP (66 mg, 0.54 mmol) was added, followed by EDC.HCl (104 mg, 0.54 mmol). 
The solution was allowed to stir for 30 min, then a solution of 8 (92 mg, 0.38 mmol) and DIPEA 
(66 µL, 0.38 mmol) in anhydrous DMF (5 mL) was added and the temperature was increased 
to 30 oC. The reaction was stirred under N2 for 3 days, after which time there was no 
conversion of the starting material observed on TLC.  
 
Method C: 
 
A solution of TBAF trihydrate (125 mg, 0.441 mmol) and acetic acid (25 µL) in anhydrous DMF 
(2 mL) was stirred under N2 at 0 oC for 30 min. This was treated dropwise with a solution of 
39 (63 mg, 0.13 mmol) in anhydrous DMF (2 mL) and stirred at 0 oC for a further 30 min. The 
reaction mixture was diluted with H2O (40 mL) and extracted with Et2O (3 x 40 mL) and EtOAc 
(1 x 40 mL). The combined organic phases were dried over MgSO4, filtered and the solvent 
was evaporated to give a yellow oil. Purification by column chromatography eluting with 4% 
MeOH in DCM + 0.1% pyridine gave 36 as an off-white solid (43 mg, 86%). Rf = 0.6 (10% MeOH: 
DCM); Rt = 7.0 min (solvent system A); mp = 145- 148 oC; UV (EtOH) ʎmax 290 (15200); 1H NMR 
(DMSO-d6, 400 MHz) δ 6.95 (1H, t, J = 7.6, Ar), 7.02 (1H, d, J = 16.0, HC=C), 7.02 (1H, d, J = 8.4, 
Ar), 7.36 (2H, m, Ar), 7.47 (1H, t, J = 7.6, Ar), 7.60 (1H, td, J = 7.8, 1.6, Ar), 7.79 (1H, d, J = 7.2, 
Ar), 7.85 (2H, d, J = 6, Pyr), 8.10 (1H, dd, J = 7.8, 1.4, Ar), 8.17 (1H, d, J = 16.0, HC=C), 8.60 (1H, 
s, HC=N), 8.81 (2H, d, J = 3.6, Pyr), 10.49 (1H, s, OH), 12.17 (1H, s, NH); 13C NMR (CD3OD, 100 
MHz) δ 115.56 (Ar), 121.76 (Ar), 123.34 (Pyr), 124.76 (Ar), 126.43 (Ar), 126.98 (Ar), 127.54 
(Ar), 127.87 (Ar), 128.56 (Ar), 129.23 (Ar), 132.45 (Ar), 133.21 (Ar), 141.67 (Pyr), 143.42 (C=C), 
145.87 (C=N), 149.91 (Pyr), 151.03 (Ar), 156.29 (Ar), 163.79 (C=O), 166.17 (C=O); [Found (ESI+) 
410.1105 [M+H]+, C22H17N3O4Na requires 410.1117]. 
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tert-Butyldimethylsilyl (E)-3-(2,4-bis((tert-butyldimethylsilyl)oxy)phenyl)acrylate (41)272 
 
trans-2,4-Dihydroxycinnamic acid (1.5 g, 8.3 mmol), imidazole (1.77 g, 26 mmol) and TBDMS-
Cl (3.92 g, 26 mmol) were added to an N2 purged flask. Anhydrous DMF (30 mL) was added 
and the solution was stirred at 60 oC under N2 overnight. The solvent was evaporated to give 
an oil which was dissolved in DCM (80 mL) and extracted with brine (3 x 80 mL). The organic 
phase was dried over MgSO4, filtered and the solvent was evaporated. Purification by column 
chromatography eluting with 1% MeOH in DCM + 0.1% pyridine gave 41 as a colourless oil 
(3.17 g, 73%). Rf = 0.80 (5% acetone: DCM); Rt = 15.0 min (solvent system A); 1H NMR (CDCl3, 
400 MHz) δ 0.21 (6H, s, Si(CH3)2), 0.24 (6H, s, Si(CH3)2), 0.31 (6H, s, Si(CH3)2), 0.97 (9H, s, SitBu), 
0.98 (9H, s, SitBu),  1.01 (9H, s, SitBu), 6.26 (1H, d, J = 16.0, HC=C), 6. 32 (1H, d, J = 2.4, Ar), 
6.46 (1H, dd, J = 8.6, 2.4, Ar), 7.41 (1H, d, J = 8.6, Ar), 7.89 (1H, d, J = 16.0, HC=C); 13C NMR 
(CDCl3, 100 MHz) δ -4.66 (Si(CH3)2), -4.42 (Si(CH3)2), -4.21 (Si(CH3)2), 17.80 (C(CH3)3), 18.19 
(C(CH3)3), 18.31 (C(CH3)3), 25.55 ((CH3)3), 25.73 ((CH3)3), 25.78 ((CH3)3), 111.24 (Ar), 114.03 
(Ar), 117.64 (Ar), 119.53 (C=C), 128.49 (Ar), 139.96 (Ar), 155.68 (Ar), 158.51 (C=C), 167.41 
(C=O).     
 
 
 
 
 
 
 
(E)-3-(2,4-Bis((tert-butyldimethylsilyl)oxy)phenyl)acrylic acid (42a) 
 
A solution of 41 (0.63 g, 0.62 mmol) in 0.3% TFA in MeCN (10 mL) was stirred at RT overnight, 
after which the solvent was evaporated and the residue was co-evaporated with MeCN to 
remove traces of TFA. The crude product was purified by column chromatography, eluting 
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with 2-10% acetone in DCM +0.1% pyridine, then dried under high vacuum to give 42a as a 
white solid (467 mg, 95%). Rf = 0.6 (10% acetone: DCM); Rt = 12.8 min (solvent system A); mp 
= 130-134 oC; 1H NMR (CDCl3, 400 MHz) δ 0.22 (6H, s, Si(CH3)2), 0.24 (6H, s, Si(CH3)2), 0.98 (9H, 
s, SitBu),  1.03 (9H, s, SitBu), 6.28 (1H, d, J = 16.4, HC=C), 6. 33 (1H, d, J = 2.4, Ar), 6.49 (1H, dd, 
J = 8.4, 2.4, Ar), 7.43 (1H, d, J = 8.4, Ar), 8.08 (1H, d, J = 16.0, HC=C); 13C NMR (CDCl3, 100 MHz) 
δ -4.41 (Si(CH3)2), -4.30 (Si(CH3)2), 18.20 (C(CH3)3), 18.28 (C(CH3)3), 25.55 ((CH3)3), 25.70 
((CH3)3), 111.49 (Ar), 114.20 (Ar), 114.47 (Ar), 119.27 (C=C), 128.68 (Ar), 142.16 (Ar), 156.18 
(Ar), 159.07 (C=C), 173.12 (C=O). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2-((E)-(2-Isonicotinoylhydrazono)methyl)phenyl (E)-3-(2,4-bis((tert-
butyldimethylsilyl)oxy)phenyl)acrylate (43) 
 
Method A: 
 
Acid chloride formation via the cinnamic acid187: 
 
A solution of 42a (0.30 g, 0.73 mmol) in anhydrous DCM (3 mL) was treated with SOCl2 (0.60 
mL, 8.27 mmol) and the mixture was stirred under N2 at reflux for 4.5 h. The volatiles were 
evaporated and the residue was co-evaporated with DCM to remove traces of SOCl2.  
 
 
 
 
 191 
Coupling: 
 
The acid chloride 42b was treated with a solution of 8 (159 mg, 0.659 mmol), DMAP (10 mg, 
0.08 mmol) and anhydrous pyridine (53 µL, 0.73 mmol) in anhydrous DMF (3 mL). The solution 
was stirred at 30 oC under N2 for 48 h. The solvent was evaporated to give an orange oil which 
was dissolved in DCM (20 mL) and extracted with H2O (3 x 20 mL) and brine (3 x 20 mL). The 
organic phase was dried over MgSO4, filtered and the solvent was evaporated to give a residue 
which was purified by column chromatography, eluting with 0- 2% MeOH in DCM + 0.1% 
pyridine. This gave unchanged 42a (180 mg, 60%), and 43 as a colourless oil (16 mg, 4%; 10% 
based on recovered 42a).  Rf = 0.45 (10% acetone: DCM); Rt = 11.6 min (solvent system A); 1H 
NMR (CD3OD, 400 MHz) δ 0.32 (6H, s, Si(CH3)2), 0.32 (6H, s, Si(CH3)2), 1.07 (9H, s, SitBu), 1.08 
(9H, s, SitBu), 6.46 (1H, d, J = 2.4, Ar), 6.65 (1H, dd, J = 8.4, 2.4, Ar), 6.70 (1H, d, J = 16.0, HC=C), 
7.26 (1H, dd, J = 8.4, 0.8, Ar), 7.43 (1H, t, J = 7.6, Ar), 7.80 (1H, td, J = 7.8, 1.2, Ar), 7.74 (1H, d, 
J = 8.4, Ar), 7.91 (2H, d, J = 6.0, Pyr), 8.32 (1H, dd, J = 8.0, 1.6, Ar), 8.35 (1H, d, J = 16.4, HC=C), 
8.62 (1H, s, HC=N), 8.77 (2H, br s, Pyr); 13C NMR (CD3OD, 100 MHz) δ -4.15 (Si(CH3)2), -4.02 
(Si(CH3)2), 19.20 (C(CH3)3), 19.28 (C(CH3)3), 26.11 ((CH3)3), 26.26 ((CH3)3), 112.53 (Ar), 114.29 
(Ar), 115.77 (Ar), 120.44 (Pyr), 123.19 (Ar), 124.17 (Ar), 127.42 (Ar), 127.85 (Ar), 128.08 (Ar), 
130.03 (Pyr), 132.89 (Pyr), 142.32 (Ar), 143.76 (C=C), 146.24 (C=C), 151.13 (C=N), 151.76 (Ar), 
157.74 (Ar), 161.01 (Ar), 164.57 (C=O), 167.35 (C=O); [Found (ESI+) 654.2790 [M+H]+, 
C34H45N3O5Si2 requires 654.2795].  
 
Repeating the preparation on a similar scale but with anhydrous DCM as the coupling solvent 
gave unchanged 42a (91 mg, 45%) and 43 (28 mg, 10%; 18% based on recovered 42a). 
 
Method B:  
 
Acid chloride formation via the TBS-ester188: 
 
A solution of 41 (307 mg, 0.586 mmol) and catalytic DMF (2 drops) was treated with 2M oxalyl 
chloride in DCM (880 µL, 1.76 mmol) at 0oC and the mixture was stirred under N2 for 4 h. The 
volatiles were evaporated and the residue was co-evaporated with DCM.  
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Coupling: 
 
The acid chloride 42b was treated with a solution of 8 (114 mg, 0.473 mmol), DMAP (7 mg, 
0.06 mmol) and anhydrous pyridine (130 µL, 1.78 mmol) in anhydrous DMF (1 mL). The 
solution was stirred at 30 oC under N2 for 45 h. The solvent was evaporated to give an orange 
oil which was dissolved in DCM (20 mL) and extracted with H2O (3 x 20 mL) and brine (3 x 20 
mL). The organic phase was dried over MgSO4, filtered and the solvent was evaporated to give 
a residue which was purified by column chromatography, eluting with 0- 2% MeOH in DCM + 
0.1% pyridine. This gave unchanged 42a (170 mg, 71%) and 43 as a colourless oil (27 mg, 9%; 
31% yield based on recovered 42a). 
 
Method C: 
 
Acid chloride formation via the cinnamic acid187: 
 
A solution of 42a (180 g, 0.440 mmol) in anhydrous DCM (3 mL) was treated with SOCl2 (0.30 
mL, 4.14 mmol) and the mixture was stirred under N2 at reflux for 4.5 h. The volatiles were 
evaporated and the residue was co-evaporated with DCM to remove traces of SOCl2.  
 
Coupling: 
 
The acid chloride 42b was treated with a solution of salicylaldehyde (43 µL, 0.40 mmol), DMAP 
(5 mg, 0.04 mmol) and anhydrous pyridine (32 µL, 0.44 mmol) in anhydrous DCM (5 mL). The 
solution was stirred at 30 oC under N2 for 48 h. The solvent was evaporated to give an orange 
oil which was dissolved in DCM (20 mL) and extracted with H2O (3 x 20 mL) and brine (3 x 20 
mL). The organic phase was dried over MgSO4, filtered and the solvent was evaporated to give 
a residue which was purified by column chromatography, eluting with 0- 6% EtOAc in 
petroleum ether + 0.1% pyridine. This gave the desired product 45 (67 mg, 33%) which was 
immediately used in the next step. 
 
 
 
 193 
Condensation: 
 
A solution of 45 (67 mg, 0.13 mmol) and INH (18 mg, 0.13 mmol) in EtOH (5 mL) was heated 
at reflux for 3 h. The solvent was evaporated to give a yellow oil which was purified by column 
chromatography, eluting with 0-2% MeOH in DCM + 0.1% pyridine. This gave 43 as a 
colourless oil (17 mg, 21%). 
 
 
 
 
 
 
 
 
 
2-((E)-(2-isonicotinoylhydrazineylidene)methyl)phenyl (E)-3-(2,4-dihydroxyphenyl)acrylate 
(44) 
A solution of TBAF trihydrate (142 mg, 0.45 mmol) and acetic acid (100 µL) in anhydrous DMF 
(2 mL) was stirred under N2 at 0 oC for 30 min. A solution of 43 (63 mg, 0.10 mmol) in 
anhydrous DMF (2 mL) was added dropwise and the mixture was stirred at 0 oC for 45 min, 
then H2O (20 mL) was added and the mixture was extracted with EtOAc (3 x 20 mL). The 
combined organic phases were dried over MgSO4, filtered and the solvent was evaporated to 
give a yellow oil. Purification by column chromatography eluting with 5-10% MeOH in DCM + 
0.1% pyridine gave the product as a yellow oil (6 mg, 15%). Rf = 0.20 (10% MeOH: DCM); Rt = 
6.57 min (solvent system A); UV (EtOH) ʎmax 304 (7500);  1H NMR (DMSO-d6, 500 MHz) δ 6.33 
(1H, dd, J = 8.5, 2.5, Ar), 6.41 (1H, d, J = 2.5, Ar), 6.72 (1H, d, J = 15.5, HC=C), 7.26 (1H, dd, J = 
8.5, 1.5, Ar), 7.39 (1H, td, J= 8.0, 1.0, Ar), 7.54 (1H, td, J = 8.0, 2.0, Ar), 7.55 (1H, d, J = 9.0, Ar), 
7.80 (2H, d, J = 6.0, Pyr), 8.01 (1H, d, J = 15.5, HC=C), 8.04 (1H, dd, J = 7.5, 1.2, Ar), 8.54 (1H, s, 
HC=N), 8.77 (2H, br s, Pyr), 10.05 (1H, s, OH), 10.37 (1H, s, OH), 12.15 (1H, s, NH); 13C NMR 
(DMSO-d6, 125 MHz) δ 102.45 (Ar), 108.06 (Ar), 110.96 (C=C), 112.39 (Ar), 121.48 (Pyr), 123.43 
(Ar), 125.79 (Ar), 126.19 (Ar), 126.68 (Ar), 127.91 (Ar), 131.18 (Ar), 131.37 (Pyr), 140.35 (Ar), 
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143.03 (C=C), 143.38 (C=N), 149.78 (Ar), 150.26 (Pyr), 159.16 (Ar), 161.66 (C=O), 165.91 (C=O); 
[Found (ESI+) 404.1243 [M+H]+, C22H18N3O5 requires 404.1241]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2-(4-Oxo-4H-benzo[e][1,3]oxazin-2-yl)phenyl (E)-3-(2-((tert-
butyldimethylsilyl)oxy)phenyl)acrylate (46) 
 
Acid chloride formation via the cinnamic acid187: 
 
A solution of 38a (70 mg, 0.25 mmol) in anhydrous DCM (2 mL) was treated with SOCl2 (0.2 
mL, 2.5 mmol) and stirred under N2 at reflux for 4 h. The volatiles were evaporated and the 
residue was co-evaporated with DCM to remove traces of SOCl2.  
 
Coupling: 
 
The acid chloride 38b from the previous step was treated with a solution of 32 (55 mg, 0.23 
mmol), DMAP (4 mg, 0.03 mmol) and anhydrous pyridine (20 µL, 0.25 mmol) in anhydrous 
DMF (3 mL). The solution was stirred at 30 oC under N2 for 48 h after which time there was no 
conversion of the starting materials. 
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Ethyl-(E)-3-(4,5-dimethoxy-2-nitrophenyl)-2-methylacrylate (48)172 
 
A solution of 6-nitroveratraldehyde (2.00 g, 9.48 mmol) and ECETP (5.15 g, 14.22 mmol) in 
anhydrous toluene (85 mL) was heated overnight at 65oC under N2. The solvent was 
evaporated and the residue was purified by column chromatography eluting with DCM to give 
48 as a yellow solid (2.46 g, 88%). Rf = 0.63 (DCM); Rt= 9.53 min (solvent system A); mp = 147-
148oC (lit.172 146-147 oC); 1H NMR (CDCl3, 400  MHz) δ 1.34 (3H, t, J = 7.2, CH2CH3), 1.90 (3H, 
s, C=CCH3), 3.95 (3H, s, OCH3), 3.98 (3H, s, OCH3), 4.29 (2H, q, J = 7.2, CH2CH3), 6.71 (1H, s, Ar), 
7.74 (1H, s, Ar), 7.92 (1H, s, C=CH); 13C NMR (CDCl3, 100 MHz) δ 14.08 (CH3), 14.24 (CH3), 56.39 
(OCH3), 56.47 (OCH3), 61.04 (CH2), 107.72 (Ar), 112.23 (Ar), 126.60 (Ar), 129.32 (C=C), 136.48 
(C=C), 140.21 (Ar), 148.21 (Ar), 152.90 (Ar), 167.76 (C=O). 
 
 
 
 
 
 
 
 
(E)-3-(4,5-Dimethoxy-2-nitrophenyl)-2-methylacrylic acid (49) 
 
A solution of 48 (1.06 g, 3.59 mmol) in THF (40 mL) was treated with 1M NaOH (17 mL) and 
EtOH (10 mL) and stirred at RT overnight. The organic solvents were removed under reduced 
pressure and the remaining aqueous solution was diluted with H2O (20 mL) and the pH was 
adjusted to 3 with with 6M HCl. The resulting suspension was extracted with EtOAc (3 ´ 40 
mL) and the organic phases were dried over MgSO4, filtered, and the solvent was evaporated. 
This gave 49 as a yellow solid (950 mg, 99%). Rf = 0.63 (10% MeOH: DCM); Rt = 7.78 min 
(solvent system A); mp = 236- 237 oC; 1H NMR (acetone-d6, 400 MHz) δ 1.98 (3H, s, C=CCH3), 
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4.05 (3H, s, OCH3), 4.07 (3H, s, OCH3), 7.08 (1H, s, Ar), 7.83 (1H, s, Ar), 7.99 (1H, s, C=CH); 13C 
NMR (acetone-d6, 100 MHz) δ 14.18 (CH3), 56.67 (OCH3), 56.92 (OCH3), 108.73 (Ar), 113.66 
(Ar), 126.95 (Ar), 130.07 (C=C), 137.33 (C=C), 141.27 (Ar), 149.91 (Ar), 154.41 (Ar), 169.02 
(C=O). 
 
 
 
 
 
 
(E)-3-(2-Amino-4,5-dimethoxyphenyl)-2-methylacrylic acid (50) 
 
Method A193: 
 
A solution of 49 (80 mg, 0.30 mmol), iron powder (100 mg, 1.79 mmol) and AcOH (2 mL) in 
EtOH (2 mL) and H2O (1 mL) was heated for 2 h at reflux under N2. The reaction mixture was 
filtered through celite and the volatiles were evaporated. The resulting suspension was 
diluted with H2O (20 mL) and extracted with EtOAc (4 ́  30 mL). The organic phases were dried 
over MgSO4, filtered, and the solvent was evaporated. The resulting residue was co-
evaporated with MeCN, toluene and CHCl3 to give 50 as a dark yellow solid (60 mg, 85%).  
 
Method B194: 
 
A suspension of 49 (900 mg, 3.79 mmol) and FeSO4.7H2O (10.6 g, 38.0 mmol) in H2O (30 mL) 
was heated to 80 oC. 35% (aq.) NH3 solution (10 mL) was added to the orange solution which 
immediately turned black. After stirring for 5 min, the heat was removed and the solution was 
allowed to stir for a further 2 h at RT. The reaction mixture was filtered through celite and 
acidified to pH 4 using 1M HCl, then it was extracted with EtOAc (9 x 50 mL). The organic 
phases were dried over Na2SO4, filtered, and the solvent was evaporated to give 50 as a dark 
yellow solid (725 mg, 91%). Rf = 0.45 (10% iPrOH: DCM); Rt = 4.9 min (solvent system A); mp = 
154-156 oC; 1H NMR (DMSO-d6, 400 MHz) δ 2.02 (3H, s, C=CCH3), 3.69 (3H, s, OCH3), 3.76 (3H, 
s, OCH3), 4.91 (2H, s, NH2), 6.46 (1H, s, Ar), 6.75 (1H, s, Ar), 7.55 (1H, s, C=CH), 12.15 (1H, s, 
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OH); 13C NMR (DMSO-d6, 100 MHz) δ 14.31 (CH3), 55.15 (OCH3), 56.56 (OCH3), 100.13 (Ar), 
111.01 (Ar), 114.41 (Ar), 125.14 (C=C), 134.70 (C=C), 139.83 (Ar), 142.68 (Ar), 150.73 (Ar), 
169.64 (C=O). [Found (ESI-) 236.0924 [M-H]-, C12H14NO4 requires 236.0923].  
 
 
 
 
 
 
 
 
 
2-((E)-(2-Isonicotinoylhydrazono)methyl)phenyl (E)-3-(2-Amino-4,5-dimethoxyphenyl)-2-
methylacrylate (51) 
 
A stirred solution of 50 (700 mg, 2.95 mmol) in anhydrous DMF (20 mL) under N2 was cooled 
to 0 oC and DMAP (360 mg, 2.95 mmol) was added, followed by EDC.HCl (566 mg, 2.95 mmol). 
The solution was allowed to stir for 10 min, then a solution of 8 (499 mg, 2.07 mmol) and 
DIPEA (360 µL, 2.07 mmol) in anhydrous DMF (5 mL) was added and the temperature was 
increased to 30 oC. The reaction was stirred under N2 overnight, after which time the solvent 
was evaporated to give an orange oil. This oil was dissolved in DCM (100 mL) and extracted 
with sat. NH4Cl (3 x 100 mL) and brine (3 x 100mL). The organic phase was dried over MgSO4, 
filtered and the solvent evaporated. Purification by column chromatography eluting with 2-
6% MeOH in DCM + 0.1% pyridine gave 51 as a bright orange solid (750 mg, 79%). Rf = 0.5 
(10% MeOH: DCM); Rt = 6.1 min (solvent system A); mp = 114-117 oC; IR (KBr) 3430m (N-H), 
1657s (C=O), 1607s (C=O); UV (EtOH) λmax 302 (2870); 1H NMR (DMSO-d6, 400 MHz) δ 2.26 
(3H, d, J = 0.8, CH3), 3.73 (3H, s, OCH3), 3.79 (3H, s, OCH3), 5. 22 (2H, s, NH2), 6.50 (1H, s, Ar), 
6.88 (1H, s, Ar), 7.33 (1H, d, J = 7.6, Ar), 7.45 (1H, t, J = 7.6, Ar), 7.60 (1H, td, J = 7.7, 1.8, Ar), 
7.86 (2H, dd, J = 4.4, 1.6, Pyr), 7.94 (1H, d, J = 0.8, HC=C), 8.07 (1H, dd, J = 8.0, 1.6, Ar), 8.62 
(1H, s, HC=N), 8.83 (2H, d, J = 5.6, Pyr), 12.16 (1H, s, NH); 13C NMR (DMSO-d6, 500 MHz) δ 
14.64 (CH3), 55.15 (OCH3), 56.43 (OCH3), 99.92 (Ar), 110.03 (Ar), 113.96 (Ar), 121.97 (Ar), 
123.54 (Ar), 126.22 (Ar), 126.32 (C=C), 126.69 (Ar), 131.32 (Ar), 137.88 (Ar), 139.55 (Pyr), 
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139.89 (Pyr), 140.41 (Pyr), 143.55 (C=C), 143.79 (C=N), 150.09 (Ar), 150.34 (Ar), 151.60 (Ar), 
161.71 (C=O), 166.95 (C=O); [Found (ESI+) 461.1819 [M+H]+, C25H24N4O5 requires 461.1819].  
 
 
 
 
 
 
 
 
 
 
 
 
5-(hydroxymethyl)-4-((E)-(2-isonicotinoylhydrazineylidene)methyl)-2-methylpyridin-3-yl 
(E)-3-(2-amino-4,5-dimethoxyphenyl)-2-methylacrylate (52) 
 
A stirred solution of 50 (195 mg, 0.82 mmol) in anhydrous DMF (5 mL) under N2 was cooled 
to 0 oC and treated with DMAP (100 mg, 0.82 mmol) and EDC.HCl (157 mg, 0.82 mmol). The 
solution was allowed to stir for 10 min before a solution of 7 (129 mg, 0.45 mmol) and DIPEA 
(78 µL, 0.45 mmol) in anhydrous DMF (2 mL) was added. The temperature was increased to 
30oC and the reaction was stirred overnight. The solvent was then evaporated and the 
remaining residue was dissolved in DCM (20 mL) and extracted with sat. NH4Cl (3 x 20 mL) 
and brine (1 x 20 mL). The organic phase was dried over MgSO4, filtered and the solvent was 
evaporated to give an oil which was purified by column chromatography, eluting with 0-15% 
MeOH in DCM + 0.1% pyridine. This gave 52 as an orange oil (126 mg, 53%). Rf = 0.2 (5% 
MeOH: DCM) ;Rt = 5.18 min (solvent system A); UV (EtOH) λmax 298 (9250); 1H NMR (DMSO-
d6, 400 MHz) δ 2.23 (3H, d, J = 1.2, CH3), 2.41 (3H, s, CH3), 3.68 (3H, s, OCH3), 3.75 (3H, s, 
OCH3), 4.78 (2H, d, J = 6.4, CH2OH), 5.18 (2H, s, NH2), 5.41 (1H, t, J = 6.4, OH), 6.46 (1H, s, Ar), 
6.87 (1H, s, Ar), 7.84 (2H, d, J = 6.0, Pyr), 7.92 (1H, d, J = 1.6, C=CH), 8.57 (1H, s, Pyr), 8.64 (1H, 
s, N=CH), 8.81 (2H, br s, Pyr), 12.49 (1H, br s, NH); 13C NMR (DMSO-d6, 100 MHz) δ 14.47 (CH3), 
18.85 (CH3), 55.16 (OCH3), 56.20 (OCH3), 59.68 (CH2), 99.96 (Ar), 110.21 (Ar), 113.62 (Ar), 
121.60 (Pyr), 122.05 (C=C), 131.81 (Pyr), 133.86 (Ar), 138.03 (C=C), 139.75 (Ar), 139.94 (Pyr), 
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142.82 (Pyr), 143.25 (Pyr), 143.78 (C=N), 145.84 (Pyr), 150.22 (Pyr), 151.39 (Pyr), 151.66 (Ar), 
162.39 (C=O), 166.45 (C=O); [Found (ESI+) 528.1866 [M+H]+, C26H27N5O7Na requires 
528.1854]. 
 
 
 
 
 
 
 
 
 
 
 
 
2-(4-oxo-4H-benzo[e][1,3]oxazin-2-yl)phenyl (E)-3-(2-amino-4,5-dimethoxyphenyl)-2-
methylacrylate (53) 
 
A stirred solution of 50 (85 mg, 0.36 mmol) in anhydrous DMF (2 mL) under N2 was cooled to 
0 oC and treated with EDC.HCl (69 mg, 0.36 mmol) and DMAP (44 mg, 0.36 mmol). The mixture 
was allowed to stir for 10 min before a solution of 32 (60 mg, 0.25 mmol) and DIPEA (44 µL, 
0.25 mmol) in anhydrous DMF (2 mL) was added. The temperature was allowed to increase 
to RT and the reaction stirred for 40 h after which time the solvent was evaporated and the 
remaining residue was dissolved in DCM (20 mL) and then extracted with sat. NH4Cl (3 x 20 
mL) and brine (3 x 20 mL). The organic phase was dried over MgSO4, filtered and the solvent 
was evaporated to give a residue which was purified by column chromatography, eluting with 
2-6% acetone in DCM + 0.1% pyridine. This gave 53 as a yellow oil (43 mg, 38%) which 
decomposed on standing. Rf = 0.4 (6% acetone: DCM); Rt = 7.7 min (solvent system A); 1H NMR 
(DMSO-d6, 400 MHz) δ 2.19 (3H, d, J = 1.6, CH3), 3.83 (3H, s, OCH3), 3.88 (3H, s, OCH3), 6.32 
(1H, s, Ar), 6.80 (1H, s, Ar), 7.31 (1H, dd, J = 8.0, 0.8, Ar), 7.38 (1H, dd, J = 8.4 ,0.8, Ar), 7.47 
(2H, m, Ar), 7.70 (2H, m, Ar), 8.03 (1H, d, J = 0.8, HC=C), 8.14 (1H, dd, J = 7.8, 1.4, Ar), 8.31 (1H, 
dd, J = 8.0, 1.6, Ar); [Found (ESI+) 481.1375 [M+H]+, C26H22N2O6Na requires 481.1376]. 
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(E)-4-(5-(2-((3-(2-Amino-4,5-dimethoxyphenyl)-2-methylacryloyl)oxy)phenyl)-3-(2-
hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid (54)98 
 
4-Hydrazinobenzoic acid (17 mg, 0.11 mmol) and NEt3 (15 µL, 0.11 mmol) were dissolved in 
boiling EtOH (5 mL) under stirring. This solution was added to 53 (42 mg, 0.09 mmol) and the 
reaction was stirred at 60 oC for 48 h then allowed to cool to RT. The reaction was diluted with 
H2O (10 mL) and concentrated by 50%. 6M HCl was added (1 mL) and the solution was 
extracted with DCM (3 x 20 mL) and then brine (3 x 20 mL), dried over MgSO4, filtered and 
the solvent evaporated to give an orange residue. Purification by column chromatography (1-
6% MeOH in DCM + 0.1% pyridine) gave 54 as a yellow residue (14 mg, 26%) which 
decomposed readily under ambient lighting. Rf = 0.4 (6% MeOH: DCM); Rt = 8.1 min (solvent 
system A); [Found (ESI+) 615.1854 [M+H]+, C33H27N4O7Na requires 615.1856].  
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Methyl (E)-4-(5-(2-((3-(2-amino-4,5-dimethoxyphenyl)-2-methylacryloyl)oxy)phenyl)-3-(2-
hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoate (55)100 
 
A stirred solution of 50 (63 mg, 0.27 mmol) in anhydrous DMF (2 mL) under N2 was cooled to 
0 oC and was treated with DMAP (33 mg, 0.27 mmol) and EDC.HCl (52 mg, 0.27 mmol). The 
mixture was allowed to stir for 10 min before a solution of 33 (93 mg, 0.24 mmol) and DIPEA 
(42 µL, 0.24 mmol) in anhydrous DMF (1 mL) was added. The temperature was increased to 
30oC and the mixture was stirred overnight. The solvent was then evaporated and the 
remaining residue was dissolved in DCM (10 mL) and extracted with sat. NH4Cl (3 x 10 mL) 
and brine (3 x 10 mL). The organic phase was dried over MgSO4, filtered and the solvent was 
evaporated to give a residue which was purified by column chromatography, eluting with 0-
2% acetone in DCM + 0.1% pyridine. This gave 55 as an orange oil (41 mg, 28%). Rf = 0.45 (2% 
acetone: DCM); Rt = 9.67 min (solvent system A); UV (EtOH) λmax 302 (7640), 380 (3370); 1H 
NMR (CDCl3, 400 MHz) δ 1.92 (3H, d, J = 1.2, CH3), 3.70 (3H, s, OCH3), 3.78 (3H, s, OCH3), 3.88 
(3H, s, CO2CH3), 6.20 (1H, s, Ar), 6.60 (1H, s, Ar), 6.89 (1H, td, J = 8.8, 1.2, Ar), 6.94 (1H, dd, J = 
8.4, 1.2, Ar), 7.19- 7.21 (2H, m, Ar), 7.26 (1H, td, J = 8.0, 1.6, Ar), 7.31 (1H, d, J = 8.0, Ar), 7.49- 
7.57 (3H, m, Ar), 7.62 (1H, d, J = 1.2, C=CH), 8.01 (2H, d, J = 8.8, Ar), 8.07 (1H, dd, J = 7.6, 1.6, 
Ar), 10.92 (1H, br s, OH); 13C NMR (DMSO-d6, 100 MHz) δ 14.21 (CH3), 52.38 (OCH3), 55.15 
(OCH3), 56.36 (CO2CH3), 99.49 (Ar), 110.01 (Ar), 113.32 (Ar), 113.87 (Ar), 117.07 (Ar), 119.71 
(Ar), 120.41 (Ar), 122.01 (C=C), 123.73 (Ar), 124.47 (Ar), 126.08 (Ar), 126.80 (Ar), 129.81 (Ar), 
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130.34 (Ar), 131.31 (Ar), 131.59 (Ar), 132.43 (Ar), 138.07 (C=C), 139.90 (Ar), 140.44 (Ar), 
143.32 (Ar), 149.01 (Ar), 150.22 (Ar), 151.47 (Tri), 156.27 (Ar), 160.07 (Tri), 165.23 (C=O), 
166.16 (C=O); [Found (ESI+) 607.2192 [M+H]+, C34H30N4O7 requires 607.2193].  
 
 
 
 
 
 
 
 
N-(3,4-Dimethoxyphenyl)acetamide (57)273 
 
A solution of 3,4- dimethoxyaniline (500 mg, 3.26 mmol) and Et3N (545 µL, 3. 91 mmol) in 
anhydrous DCM (4 mL) was treated dropwise with acetyl chloride (280 µL, 3.91 mmol). The 
mixture was stirred under N2 at RT for 20 min and then extracted with sat. NH4Cl (3 x 10 mL) 
and brine (3 x 10 mL). The organic phase was dried over Na2SO4, filtered and the solvent was 
evaporated to give 57 as a dark purple solid (478 mg, 75%). Rf = 0.35 (80% EtOAc: pet. ether); 
Rt = 5.7 min (solvent system A), mp = 128-129 oC (lit274 128 -130 oC); 1H NMR (CDCl3, 400 MHz) 
δ 2.15 (3H, s, CH3), 3.84 (3H, s, OCH3), 3.85 (3H, OCH3), 6.78 (1H, s, Ar), 6.85 (1H, d, J = 2.4, 
Ar), 7. 29 (1H, d, J = 2.4, Ar); 13C NMR (CDCl3, 100 MHz) δ 24.29 (CH3), 55.85 (OCH3), 56.06 
(OCH3), 105.16 (Ar), 111.33 (Ar), 111.99 (Ar), 131.40 (Ar), 145.93 (Ar), 149.03 (Ar), 168.26 
(C=O). 
 
 
 
 
 
 
 
2-Chloro-6,7-dimethoxyquinoline-3-carbaldehyde (58)195 
 
A mixture of 57 (470 mg, 2.41 mmol) and anhydrous DMF (740 µL, 9.64 mmol) under N2 was 
cooled to 0oC and treated dropwise with POCl3 (2.7 mL, 29.0 mmol). The temperature was 
increased to 85oC and the mixture was stirred for 3 h. The reaction mixture was poured onto 
ice-cold water and stirred for 30 min. The resulting precipitate was collected by suction 
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filtration and washed with H2O before being recrystallized from MeCN to give 29 as beige 
needles (308 mg, 51%). Rf = 0.80 (80% EtOAc: pet. ether); Rt = 8.4 min (solvent system A); mp 
= 215- 218 oC (lit195 215 oC); 1H NMR (CDCl3, 400 MHz) δ 4.02 (3H, s, OCH3), 4.05 (3H, s, OCH3), 
7.13 (1H, s, Ar), 7.37 (1H, s, Ar), 8.56 (1H, s, Ar), 10.49 (1H, s, HC=O); 13C NMR (CDCl3, 400 
MHz) δ 56.21 (OCH3), 56.45 (OCH3), 106.19 (Ar), 107.20 (Ar), 122.29 (Ar), 124.58 (Ar), 137.54 
(Ar), 147.51 (Ar), 148.65 (Ar), 150.85 (Ar), 155.92 (Ar), 189.18 (HC=O). 
 
 
 
 
 
 
 
6,7-Dimethoxy-2-oxo-1,2-dihydroquinoline-3-carbaldehyde (59)195 
 
A stirred solution of 58 (300 mg, 1.19 mmol) and 70% AcOH (12 mL) was heated to reflux 
under N2 for 16 h. The solution was allowed to cool to RT then poured into ice-cold water (20 
mL). The resulting precipitate was collected by suction filtration and washed with H2O and 
EtOAc, then dried under high vacuum to give 59 as a bright yellow solid (140 mg, 50%). Rf = 
0.40 (20% acetone: DCM); Rt = 5.9 min (solvent system A); mp = >280 oC; 1H NMR (DMSO-d6, 
400 MHz) δ 3.86 (3H, s, OCH3), 3.93 (3H, s, OCH3), 6.93 (1H, s, Ar), 7.48 (1H, s, Ar), 8.43 (1H, s, 
Ar), 10.24 (1H, s, HC=O), 12.09 (1H, s, NH); 13C NMR (DMSO-d6, 100 MHz) δ 55.78 (OCH3), 
55.88 (OCH3), 97.29 (Ar), 110.40 (Ar), 111.67 (Ar), 122.55 (Ar), 138.45 (Ar), 141.46 (Ar), 145.58 
(Ar), 155.13 (Ar), 161.50 (C=O), 189.30 (HC=O); [Found (ESI+) 256.0597 [M+H]+, C12H10NO4Na 
requires 256.0586].    
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6,7-Dimethoxy-3-methylquinolin-2(1H)-one (60) 
 
Method A196: 
 
A solution of 59 (130 mg, 0.56 mmol) in TFA (3 mL) under N2 was cooled to 0oC and treated 
with Et3SiH (270 µL, 1.68 mmol), the temperature was increased to RT and the mixture was 
stirred for 2 h. The reaction mixture was poured into ice-cold water (20 mL) and extracted 
with DCM (3 x 15 mL) and brine (3 x 15 mL). The organic phases were combined and dried 
over MgSO4, filtered and the solvent was evaporated to give the crude product which was 
purified by column chromatography eluting with 2% MeOH in DCM. This gave 60 as a white 
solid (50 mg, 41%). Rf = 0.40 (5% MeOH:DCM); Rt = 6.3 min (solvent system A); mp = 236- 238 
oC; UV (EtOH) ʎmax 214 (29928), 234 (18082), 341 (4500); 1H NMR (CDCl3, 400 MHz) δ 2.26 (3H, 
d, J = 0.8, CH3), 3.91 (3H, s, OCH3), 3.98 (3H, s, OCH3), 6.81 (1H, s, Ar), 6.89 (1H, s, Ar), 7.55 
(1H, s, Ar), 11.56 (1H, s, NH); 13C NMR (CDCl3, 100 MHz) δ 16.33 (CH3), 56.13 (OCH3), 56.26 
(OCH3), 98.24 (Ar), 107.14 (Ar), 114.29 (Ar), 125.98 (Ar), 132.73 (Ar), 138.02 (Ar), 146.24 (Ar), 
151.98 (Ar), 163.61 (C=O); [Found (ESI+) 220.0984 [M+H]+, C12H13NO3 requires 220.0974].    
 
Method B194: 
 
A solution of 50 (25 mg, 0.11 mmol) and 4% HCl (2 mL) was heated to reflux and stirred for 3 
h. The reaction was cooled in an ice bath and 1% (aq.) NH3 solution (5 mL) was added, then 
extracted with DCM (3 x 10 mL). The organic phases were combined and extracted with brine 
(2 x 30 mL), then dried over Na2SO4, filtered and the solvent was evaporated to give 60 as a 
pale yellow solid (20 mg, 83%). 
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Ethyl (E)-3-(4,5-dimethoxy-2-nitrophenyl)acrylate (62) 
 
1-Bromo-4,5-dimethoxy-2-nitrobenzene (1.00 g, 3.82 mmol), Pd(OAc)2 (85 mg, 0.38 mmol) 
and PPh3 (199 mg, 0.76 mmol) were dissolved in anhydrous DMF (30 mL). The solution was 
treated with ethyl acrylate (2.0 mL, 18.8 mmol) and Et3N (1.1 mL, 7.89 mmol) and stirred 
under a N2 atmosphere at 90oC overnight. The solvent was evaporated and the resulting 
residue was dissolved in DCM and extracted with 1M HCl (3 x 50 mL) and brine (1 x 50 mL). 
The organic phase was evaporated and the residue was purified by column chromatography 
(DCM) to give 62 as a bright yellow powder (1.07 g, 80%). Rf = 0.45 (DCM); Rt = 9.3 min (solvent 
system A); mp = 148 -150oC (lit.275 148oC); 1H NMR (CDCl3, 400 MHz) δ 1.35 (3H, t, J = 7.2, 
CH2CH3), 3.98 (3H, s, OCH3), 3.99 (3H, s, OCH3), 4.29 (2H, q, J = 7.2, CH2CH3), 6.29 (1H, d, J = 
16.0, HC=C), 6.97 (1H, s, Ar), 7.63 (1H, s, Ar), 8.21 (1H, d, J = 16.0, HC=C); 13C NMR (CDCl3, 100 
MHz) δ 14.21 (CH3), 56.45 (OCH3), 56.46 (OCH3), 60.77 (CH2), 107.88 (Ar), 109.92 (Ar), 121.99 
(C=C), 125.20 (Ar), 140.64 (C=C), 141.14 (Ar), 149.83 (Ar), 153.10 (Ar), 165.90 (C=O). 
 
 
 
 
 
 
 
 
(E)-3-(4,5-Dimethoxy-2-nitrophenyl)acrylic acid (63) 
 
A solution of 62 (850 mg, 3.02 mmol) in THF (16 mL) was treated with 1M NaOH (11 mL) and 
EtOH (4 mL) and the mixture was stirred at 40oC overnight. The organic solvents were 
evaporated and the remaining solution was diluted with H2O (30 mL), the pH was adjusted to 
2 with 6M HCl and the yellow precipitate that formed was filtered and dried to give 63 (675 
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mg, 88%). Rf = 0.39 (5% MeOH:DCM); Rt = 7.5 min (solvent system A); mp = 270-273oC (lit.194 
286oC); 1H NMR (DMSO-d6, 400 MHz) δ 3.90 (3H, s, OCH3), 3.97 (3H, s, OCH3), 6.62 (1H, d, J = 
16.0, HC=C), 7.36 (1H, s, Ar), 7.65 (1H, s, Ar), 7.93 (1H, d, J = 16.0, HC=C), 12.59 (1H, s, CO2H); 
13C NMR (DMSO-d6, 100 MHz) δ 56.24 (OCH3), 56.49 (OCH3), 107.83 (Ar), 110.38 (Ar), 122.70 
(C=C), 123.67 (Ar), 138.94 (C=C), 141.20 (Ar), 149.56 (Ar), 152.78 (Ar), 167.14 (C=O). 
 
 
 
 
 
 
(E)-3-(2-Amino-4,5-dimethoxyphenyl)acrylic acid (64)194 
 
A suspension of 63 (210 mg, 0.829 mmol) and FeSO4.7H2O (2.38 g, 8.56 mmol) in H2O (10 mL) 
was heated to 80 oC under stirring. 35% (aq.) NH3 solution (3 mL) was added to the orange 
solution which immediately turned black. After stirring for 5 min, the heat was removed and 
the solution was allowed to stir for a further 2 h at RT. The reaction mixture was filtered 
through celite and acidified to pH 4 using 1M HCl, then extracted with EtOAc (4 x 30 mL). The 
organic phases were dried over Na2SO4, filtered, and the solvent was evaporated to give 64 
as a dark yellow solid (150 mg, 81%). Rf = 0.60 (20% MeOH: DCM); Rt = 4.7 min (solvent system 
A); mp = 156-158 oC (lit.194 175- 177 oC); 1H NMR (DMSO-d6, 400 MHz) δ 3.73 (3H, s, OCH3), 
3.76 (3H, s, OCH3), 5.33 (2H, s, NH2), 6.20 (1H, d, J = 15.6, C=CH), 6.40 (1H, s, Ar), 7.01 (1H, s, 
Ar), 7.81 (1H, d, J = 15.6, C=CH), 11.89 (1H, s, OH); 13C NMR (DMSO-d6, 100 MHz) δ 55.14 
(OCH3), 56.12 (OCH3), 100.33 (Ar), 109.20 (Ar), 110.14 (Ar), 112.92 (C=C), 139.88 (C=C), 140.99 
(Ar), 144.11 (Ar), 152.53 (Ar), 168.37 (C=O). 
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2-((E)-(2-Isonicotinoylhydrazono)methyl)phenyl (E)-3-(2-amino-4,5-dimethoxyphenyl) 
acrylate (65) 
 
A stirred solution of 63 (50 mg, 0.22 mmol) in anhydrous DMF (2 mL) under N2 was cooled to 
0 oC and treated with DMAP (27 mg, 0.22 mmol) and EDC.HCl (42 mg, 0.22 mmol). The solution 
was allowed to stir for 10 min before a solution of 8 (48 mg, 0.20 mmol) and DIPEA (35 µL, 
0.20 mmol) in anhydrous DMF (1 mL) was added. The temperature was increased to 30 oC 
and the reaction was stirred for 24 h. The solvent was then evaporated and the remaining 
residue was dissolved in DCM (10 mL) and extracted with sat. NH4Cl (3 x 10 mL) and brine (3 
x 10 mL). The organic phase was dried over MgSO4, filtered and the solvent was evaporated 
to give a yellow residue. Purification by column chromatography, eluting with 2-8% MeOH in 
DCM + 0.1% pyridine gave a mixture of 8 and 65 as an orange solid which was dissolved in 
DCM (20 mL) and extracted with 2M aq. FeSO4.7H2O (3 x 20 mL) and brine (3 x 20 mL). The 
solvent was evaporated to give 65 as a dark yellow solid (40 mg, 47%). Rf = 0.8 (5% MeOH: 
DCM); Rt = 6.2 min (solvent system A); mp = 110-115 oC; 1H NMR (DMSO-d6, 400 MHz) δ 3.78 
(3H, s, OCH3), 3.86 (3H, s, OCH3), 5. 65 (2H, s, NH2), 6.42 (1H, s, Ar), 6.62 (1H, d, J = 15.6, HC=C)  
7.17 (1H, s, Ar), 7.30 (1H, d, J = 8.0, Ar), 7.44 (1H, t, J = 7.4, Ar), 7.59 (1H, t, J = 7.2, Ar), 7.86 
(2H, d, J = 5.2, Pyr), 8.09 (1H, d, J = 7.2, Ar), 8.16 (1H, d, J = 15.6, HC=C), 8.63 (1H, s, HC=N), 
8.82 (2H, br s, Pyr), 12.21 (1H, s, NH); 13C NMR (DMSO-d6, 125 MHz) δ 54.17 (OCH3), 55.73 
(OCH3), 100.25 (Ar), 109.09 (Ar), 113.45 (Ar), 120.76 (Ar), 123.24 (Ar), 126.42 (Ar), 126.75 
(C=C), 127.19 (Ar), 131.345 (Ar), 137.98 (Ar), 139.76 (Pyr), 140.09 (Pyr), 141.87 (Pyr), 143.35 
(C=C), 143.95 (C=N), 149. 78 (Ar), 150.24 (Ar), 151.45 (Ar), 161.98 (C=O), 167.04 (C=O); [Found 
(ESI+) 469.1484 [M+H]+, C24H23N4O5Na requires 469.1488]. 
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Methyl (E)-4-(5-(2-((3-(2-Amino-4,5-dimethoxyphenyl)acryloyl)oxy)phenyl)-3-(2-
hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoate (66)100 
 
A stirred solution of 63 (38 mg, 0.17 mmol) in anhydrous DMF (2 mL) under N2 was cooled to 
0 oC and treated with DMAP (21 mg, 0.17 mmol) and EDC.HCl (33 mg, 0.17 mmol). The mixture 
was allowed to stir for 10 min before a solution of 33 (66 mg, 0.17 mmol) and DIPEA (30 µL, 
0.17 mmol) in anhydrous DMF (1 mL) was added. The temperature was increased to 30 oC 
and the mixture was stirred for 24 h. The solvent was then evaporated and the remaining 
residue was dissolved in DCM (10 mL) and extracted with sat. NH4Cl (3 x 10 mL) and brine (3 
x 10 mL). The organic phase was dried over MgSO4, filtered and the solvent was evaporated 
to give a residue which was purified by column chromatography, eluting with 0-4% acetone 
in DCM + 0.1% pyridine. This gave unchanged deferasirox methyl ester (27 mg, 41%) and 25 
as a yellow residue (17 mg, 17%, 28% yield based on recovered deferasirox methyl ester). Rf 
= 0.85 (5% MeOH: DCM); Rt = 10.1 min (solvent system A); 1H NMR (CDCl3, 400 MHz) δ 3.80 
(3H, s, OCH3), 3.85 (3H, s, OCH3), 3.93 (3H, s, CH3), 6.07 (1H, d, J = 15.6, HC=C), 6.19 (1H, s, Ar), 
6.92 (1H, td, J = 7.3, 1.2, Ar), 6.98 (1H, dd, J = 8.4, 0.8, Ar), 7.32 (4H, m, Ar), 7.57 (3H, m, Ar), 
7.77 (1H, d, J = 15.6, HC=C), 8.06 (2H, d, J = 8.8, Ar), 8.12 (1H, dd, J = 7.6, 1.6, Ar), 11.00 (1H, 
s, OH). 13C NMR (CDCl3, 100 MHz) δ 52.33 (OCH3), 55.79 (OCH3), 56.30 (CO2CH3), 100.60 (Ar), 
110.09 (Ar), 110.91 (Ar), 112.00 (Ar), 113.51 (Ar), 117.21 (Ar), 119.53 (Ar), 120.87 (Ar), 123.71 
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(Ar), 124.04 (C=C), 125.83 (Ar), 126.85 (Ar), 130.20 (Ar), 130.73 (C=C), 130.88 (Ar), 131.41 (Ar), 
132.09 (Ar), 140.93 (Ar), 142.16 (Ar), 142.37 (Ar), 142.66 (Ar), 149.20 (Ar), 150.04 (Ar), 153.20 
(Tri), 156.98 (Ar), 161.24 (Tri), 165.08 (C=O), 165.96 (C=O); [Found (ESI+) 615.1837 [M+H]+, 
C33H28N4O7Na requires 615.1856]. 
 
 
 
 
 
 
2-Amino-4,5-dimethoxybenzaldehyde (67)194 
 
A suspension of 6-nitroveratraldehyde (500 mg, 2.37 mmol) and FeSO4.7H2O (6.60 g, 23.7 
mmol) in H2O (20 mL) was heated to 80 oC under vigorous stirring. 35% (aq.) NH3 solution (6 
mL) was added to the orange solution which immediately turned black. After stirring for 5 
min, the heat was removed and the solution was allowed to stir for a further 2 h at RT. The 
reaction mixture was filtered through celite and acidified to pH 4 using 1M HCl, then extracted 
with EtOAc (4 x 100 mL). The organic phases were dried over Na2SO4, filtered, and the solvent 
was evaporated to give 67 as an orange oil (325 mg, 76%). Rf = 0.75 (20% MeOH: DCM); Rt = 
6.2 min (solvent system A); 1H NMR (CDCl3, 400 MHz) δ 3.77 (3H, s, OCH3), 3.79 (3H, s, OCH3),  
6.06 (1H, s, Ar), 6.80 (1H, s, Ar), 6.61 (1H, d, J = 0.4, HC=O); 13C NMR (CDCl3, 100 MHz) δ 55.82 
(OCH3), 56.44 (OCH3), 98.34 (Ar), 111.20 (Ar), 116.02 (Ar), 140.88 (Ar), 147.36 (Ar), 156.14 
(Ar), 191.26 (C=O). 
 
 
 
 
 
 
 
 
N-(2-Formyl-4,5-dimethoxyphenyl)acetamide (68)198 
 
A solution of 67 (210 mg, 1.16 mmol) and Et3N (195 µL, 1. 39 mmol) in anhydrous DCM (4 mL) 
was treated dropwise with acetyl chloride (100 µL, 1.39 mmol). The reaction was stirred under 
N2 at RT for 30 min and then quenched with H2O (20 mL), before extraction with sat. NH4Cl (3 
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x 20 mL) and brine (3 x 20 mL). The organic phase was dried over Na2SO4, filtered and the 
solvent was evaporated to give 68 as a bright yellow solid (205 mg, 81%). Rf = 0.80 (3% MeOH: 
DCM); Rt = 6.8 min (solvent system A), mp = 174-178 oC (lit.276 178 -179 oC); 1H NMR (CDCl3, 
400 MHz) δ 2.22 (3H, s, CH3), 3.89 (3H, s, OCH3), 3.97 (3H, s, OCH3), 7.01 (1H, s, Ar), 8.45 (1H, 
s, Ar), 9.73 (1H, s, HC=O), 11.29 (1H, br s, NH); 13C NMR (CDCl3, 100 MHz) δ 25.32 (CH3), 56.21 
(OCH3), 56.35 (OCH3), 102.94 (Ar), 114.36 (Ar), 116.45 (Ar), 137.62 (Ar), 144.39 (Ar), 155.57 
(Ar), 169.63 (C=O), 191.26 (C=O). 
 
 
 
 
 
 
 
 
6,7-Dimethoxyquinolin-2(1H)-one (69) 
 
Method A198: 
 
A stirred mixture of 68 (122 mg, 0.56 mmol) and Cs2CO3 (920 mg, 2.8 mmol) in anhydrous 
DMF (5 mL) was heated to 60 oC under N2 for 22 h. The solvent was evaporated and the 
remaining residue was dissolved in DCM (30 mL) and extracted with sat. NH4Cl (3 x 30 mL), 
H2O (3 x 30 mL) and brine (3 x 30 mL). The organic phase was dried over Na2SO4, filtered, and 
then the solvent was evaporated to give an orange residue which was purified by column 
chromatography eluting with 2-4% MeOH in DCM + 0.1% pyridine. This gave 69 as a pale 
yellow powder (11 mg, 10%).  
 
Method B194:  
 
A solution of 64 (55 mg, 0.25 mmol) and 4% HCl (2 mL) was heated to reflux and stirred for 2 
h. The reaction was cooled in an ice bath and 1% (aq.) NH3 solution (5 mL) was added, then 
extracted with DCM (3 x 10 mL). The organic phases were combined and extracted with brine 
(2 x 30 mL) and dried over Na2SO4, filtered and the solvent was evaporated to give 69 as a 
pale yellow solid (40 mg, 78%). Rf = 0.4 (5% MeOH: DCM); Rt = 5.7 min (solvent system A), mp 
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= 222-225 oC (lit194 229 oC); UV (EtOH) ʎmax 214 (5575), 237 (4888), 344 (1890);  1H NMR 
(DMSO-d6, 400 MHz) δ 3.79 (3H, s, OCH3), 3.82 (3H, s, OCH3), 6.32 (1H, d, J = 7.6, Ar), 6.87 (1H, 
s, Ar), 7.19 (1H, s, Ar), 7.78 (1H, d, J = 7.6, Ar), 11.51 (1H, br s, NH); 13C NMR (DMSO-d6, 100 
MHz) δ 55.52 (OCH3), 55.73 (OCH3), 97.67 (Ar), 108.86 (Ar), 112.26 (Ar), 118.72 (Ar), 134.52 
(Ar), 139.64 (Ar), 144.69 (Ar), 151.81 (Ar), 161.78 (C=O); [Found (ESI+) 206.0831 [M+H]+, 
C11H11NO3 requires 206.0817]. 
 
 
 
 
 
 
 
 
 
4-(Benzyloxy)-3-methoxybenzaldehyde (76)209 
 
A mixture of vanillin (2.17 g, 14.27 mmol) and K2CO3 (2.37 g, 17.13 mmol) in MeOH (20 mL) 
was treated with benzyl bromide (2.03 mL, 17.13 mmol) and stirred at reflux for 4 h. After 
cooling, the solvent was evaporated and the residue was dissolved in CHCl3 (40 mL). The 
organic phase was extracted with H2O (3 x 40 mL) and brine (40 mL) and evaporated to give a 
yellow solid which was recrystallized from EtOH to give 76 as white needles (3.04 g, 93%). Rf 
= 0.39 (DCM); Rt = 8.7 min (solvent system A); mp = 59- 61oC (lit.277 58-60oC); 1H NMR (CDCl3, 
400 MHz) δ 3.90 (3H, s, OCH3), 5.20 (2H, s, CH2), 6.94 (1H, d, J= 8.0, Ar), 7.25-7.40 (7H, m, Ar), 
9.79 (1H, s, HC=O); 13C NMR (CDCl3, 100 MHz) δ 56.00 (OCH3), 70.84 (CH2), 109.43 (Ar), 112.43 
(Ar), 126.43 (Ar), 127.12 (Ar), 128.12 (Ar), 128.64 (Ar), 130.30 (Ar), 135.98 (Ar), 150.07 (Ar), 
153.57 (Ar), 190.75 (C=O). 
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4-(Benzyloxy)-5-methoxy-2-nitrobenzaldehyde (77)278 
 
65% (aq.) nitric acid (35 mL) was added slowly to 76 (2.80 g, 11.57 mmol) at 0oC and the 
resulting suspension was stirred for 1 h. The suspension was filtered and washed with H2O 
and then recrystallized from EtOAc to give 77 as bright yellow crystals (1.99 g, 60%). Rf = 0.63 
(DCM); Rt = 9.7 min (solvent system A); mp = 133oC (lit.279 132-133oC); 1H NMR (CDCl3, 400 
MHz) δ 3.97 (3H, s, OCH3), 5.22 (2H, s, CH2), 7.29-7.42 (6H, m, Ar), 7.62 (1H, s, Ar), 10.39 (1H, 
s, HC=O); 13C NMR (CDCl3, 100 MHz) δ 56.64 (OCH3), 71.52 (CH2), 108.90 (Ar), 109.99 (Ar), 
125.68 (Ar), 127.48 (Ar), 128.62 (Ar), 128.82 (Ar), 134.79 (Ar), 144.91 (Ar), 151.37 (Ar), 153.57 
(Ar), 190.75 (C=O); [Found (ESI+) 310.0686. [M+H]+, C15H13NNaO5 requires 310.0691]. 
 
 
 
 
 
 
 
 
5-(Benzyloxy)-2-nitrobenzaldehyde (78)209 
 
A mixture of 5-hydroxy-2-nitrobenzaldehyde (500 mg, 2.99 mmol) and K2CO3 (496 mg, 3.59 
mmol) in MeOH (10 mL) was treated with benzyl bromide (430 µL, 3.62 mmol) and stirred at 
reflux for 4 h. After cooling, the solvent was evaporated and the residue was dissolved in 
CHCl3 (30 mL). The organic phase was extracted with H2O (3 x 30 mL) and brine (40 mL) and 
the solvent was evaporated to give a yellow solid which was recrystallized from EtOAc:hexane 
to give 78 as beige needles (580 mg, 80%). Rf = 0.84 (DCM); Rt = 9.8 min (solvent system A); 
mp = 73- 75oC (lit.280 70-72oC); 1H NMR (CDCl3, 400 MHz) δ 5.21 (2H, s, CH2), 7.21 (1H, dd, J= 
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9.0, 3.0, Ar), 7.37-7.43 (6H, m, Ar), 8.15 (1H, d, J = 9.2, Ar), 10.47 (1H, s, HC=O); 13C NMR 
(CDCl3, 100 MHz) δ 71.02 (CH2), 114.14 (Ar), 119.26 (Ar), 127.23 (Ar), 127.53 (Ar), 128.65 (Ar), 
128.82 (Ar), 134.24 (Ar), 134.85 (Ar), 142.43 (Ar), 163.01 (Ar), 188.37 (C=O). 
 
 
 
 
 
 
Ethyl (E)-2-methyl-3-(6-nitrobenzo[d][1,3]dioxol-5-yl)acrylate (79)281  
 
A mixture of 2-nitropiperonal (1.50 g, 7.69 mmol) and ECETP (3.34 g, 9.22 mmol) in anhydrous 
toluene (60 mL) was stirred at 65oC under an argon atmosphere for 18 h. The solvent was 
evaporated and the resulting residue was purified by column chromatography (DCM) to give 
79 as a bright yellow solid (2.13 g, 99%). Rf = 0.49 (DCM); Rt = 9.57 min (solvent system A); 
mp= 119-122oC (lit.281 115-117oC); 1H NMR (CDCl3, 400 MHz) δ 1.30 (3H, t, J = 8.0, CH2CH3), 
1.85 (3H, s, CH3), 4.23 (2H, q, J = 8.0, CH2CH3), 6.11 (2H, s, OCH2O), 6.66 (1H, s, Ar), 7.60 (1H, 
s, Ar), 7.79 (1H, s, HC=C); 13C NMR (CDCl3, 100 MHz) δ 13.92 (CH3), 14.19 (CH3), 61.00 (CH2), 
103.13 (CH2), 105.57 (Ar), 109.65 (Ar), 128.66 (C=C), 129.60 (Ar), 136.00 (C=C), 141.93 (Ar), 
147.73 (Ar), 151.71 (Ar), 167.57 (C=O). 
 
 
 
 
 
 
Ethyl (E)-2-methyl-3-(2-nitrophenyl)acrylate (80)281  
 
A mixture of 2-nitrobenzaldehyde (1.00 g, 6.62 mmol) and ECETP (2.88 g, 7.94 mmol) in 
anhydrous toluene (40 mL) was stirred at 65oC under an argon atmosphere for 5 h. The solvent 
was evaporated and the resulting residue was purified by column chromatography (DCM) to 
give 80 as a yellow oil (1.55 g, 99%). Rf = 0.6 (DCM); Rt = 9.7 min (solvent system A); 1H NMR 
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(CDCl3, 400 MHz) δ 1.29 (3H, t, J = 7.2, CH2CH3), 1.83 (3H, s, CH3), 4.22 (2H, q, J = 7.2, CH2CH3), 
7.30 (1H, dd, J = 7.6, 1.2, Ar), 7.44 (1H, td, J = 7.2, 1.6, Ar), 7.59 (1H, td, J = 7.6, 1.2, Ar), 7.83 
(1H, s, HC=C), 8.06 (1H, dd, J = 8.4, 1.2, Ar); 13C NMR (CDCl3, 100 MHz) δ 13.85 (CH3), 14.16 
(CH3), 61.00 (CH2), 124.71 (Ar), 128.84 (C=C), 130.45 (Ar), 131.21 (Ar), 131.83 (Ar), 133.13 (Ar), 
135.21 (C=C), 147.74 (Ar), 167.47 (C=O). 
 
  
 
 
 
 
Ethyl (E)-3-(4-(benzyloxy)-5-methoxy-2-nitrophenyl)-2-methylacrylate (81)  
 
A solution of 77 (1.65 g, 5.74 mmol) and ECETP (2.50 g, 6.89 mmol) in anhydrous toluene (50 
mL) was stirred at 65oC under an argon atmosphere for 4 h. The solvent was evaporated and 
the resulting residue was purified by column chromatography (DCM) to give 81 as a bright 
yellow solid (2.09 g, 98%). Rf = 0.48 (DCM); Rt = 10.7 min (solvent system A); mp= 129-131oC; 
1H NMR (CDCl3, 400 MHz) δ 1.35 (3H, t, J = 7.0, CH2CH3), 1.92 (3H, d, J = 1.6, CH3), 3.95 (3H, s, 
OCH3), 4.29 (2H, q, J = 7.0, CH2CH3), 5.22 (2H, s, CH2), 6.73 (1H, s, Ar), 7.35-7.48 (5H, m, Ar), 
7.80 (1H, s, Ar), 7.91 (1H, q, J = 0.7, HC=C); 13C NMR (CDCl3, 100 MHz) δ 14.03 (CH3), 14.21 
(CH3), 56.64 (OCH3), 60.97 (CH2), 71.28 (CH2), 109.79 (Ar), 112.56 (Ar), 126.80 (Ar), 127.53 
(Ar), 128.39 (C=C), 128.71 (Ar), 129.34 (Ar), 135.46 (Ar), 136.39  (C=C), 140.08 (Ar), 147.54 
(Ar), 153.47 (Ar), 167.70 (C=O); [Found (ESI+) 372.1461 [M+H]+, C20H22NO6 requires 372.1442]. 
 
 
 
 
 
 215 
 
 
 
 
 
 
Ethyl (E)-3-(5-(benzyloxy)-2-nitrophenyl)-2-methylacrylate (82)  
 
A solution of 78 (312 mg, 1.29 mmol) and ECETP (570 mg, 1.57 mmol) in anhydrous toluene 
(20 mL) was stirred at 65oC under an argon atmosphere for 3 h. The solvent was evaporated 
and the resulting residue was purified by column chromatography (DCM) to give 82 as a 
yellow oil (429 mg, 98%). Rf = 0.64 (DCM); Rt = 10.88 min (solvent system A); 1H NMR (CDCl3, 
400 MHz) δ 1.35 (3H, t, J = 7.2, CH2CH3), 1.81 (3H, d, J = 1.6, CH3), 4.28 (2H, q, J = 7.2, CH2CH3), 
5.17 (2H, s, CH2), 6.81 (1H, dd, J = 2.8, 0.8, Ar), 7.02 (1H, dd, J = 9.2, 2.8, Ar), 7.36-7.42 (5H, m, 
Ar), 7.91 (1H, q, J = 0.8, HC=C), 8.19 (1H, d, J = 9.2, Ar); 13C NMR (CDCl3, 100 MHz) δ 13.81 
(CH3), 14.21 (CH3), 61.04 (CH2), 70.65 (CH2), 114.62 (Ar), 116.82 (Ar), 127.30 (Ar), 127.48 (Ar), 
128.49 (Ar), 128.80 (Ar), 129.77 (C=C), 134.67 (Ar), 135.29  (Ar), 136.09 (C=C), 140.77 (Ar), 
162.11 (Ar), 167.60 (C=O); [Found (ESI+) 342.1349 [M+H]+, C19H20NO5 requires 342.1336]. 
 
 
 
 
 
(E)-2-Methyl-3-(6-nitrobenzo[d][1,3]dioxol-5-yl)acrylic acid (83) 
 
A solution of 79 (1.50 g, 5.37 mmol) in THF (30 mL) was treated with 1M NaOH (19 mL) and 
EtOH (8 mL) and the mixture was stirred at 40oC for 3 h. The organic solvents were 
evaporated and the remaining solution was diluted with H2O (30 mL), the pH adjusted to 2 
with 6M HCl, and the aqueous phase was extracted with EtOAc (3 x 100 mL). The combined 
organic layers were extracted with brine (100 mL) then dried over MgSO4, filtered and the 
solvent was evaporated to give a pale peach powder (1.34 g, 99%). Rf = 0.63 (10% 
MeOH:DCM); Rt = 7.83 min (solvent system A); mp= 197-202oC; 1H NMR (DMSO-d6, 400 
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MHz) δ 1.82 (3H, s, CH3), 6.29 (2H, s, CH2), 7.07 (1H, s, Ar), 7.69 (1H, s, HC=C),  7.76 (1H, s, 
Ar), 12.64 (1H, s, CO2H); 13C NMR (DMSO-d6, 100 MHz) δ 13.72 (CH3), 103.67 (CH2), 105.07 
(Ar), 109.63 (Ar), 127.89 (C=C), 129.63 (Ar), 135.28 (C=C), 141.56 (Ar), 147.67 (Ar), 151.80 
(Ar), 168.47 (C=O); [Found (ESI+) 274.0331 [M+Na]+, C11H9NNaO6 requires 274.0322]. 
 
 
 
 
 
 
 
 
(E)-2-Methyl-3-(2-nitrophenyl)acrylic acid (84) 
 
A solution of 80 (1.51 g, 6.42 mmol) in THF (32 mL) was treated with 1M NaOH (22 mL) and 
EtOH (8 mL) and the mixture was stirred at 40oC for 2 h. The organic solvents were evaporated 
and the remaining solution was diluted with H2O (30 mL), the pH adjusted to 2 with 6M HCl 
and the aqueous phase was extracted with EtOAc (3 x 50 mL). The combined organic layers 
were extracted with brine (50 mL), then dried over MgSO4, filtered and the solvent was 
evaporated to give 84 as a pale yellow solid (1.35 g, 99%). Rf = 0.51 (5% MeOH:DCM); Rt = 7.80 
min (solvent system A); mp= 191-195oC (lit.282 196-196.5oC); 1H NMR (DMSO-d6, 400 MHz) δ 
1.82 (3H, s, CH3), 7.55 (1H, d, J = 7.6, Ar), 7.66 (1H, t, J = 7.6, Ar), 7.76 (1H, s, HC=C),  7.82 (1H, 
t, J = 7.6, Ar), 8.16 (1H, d, J = 8.0, Ar), 12.71 (1H, s, CO2H); 13C NMR (DMSO-d6, 100 MHz) δ 
13.72 (CH3), 124.58 (Ar), 129.46 (C=C), 130.51 (Ar), 130.89 (Ar), 131.32 (Ar), 133.74 (Ar), 
134.50 (C=C), 147.54 (Ar), 168.47 (C=O). 
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(E)-3-(4-(Benzyloxy)-5-methoxy-2-nitrophenyl)-2-methylacrylic acid (85) 
 
A solution of 81 (940 mg, 2.53 mmol) in THF (20 mL) was treated with 1M NaOH (10 mL) and 
EtOH (5 mL) and the mixture was stirred at 40oC overnight. The organic solvents were 
evaporated and the remaining solution was diluted with H2O (30 mL), the pH adjusted to 2 
with 6M HCl and the aqueous phase was extracted with EtOAc (3 x 40 mL). The combined 
organic layers were extracted with brine (50 mL) and dried over MgSO4, then filtered and the 
solvent evaporated to give a pale yellow solid (824 mg, 95%). Rf = 0.36 (5% MeOH:DCM); Rt = 
9.41 min (solvent system A); mp= 167-170oC; 1H NMR (DMSO-d6, 400 MHz) δ 1.86 (3H, d, J = 
1.6, CH3), 3.93 (3H, s, OCH3), 5.25 (2H, s, CH2), 7.02 (1H, s, Ar), 7.35-7.50 (5H, m, Ar), 7.78 (1H, 
q, J = 0.8, HC=C), 7.86 (1H, s, Ar), 12.62 (1H, br s, CO2H); 13C NMR (DMSO-d6, 100 MHz) δ 13.83 
(CH3), 56.53 (OCH3), 70.39 (CH2), 109.26 (Ar), 113.10 (Ar), 126.01 (Ar), 127.97 (Ar), 128.14 
(C=C), 128.49 (Ar), 129.50 (Ar), 135.49 (Ar), 136.09  (C=C), 139.69 (Ar), 147.16 (Ar), 153.18 
(Ar), 168.73 (C=O); [Found (ESI+) 366.1032 [M+Na]+, C18H17NNaO6 requires 366.0948]. 
 
 
 
 
 
 
 
 
(E)-3-(5-(Benzyloxy)-2-nitrophenyl)-2-methylacrylic acid (86) 
 
A solution of 82 (396 mg, 1.16 mmol) in THF (10 mL) was treated with 1M NaOH (5 mL) and 
EtOH (3 mL) and the mixture was stirred at 40oC for 3 h. The organic solvents were evaporated 
and the remaining solution was diluted with H2O (20 mL), the pH adjusted to 2 with 6M HCl, 
and the aqueous phase was extracted with EtOAc (3 x 30 mL). The combined organic layers 
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were extracted with brine (40 mL) and dried over MgSO4, then filtered and the solvent was 
evaporated to give a pale yellow solid (326 mg, 90%). Rf = 0.35 (5% MeOH:DCM); Rt = 9.46 
min (solvent system A); mp = 175-180oC; 1H NMR (DMSO-d6, 400 MHz) δ 1.74 (3H, d, J = 1.6, 
CH3), 5.30 (2H, s, CH2), 7.04 (1H, dd, J = 2.8, 0.8, Ar), 7.24 (1H, dd, J = 9.2, 2.8, Ar), 7.36-7.49 
(5H, m, Ar), 7.78 (1H, q, J = 0.8, HC=C), 8.21 (1H, d, J = 9.2, Ar), 12.72 (1H, br s, CO2H); 13C NMR 
(DMSO-d6, 100 MHz) δ 13.63 (CH3), 70.13 (CH2), 115.31 (Ar), 116.71 (Ar), 127.44 (Ar), 127.79 
(Ar), 128.14 (Ar), 128.54 (Ar), 129.82 (C=C), 134.04 (Ar), 135.43 (Ar), 135.94 (C=C), 140.30 (Ar), 
161.99 (Ar), 168.60 (C=O); [Found (ESI+) 336.0864 [M+Na]+, C17H15NNaO5 requires 336.0842]. 
 
 
 
 
 
 
 
(E)-3-(6-Aminobenzo[d][1,3]dioxol-5-yl)-2-methylacrylic acid (87)  
 
A suspension of 83 (590 mg, 2.35 mmol) and FeSO4.7H2O (6.67 g, 24.00 mmol) in H2O (20 mL) 
was heated to 80oC under stirring. 35% (aq.) NH3 solution (7 mL) was added. After stirring for 
5 min, the heat was removed and the mixture was allowed to stir for a further 3 h at RT. Then 
the reaction mixture was filtered through celite and acidified to pH 3 using 1M HCl. The 
aqueous phase was extracted with EtOAc (3 x 100 mL) and brine (100 mL). The organic phases 
were dried over Na2SO4, filtered, and the solvent was evaporated to give 87 as a bright yellow 
solid (442 mg, 85%). Rf = 0.53 (10% MeOH: DCM); Rt = 5.08 min (solvent system A); mp = 197-
200oC; 1H NMR (DMSO-d6, 400 MHz) δ 1.95 (3H, d, J = 1.2, CH3), 4.95 (2H, br s, NH2), 5.89 (2H, 
s, CH2), 6.39 (1H, s, Ar), 6.69 (1H, s, Ar), 7.46 (1H, s, HC=C) 12.14 (1H, br s, CO2H); 13C NMR 
(DMSO-d6, 100 MHz) δ 14.23 (CH3), 96.83 (CH2), 100.35 (Ar), 108.25 (Ar), 111.38 (Ar), 125.50 
(C=C), 134.69 (Ar), 138.23 (Ar), 143.46 (C=C), 148.31 (Ar), 169.44 (C=O). [Found (ESI-) 
220.0628 [M-H]-, C11H10NO4 requires 220.0610]. 
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(E)-3-(2-Aminophenyl)-2-methylacrylic acid (88)  
 
A suspension of 84 (1.34 g, 6.47 mmol) and FeSO4.7H2O (18.1 g, 65.0 mmol) in H2O (60 mL) 
was heated to 80oC under stirring. 35% (aq.) NH3 solution (20 mL) was added. After stirring 
for 5 min, the heat was removed and the mixture was allowed to stir for a further 2.5 h at RT. 
Then the reaction mixture was filtered through celite and acidified to pH 3 using 1M HCl then 
it was extracted with EtOAc (3 x 150 mL). The organic phases were dried over Na2SO4, filtered, 
and the solvent was evaporated to give 88 as a peach-coloured solid (1.07 g, 71%). Rf = 0.46 
(10% iPrOH:DCM); Rt = 5.20 min (solvent system A); mp = 143-145oC; 1H NMR (DMSO-d6, 400 
MHz) δ 1.92 (3H, s, CH3), 5.08 (2H, br s, NH2), 6.58 (1H, t, J = 8.0, Ar), 6.71 (1H, d, J = 8.0, Ar), 
7.04 (2H, m, Ar), 7.51 (1H, s, HC=C) 12.29 (1H, br s, CO2H); 13C NMR (DMSO-d6, 100 MHz) δ 
14.20 (CH3), 115.15 (Ar), 115.66 (Ar), 119.64 (Ar), 127.91 (C=C), 129.19 (Ar), 129.35 (Ar), 
134.98 (C=C), 146.89 (Ar), 169.44 (C=O). [Found (ESI-) 176.0727 [M-H]-, C10H10NO2 requires 
176.0712]. 
 
 
 
 
 
 
 
(E)-3-(2-Amino-4-(benzyloxy)-5-methoxyphenyl)-2-methylacrylic acid (89)  
 
A suspension of 85 (1.18 g, 3.44 mmol) and FeSO4.7H2O (9.56 g, 34.4 mmol) in H2O (60 mL) 
was heated to 80oC under stirring. 35% (aq.) NH3 solution (20 mL) was added. After stirring 
for 5 min, the heat was removed and the mixture was allowed to stir for 2.5 h at RT. Then the 
reaction mixture was filtered through celite and acidified to pH 3 using 1M HCl. The aqueous 
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phase was extracted with EtOAc (3 x 80 mL) and brine (100 mL). The organic phases were 
dried over Na2SO4, filtered, and the solvent was evaporated to give a residue which was 
purified by column chromatography eluting with 0-10% MeOH in DCM to give the product as 
a yellow solid (640 mg, 59%). Rf = 0.54 (10% MeOH: DCM); Rt = 6.79 min (solvent system A); 
mp = 127-131oC; 1H NMR (DMSO-d6, 400 MHz) δ 1.98 (3H, d, J = 1.6, CH3), 3.67 (3H, s, OCH3), 
4.85 (2H, br s, NH2), 5.03 (2H, s, CH2), 6.51 (1H, s, Ar), 6.74 (1H, s, Ar), 7.33-7.47 (5H, m, Ar), 
7.50 (1H, s, HC=C), 12.14 (1H, br s, CO2H); 13C NMR (DMSO-d6, 100 MHz) δ 14.31 (CH3), 56.69 
(OCH3), 69.56 (CH2), 101.64 (Ar), 111.55 (Ar), 114.79 (Ar), 125.38 (Ar), 127.71 (Ar), 127.80 
(C=C), 128.37 (Ar), 134.62 (Ar), 136.99  (C=C), 140.11 (Ar), 142.52 (Ar), 149.74 (Ar), 169.69 
(C=O); [Found (ESI-) 312.1243 [M-H]-, C18H18NO4 requires 312.1236]. 
 
 
 
 
 
 
 
(E)-3-(2-Amino-5-(benzyloxy)phenyl)-2-methylacrylic acid (90)  
 
A suspension of 86 (318 mg, 1.02 mmol) and FeSO4.7H2O (2.84 g, 10.20 mmol) in H2O (20 mL) 
was heated to 80oC under stirring. 35% (aq.) NH3 solution (7 mL) was added. After stirring for 
5 min, the heat was removed and the mixture was allowed to stir for a further 20 h at RT. The 
reaction mixture was filtered through celite and acidified to pH 3 using 1M HCl. The aqueous 
phase was extracted with EtOAc (3 x 100 mL) and the combined organic phases were 
extracted with brine (100 mL), then dried over Na2SO4, filtered, and the solvent was 
evaporated to give 90 as a bright yellow solid (230 mg, 80%). Rf = 0.53 (10% MeOH:DCM); Rt 
= 6.73 min (solvent system A); mp= 118-123oC; 1H NMR (DMSO-d6, 400 MHz) δ 1.86 (3H, d, J 
= 1.6, CH3), 4.82 (2H, br s, NH2), 5.00 (2H, s, CH2), 6.67 (1H, d, J = 8.8, Ar), 6.70 (1H, d, J = 2.8, 
Ar), 6.81 (1H, dd, J = 8.8, 2.8, Ar), 7.29-7.43 (5H, m, Ar), 7.48 (1H, s, HC=C), 12.21 (1H, br s, 
CO2H); 13C NMR (DMSO-d6, 100 MHz) δ 14.10 (CH3), 69.80 (CH2), 115.34 (Ar), 116.41 (Ar), 
117.23 (Ar), 120.40 (Ar), 127.50 (Ar), 127.56 (Ar), 128.03 (C=C), 128.30 (Ar), 134.80 (Ar), 
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137.63 (Ar), 141.20 (C=C), 149.11 (Ar), 169.41 (C=O). [Found (ESI-) 282.1131 [M-H]-, C17H16NO3 
requires 282.1136]. 
 
 
 
 
 
7-Methyl-[1,3]dioxolo[4,5-g]quinolin-6(5H)-one (91)  
 
A solution of 87 (105 mg, 0.47 mmol) and 4% (aq.) HCl (6 mL) was heated to reflux and stirred 
overnight. After cooling, the solution was diluted with H2O (10 mL) and extracted with DCM 
(4 x 20 mL) and brine (50 mL). The combined organic phases were evaporated to give 91 as a 
cream solid (38 mg, 57%). Rf = 0.63 (10% MeOH: DCM); Rt = 6.65 min (solvent system A); mp= 
202-209oC; UV (EtOH) λmax 212 (4433), 236 (2384), 343 (930);  1H NMR (DMSO-d6, 400 MHz) 
δ 2.04 (3H, d, J = 1.2, CH3), 6.06 (2H, s, CH2), 6.87 (1H, s, Ar), 7.09 (1H, s, Ar), 7.63 (1H, d, J = 
1.2, Ar), 11.67 (1H, br s, NH); 13C NMR (DMSO-d6, 100 MHz) δ 16.32 (CH3), 94.91 (CH2), 99.48 
(Ar), 101.43 (Ar), 104.58 (Ar), 113.56 (Ar), 134.43 (Ar), 136.26 (Ar), 142.90 (Ar), 148.85 (Ar), 
164.31 (C=O); [Found (ESI+) 226.0467. [M+H]+, C11H9NNaO3 requires 226.0480].    
 
 
 
 
 
 
3-Methylquinolin-2(1H)-one (92) 
 
Method A:194  
 
A solution of 88 (178 mg, 1.00 mmol) and 4% (aq.) HCl (8 mL) was heated to reflux and stirred 
overnight. No conversion of starting material was observed by TLC or HPLC analysis. 
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Method B:  
 
A solution of 88 (89 mg, 0.50 mmol) and 70% (aq.) H2SO4 (4 mL) was heated to reflux 
overnight. The pH was adjusted 10 with 35% (aq.) NH3 solution then the solution was 
extracted with DCM (3 x 15 mL) and brine (30 mL). The solvent was evaporated to give 92 as 
a white solid (20 mg, 25%). Rf = 0.55 (10% MeOH: DCM); Rt = 6.75 min (solvent system A); mp= 
232-238oC (lit.283 226-228oC); UV (EtOH) λmax 214 (2701), 269 (507), 323 (566);  1H NMR (CDCl3, 
400 MHz) δ 2.25 (3H, s, CH3), 7.14 (1H, t, J= 8.0, Ar), 7.30 (1H, d, J = 8.0, Ar), 7.40 (1H, t, J = 
8.0, Ar), 7.45 (1H, d, J = 8.0, Ar), 7.60 (1H, s, Ar), 11.35 (1H, br s, NH); 13C NMR (CDCl3, 100 
MHz) δ 16.74 (CH3), 115.38 (Ar), 120.26 (Ar), 122.33 (Ar), 126.81 (Ar), 129.18 (Ar), 130.13 (Ar), 
137.28 (Ar), 137.41 (Ar), 164.31 (C=O); [Found (ESI+) 160.0767 [M+H]+, C10H10NO requires 
160.0762].    
 
 
 
 
 
 
 
7-Hydroxy-6-methoxy-3-methylquinolin-2(1H)-one (93)  
 
Method A:194 
 
A solution of 89 (63 mg, 0.20 mmol) in 4% (aq.) HCl (4 mL) was heated to reflux and stirred 
for 2 h. After cooling, the solution was diluted with H2O (10 mL) and the solvent was 
evaporated. The resulting oil was purified by column chromatography (5-10% MeOH:DCM) to 
give 93 as a brown oil (31 mg, 76%). Rf = 0.20 (10% MeOH: DCM); Rt = 4.3 min (solvent system 
A); UV (EtOH) ʎmax 214 (12073), 235 (7559), 341 (4710); 1H NMR (DMSO-d6, 400 MHz) δ 1.98 
(3H, d, J = 1.2, CH3), 3.65 (3H, s, OCH3), 6.29 (1H, s, Ar), 6.69 (1H, s, Ar), 7.50 (1H, d, J = 1.2, 
Ar), 9.18 (1H, br s, NH); 13C NMR (DMSO-d6, 100 MHz) δ 14.36 (CH3), 56.61 (OCH3), 103.62 
(Ar), 110.83 (Ar), 114.60 (Ar), 124.34 (Ar), 134.81 (Ar), 139.40 (Ar), 142.15 (Ar), 148.73 (Ar), 
169.84 (C=O); [Found (ESI+) 206.0803. [M+H]+, C11H12NO3 requires 206.0812]. 
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Method B:218 
 
A solution of 89 (47 mg, 0.15 mmol) in TFA (500 µL) was stirred at RT under a N2 atmosphere 
overnight. The solution was diluted with H2O (5 mL) and the solvent was evaporated to give 
93 as a brown oil (23 mg, 74%). 
 
 
 
 
 
6-Hydroxy-3-methylquinolin-2(1H)-one (94)  
 
A solution of 90 (60 mg, 0.21 mmol) in 4% (aq.) HCl (5 mL) was heated to reflux and stirred 
for 3 h. After cooling, the solution was diluted with H2O (5 mL) and the solvent was evaporated 
to give 94 as a white solid (35 mg, 95%). Rf = 0.45 (20% MeOH:DCM); Rt = 3.78 min (solvent 
system A); mp = 239-245oC; UV (EtOH) ʎmax 203 (9070); 1H NMR (CD3OD, 400 MHz) δ 2.02 (3H, 
d, J = 1.6, CH3), 6.89- 6.92 (2H, m, Ar), 7.31 (1H, d, J = 8.0, Ar), 7.70 (1H, dd, J = 2.8, 1.6, Ar); 
13C NMR (CD3OD, 100 MHz) δ 14.44 (CH3), 117.34 (Ar), 118.23 (Ar), 121.23 (Ar), 125.83 (Ar), 
133.05 (Ar), 133.36 (Ar), 135.38 (Ar), 159.30 (Ar), 170.59 (C=O); [Found (ESI+) 176.0704. 
[M+H]+, C10H10NO2 requires 176.0706]. 
 
 
 
 
 
6,7-Dihydroxy-3-methylquinolin-2(1H)-one (95)  
 
A solution of 60 (25 mg, 0.11 mmol) in anhydrous DCM (2 mL) was cooled to 0oC and treated 
with a solution of 1M BBr3 in DCM (570 µL, 0.57 mmol) under an argon atmosphere. The 
reaction was allowed to warm to RT and stirred for 18 h. The mixture was treated with ice-
water (10 mL) and then stirred for 30 min. A white precipitate formed which was filtered and 
dried to give 95 (18 mg, 82%). Rf = 0.18 (10% MeOH: DCM); Rt = 5.03 min (solvent system A); 
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mp = 245-247oC; UV (EtOH) ʎmax 213.5 (32166), 233.5 (16306), 344.5 (10130); 1H NMR (DMSO-
d6, 400 MHz) δ 2.01 (3H, d, J = 1.2, CH3), 6.72 (1H, s, Ar), 6.86 (1H, s, Ar), 7.52 (1H, d, J = 1.2, 
Ar), 11.34 (1H, br s, NH); 13C NMR (DMSO-d6, 100 MHz) δ 16.36 (CH3), 100.51 (Ar), 111.17 (Ar), 
112.40 (Ar), 125.25 (Ar), 132.54 (Ar), 135.95 (Ar), 141.45 (Ar), 148.34 (Ar), 162.20 (C=O); 
[Found (ESI+) 214.0474. [M+H]+, C10H9NNaO3 requires 214.0475]. 
 
 
 
 
 
 
(E)-3-(2-Amino-4-hydroxy-5-methoxyphenyl)-2-methylacrylic acid (96) 
 
Method A:218 
 
A solution of 89 (47 mg, 0.15 mmol) in TFA (500 µL) was stirred at RT under a N2 atmosphere 
overnight. The solution was diluted with H2O (5 mL) and the solvent was evaporated. 1H NMR 
analysis showed that the resulting brown oil was pure 93 (23 mg, 74%), rather than the 
desired product. 
 
Method B:  
 
A mixture of 89 (52 mg, 0.17 mmol) and 10% Pd/C (5 mg) in EtOAc (10 mL) was stirred at RT 
for 12 h under a H2 atmosphere. No conversion of the starting material was observable by 
TLC. 
 
Method C: 
 
A mixture of 89 (25 mg, 0.08 mmol) and 10% Pd/C (3 mg) in AcOH (5 mL) was stirred at RT for 
3 h under a H2 atmosphere. The reaction mixture was filtered through celite and the solvent 
was evaporated. 1H NMR and mass spectrometry analysis of the crude material showed that 
the alkene unit had been saturated. 
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Method D:220 
 
A solution of 89 (134 mg, 0.43 mmol) in anhydrous DCM (10 mL) under an argon atmosphere 
was treated with trimethylsilyl iodide (80 µL, 0.56 mmol) and heated to reflux for 2 h after 
which time there was no conversion of starting material observable on TLC.  
 
Method E:220 
 
A solution of 89 (127 mg, 0.40 mmol) in anhydrous MeCN (10 mL) under an argon atmosphere 
was treated with trimethylsilyl iodide (74 µL, 0.52 mmol) and heated to reflux for 5 h after 
which time there was no conversion of starting material observable on TLC.  
 
Method F:194  
 
A suspension of 98 (530 mg, 2.09 mmol) and FeSO4.7H2O (5.80 g, 21.0 mmol) in H2O (30 mL) 
was heated to 80oC under stirring. 35% (aq.) NH3 solution (10 mL) was added. After stirring 
for 5 min, the heat was removed and the mixture was allowed to stir for a further 22 h at RT. 
The reaction mixture was filtered through celite and acidified to pH 3 using 1M HCl. The H2O 
was evaporated and the residue was dissolved in hot MeOH, filtered and the solvent was 
evaporated. This gave a complex mixture of products on TLC analysis. 
 
Method G:193  
 
A suspension of 98 (456 mg, 1.8 mmol), iron powder (402 mg, 7.2 mmol) and NH4Cl (144 mg, 
2.7 mmol) in 80% (aq.) EtOH (15 mL) was stirred at 80 oC for 5 h. The hot reaction mixture was 
filtered through celite and the solvent was evaporated to give a brown solid which was a 
complex mixture of products on TLC and 1H NMR. 
 
Method H:221 
 
Hydrazinium monoformate was generated by neutralising one equivalent of hydrazine 
monohydrate (1 mL, 2.06 mmol) with formic acid (778 µL, 2.06 mmol). The mixture was stirred 
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for 1 h at 0 oC. Hydrazinium monoformate (500 µL) was added to a suspension of 98 (142 mg, 
0.56 mmol) and zinc dust (73 mg, 1.12 mmol) in MeOH (2 mL). The reaction mixture was 
stirred at 30 oC under an argon atmosphere for 2 h after which time there was no conversion 
of the starting material observable on TLC. 
 
Method I: 
 
A solution of 102 (75 mg, 0.30 mmol) in THF (4 mL) was treated with 1M NaOH (1.2 mL) and 
EtOH (1 mL) and stirred at 40 oC overnight. The organic solvents were evaporated and the 
remaining solution was diluted with H2O (10 mL), the pH adjusted to 2 with 6M HCl, and the 
aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic layers were 
extracted with brine (10 mL) then dried over MgSO4, filtered and the solvent was evaporated 
to give an orange residue. TLC and HPLC analysis showed a mixture of products including 
carbostyril 93. 
 
 
 
 
 
Ethyl (E)-3-(4-hydroxy-5-methoxy-2-nitrophenyl)-2-methylacrylate (97)  
 
A solution of 81 (300 mg, 0.81 mmol) in TFA (3 mL) was stirred at 30oC under an argon 
atmosphere overnight. The solution was diluted with H2O (20 mL) and extracted with DCM (3 
x 20 mL). The combined organic phases were extracted with sat. NaHCO3 (2 x 20 mL) and brine 
(20 mL), then were dried over MgSO4, filtered and the solvent was evaporated to give an 
orange oil. Purification by column chromatography (DCM) gave 97 as an orange oil (213 mg, 
93%). Rf = 0.32 (DCM); Rt = 8.7 min (solvent system A); 1H NMR (CDCl3, 400 MHz) δ 1.29 (3H, 
t, J = 7.2, CH3), 1.85 (3H, d, J = 1.2, CH3), 3.92 (3H, s, OCH3), 4.23 (2H, q, J= 7.2, CH2), 6.06 (1H, 
s, OH), 6.66 (1H, s, Ar), 7.71 (1H, s, Ar), 7.83 (1H, d, J = 0.4, C=CH); 13C NMR (CDCl3, 100 MHz) 
δ 13.96 (CH3), 14.18 (CH3), 56.48 (OCH3), 61.03 (CH2), 111.51 (Ar), 111.86 (Ar), 125.52 (Ar), 
129.21 (Ar), 136.46 (C=C), 140.96 (Ar), 145.39 (C=C), 150.39 (Ar), 167.86 (C=O); [Found (ESI-) 
280.0826 [M+H]-, C13H14NO6 requires 280.0827]. 
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(E)-3-(4-Hydroxy-5-methoxy-2-nitrophenyl)-2-methylacrylic acid (98) 
 
A solution of 97 (600 mg, 2.13 mmol) in THF (15 mL) was treated with 1M NaOH (9 mL) and 
EtOH (5 mL) and stirred at 40 oC overnight. The organic solvents were evaporated and the 
remaining solution was diluted with H2O (30 mL), the pH was adjusted to 2 with 6M HCl and 
the aqueous phase was extracted with EtOAc (4 x 30 mL). The combined organic layers were 
extracted with brine (40 mL) and dried over MgSO4, filtered and the solvent was evaporated 
to give an orange oil (530 mg, 98%). Rf = 0.40 (10% MeOH: DCM); Rt = 6.95 min (solvent system 
A); 1H NMR (DMSO-d6, 400 MHz) δ 1.86 (3H, s, CH3), 3.91 (3H, s, OCH3), 6.95 (1H, s, Ar), 7.61 
(1H, s, Ar), 7.76 (1H, s, HC=C), 10.31 (1H, br s, OH), 12.57 (1H, br s, CO2H); 13C NMR (DMSO-
d6, 100 MHz) δ 13.82 (CH3), 56.36 (OCH3), 111.25 (Ar), 113.30 (Ar), 124.08 (Ar), 128.94 (C=C), 
135.80 (C=C), 139.83 (Ar), 146.54 (Ar), 152.18 (Ar), 168.85 (C=O); [Found (ESI+) 276.0476 
[M+Na]+, C11H11NNaO6 requires 276.0479]. 
 
 
 
 
 
Ethyl (E)-3-(5-hydroxy-2-nitrophenyl)-2-methylacrylate (100)  
 
A solution of 82 (400 mg, 1.17 mmol) was stirred in TFA (5 mL) at 40oC under an argon 
atmosphere overnight. The mixture was diluted with H2O (20 mL) and extracted with DCM (3 
x 20 mL). The combined organic phases were extracted with sat. NaHCO3 (2 x 20 mL) and brine 
(20 mL) then dried over MgSO4, filtered and the solvent was evaporated to give a yellow oil. 
Purification by column chromatography (0-6% MeOH in DCM) gave 100 as a yellow oil (273 
mg, 93%). Rf = 0.70 (10% MeOH:DCM) ; Rt = 8.70 min (solvent system A); 1H NMR (CDCl3, 400 
MHz) δ 1.36 (3H, t, J = 7.2, CH2CH3), 1.90 (3H, d, J = 1.6, CH3), 4.31 (2H, q, J= 7.2, CH2CH3), 6.46 
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(1H, br s, OH), 6.74 (1H, d, J = 2.8, Ar), 6.91 (1H, dd, J = 8.8, 2.8, Ar), 7.91 (1H, s, C=CH), 8.16 
(1H, d, J = 8.8, Ar); 13C NMR (CDCl3, 100 MHz) δ 13.96 (CH3), 14.57 (CH3), 62.20 (CH2), 116.53 
(Ar), 118.17 (Ar), 128.83 (Ar), 130.20 (C=C), 135.92 (Ar), 138.25 (C=C), 140.93 (Ar), 163.86 (Ar), 
169.34 (C=O); [Found (ESI+) 274.0687 [M+Na]+, C12H13NNaO5 requires 274.0686]. 
 
 
 
 
 
(E)-3-(5-Hydroxy-2-nitrophenyl)-2-methylacrylic acid (101) 
 
A solution of 100 (333 mg, 1.33 mmol) in THF (8 mL) was treated with 1M NaOH (6 mL) and 
EtOH (2 mL) and stirred at 40 oC overnight. The organic solvents were evaporated and the 
remaining solution was diluted with H2O (30 mL), the pH was adjusted to 2 with 6M HCl, and 
the aqueous phase was extracted with EtOAc (4 x 30 mL). The combined organic layers were 
extracted with brine (40 mL) and dried over MgSO4, filtered and the solvent was evaporated 
to give 101 as an orange oil (292 mg, 98%). Rf = 0.25 (10% MeOH:DCM); Rt = 3.68 min (solvent 
system A); 1H NMR (DMSO-d6, 400 MHz) δ 1.81 (3H, d, J = 1.6, CH3), 6.76 (1H, dd, J = 2.4, 0.8, 
Ar), 6.95 (1H, dd, J = 9.2, 2.4, Ar), 7.77 (1H, s, HC=C), 8.13 (1H, d, J= 9.2, Ar), 11.11 (1H, br s, 
OH), 12.60 (1H, br s, CO2H); 13C NMR (DMSO-d6, 100 MHz) δ 13.97 (CH3), 116.47 (Ar), 118.18 
(Ar), 128.80 (C=C), 130.46 (Ar), 136.09 (Ar), 138.27 (C=C), 140.96 (Ar), 163.81 (Ar), 171.14 
(C=O); [Found (ESI+) 246.0363 [M+Na]+, C10H9NNaO5 requires 246.0373]. 
 
 
 
 
 
(E)-3-(2-Amino-5-hydroxyphenyl)-2-methylacrylic acid (99)193 
 
A mixture of 101 (288 mg, 1.29 mmol), iron powder (288 mg, 5.16 mmol) and NH4Cl (104 mg, 
1.94 mmol) in 80% (aq.) EtOH (10 mL) was stirred at 80 oC for 5 h. The hot reaction mixture 
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was filtered through celite and the H2O was evaporated to give a brown solid. TLC analysis 
gave a complex mixture of products. 
 
 
 
 
 
Ethyl (E)-3-(2-amino-4-hydroxy-5-methoxyphenyl)-2-methylacrylate (102)  
 
A mixture of 97 (116 mg, 0.41 mmol), iron powder (87 mg, 1.56 mmol) and NH4Cl (30 mg, 0.57 
mmol) in 80% (aq.) EtOH (5 mL) was stirred at 80 oC for 2 h. The hot reaction mixture was 
filtered through celite and the solvent was evaporated to give a brown residue which was 
dissolved in EtOAc (10 mL) and washed with H2O (3 x 10 mL) and brine (10 mL). The organic 
phase was dried over Na2SO4, filtered and the solvent was evaporated to give 102 as an 
orange oil (95 mg, 92%). %). Rf = 0.65 (10% MeOH: DCM); Rt = 8.50 min (solvent system A); 1H 
NMR (CDCl3, 400 MHz) δ 1.29 (3H, t, J = 7.2, CH2CH3), 1.98 (3H, d, J = 1.2, CH3), 3.50 (2H, br s, 
NH2), 3.76 (3H, s, OCH3), 4.21 (2H, q, J = 7.2, CH2CH3), 5.70 (1H, br s, OH),  6.30 (1H, s, Ar), 6.61 
(1H, s, Ar), 7.52 (1H, s, HC=C); 13C NMR (CDCl3, 100 MHz) δ 14.22 (CH3), 14.27 (CH3), 56.63 
(OCH3), 60.65 (CH2), 102.72 (Ar), 112.49 (Ar), 112.67 (Ar), 127.99 (C=C), 134.69 (C=C), 139.38 
(Ar), 139.90 (Ar), 147.18 (Ar), 168.52 (C=O); [Found (ESI+) 252.1230 [M+H]+, C13H18NO4 
requires 252.1230]. 
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3,4-bis(Benzyloxy)benzaldehyde (103)284  
 
A mixture of 3,4-dihydroxybenzaldehyde (1.52 g, 11.0 mmol) and K2CO3 (3.32 g, 24.0 mmol) 
in DMF (50 mL) was treated with benzyl chloride (2.76 mL, 24.0 mmol) and the mixture was 
stirred at 80 oC for 3 h. The solvent was evaporated and the residue was dissolved in CHCl3 
(30 mL) and extracted with H2O (3 x 30 mL) and brine (50 mL). The organic phase was dried 
over MgSO4, then filtered and the solvent was evaporated to give 103 as a brown oil (3.37 g, 
96%). Rf = 0.55 (DCM); Rt = 10.50 min (solvent system A) ; 1H NMR (CDCl3, 400 MHz) δ 5.16 
(2H, s, CH2), 5.19 (2H, s, CH2), 6.98 (1H, d, J= 8.0, Ar), 7.26- 7.47 (12H, m, Ar), 9.77 (1H, s, 
HC=O); 13C NMR (CDCl3, 100 MHz) δ 70.81 (CH2), 70.97 (CH2), 112.50 (Ar), 113.15 (Ar), 126.57 
(Ar), 127.06 (Ar), 127.29 (Ar), 127.96 (Ar), 128.06 (Ar), 128.52 (Ar), 128.60 (Ar), 130.33 (Ar), 
136.24 (Ar), 136.57 (Ar), 149.20 (Ar), 154.26 (Ar), 190.66 (C=O). 
 
 
 
 
 
 
 
 
 
4,5-bis(benzyloxy)-2-nitrobenzaldehyde (104)  
 
AH178 (3.30 g, 10.4 mmol) in CHCl3 (20 mL) was treated slowly with 65% (aq.) nitric acid (30 
mL) at 0oC and allowed to stir for 4 h. The mixture was then treated with H2O (50 mL) and the 
aqueous phase was extracted with EtOAc (3 x 60 mL). The combined organic phases were 
washed with brine (100 mL), dried over MgSO4, filtered and the solvent evaporated. This gave 
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a yellow solid which was recrystallized from EtOAc to give 104 (3.35 g, 92%). Rf = 0.80 (DCM); 
Rt = 10.70 min (solvent system A); mp=140-142oC (lit.285 137.5-138.5oC); 1H NMR (CDCl3, 400 
MHz) δ 5.24 (4H, s, CH2), 7.29- 7.42 (10H, m, Ar), 7.44 (1H, s, Ar), 7.63 (1H, s, Ar), 10.35 (1H, 
s, HC=O); 13C NMR (CDCl3, 100 MHz) δ 71.25 (CH2), 71.45 (CH2), 109.46 (Ar), 111.92 (Ar), 
125.58 (Ar), 127.23 (Ar), 127.26 (Ar), 128.40 (Ar), 128.48 (Ar), 128.69 (Ar), 128.75 (Ar), 135.05 
(Ar), 135.21 (Ar), 143.70 (Ar), 151.83 (Ar), 152.82 (Ar), 187.50 (C=O). 
 
 
 
 
 
 
 
 
 
 
 
Ethyl (E)-3-(4,5-bis(benzyloxy)-2-nitrophenyl)-2-methylacrylate (105)  
 
A solution of 104 (2.9 g, 7.98 mmol) and ECETP (4.34 g, 11.97 mmol) in anhydrous toluene (50 
mL) was heated for 24 h at 65oC under N2. The solvent was evaporated and the residue was 
purified by column chromatography (10-20% EtOAc in petroleum ether) to give 105 as a 
yellow oil (2.7 g, 76%). Rf = 0.60 (DCM); Rt= 11.55 min (solvent system A); 1H NMR (CDCl3, 400  
MHz) δ 1.34 (3H, t, J = 7.0, CH2CH3), 1.65 (3H, d, J = 1.6, CH3), 4.27 (2H, q, J = 7.0, CH2CH3), 
5.25 (2H, s CH2), 5.26 (2H, s, CH2) 6.71 (1H, d, J = 0.8, Ar), 7.35- 7.50 (10H, m, Ar), 7.82 (1H, s, 
Ar), 7.85 (1H, q, J = 0.8, C=CH); 13C NMR (CDCl3, 100 MHz) δ 13.64 (CH3), 14.19 (CH3), 60.94 
(CH2), 71.11 (CH2), 71.34 (CH2), 110.44 (Ar), 115.28 (Ar), 126.56 (Ar), 126.78 (Ar), 127.39 (Ar), 
128.26 (Ar), 128.30 (Ar), 128.67 (Ar), 128.77 (Ar), 129.34 (C=C), 135.58 (Ar), 135.68 (Ar), 
136.10 (C=C), 140.35 (Ar), 148.07 (Ar), 152.37 (Ar), 167.72 (C=O); [Found (ESI+) 448.1768 
[M+H]+, C26H26NO6 requires 448.1755]. 
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(E)-3-(4,5-bis(Benzyloxy)-2-nitrophenyl)-2-methylacrylic acid (106) 
 
A solution of 105 (1.27 g, 2.84 mmol) in THF (40 mL) was treated with 1M NaOH (14 mL) and 
EtOH (10 mL) and stirred at 40oC overnight. The organic solvents were evaporated and the 
remaining solution was diluted with H2O (20 mL), the pH adjusted to 2 with 6M HCl, and the 
aqueous phase was extracted with CHCl3 (3 x 30 mL). The combined organic layers were 
extracted with brine (50 mL) then dried over MgSO4, filtered and the solvent was evaporated 
to give 106 as a yellow solid (1.10 mg, 92%). Rf = 0.21 (5% MeOH: DCM); Rt = 10.37 min (solvent 
system A); mp= 162-167oC; 1H NMR (CDCl3, 400  MHz) δ 1.61 (3H, d, J = 1.2, CH3), 5.21 (2H, s 
CH2), 5.23 (2H, s, CH2) 6.67 (1H, s, Ar), 7.27- 7.45 (10H, m, Ar), 7.78 (1H, s, Ar), 7.93 (1H, q, J = 
0.8, C=CH); 13C NMR (CDCl3, 100 MHz) δ 13.31 (CH3), 71.16 (CH2), 71.35 (CH2), 110.44 (Ar), 
115.14 (Ar), 126.07 (Ar), 126.78 (Ar), 127.39 (Ar), 128.13 (C=C), 128.30 (Ar), 128.33 (Ar), 
128.69 (Ar), 128.80 (Ar), 135.53 (Ar), 135.61 (Ar), 138.59 (C=C), 140.30 (Ar), 148.29 (Ar), 
152.42 (Ar), 171.72 (C=O); [Found (ESI+) 442.1313 [M+Na]+, C24H21NNaO6 requires 442.1261]. 
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(E)-3-(2-Amino-4,5-bis(benzyloxy)phenyl)-2-methylacrylic acid (107)  
 
A suspension of 106 (1.0 g, 2.38 mmol) and FeSO4.7H2O (6.67 g, 24.00 mmol) in H2O (60 mL) 
was heated to 80oC under stirring. 35% (aq.) NH3 solution (20 mL) was added. After stirring 
for 5 min, the heat was removed and the mixture was allowed to stir for a further 18 h at RT. 
The reaction mixture was filtered through celite and acidified to pH 3 using 1M HCl. The 
aqueous phase was extracted with EtOAc (3 x 100 mL) and the combined organic phases were 
washed with brine (150 mL), dried over Na2SO4, filtered, and the solvent was evaporated to 
give 107 a yellow solid (149 mg, 16%). Rf = 0.37 (10% MeOH:DCM); Rt = 8.13 min (solvent 
system A); mp = 102-105oC; 1H NMR (CD3OD, 400  MHz) δ 1.85 (3H, d, J = 1.2, CH3), 5.01 (2H, 
s, CH2), 5.12 (2H, s, CH2), 6.56 (1H, s, Ar), 6.76 (1H, s, Ar), 7.27- 7.48 (10H, m, Ar), 7.57 (1H, s, 
C=CH); 13C NMR (CD3OD, 100 MHz) δ 14.46 (CH3), 71.78 (CH2), 74.27 (CH2), 103.85 (Ar), 114.75 
(Ar), 120.43 (Ar), 128.22 (C=C), 128.72 (Ar), 128.86 (Ar), 128.97 (Ar), 129.06 (Ar), 129.40 (Ar), 
129.53 (Ar), 136.17 (C=C), 138.57 (Ar), 139.12 (Ar), 141.28 (Ar), 143.60 (Ar), 152.60 (Ar), 
172.45 (C=O); [Found (ESI+) 390.1696 [M+H]+, C24H24NO4 requires 390.1700].  
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2-((E)-(2-Isonicotinoylhydrazineylidene)methyl)phenyl (E)-3-(2-amino-4-(benzyloxy)-5-
methoxyphenyl)-2-methylacrylate (108) 
 
A stirred solution of 89 (125 mg, 0.40 mmol) in anhydrous DMF (4 mL) under argon was cooled 
to 0 oC and treated with DMAP (49 mg, 0.40 mmol) and EDC.HCl (77 mg, 0.40 mmol). The 
mixture was allowed to stir for 10 min before 8 (53 mg, 0.22 mmol) was added. The mixture 
was allowed to warm to RT and stirred overnight. The solvent was evaporated and the 
remaining residue was dissolved in DCM (10 mL) and extracted with sat. NH4Cl (3 x 10 mL), 
H2O (3 x 10 mL) and brine (10 mL). The organic phase was dried over MgSO4, filtered and the 
solvent was evaporated to give 108 as a yellow oil which was used without further purification 
(103 mg, 87%). Rf = 0.20 (20% acetone:DCM); Rt = 7.3 min (solvent system A); [Found (ESI+) 
537.2114 [M+H]+, C31H29N4O5 requires 537.2132]. 
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2-((E)-(2-Isonicotinoylhydrazineylidene)methyl)phenyl (E)-3-(2-amino-5-
(benzyloxy)phenyl)-2-methylacrylate (109) 
 
A stirred solution of 90 (154 mg, 0.54 mmol) in anhydrous DMF (4 mL) under argon was cooled 
to 0 oC and treated with DMAP (66 mg, 0.54 mmol) and EDC.HCl (104 mg, 0.54 mmol). The 
mixture was allowed to stir for 10 min before 8 (109 mg, 0.45 mmol) was added. The mixture 
was allowed to warm to RT and stirred overnight. The solvent was evaporated and the 
remaining residue was dissolved in DCM (10 mL) and extracted with sat. NH4Cl (3 x 10 mL), 
H2O (3 x 10 mL) and brine (10 mL). The organic phase was dried over MgSO4, filtered and the 
solvent was evaporated to give 109 as a yellow residue which was used without further 
purification (192 mg, 84%). Rf = 0.20 (20% acetone: DCM); Rt = 7.1 min (solvent system A); 
[Found (ESI+) 529.1855 [M+Na]+, C30H26N4NaO4 requires 529.1846]. 
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2-((E)-(2-Isonicotinoylhydrazineylidene)methyl)phenyl (E)-3-(2-amino-4,5-
bis(benzyloxy)phenyl)-2-methylacrylate (110) 
 
A stirred solution of 103 (143 mg, 0.37 mmol) in anhydrous DMF (4 mL) under argon was 
chilled to 0 oC and treated with DMAP (45 mg, 0.37 mmol) and EDC.HCl (71 mg, 0.37 mmol). 
The mixture was allowed to stir for 10 min before 8 (75 mg, 0.31 mmol) was added. The 
mixture was allowed to warm to RT and stirred for 24 h. The solvent was evaporated and the 
remaining residue was dissolved in DCM (10 mL) and extracted with sat. NH4Cl (3 x 10 mL), 
water (3 x 10 mL) and brine (10 mL). The organic phase was dried over MgSO4, filtered and 
the solvent was evaporated to give 110 as a yellow residue which was used without further 
purification (114 mg, 60%). Rf = 0.37 (30% acetone: DCM); Rt = 8.4 min (solvent system A); 
[Found (ESI+) 613.2452 [M+H]+, C37H33N4O5 requires 613.2445]. 
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Methyl (E)-4-(5-(2-((3-(2-amino-4-(benzyloxy)-5-methoxyphenyl)-2-
methylacryloyl)oxy)phenyl)-3-(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoate (111) 
 
A stirred solution of 89 (116 mg, 0.37 mmol) in anhydrous DMF (4 mL) under argon was cooled 
to 0 oC and treated with DMAP (45 mg, 0.37 mmol) and EDC.HCl (71 mg, 0.37 mmol). The 
mixture was allowed to stir for 10 min before a solution of 33 (131 mg, 0.34 mmol) and DIPEA 
(59 µL, 0.34 mmol) in anhydrous DMF (4 mL) was added. The mixture was heated to 30 oC and 
stirred for 24 h. The solvent was evaporated and the remaining residue was dissolved in DCM 
(20 mL) and extracted with sat. NH4Cl (3 x 20 mL), H2O (3 x 20 mL) and brine (20 mL). The 
organic phase was dried over MgSO4, filtered and the solvent was evaporated to give 111 as 
a yellow residue which was used without further purification (90 mg, 39%). Rf = 0.56 (4% 
acetone: DCM); Rt = 10.7 min (solvent system A); [Found (ESI+) 683.2497 [M+H]+, C40H35N4O7 
requires 683.2500]. 
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Methyl (E)-4-(5-(2-((3-(2-amino-5-(benzyloxy)phenyl)-2-methylacryloyl)oxy)phenyl)-3-(2-
hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoate (112) 
 
A stirred solution of 90 (113 mg, 0.40 mmol) in anhydrous DMF (5 mL) under argon was cooled 
to 0 oC and treated with DMAP (49 mg, 0.40 mmol) and EDC.HCl (77 mg, 0.40 mmol). The 
mixture was allowed to stir for 10 min before a solution of 33 (139 mg, 0.36 mmol) and DIPEA 
(63 µL, 0.36 mmol) in anhydrous DMF (5 mL) was added. The mixture was heated to 30 oC and 
stirred for 24 h. The solvent was evaporated and the remaining residue was dissolved in DCM 
(20 mL) and extracted with sat. NH4Cl (3 x 20 mL), H2O (3 x 20 mL) and brine (20 mL). The 
organic phase was dried over MgSO4, filtered and the solvent was evaporated to give 112 as 
a yellow residue which was used without further purification (76 mg, 32%). Rf = 0.60 (2% 
acetone: DCM); Rt = 10.1 min (solvent system A); [Found (ESI+) 653.2439 [M+H]+, C29H33N4O6 
requires 653.2395]. 
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Methyl (E)-4-(5-(2-((3-(2-amino-4,5-bis(benzyloxy)phenyl)-2-methylacryloyl)oxy)phenyl)-3-
(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoate (113) 
 
A stirred solution of 103 (72 mg, 0.18 mmol) in anhydrous DMF (3 mL) under argon was cooled 
to 0 oC and treated with DMAP (22 mg, 0.18 mmol) and EDC.HCl (35 mg, 0.18 mmol). The 
mixture was allowed to stir for 10 min before a solution of 33 (66 mg, 0.17 mmol) and DIPEA 
(30 µL, 0.17 mmol) in anhydrous DMF (2 mL) was added. The reaction was heated to 30 oC 
and stirred for 24 h. The solvent was evaporated and the remaining residue was dissolved in 
DCM (20 mL) and extracted with sat. NH4Cl (3 x 20 mL), H2O (3 x 20 mL) and brine (20 mL). 
The organic phase was dried over MgSO4, filtered and the solvent was evaporated to give 113 
as a yellow residue which was used without further purification (24 mg, 19%). Rf = 0.50 (2% 
acetone: DCM); Rt = 11.56 min (solvent system A); [Found (ESI+) 759.2827 [M+H]+, C46H39N4O7 
requires 759.2813]. 
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2-((E)-(2-Isonicotinoylhydrazineylidene)methyl)phenyl (E)-3-(2-amino-4-hydroxy-5-
methoxyphenyl)-2-methylacrylate (114) 
 
A solution of 108 (93 mg, 0.17 mmol) in TFA (2 mL) was stirred at 30oC under an argon 
atmosphere overnight. The TFA was evaporated and the residue was co-evaporated with 
MeCN (3 x 10 mL). The resulting oil was purified by column chromatography eluting with 5-
10% MeOH in DCM to give 114 as a yellow oil (59 mg, 78%). Rf = 0.35 (10% MeOH: DCM); Rt = 
5.7 min (solvent system A); UV (EtOH) 298 (14250); 1H NMR (DMSO-d6, 400 MHz) δ 2.21 (3H, 
d, J = 1.2, CH3), 3.69 (3H, s, OCH3), 5.07 (2H, br s, NH2), 6.29 (1H, s, Ar), 6.82 (1H, s, Ar), 7.28 
(1H, dd, J = 6.4, 0.8, Ar), 7.40 (1H, td, J = 6.0, 0.8, Ar), 7.55 (1H, td, J = 6.0, 1.2, Ar), 7.80 (2H, 
dd, J = 3.6, 1.2, Pyr), 7.89 (1H, q, J = 0.8, HC=C), 8.03 (1H, dd, J = 6.0, 1.2, Ar), 8.57 (1H, s, 
HC=N), 8.79 (2H, dd, J = 3.6, 1.2, Pyr), 9.30 (1H, s, OH), 12.13 (1H, s, NH); 13C NMR (DMSO-d6, 
100 MHz) δ 14.63 (CH3), 56.58 (OCH3), 103.16 (Ar), 109.67 (Ar), 114.42 (Ar), 120.87 (Ar), 
121.20 (Ar), 121.52 (Pyr), 123.52 Ar), 126.17 (Ar), 126.67 (C=C), 138.07 (Ar), 139.21 (Ar), 
140.39 (Ar), 143.47 (C=C), 144.00 (C=N), 149.87 (Pyr), 150.12 (Ar), 150.29 (Ar), 150.60 (Pyr), 
161.67 (C=O), 167.01 (C=O); [Found (ESI+) 469.1487 [M+Na]+, C24H22N4NaO5 requires 
469.1482]. 
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2-((E)-(2-Isonicotinoylhydrazineylidene)methyl)phenyl (E)-3-(2-amino-5-hydroxyphenyl)-2-
methylacrylate (115) 
 
A solution of 109 (236 mg, 0.47 mmol) in TFA (10 mL) was stirred at 30oC under an argon 
atmosphere overnight. The TFA was evaporated and the residue co-evaporated with MeCN 
(3 x 10 mL). The resulting oil was purified by column chromatography eluting with 5-15% 
MeOH in DCM to give 115 as a yellow oil (150 mg, 77%). Rf = 0.30 (10% MeOH: DCM); Rt = 5.4 
min (solvent system A); UV (EtOH) 296 (5500); 1H NMR (DMSO-d6, 500 MHz) δ 2.15 (3H, d, J = 
1.5, CH3), 6.78 (1H, dd, J = 11.0, 3.0, Ar), 6.84 (1H, d, J = 3.5, Ar), 7.00 (1H, d, J = 11.0, Ar), 7.31 
(1H, dd, J = 10.0, 1.5, Ar), 7.43 (1H, td, J = 9.5, 1.5, Ar), 7.53 (1H, td, J = 10.0, 2.0, Ar), 7.84 (2H, 
dd, J = 5.5, 2.0, Pyr), 7.91 (1H, d, J = 2.0, HC=C), 8.02 (1H, dd, J = 10.0, 2.0, Ar), 8.61 (1H, s, 
HC=N), 8.79 (2H, dd, J = 5.5, 2.0, Pyr), 9.46 (1H, br s, OH), 12.22 (1H, s, NH); 13C NMR (DMSO-
d6, 125 MHz) δ 14.33 (CH3), 115.89 (Ar), 117.32 (Ar), 118.53 (C=C), 121.55 (Pyr), 123.40 (Ar), 
124.53 (Ar), 126.43 (Ar), 126.49 (Ar), 126.71 (Ar), 131.37 (Ar), 136.62 (Ar), 138.08 (Ar), 140.35 
(C=C), 143.62 (Ar), 144.31 (C=N), 148.12 (Ar), 149.64 (Ar), 150.25 (Pyr), 161.63 (C=O), 166.25 
(C=O); [Found (ESI+) 469.1487 [M+Na]+, C24H22N4NaO5 requires 469.1482]. 
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2-((E)-(2-Isonicotinoylhydrazineylidene)methyl)phenyl (E)-3-(2-amino-4,5-
dihydroxyphenyl)-2-methylacrylate (116) 
 
A solution of 110 (110 mg, 0.18 mmol) in TFA (10 mL) was stirred at 30oC under an argon 
atmosphere overnight. The TFA was evaporated and the residue was co-evaporated with 
MeCN (3 x 10 mL). The resulting oil was purified by column chromatography eluting with 30-
70% acetone in DCM to give 116 as a yellow glass (29 mg, 37%). Rf = 0.25 (10% MeOH:DCM); 
Rt = 5.2 min (solvent system A); UV (EtOH) lmax 298 (4800) ; 1H NMR (DMSO-d6, 500 MHz) d 
2.18 (3H, d, J= 0.8, CH3), 6.76 (1H, s, Ar), 6.98 (1H, s, Ar), 7.28 (1H, dd, J= 7.6, 1.8, Ar), 7.42 (1H, 
t, J = 7.6, Ar), 7.57 (1H, td, J = 7.6, 1.8, Ar), 7.84 (2H, d, J = 4.4, Pyr), 7.91 (1H, d, J = 0.8, HC=C), 
8.03 (1H, dd, J = 7.8, 1.6, Ar), 8.58 (1H, s, HC=N), 8.80 (2H, d, J = 4.6, Pyr), 12.19 (1H, s, NH); 
13C NMR (DMSO-d6, 125 MHz) δ 14.40 (CH3), 116.60 (Ar), 116.75 (Ar), 121.61 (Ar), 121.87 (Ar), 
123.37 (Ar), 126.37 (Ar), 126.53 (C=C), 126.61 (Ar), 131.37 (Ar), 135.95 (Ar), 140.52 (Pyr), 
143.63 (Pyr), 147.60 (Pyr), 149.60 (C=C), 149.75 (C=N), 149.99 (Ar), 150.08 (Ar), 158.15 (Ar), 
161.59 (C=O), 166.50 (C=O); [Found (ESI+) 433.1533 [M+H]+, C23H21N4O5 requires 433.1506].  
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Methyl (E)-4-(5-(2-((3-(2-amino-4-hydroxy-5-methoxyphenyl)-2-
methylacryloyl)oxy)phenyl)-3-(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoate (117) 
 
A solution of 111 (90 mg, 0.13 mmol) in TFA (8 mL) was stirred at 30oC under an argon 
atmosphere overnight. The TFA was evaporated and the residue was co-evaporated with 
MeCN (3 x 10 mL). The resulting residue was purified by column chromatography eluting with 
0-30% acetone in DCM to give 117 as a yellow oil (71 mg, 92%). Rf = 0.80 (5% MeOH: DCM); 
Rt = 8.8 min (solvent system A); UV (EtOH) lmax 304 (1100), 378 (3630); 1H NMR (CDCl3, 500 
MHz) δ 1.90 (3H, d, J = 1.0, CH3), 3.69 (3H, s, OCH3), 3.86 (3H, s, OCH3), 5.07 (1H, s, OH), 6.24 
(1H, s, Ar), 6.54 (1H, s, Ar), 6.87 (1H, td, J = 7.5, 1.0, Ar), 6.92 (1H, dd, J = 8.0, 1.0, Ar), 7.16-
7.18 (2H, m, Ar), 7.24 (1H, td, J = 7.5, 2.0, Ar), 7.27 (1H, d, J = 8.5, Ar), 7.50 (1H, td, J = 6.0, 2.5, 
Ar), 7.54 (2H, d, J = 8.5, Ar), 7.60 (1H, d, J = 2.0, HC=C), 7.99 (2H, d, J = 8.5, Ar), 8.05 (1H, dd, J 
= 10.0, 2.5, Ar), 10.94 (1H, br s, OH). 13C NMR (CDCl3, 125 MHz) δ 14.48 (CH3), 52.47 (OCH3), 
56.62 (OCH3), 102.76 (Ar), 112.08 (Ar), 112.35 (Ar), 113.44 (Ar), 117.32 (Ar), 119.65 (Ar), 
120.93 (Ar), 123.84 (Ar), 124.20 (Ar), 125.04 (C=C), 125.90 (Ar), 126.87 (Ar), 130.22 (Ar), 
130.81 (Ar), 130.88 (Ar), 131.54 (Ar), 132.18 (Ar), 137.94 (C=C), 139.30 (Ar), 140.80 (Ar), 
140.94 (Ar), 147.86 (Ar), 149.59 (Ar), 150.01 (Tri), 157.02 (Ar), 161.17 (Tri), 166.01 (C=O), 
166.50 (C=O); [Found (ESI+) 593.2041 [M+H]+, C33H29N4O7 requires 593.2031]. 
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Methyl (E)-4-(5-(2-((3-(2-amino-5-hydroxyphenyl)-2-methylacryloyl)oxy)phenyl)-3-(2-
hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoate (118) 
 
A solution of 112 (76 mg, 0.12 mmol) in TFA (5 mL) was stirred at 30oC under an argon 
atmosphere overnight. The TFA was evaporated and the residue was co-evaporated with 
MeCN (3 x 10 mL). The resulting oil was purified by column chromatography eluting with 0-
30% acetone in DCM to give 118 as a yellow glass (39 mg, 57%). Rf = 0.80 (5% MeOH: DCM); 
Rt = 8.2 min (solvent system A); UV (EtOH) lmax 290 (6500), 378 (1250); 1H NMR (DMSO-d6, 
400 MHz) δ 1.86 (3H, d, J = 1.6, CH3), 3.87 (3H, s, OCH3), 4.59 (2H, br s, NH2), 6.54 (1H, s, Ar), 
6.59 (2H, d, J = 1.2, Ar), 6.99 (1H, td, J = 7.2, 1.2, Ar), 7.02 (1H, dd, J = 8.4, 1.6, Ar), 7.37 (1H, 
td, J = 7.6, 1.6, Ar), 7.40-7.47 (3H, m, Ar and HC=C), 7.58 (1H, dd, J = 7.6, 1.6, Ar), 7.63 (2H, d, 
J = 6.4, Ar), 7.70 (1H, td, J = 7.2, 1.6, Ar), 8.01-8.04 (3H, m, Ar), 8.62 (1H, s, OH), 10.70 (1H, s, 
OH); 13C NMR (DMSO-d6, 100 MHz) δ 14.09 (CH3), 52.42 (OCH3), 113.27 (Ar), 114.95 (Ar), 
116.86 (Ar), 117.12 (Ar), 117.94 (Ar), 119.76 (Ar), 120.29 (Ar), 123.72 (Ar), 124.43 (Ar), 124.69 
(C=C), 126.21 (Ar), 126.79 (Ar), 129.78 (Ar), 130.38 (Ar), 131.37 (Ar), 131.63 (Ar), 132.46 (Ar), 
138.28 (C=C), 139.91 (Ar), 140.40 (Ar), 140.94 (Ar), 147.85 (Ar), 148.72 (Ar), 150.12 (Tri), 
156.24 (Ar), 160.08 (Tri), 165.22 (C=O), 165.82 (C=O); [Found (ESI+) 563.1937 [M+H]+, 
C32H27N4O6 requires 563.1925]. 
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Methyl (E)-4-(5-(2-((3-(2-amino-4,5-dihydroxyphenyl)-2-methylacryloyl)oxy)phenyl)-3-(2-
hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoate (119) 
 
A solution of 113 (24 mg, 0.032 mmol) in TFA (3 mL) was stirred at 30oC under an argon 
atmosphere overnight. The TFA was evaporated and the residue was co-evaporated with 
MeCN (3 x 10 mL). The resulting oil was purified by column chromatography eluting with 0-
30% acetone in DCM to give 119 as a yellow glass (3 mg, 16%). Rf = 0.50 (20% acetone: DCM); 
Rt = 8.1 min (solvent system A); UV (EtOH) lmax 300 (2675); 1H NMR (DMSO-d6, 500 MHz) δ 
1.89 (3H, s, CH3), 3.88 (3H, s, CO2CH3), 6.47 (1H, s, Ar), 6.72 (1H, s, Ar), 6.98 (1H, td, J = 8.2, 
1.2, Ar), 7.02 (1H, dd, J = 8.4, 1.2, Ar), 7.37 (1H, td, J = 8.2, 1.6, Ar), 7.40- 7.43 (2H, m, Ar), 7.53 
(1H, d, J = 1.2, C=CH), 7.58 (1H, dd, J = 8.0, 1.6), 7.62 (2H, d, J = 8.4, Ar), 8.07 (1H, td, J = 8.0, 
1.2, Ar), 8.01- 8.05 (3H, m, Ar), 8.54 (1H, br s, OH), 9.50 (1H, br s, OH), 10.67 (1H, br s, OH); 
13C NMR (DMSO-d6, 125 MHz) δ 14.18 (CH3), 52.41 (CO2CH3), 113.30 (Ar), 116.24 (Ar), 117.10 
(Ar), 119.72 (Ar), 120.35 (Ar), 122.95 (Ar), 123.62 (Ar), 124.39 (Ar), 126.17 (Ar), 126.81 (C=C), 
129.32 (Ar), 129.78 (Ar), 130.37 (Ar), 131.37 (Ar), 131.49 (Ar), 131.61 (Ar), 132.46 (Ar), 137.43 
(Ar), 138.45 (Ar), 140.39 (C=C), 148.02 (Ar), 148.79 (Ar), 150.17 (Ar), 150.89 (Tri), 156.27 (Ar), 
160.10 (Tri), 165.24 (C=O), 165.95 (C=O); [Found (ESI+) 679.1917 [M+H]+, C32H27N4O7 requires 
579.1874].  
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Methyl (tert-butoxycarbonyl)-L-leucyl-L-leucinate (122)268 
 
A stirred solution of Boc-L-leucine (10 g, 43 mmol) in anhydrous DMF (60 mL) was cooled to 
0 oC and treated with HOBt (8.8 g, 65 mmol) and EDC.HCl (12.5 g, 65 mmol) and the mixture 
was allowed to stir for 30 min. A solution of L-leucine methyl ester hydrochloride (7.8 g, 43 
mmol) and DIPEA (22.6 mL, 130 mmol) in anhydrous DMF (40 mL) was added and the mixture 
was allowed to warm to RT and was stirred for 24 h. The solvent was evaporated and the 
residue was dissolved in DCM (150 mL) and washed with sat. NH4Cl (3 x 150 mL), 10% NaHCO3 
(3 x 150 mL) and brine (100 mL). The organic phase was dried over MgSO4, filtered and the 
solvent was evaporated to give 122 as a white solid (15.3 g, 74%). Rf = 0.50 (5% MeOH: DCM); 
mp = 128-134oC (lit.286 135-136oC); 1H NMR (CDCl3, 400  MHz) δ 0.86- 0.90 (12H, m, 2x (CH3)2), 
1.39 (9H, s, (CH3)3), 1.41- 1.66 (6H, m, 2x (CH3)2CHCH2), 3.67 (3H, s, OCH3), 4.04 (1H, br s, CH), 
4.56 (1H, td, J = 8.8, 4.4, CH), 4.81 (1H, br s, NH), 6.37 (1H, d, J = 8.8, NH); 13C NMR (CDCl3, 100  
MHz) δ 21.75 (CH3), 22.74 (CH3), 24.62 (CH), 24.66 (CH), 28.19 ((CH3)3), 40.77 (CH2), 41.53 
(CH2), 50.56 (OCH3), 52.12 (NHCH), 52.13 (NHCH), 77.10 (C(CH3)3) 149.84 (C=O), 170.91 (C=O), 
174.07 (C=O). 
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L-Leucyl-L-leucine methyl ester trifluoroacetate (123) 
 
A stirred solution of 122 (11.3 g, 31.7 mmol) in DCM (50 mL) was treated with TFA (50 mL) 
and the mixture was stirred at RT for 1.5 h. The solvent was evaporated and the product was 
dried to give 123 as a white solid (11.8 g, 99%). Rf = 0.63 (12% MeOH:DCM); mp = 115-120oC; 
1H NMR (CD3OD, 400  MHz) δ 0.96- 1.06 (12H, m, 2x (CH3)2), 1.65- 1.83 (6H, m, 2x 
(CH3)2CHCH2), 3.74 (3H, s, OCH3), 3.92 (1H, q, J= 8.0, CH), 4.53 (1H, t, J = 8.0, CH); 13C NMR 
(CD3OD, 100  MHz) δ 21.79 (CH3), 22.10 (CH3), 23.10 (CH3), 23.23 (CH3), 25.27 (CH), 25.92 (CH), 
41.30 (CH2), 41.80 (CH2), 52.39 (CHNH), 52.75 (CHNH), 52.88 (OCH3), 170.91 (C=O), 174.07 
(C=O). 
 
 
 
 
 
 
 
 
 
(3S,6S)-3,6-diisopentylpiperazine-2,5-dione (124)268  
 
A solution of 122 (11.8 g, 31.7 mmol) in 0.1M acetic acid in butan-1-ol (200 mL) was treated 
with DIPEA (5.7 mL, 32.7 mmol) was added and the mixture was stirred at reflux under an 
argon atmosphere overnight. The mixture was cooled to RT and the solvent was evaporated. 
The resulting clear residue was dissolved in CHCl3 (100 mL) and extracted with H2O (4 x 100 
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mL) and brine (100 mL), then dried over MgSO4, filtered and the solvent was evaporated to 
give 124 as a white solid (6.67 g, 93%). Rf = 0.40 (10% MeOH: DCM); mp = 275-278oC (lit.287 
270-272oC); 1H NMR (CDCl3, 400  MHz) δ 0.90 (6H, d, J = 6.0z, 2x CH3), 0.94 (6H, d, J = 6.0, 2x 
CH3), 1.53- 1.61 (2H, m, 2x CH(CH3)2), 1.71- 1.83 (4H, m, 2x CH2), 3.93 (2H, dt, J = 6.0, 2.8, 2x 
CHCH2), 6.63 (2H, br s, 2x NH); 13C NMR (CDCl3, 100  MHz) δ 21.10 (CH3), 23.16 (CH3), 24.22 
(CH), 43.39 (CH2), 53.28 (CH), 168.81 (C=O); [Found (ESI+) 249.1574 [M+Na]+, C12H22N2NaO2 
requires 249.1573]. 
 
 
 
 
 
 
 
 
3-Chloro-2,5-diisobutylpyrazine (128) 
 
Method A:261 
 
 A stirred suspension of 124 (625 mg, 2.76 mmol) in POCl3 (5 mL) was heated overnight at 100 
oC in a sealed pressure tube. The mixture was cooled to RT then poured onto ice water (50 
mL) and allowed to stir for 30 min. The aqueous phase was extracted with DCM (3 x 50 mL) 
and the combined organic phases were washed with 1M NaOH (2 x 100 mL) and brine (100 
mL), then dried over MgSO4 and filtered. The solvent was evaporated to give an orange oil 
which was purified by column chromatography eluting with toluene to give 128 as a colourless 
oil (242 mg, 39%) along with 127 (120 mg, 17%). Rf = 0.30 (5% EtOAc: petroleum ether); Rt = 
11.59 min (solvent system A); 1H NMR (CDCl3, 400  MHz) δ 0.79- 0.84 (12H, m, 4x CH3), 1.97 
(1H, nonet, J = 6.8, CH), 2.09 (1H, nonet, J = 6.8, CH), 2.48 (2H, d, J = 7.2, CH2), 2.67 (2H, d, J = 
7.2, CH2), 8.11 (1H, s, Pyr); 13C NMR (CDCl3, 100  MHz) δ 22.12 (CH3), 22.27 (CH3), 27.77 (CH), 
28.65 (CH), 43.01 (CH2), 43.36 (CH2), 141.62 (Pyr), 148.02 (Pyr), 152.25 (Pyr), 153.93 (Pyr); 
[Found (ESI-) 451.2383 [(M)(M-H)]-, C24H37N4Cl2 requires 451.2390].  
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Method B:260  
 
A suspension of 124 (132 mg, 0.58 mmol) in POCl3 (1 mL) was stirred at RT overnight in a 
sealed pressure tube. The mixture was poured onto ice water (20 mL) and allowed to stir for 
30 min. The aqueous phase was extracted with DCM (3 x 20 mL) and the combined organic 
phases were washed with 1M NaOH (2 x 50 mL) and brine (50 mL), then dried over MgSO4 
and filtered. The solvent was evaporated to give an orange oil which was purified by column 
chromatography eluting with toluene to give 128 as a colourless oil (39 mg, 30%). 
 
Method C:263  
 
A stirred suspension of 124 (1.01 g, 4.46 mmol) and pyridine (318 µL, 4.46 mmol) in POCl3 
(834 µL, 8.92 mmol) was heated for 2 h at 160oC in a sealed pressure tube. The mixture was 
cooled to RT then poured onto ice water (50 mL) and allowed to stir for 30 min. The aqueous 
phase was extracted with DCM (3 x 50 mL) and the combined organic phases were washed 
with 1M NaOH (2 x 100 mL) and brine (100 mL), then dried over MgSO4 and filtered. The 
solvent was evaporated to give an orange oil which was purified by column chromatography 
eluting with toluene to give 128 as a colourless oil (575 mg, 56%) along with 127 (43 mg, 4%). 
 
 
 
 
 
 
 
 
3-chloro-2,5-diisobutylpyrazine 1-oxide (129)  
 
Method A:261 
 
A solution of 128 (221 mg, 0.97 mmol) and 70% m-CPBA (717 mg, 2.91 mmol) in anhydrous 
DCM (10 mL) was stirred at 40 oC overnight. The organic phase was extracted with 5% Na2S2O5 
(3 x 20 mL) and brine (20 mL). Peroxide levels were tested using Merck peroxide test strips to 
N
N
Cl
O
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ensure that the concentration was <3 mg/L, then the organic phase was dried over MgSO4, 
filtered and the solvent was evaporated to give a yellow oil which was a 4:1 mixture of 129 
and 130 respectively (231 mg), determined by 1H NMR integration. 
 
Method B: 
 
A solution of 128 (570 mg, 2.51 mmol) and 70% m-CPBA (1.85 g, 7.53 mmol) in anhydrous 
DCM (40 mL) was stirred at 40 oC for 3 h. The organic phase was extracted with 5% Na2S2O5 
(3 x 50 mL) and brine (50 mL). Peroxide levels were tested using Merck peroxide test strips to 
ensure that the concentration was <3 mg/L, then the organic phase was dried over MgSO4, 
filtered and the solvent was evaporated to give 129 as a yellow oil (600 mg, 98%). Rf = 0.2 (5% 
EtOAc: petroleum ether); Rt = 10.37 min (solvent system A); 1H NMR (CDCl3, 400 MHz) d 0.87-
0.93 (12H, m, CH3), 2.03 (1H, nonet, J = 6.8, CH), 2.19 (1H, nonet, J = 6.8, CH), 2.43 (2H, d, J = 
7.2, CH2), 2.85 (2H, d, J = 7.2, CH2), 7.84 (1H, s, Pyr); 13C NMR (CDCl3, 100 MHz) δ 22.24 (CH3), 
22.63 (CH3), 26.19 (CH), 28.41 (CH), 35.51 (CH2), 43.93 (CH2), 141.62 (Pyr), 151.22 (Pyr), 155.25 
(Pyr), 155.93 (Pyr); 15N NMR (CDCl3, 40  MHz) δ 273.95 (N+-O-), 282.56 (C=N);  [Found (ESI+) 
243.1275 [M+H]+, C12H20N2OCl requires 243.1259]. 
 
 
 
 
 
 
 
 
 
2,5-dichloro-3,6-diisobutylpyrazine (127)  
 
Method A:261  
 
A suspension of 4:1 129 and 130 (200 mg, 0.82 mmol) in POCl3 (2 mL) was stirred overnight 
at 100 oC in a sealed pressure tube. The mixture was cooled to RT then poured onto ice water 
(20 mL) and allowed to stir for 30 min. The aqueous phase was extracted with DCM (3 x 30 
mL) and the combined organic phases were washed with 1M NaOH (2 x 80 mL) and brine (80 
N
N
Cl
Cl
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mL), then dried over MgSO4 and filtered. The solvent was evaporated to give an orange oil 
which was purified by column chromatography eluting with toluene to give 127 as a colourless 
oil (125 mg, 59%). 
 
Method B: 
 
A suspension of 129 (600 mg, 2.47 mmol) in POCl3 (6 mL) was stirred overnight at 100 oC in a 
sealed pressure tube. The mixture was cooled to RT then poured onto ice water (50 mL) and 
allowed to stir for 30 min. The aqueous phase was extracted with DCM (3 x 50 mL) and the 
combined organic phases were washed with 1M NaOH (2 x 100 mL) and brine (100 mL), then 
dried over MgSO4 and filtered. The solvent was evaporated to give an orange oil which was 
purified by column chromatography eluting with toluene to give 127 as a colourless oil (540 
mg, 84%). Rf = 0.75 (5% EtOAc: petroleum ether); Rt = 12.48 min (solvent system A); 1H NMR 
(CDCl3, 400  MHz) δ 0.92 (12H, d, J = 6.8, 2x CH3), 2.16 (2H, nonet, J = 6.8, 2x CH), 2.72 (4H, d, 
J = 7.2, 2x CH2); 13C NMR (CDCl3, 100  MHz) δ 22.27 (CH3), 27.99 (CH), 42.60 (CH2), 145.77 (Pyr), 
152.45 (Pyr); 15N NMR (CDCl3, 40  MHz) δ 305.25 (C=N). 
 
 
 
 
 
 
 
 
 
 
2,5-dichloro-3,6-diisobutylpyrazine 1,4-dioxide (131)  
 
A solution of 127 (541 mg, 2.07 mmol) in TFA (5.4 mL) was treated with 50% H2O2 (1.10 mL, 
19.3 mmol) added dropwise and then heated gently under stirring at 50 oC for 3 h. The mixture 
was cooled to RT and slowly poured onto ice cold sat. Na2S2O5 (50 mL) and was neutralised 
with 1M NaOH (60 mL). Peroxide levels were tested using Merck peroxide test strips to ensure 
that the concentration was <3 mg/L, The aqueous phase was then extracted with DCM (3 x 
50 mL) and washed with brine (100 mL), dried over MgSO4, filtered and the solvent was 
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evaporated. Purification by column chromatography eluting with DCM gave 131 as a white 
solid (410 mg, 67%). Rf = 0.40 (DCM); Rf = 9.3 min (solvent system A); mp = 185- 190oC; IR 
(KBr) 1466s (N+-O-); 1H NMR (CDCl3, 500  MHz) δ 0.95 (12H, d, J = 7.0, 4x CH3), 2.27 (2H, nonet, 
J = 7.0, 2x CH), 2.96 (4H, d, J = 7.5, 2x CH2);13C NMR (CDCl3, 125  MHz) δ 22.61 (CH3), 26.23 
(CH), 37.86 (CH2), 139.70 (Pyr), 146.11 (Pyr); 15N NMR (CDCl3, 50  MHz) δ 248.05 (N+-O-);  
[Found (ESI+) 293.0825 [M+H]+, C12H19Cl2N2O2 requires 293.0818]. 
 
132 was also isolated (109 mg, 20%). Rf = 0.85 (DCM); Rf = 11.2 min (solvent system A); 1H 
NMR (CDCl3, 500  MHz) δ 0.92 (12H, m, 4x CH3), 2.15 (1H, nonet, J = 7.0, CH), 2.23 (1H, nonet, 
J = 7.0, CH), 2.71 (2H, d, J = 7.0, CH2), 2.89 (2H, d, J = 7.0, CH2); 13C NMR (CDCl3, 125  MHz) δ 
22.32 (CH3), 22.69 (CH3), 26.00 (CH), 27.95 (CH), 36.77 (CH2), 43.60 (CH2),  138.61 (Pyr), 144.83 
(Pyr), 147.22 (Pyr), 154.01 (Pyr); 15N NMR (CDCl3, 50  MHz) δ 270.83 (N+-O-), 276.54 (C=N);   
[Found (ESI+) 277.0876 [M+H]+, C12H19Cl2N2O requires 277.0869]. 
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2,5-bis(benzyloxy)-3,6-diisobutylpyrazine 1,4-dioxide (133)  
 
Method A:  
 
A solution of 131 (112 mg, 0.38 mmol) in anhydrous THF (4 mL) was treated with KOtBu (150 
mg, 1.34 mmol) and benzyl alcohol (139 µL, 1.34 mmol) and stirred overnight at RT under an 
argon atmosphere. The mixture was quenched by addition of H2O (20 mL) and extracted with 
DCM (3 x 20 mL). The combined organic phases were washed with brine (20 mL), then dried 
over MgSO4, filtered and the solvent was evaporated to give an orange oil. Purification by 
column chromatography eluting with 0-2 % acetone in DCM gave 133 and 134 in a 6:1 ration 
respectively as a yellow oil (77 mg, 46%). Rf = 0.55 (DCM); Rt = 11.33 min (solvent system A); 
1H NMR (133) (CDCl3, 400 MHz) δ 0.85 (12H, d, J = 6.8, 4x CH3), 2.19 (2H, nonet, J = 6.8, 2x 
CH), 2.59 (4H, d, J = 7.6, 2x CH2CH), 5.44 (4H, s, CH2), 7.28-7.35 (10H, m, Ar); 13C NMR (CDCl3, 
100 MHz) δ 22.55 (CH3), 25.91 (CH), 33.80 (CH2), 74.06 (CH2), 128.62 (Ar), 129.04 (Ar), 129.07 
(Ar), 134.78 (Ar), 139.86 (Pyr), 150.66 (Pyr); [Found (ESI+) 459.2297 [M+Na]+, C26H32N2NaO4 
requires 459.2254]. 
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Method B:260  
 
A solution of 131 (28 mg, 0.096 mmol) in anhydrous THF (2 mL) was treated with NaOtBu (28 
mg, 0.29 mmol) and benzyl alcohol (30 µL, 0.29 mmol) and stirred overnight at RT under an 
argon atmosphere. The reaction was quenched by addition of H2O (10 mL) and extracted with 
DCM (3 x 10 mL). The combined organic phases were washed with brine (20 mL), then dried 
over MgSO4, filtered and the solvent was evaporated to give an orange oil. Purification by 
column chromatography eluting with 0-30 % EtOAc in petroleum ether gave 134 as a yellow 
oil (11 mg, 44%). Rf = 0.55 (DCM); Rt = 11.33 min (solvent system A); IR (KBr) 1644s (C=O), 
1505s (N+-O-);  1H NMR (CDCl3, 400 MHz) δ 0.80 (6H, d, J = 6.8, 2x CH3), 0.90 (6H, d, J = 6.8, 2x 
CH3), 2.03 (1H, nonet, J = 6.8, CH), 2.25 (1H, nonet, J = 6.8, CH), 2.37 (2H, d, J = 7.6, CH2CH), 
2.79 (2H, d, J = 7.6, CH2CH), 5.26 (2H, s, OCH2), 5.29 (2H, s, OCH2), 7.26-7.39 (10H, m, Ar). 
 
 
 
 
 
 
 
 
2,5-Dihydroxy-3,6-diisobutylpyrazine 1,4-dioxide, pulcherriminic acid (14) 
 
A solution of 133 and 134 (62 mg, 0.14 mmol) in anisole (2 mL) was treated with TFA (2 mL) 
and the mixture was stirred for 2.5 h at RT under an argon atmosphere. The solvent was 
evaporated to give a yellow solid which was filtered off and washed with cold MeOH (3 x 10 
mL) and then dried to give 14 as a pale yellow powder (27 mg, 75%). Rf = 0.30 (5% acetone: 
DCM); Rt = 7.7 min (solvent system A); mp = 160-165oC (lit.248 162-164oC); 1H NMR (DMSO-d6, 
400 MHz) δ 0.90 (12H, d, J = 6.4, CH3), 2.12 (2H, nonet, J = 6.8, CH), 2.68 (4H, d, J = 7.6, CH2); 
13C NMR (DMSO-d6, 100 MHz) δ 22.34 (CH3), 26.17 (CH), 33.36 (CH2), 129.56 (Pyr), 145.46 
(Pyr); [Found (APCI+ direct probe) 257.1515 [M+H]+, C12H21N2O4 requires 257.1496]. 
 
 255 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2,5-Diisobutyl-3,6-bis(1-(2-nitrophenyl)ethoxy)pyrazine 1,4-dioxide (135) 
 
A solution of 131 (26 mg, 0.089 mmol) in anhydrous THF (2 mL) was treated with NaOtBu (26 
mg, 0.27 mmol) and 2-trimethylsilyl ethanol (36 µL, 0.27 mmol) and the mixture was stirred 
at RT overnight under an argon atmosphere. The reaction was quenched by addition of H2O 
(10 mL) and extracted with DCM (3 x 10 mL). The combined organic phases were washed with 
brine (20 mL), then dried over MgSO4, filtered and the solvent was evaporated. Purification 
by column chromatography eluting with 0-2% acetone in DCM gave a mixture of 135 and 136 
(20 mg). 135: [Found (ESI+) 555.2481 [M+H]+, C28H35N4O8 requires 555.2449]; 136: [Found 
(ESI+) 446.1485 [M+Na]+, C20H26ClN3NaO5 requires 446.1459]. 
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2. Biology 
 
2.1. General 
 
Chemical reagents and dyes were purchased from Sigma-Aldrich Chemical Co. (Poole, UK) and 
Invitrogen (Thermo Fischer Scientific). Cell culture media was obtained from Sigma-Aldrich 
Chemical Co. and foetal calf serum (FCS) was obtained from Gibco (Thermo Fischer Scientific). 
Nunclon Delta treated plasticware for adherent cells was purchased from Thermo Fisher 
Scientific. All buffers, solutions and phosphate buffered saline (PBS) were prepared from 
sterilised MilliQ water to minimize the presence of trace elements including transition metals. 
Stock solutions of 2.5% w/v trypsin, 200 mM glutamine, 10000 µg/mL penicillin/streptomycin 
and 50 mg/mL MTT were kept at -4 oC. Unless stated, all cell culture reagents were warmed 
to 37 oC prior to use. 
 
2.2 Cell Culture 
 
All cells were cultured and incubated in a 5% CO2 cell culture incubator set at 37 oC. The cell 
model used was FEK4, a primary human dermal fibroblast cell line.52 The medium used to 
culture the cells was 15% FCS EMEM with 0.22% w/v sodium bicarbonate, 2 mM L-glutamine, 
and 2.5 mg of penicillin/streptomycin premix. The FCS stock was heat-inactivated at 56 oC for 
30 min before use. Stock cells were passaged by trypsinisation once or twice a week. Flasks 
were usually maintained in culture until they reached 80-90% confluency before being 
trypsinised as follows: 
 
The medium was aspirated from the flask, and the cells were washed with PBS (10 mL) before 
being treated with 0.25% w/v trypsin (4-5 mL). Cells were incubated at 37 oC for 5 min until 
detached. Further medium (4-5 mL) was then added back to the flask to deactivate the 
trypsin. The cell suspension was transferred to a Falcon tube and centrifuged for 5 min at 
1000 rpm (Jouan B3.11 centrifuge) followed by aspiration of the supernatant and 
resuspension of the remaining cell pellet in 15% FCS EMEM (4 mL). An aliquot (50 µL) of the 
cell suspension was mixed with 0.4% w/v trypan blue solution (50 µL) and counted under a 
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microscope using a Haemocytometer (Marienfeld, Germany). Cells were then diluted with 
15% FCS EMEM at the required density for seeding. Passages up to 20 were used for 
experiments. 
 
2.3 Chemical Treatment of Cells 
 
Stock solutions at 20 mM and 100 mM in DMSO were prepared for all synthesised ICs, CICs 
and carbostyrils. These solutions were stored at -4 oC, wrapped in foil. For all experiments, 
including those with chemical treatment, cells were seeded at a density of 5 x 104 in media (2 
mL/3.5 cm dish) and incubated for 48 h at 37 oC prior to treatment. 3 x 3.5 cm dishes per 
condition were typically used. The conditioned medium (CM, the medium in which the cells 
had grown for 48 h) was removed from the dish and the required amount of 20 mM stock 
solution was added to the CM to give a final concentration of 20 µM of compound. The CM 
was added back to the dishes and the cells were incubated at 37 oC for 18 h before irradiation 
to analyse the photoprotective effect of the compounds. For analysis of the cytotoxicity of 
compounds, CM containing 20-50 µM of compound was incubated with cells for 24-72 h. 
 
2.4 Irradiation Procedures 
 
UVA irradiation was carried out using a broad spectrum 4 kW lamp (Sellas, Germany) which 
emits in the range of 340- 400 nm, the spectral output of the UVA lamp is shown in Figure 73. 
The UVA doses were measured using an IL1700 radiometer (International light, Newbury, 
MA), with irradiation times varying from 15 s to 75 min depending on the experiment. 
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Figure 73. Output spectrum of the 4 kW UVA lamp (Sellas, Germany) in wavelength (nm). 
 
2.4.1 Cellular Experiments 
 
Irradiation of cells was carried out in an air-cooled room to keep the cells at 25 oC throughout 
the irradiation procedure. Before irradiation, the medium was aspirated from the cells which 
were then washed with PBS (1 mL/dish), aspirated and covered with PBS (1 mL/dish). Cells 
were irradiated in dishes covered by lids to prevent evaporation with UVA doses of 250-750 
kJ/m2. After irradiation, the PBS was aspirated and then either replaced by CM (1 mL/dish) 
followed by incubation of the cells at 37 oC for 24 h before carrying out an assay, or the assay 
was carried out immediately post-irradiation. Control cells were treated in the same manner, 
but were kept in the laminar flow cabinet in the dark. 
 
2.4.2 Uncaging Experiments 
 
Chemical irradiation of CICs to elucidate the uncaging profile was carried out on 1 mg/mL 
solutions in DMSO (500 µL) in a quartz cuvette at UVA doses of 5- 250 kJ/m2 (see Figure 74). 
Aliquots (50 µL) were diluted 1 in 10 with MeOH at the required time points before injection 
on analytical HPLC. The following HPLC gradient programs were used for CIC uncaging 
analysis: 51, 44, 55, 117 and 118: 5% to 95% over 10 min (solvent system A); 114-116 and 
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Fl
ue
nc
e 
Ra
te
 
 259 
119: 5% to 95% over 10 min (solvent system B); 36: 5% to 95% over 20 min (solvent system 
A); 52: 5% to 95% over 20 min (solvent system B).  
 
 
 
 
 
 
 
 
 
 
Figure 74. UVA uncaging of CICs (1 mg/mL in DMSO) carried out in a quartz cuvette under the Sellas UVA lamp. 
 
2.4.3 Sunlight Radiometer Readings  
 
The IL1700 radiometer was used outdoors to obtain readings for solar UVA on a British 
summer day (26th June 2017, University of Bath). The latitude of the test position was 51o N, 
and the temperature in direct sunlight was 35 oC with readings being taken between 12.00 
and 15.00 BST. The stability of a 1 mg/mL solution of avobenzone in DMSO was also tested 
under normal sunlight conditions during these experiments. The avobenzone solution was 
exposed to solar UVA doses of 100- 1000 kJ/m2 and samples (50 µL) were diluted 1 in 10 with 
MeOH at the required time points before injection on analytical HPLC. In this way, any 
changes in the amount of the UVA-inactive keto tautomer of avobenzone in the solution could 
be observed. 
 
2.5 Evaluation of the Efficiency of UV Filters/Sunscreen Formulations 
 
Cells were seeded and treated in the same way as in the irradiation procedure described 
above, except that the dishes were covered with an extra dish containing a reservoir of a UV 
filter or sunscreen formulation in DMSO at varying concentrations relating to thickness of 
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sunscreen applications (Figure 75). After irradiation, the upper dish was removed, the PBS 
was aspirated and the cells were treated accordingly depending on the assay. The control 
samples were treated in the same manner, but were kept in the laminar flow cabinet in the 
dark. 
 
 
 
 
 
 
 
 
 
Figure 75. UV filter irradiation protocol. A ‘reservoir’ of filter or sunscreen formulation in DMSO is placed above 
the cells during irradiation. Using this technique it is possible to alter the concentration of sunscreen to mimic 
the thickness of sunscreen applied to the skin by a consumer.71  
 
2.6 DPPH Assay 
 
A stock solution of 1M DPPH in MeOH was stored at -4 oC and wrapped in foil. A working 
solution of 100 µM DPPH in MeOH was prepared from the stock solution immediately prior 
to use. All compounds to be tested were stored as 400 mM stock solutions in DMSO, and 
freshly diluted before the assay to 10- 400 µM in MeOH. Trolox was used as the positive 
control. An aliquot of each concentration of compound to be tested (50 µL) was added to 100 
µM DPPH (150 µL) in triplicate in a 96-well plate (Figure 76). After mixing, the plate was 
incubated in the dark at room temperature for 30 min. The absorbance was read at 520 nm 
on a UV/Vis microplate reader (SPECTROstar, BMG Labtech, Ortenberg, Germany), with 
MeOH used as the blank (200 µL). The control was 100 µM DPPH (150 µL) and MeOH (50 µL). 
The percentage radical scavenging activity of each concentration of compound was calculated 
using the following expression = 
 
FEK4 cells in PBS 
Reservoir of UV 
filter/sunscreen 
formulation 
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(control – sample)      x 100 
          control   
 
The average percentage radical scavenging activity of n=3 was plotted against concentration 
and the IC50 value was determined from the line of best fit within the linear range of activity. 
 
 
 
 
 
 
 
 
 
 
Figure 76. DPPH assay. The colour change is shown from violet (top line: control DPPH) to colourless at increasing 
concentrations of an active antioxidant compound. 
 
2.7 MTT Assay 
 
A solution of 0.5 mg/mL MTT in serum-free EMEM (SFM) was prepared as required from a 
stock solution of 50 mg/mL MTT in PBS and warmed at 37 oC prior to adding to cells. CM was 
aspirated from the dishes which were then washed with PBS before 0.5 mg/mL MTT/SFM 
(500 µL) was added to each dish. The cells were incubated at 37 oC for 3 h. The MTT solution 
was aspirated and DMSO (500 µL) was added to each dish to dissolve any formazan produced. 
Dishes were swirled for 3 min on a 3D rocking platform (Stuart Scientific, UK) and then 
triplicates (20 µL) from each dish were pipetted into a 96-well micro plate, diluted 1 in 5 with 
DMSO. The absorbance was read at 550 nm on a UV/Vis microplate reader (SPECTROstar, 
BMG Labtech, Ortenberg, Germany). DMSO (100 µL) was used as the blank. The mean values 
calculated from the raw data (optical density, OD) for the untreated unirradiated control were 
set as 100% enzymatic activity. The mean values of the triplicates for each treated and/or 
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irradiated sample were then expressed as a percentage of the unirradiated and untreated 
control. 
 
2.8 CM-H2DCFDA Assay 
 
A vial of 50 µg CM-H2DCFDA was thawed and dissolved in DMSO (17.3 µL) before use to make 
a 5 mM stock solution. This was diluted 1 in 1000 into PBS to give a working solution of 5 µM 
CM-H2DCFDA, which was wrapped in foil. Immediately after irradiation at 250 kJ/m2, the PBS 
was aspirated from the dishes and the cells were covered with 5 µM CM-H2DCFDA (1 
mL/dish), PBS (1 mL) was added to the unstained control. The cells were incubated at 37 oC 
for 20 min in the dark before the CM-H2DCFDA solution was aspirated and the dishes were 
washed with PBS. 0.125% w/v Trypsin (1 mL) was added to each dish and the cells were 
incubated for 5 min. Once the cells were detached, the trypsin was neutralised with 15% FCS 
EMEM (1 mL) and the contents of the dishes for each condition were transferred to 
corresponding Falcon tubes. The Falcon tubes were centrifuged at 1000 rpm for 7 min, then 
the supernatant was aspirated and the cell pellet was resuspended in 0.1% BSA in PBS (200 
µL). This volume was transferred to flow cytometry tubes which were kept on ice for a 
maximum of 15 min before analysis on the flow cytometer (FACS ARIA III, Becton Dickinson 
UK Ltd, Berkshire). 10,000 Events were recorded per condition and these were gated for intact 
cells, excluding cell debris. The median fluorescence of each condition was recorded and all 
medians were corrected for cell autofluorescence using the unstained control. 
 
2.9 Annexin V/PI Assay 
 
Stock solutions of incubation buffer (IB) ± Ca2+ were prepared in advance and stored at 2-8 
oC. The composition of IB-Ca2+ was 140 mM NaCl and 10 mM HEPES-NaOH (pH 7.4) in MilliQ 
water. The composition of IB+Ca2+ was the same with the addition of 5 mM CaCl2. After 
irradiation of cells in dishes at 500- 750 kJ/m2, the PBS was aspirated and the cells were 
covered with CM (1 mL/dish) and incubated at 37 oC for 24 h. After this incubation, the CM in 
each dish was added to one Falcon tube per condition. The cells were then washed with PBS, 
which was also added to the respective Falcon tube. 0.125% w/v Trypsin (1 mL) was added to 
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each dish and incubated for 5 min and once the cells were detached the trypsin was 
neutralised with 15% FCS EMEM (1 mL) and the contents of the dishes were transferred to 
the corresponding Falcon tubes. The Falcon tubes were centrifuged at 1000 rpm for 7 min 
then the supernatant was aspirated and the cell pellet was resuspended in IB+Ca2+ (1 mL). A 
portion of each cell suspension was counted as previously described, and the volume of cell 
suspension correlating to 0.5 x 106 cells in each condition was transferred to flow cytometry 
tubes. These tubes were centrifuged at 1000 rpm for 5 min then supernatant from each tube 
was aspirated and each pellet was resuspended in annexin V premix (100 µL: 2 µL of annexin 
V and 98 µL of IB+Ca2+). The cell suspensions were incubated for 20 min in the dark at RT, 10 
µg/mL PI in IB-Ca2+ (100 µL) was then added to each tube to give a final concentration of 5 
µg/mL PI. The cells were incubated for a further 5 min in the dark at RT before analysis on the 
flow cytometer (FACS ARIA III, Becton Dickinson UK Ltd, Berkshire). 10,000 events were 
recorded per condition and these were gated for intact cells, excluding cell debris. This 
selection of cells was then gated into quadrants Q1-4, where Q1= PI-positive cells only; Q2= 
dual stained annexin V/PI-positive cells; Q3= cells negative for both stains; Q4= annexin V-
positive cells only. 
 
2.10 Calcein (CA-AM) Assay 
 
2.10.1 LIP Determination in a Cuvette 
 
This method was adapted from the method laid out by Breuer et al.288 A stock of fixing 
solution was prepared in advance and stored at 2-8 oC. The composition of fixing solution was 
150 mM NaCl, 2 mM EDTA and 10 mM HEPES-NaOH (pH 7.4) in MilliQ water. All other 
solutions were made freshly before the assay. The composition of loading buffer (LB) was 20 
mM HEPES-NaOH (pH 7.4) in SFM. Aliquots of CA-AM were as a 0.25 mM solution in DMSO 
and were stored at -4 oC. After irradiation at 250 kJ/m2, the PBS was aspirated from the cells 
in dishes and 0.05 µM CA-AM in LB (1 mL/dish) was added. The dishes were incubated at 37 
oC for 15 min in the dark. After the incubation the CA-AM solution was aspirated and each 
dish was washed with PBS. 0.125% w/v Trypsin (1 mL/dish) was added and incubated for 5 
min. Once the cells were detached, the trypsin was neutralised with 3% w/v BSA in PBS (1 mL) 
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and the contents of the dishes for each condition were transferred to corresponding Falcon 
tubes. The Falcon tubes were centrifuged at 900 rpm for 7 min then the supernatant was 
aspirated and each cell pellet was resuspended in 0.3% w/v BSA in PBS (1 mL). This volume 
was transferred to 1.5 mL Eppendorf tubes. The Eppendorf tubes were centrifuged at 5000 
rpm for 5 min then the supernatant was aspirated and each cell pellet was resuspended in 
0.3% w/v BSA in fixing solution (1 mL). The cell suspension for each condition was transferred 
sequentially to a quartz cuvette for analysis on the spectrofluorimeter (F-4500, Hitachi High-
Technologies). The fluorescence intensity (F1) was read in real time and once the signal had 
stabilised (approximately 2 min), 40 mM SIH in DMSO (1 µL) was added to the cuvette. The 
cuvette was mixed and the fluorescence intensity (F2) was read for at least 5 min. This was 
repeated for each cell suspension to give the ΔF as (F2 – F1)/F2 which is equivalent to [CA-Fe]. 
After all the fluorescence readings were completed, a portion of cells from each condition 
was counted in order to normalize the ΔF per 106 cells. Experimental parameters used on the 
spectrofluorimeter were: time scan function, excitation slit: 5 nm, emission slit: 10 nm, PMT 
voltage: 950 V. 
 
2.10.2 LIP Determination in a 96-well Plate Format 
 
After irradiation of cells in dishes at 500 kJ/m2 the PBS was aspirated from the dishes and 0.05 
µM CA-AM in LB (1 mL/dish) was added. The dishes were incubated at 37 oC for 15 min in the 
dark. After the incubation, the CA-AM solution was aspirated and each dish was washed with 
PBS. 0.125% w/v Trypsin (1 mL/dish) was added and incubated for 5 min. Once the cells were 
detached, the trypsin was neutralised with 3% w/v BSA in PBS (1 mL) and the contents of the 
dishes for each condition were transferred to corresponding Falcon tubes. The Falcon tubes 
were centrifuged at 900 rpm for 7 min then the supernatant was aspirated and each cell pellet 
was resuspended in 0.3% w/v BSA in PBS (1 mL). This volume was transferred to 1.5 mL 
Eppendorf tubes. The Eppendorf tubes were centrifuged at 5000 rpm for 5 min then the 
supernatant was aspirated and each cell pellet was resuspended in 0.3% w/v BSA in fixing 
solution (500 µL). Duplicates of 200 µL of cell suspension per condition were pipetted into a 
black 96-well plate (Greiner CELLSTAR) for analysis on the CLARIOstar plate reader (BMG 
LABTECH). 0.3% w/v BSA in fixing solution (200 µL) was used as the blank. An initial 
fluorescence intensity reading was taken (F1) before 5 mM SIH in DMSO (1.6 µL) was added 
 265 
to each well. After mixing the wells with the pipette, the fluorescence was read again (F2). As 
in the previous method, the ΔF for each condition was calculated as (F2 – F1)/F2 which is 
equivalent to [CA-Fe]. A portion of the cell suspension of each condition (remaining in the 
Eppendorf tube) was counted to normalize ΔF per 106 cells. An aliquot (200 µL) of the 
supernatant from the final centrifugation (of the untreated and irradiated condition) was also 
added to the 96-well plate to analyse CA leakage out of the cells due to the loss of membrane 
integrity during irradiation. The average CA leakage was 10.6% (n=6). The focal height was 
adjusted automatically by the CLARIOstar to ensure a gain of 1800 in every experiment. 
 
2.10.3 Ferrous Ammonium Sulphate (FAS) Titration of CA-AM Loaded Cells 
 
A stock of fixing solution- EDTA was prepared in advance and stored at 2-8 oC. The 
composition of fixing solution-EDTA was 150 mM NaCl and 10 mM HEPES-NaOH (pH 7.4) in 
MilliQ water. After 72 h incubation at 37 oC, the CM was aspirated from the cells in dishes and 
0.05 µM CA-AM in LB (1 mL/dish) was added. The dishes were incubated at 37 oC for 15 min 
in the dark. During the incubation 100 µM FAS solution (10 mL) was prepared in de-
oxygenated MilliQ water. After the incubation the CA-AM solution was aspirated and each 
dish was washed with PBS. 0.125% w/v Trypsin (1 mL/dish) was added and incubated for 5 
min. Once the cells were detached, the trypsin was neutralised with 3% w/v BSA in PBS (1 mL) 
and the contents of the dishes were transferred to a Falcon tube. The Falcon tube was 
centrifuged at 900 rpm for 7 min then the supernatant was aspirated and the cell pellet was 
resuspended in 0.3% w/v BSA in PBS (1 mL). This volume was transferred to a 1.5 mL 
Eppendorf tube. The Eppendorf tube was centrifuged at 5000 rpm for 5 min then the 
supernatant was aspirated and the pellet was resuspended in 0.3% w/v BSA in fixing solution 
(500 µL). Duplicates of 200 µL of the cell suspension were pipetted into a black 96-well plate 
(Greiner CELLSTAR) for analysis on the CLARIOstar plate reader (BMG LABTECH). 0.3% w/v 
BSA in fixing solution (200 µL) was used as the blank. 1 mM ionophore (A23187) in DMSO (1 
µL) was added to each well for a final ionophore concentration of 5 µM per well. After mixing 
the wells with the pipette, an initial fluorescence reading was taken (F1). 100 µM aqueous FAS 
(1 µL) was sequentially added to each well every 2 min to give increasing increments of 0.5 
µM FAS per well. The fluorescence was read after each addition and mixing to give F2- F8. The 
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ΔF after each addition was calculated using (F2 – F1) and plotted against FAS concentration. A 
portion of the cell suspension (remaining in the Eppendorf tube) was counted to normalize 
the ΔF per 106 cells. The focal height was adjusted automatically by the CLARIOstar to ensure 
a gain of 1800 in every experiment. 
 
2.11 Statistical Analysis of Data 
 
All results were expressed as an average of a minimum of n=3 experiments ± 1 standard 
deviation. GraphPad Prism and Microsoft Excel were used to statistically analyse data. An  
ANOVA test was initially carried out to determine whether there was any statistically 
significant differences between the means in a group of data. Following a positive ANOVA test 
the Student’s one-tailed t-test was used to compare two sets of data within the group, using 
paired or unpaired as appropriate for the data. A p-value of <0.05 was considered to reflect a 
significant difference between two groups of data. 
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2.12 Assay Timelines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day 2: ± chemical compound 
treatment (20 µM) for overnight 
(18 h) incubation at 37 oC 
OR 
incubation for 24-72 h for 
cytotoxicity MTT assay 
Immediate 24 h 
Day 0: FEK4 cells seeded at 
the density of 5 x 104/2 mL 
15% FCS EMEM in 3 x 3.5 cm 
dish per condition 
Day 3: ± UVA irradiation 
(250-750 kJ/m2) 
Day 4: MTT assay OR annexin 
V/PI flow cytometry assay 
carried out 
 
Day 3: Calcein assay OR CM-
H2DCFDA flow cytometry 
assay carried out 
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Appendix 1 
 
Figure 63. HPLC chromatograms of CIC 114: A. Non-irradiated control of ‘intact’ 114; B. 25 kJ/m2 irradiation; C. 
50 kJ/m2 irradiation; D. 100 kJ/m2 irradiation showing complete uncaging. Irradiated using a 4 kW UVA lamp 
(Sellas, Germany). 
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Figure 64. HPLC chromatograms of CIC 115: A. Non-irradiated control of ‘intact’ 115; B. 50 kJ/m2 irradiation; C. 
100 kJ/m2 irradiation; D. 250 kJ/m2 irradiation showing complete uncaging. Irradiated using a 4 kW UVA lamp 
(Sellas, Germany). 
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Figure 65. HPLC chromatograms of CIC 116: A. Non-irradiated control of ‘intact’ 116; B. 50 kJ/m2 irradiation; C. 
100 kJ/m2 irradiation; D. 250 kJ/m2 irradiation showing nearly complete uncaging. Irradiated using a 4 kW UVA 
lamp (Sellas, Germany). 
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Figure 66. HPLC chromatograms of CIC 117: A. Non-irradiated control of ‘intact’ 117; B. 10 kJ/m2 irradiation; C. 
25 kJ/m2 irradiation showing complete uncaging. Irradiated using a 4 kW UVA lamp (Sellas, Germany). 
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Figure 67. HPLC chromatograms of CIC 118: A. Non-irradiated control of ‘intact’ 118; B. 25 kJ/m2 irradiation; C. 
50 kJ/m2 irradiation showing complete uncaging. Irradiated using a 4 kW UVA lamp (Sellas, Germany). 
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Figure 68. HPLC chromatograms of CIC 119: A. Non-irradiated control of ‘intact’ 119; B. 10 kJ/m2 irradiation; C. 
25 kJ/m2 irradiation; D. 50 kJ/m2 irradiation showing complete uncaging. Irradiated using a 4 kW UVA lamp 
(Sellas, Germany). 
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